data_2n2g_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2n2g _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.487 1.404 0 CA-C-O 119.528 -0.272 . . . . 0.0 111.164 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -83.78 -178.85 3.78 Favored 'Trans proline' 0 C--N 1.372 1.806 0 C-N-CA 122.47 2.113 . . . . 0.0 113.949 -179.099 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . 0.503 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.27 -152.32 6.45 Favored Glycine 0 C--N 1.342 0.913 0 CA-C-N 115.613 -0.722 . . . . 0.0 112.04 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -73.25 113.76 10.67 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.916 0.389 . . . . 0.0 111.621 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.32 32.47 10.44 Favored Glycine 0 C--N 1.341 0.816 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.795 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.55 162.26 26.86 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-O 120.663 0.268 . . . . 0.0 111.251 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.486 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.8 tt0 -80.09 127.0 31.79 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.816 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.47 150.55 50.76 Favored 'General case' 0 C--O 1.233 0.237 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.664 -179.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.451 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.17 154.62 23.08 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.597 -0.729 . . . . 0.0 109.785 179.008 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.7 m -102.93 4.23 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 116.123 -0.49 . . . . 0.0 112.14 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.451 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.0 mt-10 -100.27 -48.57 4.55 Favored 'General case' 0 C--O 1.235 0.329 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.113 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.4 p90 -148.45 2.0 0.62 Allowed 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 113.293 0.849 . . . . 0.0 113.293 -178.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.08 63.46 70.34 Favored Pre-proline 0 CA--C 1.548 0.903 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -74.46 175.59 10.82 Favored 'Trans proline' 0 C--N 1.369 1.649 0 C-N-CA 122.493 2.128 . . . . 0.0 112.594 179.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.7 m -79.69 140.87 36.87 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.503 179.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -80.0 -52.58 1.02 Allowed Pre-proline 0 CA--C 1.543 0.702 0 CA-C-O 118.996 -0.526 . . . . 0.0 112.006 -179.326 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -73.79 175.98 10.04 Favored 'Trans proline' 0 C--N 1.375 1.928 0 C-N-CA 122.143 1.895 . . . . 0.0 111.963 179.258 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.38 64.78 1.58 Allowed 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 122.387 2.058 . . . . 0.0 112.731 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 39.7 mt -127.46 161.32 29.0 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.748 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.0 t -112.4 149.57 32.33 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.015 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.2 t -93.91 108.61 20.39 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.59 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.428 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -127.91 130.78 23.59 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.301 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -73.36 -38.99 1.56 Allowed 'Cis proline' 0 C--N 1.372 1.802 0 C-N-CA 124.671 -0.97 . . . . 0.0 113.464 -0.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.65 39.69 13.86 Favored Glycine 0 C--N 1.344 0.999 0 O-C-N 123.453 0.471 . . . . 0.0 113.047 -179.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -141.19 83.34 13.82 Favored Pre-proline 0 CA--C 1.546 0.791 0 C-N-CA 122.182 0.193 . . . . 0.0 111.315 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.56 -33.5 2.71 Favored 'Cis proline' 0 C--N 1.372 1.779 0 CA-C-N 119.061 0.7 . . . . 0.0 112.826 -0.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -106.69 156.32 18.75 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.932 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.486 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.78 -154.2 6.61 Favored Glycine 0 C--N 1.338 0.642 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.526 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.503 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.9 mm -127.62 147.17 32.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.503 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.1 m -84.38 107.93 16.92 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.13 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.503 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.4 m-85 -106.09 158.99 16.41 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.824 -179.073 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -93.29 122.99 45.23 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.6 179.664 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.3 pt . . . . . 0 C--O 1.251 1.141 0 CA-C-O 118.472 -0.775 . . . . 0.0 111.349 179.94 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.37 0 CA-C-O 119.533 -0.27 . . . . 0.0 111.133 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -83.89 -178.83 3.73 Favored 'Trans proline' 0 C--N 1.373 1.816 0 C-N-CA 122.458 2.105 . . . . 0.0 114.008 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . 0.505 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.4 -152.35 6.44 Favored Glycine 0 C--N 1.343 0.922 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.961 179.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -73.08 113.89 10.63 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-O 120.789 0.328 . . . . 0.0 111.641 -179.49 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.06 32.63 10.46 Favored Glycine 0 C--N 1.34 0.757 0 CA-C-N 115.448 -0.796 . . . . 0.0 112.781 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.3 mt-10 -127.6 162.39 26.61 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.647 0.26 . . . . 0.0 111.282 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.498 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.6 tt0 -80.05 127.1 31.89 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.793 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.84 150.7 51.02 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.681 -179.262 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.448 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.54 154.71 23.32 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.775 179.024 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.9 m -102.85 4.07 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-N 116.18 -0.464 . . . . 0.0 112.156 -179.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.448 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.4 mt-10 -100.01 -48.65 4.58 Favored 'General case' 0 C--O 1.235 0.312 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.002 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -148.54 2.13 0.62 Allowed 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 113.407 0.891 . . . . 0.0 113.407 -178.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -131.17 63.68 70.95 Favored Pre-proline 0 CA--C 1.55 0.962 0 N-CA-C 111.678 0.251 . . . . 0.0 111.678 -179.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.65 175.71 10.75 Favored 'Trans proline' 0 C--N 1.369 1.641 0 C-N-CA 122.493 2.129 . . . . 0.0 112.663 179.235 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.5 m -79.66 140.87 36.91 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 123.288 0.368 . . . . 0.0 110.618 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.94 -52.58 1.03 Allowed Pre-proline 0 CA--C 1.543 0.705 0 CA-C-O 119.131 -0.462 . . . . 0.0 111.925 -179.212 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 66.4 Cg_endo -73.78 175.87 10.17 Favored 'Trans proline' 0 C--N 1.376 1.986 0 C-N-CA 122.105 1.87 . . . . 0.0 112.01 179.227 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -69.37 64.89 1.57 Allowed 'Trans proline' 0 C--N 1.377 2.068 0 C-N-CA 122.373 2.049 . . . . 0.0 112.721 179.478 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 41.1 mt -127.55 161.45 28.76 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.746 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.7 t -112.34 149.58 32.24 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.084 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -94.02 108.93 20.71 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.496 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mt -128.14 130.68 23.57 Favored Pre-proline 0 CA--C 1.541 0.612 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.314 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -73.55 -38.95 1.58 Allowed 'Cis proline' 0 C--N 1.374 1.872 0 C-N-CA 124.581 -1.008 . . . . 0.0 113.456 -0.181 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.85 39.84 12.98 Favored Glycine 0 C--N 1.345 1.08 0 O-C-N 123.483 0.489 . . . . 0.0 113.111 -179.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -140.98 82.88 14.56 Favored Pre-proline 0 CA--C 1.546 0.818 0 C-N-CA 122.205 0.202 . . . . 0.0 111.26 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -83.76 -33.54 2.65 Favored 'Cis proline' 0 C--N 1.372 1.766 0 CA-C-N 119.066 0.702 . . . . 0.0 112.857 -0.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -106.97 156.32 18.85 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.01 -179.324 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.498 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.76 -152.13 5.89 Favored Glycine 0 C--N 1.337 0.635 0 CA-C-N 115.869 -0.605 . . . . 0.0 112.554 179.815 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.493 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.2 mm -129.11 147.13 33.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.505 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.2 m -84.4 108.13 17.05 Favored 'General case' 0 C--O 1.238 0.48 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.174 179.198 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.493 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.0 m-85 -106.2 159.23 16.25 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.79 -179.056 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.91 123.25 44.94 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.641 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.459 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.173 -0.918 . . . . 0.0 111.495 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.37 0 CA-C-O 119.499 -0.286 . . . . 0.0 111.115 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -83.89 -178.81 3.73 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.424 2.083 . . . . 0.0 113.995 -179.161 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . 0.504 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.31 -152.41 6.47 Favored Glycine 0 C--N 1.343 0.965 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.993 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -73.03 113.84 10.52 Favored 'General case' 0 N--CA 1.471 0.594 0 CA-C-O 120.961 0.41 . . . . 0.0 111.669 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.09 32.48 10.62 Favored Glycine 0 C--N 1.342 0.886 0 CA-C-N 115.415 -0.812 . . . . 0.0 112.78 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.54 162.34 26.66 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.63 0.252 . . . . 0.0 111.302 -179.731 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.486 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.15 127.31 32.18 Favored 'General case' 0 C--N 1.346 0.428 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.794 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.4 p -129.7 150.49 50.99 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 115.815 -0.629 . . . . 0.0 111.605 -179.234 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.451 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.1 t70 -110.2 154.58 23.17 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.831 178.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.5 m -102.88 3.94 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 CA-C-N 116.165 -0.47 . . . . 0.0 112.225 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.451 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -99.71 -48.76 4.6 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 111.981 0.363 . . . . 0.0 111.981 -179.046 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -148.64 2.18 0.61 Allowed 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 113.204 0.816 . . . . 0.0 113.204 -178.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.28 63.67 70.74 Favored Pre-proline 0 CA--C 1.548 0.903 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -74.55 176.11 10.17 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 122.434 2.089 . . . . 0.0 112.66 179.209 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 36.2 m -79.81 140.9 36.68 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.557 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.96 -52.64 1.02 Allowed Pre-proline 0 CA--C 1.544 0.75 0 CA-C-O 119.068 -0.491 . . . . 0.0 111.926 -179.197 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -73.76 175.96 10.04 Favored 'Trans proline' 0 C--N 1.376 1.99 0 C-N-CA 122.114 1.876 . . . . 0.0 112.039 179.26 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.36 64.89 1.57 Allowed 'Trans proline' 0 C--N 1.377 2.069 0 C-N-CA 122.327 2.018 . . . . 0.0 112.747 179.479 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 40.6 mt -127.6 161.42 28.88 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.736 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.9 t -112.34 149.57 32.25 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 115.888 -0.597 . . . . 0.0 111.068 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.2 t -94.06 108.76 20.56 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.551 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.1 mt -127.99 130.75 23.58 Favored Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.337 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.38 -39.02 1.55 Allowed 'Cis proline' 0 C--N 1.374 1.87 0 C-N-CA 124.583 -1.007 . . . . 0.0 113.444 -0.22 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.91 39.68 13.02 Favored Glycine 0 C--N 1.345 1.06 0 O-C-N 123.423 0.452 . . . . 0.0 113.069 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.23 83.39 13.73 Favored Pre-proline 0 CA--C 1.547 0.841 0 C-N-CA 122.116 0.166 . . . . 0.0 111.217 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.65 -33.41 2.73 Favored 'Cis proline' 0 C--N 1.372 1.772 0 C-N-CA 125.335 -0.694 . . . . 0.0 112.841 -0.364 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -106.79 156.2 18.92 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.018 -179.378 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.486 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.53 -153.88 6.46 Favored Glycine 0 C--N 1.338 0.639 0 CA-C-N 115.866 -0.606 . . . . 0.0 112.508 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.499 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.4 mm -127.85 147.11 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.504 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.6 m -84.3 107.9 16.85 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.142 179.26 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.499 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -106.03 159.25 16.2 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.785 -179.094 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -93.06 123.15 45.05 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.622 179.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.46 ' O ' HD11 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.295 -0.86 . . . . 0.0 111.519 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.37 0 CA-C-O 119.576 -0.25 . . . . 0.0 111.05 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -83.75 -178.86 3.8 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.53 2.153 . . . . 0.0 114.019 -179.129 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . 0.503 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.04 -152.29 6.48 Favored Glycine 0 C--N 1.342 0.888 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.996 179.659 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -73.52 113.98 11.23 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-O 120.986 0.422 . . . . 0.0 111.561 -179.54 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.13 32.57 10.48 Favored Glycine 0 C--N 1.341 0.818 0 CA-C-N 115.418 -0.81 . . . . 0.0 112.8 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.44 162.3 26.68 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-O 120.476 0.179 . . . . 0.0 111.345 -179.645 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.494 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.07 127.27 32.1 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.795 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.78 150.38 51.11 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.631 -179.248 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.451 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.42 154.89 22.95 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.821 178.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.7 m -102.93 4.21 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 CA-C-N 116.174 -0.466 . . . . 0.0 112.137 -179.507 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.451 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.3 mt-10 -100.32 -48.57 4.54 Favored 'General case' 0 C--O 1.235 0.307 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -179.123 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.6 p90 -148.28 2.0 0.64 Allowed 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 113.279 0.844 . . . . 0.0 113.279 -178.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.12 63.58 70.7 Favored Pre-proline 0 CA--C 1.548 0.903 0 N-CA-C 111.73 0.27 . . . . 0.0 111.73 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.59 175.36 11.19 Favored 'Trans proline' 0 C--N 1.371 1.712 0 C-N-CA 122.461 2.107 . . . . 0.0 112.61 179.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.8 m -79.58 140.69 37.08 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.537 179.664 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.98 -52.57 1.03 Allowed Pre-proline 0 N--CA 1.473 0.687 0 CA-C-O 118.98 -0.533 . . . . 0.0 111.983 -179.367 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -73.88 175.93 10.14 Favored 'Trans proline' 0 C--N 1.375 1.951 0 C-N-CA 122.135 1.89 . . . . 0.0 111.984 179.287 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.43 64.91 1.61 Allowed 'Trans proline' 0 C--N 1.378 2.102 0 C-N-CA 122.277 1.985 . . . . 0.0 112.769 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 40.7 mt -127.35 161.6 28.26 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.782 179.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.7 t -112.65 149.38 32.93 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.009 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -93.88 108.81 20.56 Favored 'General case' 0 C--O 1.238 0.49 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.544 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mt -127.99 130.8 23.58 Favored Pre-proline 0 CA--C 1.542 0.665 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.247 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -73.47 -38.82 1.64 Allowed 'Cis proline' 0 C--N 1.374 1.872 0 C-N-CA 124.553 -1.019 . . . . 0.0 113.475 -0.296 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.95 39.66 12.96 Favored Glycine 0 C--N 1.345 1.042 0 O-C-N 123.38 0.425 . . . . 0.0 113.089 -179.743 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -141.24 83.16 13.92 Favored Pre-proline 0 CA--C 1.547 0.827 0 C-N-CA 122.161 0.185 . . . . 0.0 111.265 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -83.84 -33.52 2.64 Favored 'Cis proline' 0 C--N 1.373 1.823 0 CA-C-N 119.052 0.697 . . . . 0.0 112.829 -0.282 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.1 m-85 -106.96 156.42 18.74 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.928 -179.354 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.494 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.82 -152.47 5.99 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 115.85 -0.614 . . . . 0.0 112.603 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.496 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.5 mm -129.02 147.04 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 O-C-N 123.8 0.353 . . . . 0.0 110.08 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.503 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 76.6 m -84.18 107.79 16.7 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.262 179.2 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.496 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.1 m-85 -105.91 159.13 16.27 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.835 -179.044 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.9 123.25 44.92 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.627 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.458 ' O ' HD11 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.32 -0.848 . . . . 0.0 111.398 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.371 0 CA-C-O 119.586 -0.245 . . . . 0.0 111.171 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -83.8 -178.82 3.76 Favored 'Trans proline' 0 C--N 1.372 1.805 0 C-N-CA 122.445 2.097 . . . . 0.0 114.031 -179.137 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . 0.503 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.87 -152.18 6.49 Favored Glycine 0 C--N 1.343 0.942 0 CA-C-N 115.539 -0.755 . . . . 0.0 112.002 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.46 114.24 11.46 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-O 120.891 0.377 . . . . 0.0 111.6 -179.569 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.69 32.6 11.08 Favored Glycine 0 C--N 1.34 0.801 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.838 -179.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -127.4 162.65 25.83 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 120.625 0.25 . . . . 0.0 111.255 -179.576 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.512 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.07 127.25 32.08 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.805 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.8 p -130.32 150.47 51.54 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.631 -179.372 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.496 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.4 t70 -110.65 154.93 23.12 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.876 178.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.543 HG23 ' OE2' ' A' ' 11' ' ' GLU . 9.6 m -102.9 3.31 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-N 116.172 -0.467 . . . . 0.0 112.152 -179.481 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.543 ' OE2' HG23 ' A' ' 10' ' ' VAL . 4.9 mp0 -97.85 -49.02 4.96 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.443 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 42.1 p90 -149.26 2.52 0.56 Allowed 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 113.375 0.88 . . . . 0.0 113.375 -178.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -130.69 63.67 70.71 Favored Pre-proline 0 CA--C 1.548 0.887 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -74.66 175.99 10.37 Favored 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 122.507 2.138 . . . . 0.0 112.604 179.3 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 34.8 m -79.7 140.92 36.83 Favored 'General case' 0 CA--C 1.534 0.352 0 O-C-N 123.271 0.357 . . . . 0.0 110.603 179.648 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.89 -52.76 1.03 Allowed Pre-proline 0 CA--C 1.545 0.752 0 CA-C-O 119.039 -0.505 . . . . 0.0 111.939 -179.283 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -73.53 175.72 10.28 Favored 'Trans proline' 0 C--N 1.374 1.893 0 C-N-CA 122.097 1.865 . . . . 0.0 112.006 179.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.35 64.94 1.56 Allowed 'Trans proline' 0 C--N 1.377 2.064 0 C-N-CA 122.347 2.031 . . . . 0.0 112.792 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 38.5 mt -127.6 161.84 27.89 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.741 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.2 t -112.57 149.74 32.31 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.076 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.4 t -94.14 109.05 20.86 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.555 179.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.6 mt -128.02 130.99 23.56 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.251 -179.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -73.44 -38.82 1.64 Allowed 'Cis proline' 0 C--N 1.374 1.878 0 C-N-CA 124.686 -0.964 . . . . 0.0 113.56 -0.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.37 42.05 10.88 Favored Glycine 0 C--N 1.344 1.009 0 O-C-N 123.379 0.424 . . . . 0.0 113.035 -179.584 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.07 80.68 16.75 Favored Pre-proline 0 CA--C 1.547 0.841 0 C-N-CA 122.194 0.198 . . . . 0.0 111.352 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -84.81 -32.77 2.73 Favored 'Cis proline' 0 C--N 1.372 1.804 0 C-N-CA 125.365 -0.681 . . . . 0.0 112.889 -0.359 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 83.2 m-85 -105.86 156.49 18.29 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.107 -179.173 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.512 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -154.31 -150.95 5.64 Favored Glycine 0 C--N 1.338 0.672 0 CA-C-N 115.883 -0.599 . . . . 0.0 112.452 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.476 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.8 mm -129.25 146.99 33.39 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.503 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.1 m -84.64 108.62 17.47 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.204 179.237 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.476 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.7 m-85 -106.1 158.83 16.53 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.874 -179.002 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tp -93.63 123.89 45.89 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.517 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.623 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.3 pt . . . . . 0 C--O 1.248 0.984 0 CA-C-O 118.115 -0.945 . . . . 0.0 111.279 179.987 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.348 0 CA-C-O 119.554 -0.26 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -83.71 -178.88 3.82 Favored 'Trans proline' 0 C--N 1.372 1.814 0 C-N-CA 122.496 2.131 . . . . 0.0 114.038 -179.088 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . 0.502 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.04 -152.28 6.48 Favored Glycine 0 C--N 1.341 0.86 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.031 179.608 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.1 tt0 -73.45 113.75 10.9 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 120.932 0.396 . . . . 0.0 111.715 -179.66 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.45 32.62 10.14 Favored Glycine 0 C--N 1.34 0.8 0 CA-C-N 115.46 -0.791 . . . . 0.0 112.846 -179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.66 162.07 27.4 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-O 120.58 0.228 . . . . 0.0 111.314 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.492 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.8 tt0 -79.96 127.13 31.9 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.804 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.71 150.67 50.92 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.619 -179.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.449 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.1 t70 -110.36 154.9 22.88 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.811 178.834 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.5 m -102.79 4.27 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-N 116.186 -0.461 . . . . 0.0 112.132 -179.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.449 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -100.93 -48.51 4.42 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 112.084 0.401 . . . . 0.0 112.084 -179.052 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 39.9 p90 -147.78 1.8 0.69 Allowed 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 113.42 0.896 . . . . 0.0 113.42 -178.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.05 63.29 69.82 Favored Pre-proline 0 CA--C 1.55 0.97 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.344 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.48 175.06 11.55 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.381 2.054 . . . . 0.0 112.617 179.281 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.4 m -79.68 140.81 36.9 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.484 179.733 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.98 -52.56 1.03 Allowed Pre-proline 0 CA--C 1.543 0.7 0 CA-C-O 119.087 -0.483 . . . . 0.0 111.993 -179.368 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -73.85 175.94 10.11 Favored 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 122.071 1.848 . . . . 0.0 112.045 179.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -69.34 64.83 1.55 Allowed 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 122.384 2.056 . . . . 0.0 112.759 179.547 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 41.8 mt -127.28 161.59 28.23 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.818 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.9 t -112.81 149.26 33.3 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.995 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.2 t -93.78 108.76 20.48 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.551 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.425 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.4 mt -127.95 130.93 23.57 Favored Pre-proline 0 CA--C 1.541 0.626 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.226 -179.748 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -73.34 -39.02 1.56 Allowed 'Cis proline' 0 C--N 1.374 1.91 0 C-N-CA 124.705 -0.956 . . . . 0.0 113.468 -0.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.64 39.64 13.99 Favored Glycine 0 C--N 1.344 0.981 0 O-C-N 123.455 0.472 . . . . 0.0 113.075 -179.682 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -140.89 82.99 14.64 Favored Pre-proline 0 CA--C 1.549 0.925 0 C-N-CA 122.188 0.195 . . . . 0.0 110.956 -179.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -83.92 -33.75 2.53 Favored 'Cis proline' 0 C--N 1.372 1.777 0 CA-C-N 119.101 0.715 . . . . 0.0 112.877 -0.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.7 m-85 -106.6 156.25 18.79 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.025 -179.408 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.492 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.85 -152.74 6.08 Favored Glycine 0 C--N 1.338 0.67 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.538 179.741 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.506 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.2 mm -128.69 147.0 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -179.838 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.502 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 78.8 m -84.06 107.97 16.72 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.183 179.175 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.506 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.4 m-85 -106.17 159.3 16.19 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.805 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -93.02 122.81 44.81 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.681 179.552 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.458 ' O ' HD13 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.363 -0.827 . . . . 0.0 111.449 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.361 0 CA-C-O 119.522 -0.275 . . . . 0.0 111.098 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -83.7 -178.86 3.82 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.47 2.114 . . . . 0.0 113.967 -179.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . 0.502 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.98 -152.23 6.48 Favored Glycine 0 C--N 1.343 0.945 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.031 179.53 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -73.53 113.84 11.09 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-O 120.833 0.349 . . . . 0.0 111.581 -179.504 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.33 32.69 10.15 Favored Glycine 0 C--N 1.339 0.747 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.793 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.62 162.22 27.0 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 120.564 0.221 . . . . 0.0 111.275 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.496 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -79.93 127.26 32.05 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.828 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.6 p -129.92 150.65 51.11 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.592 -179.278 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.446 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.64 154.71 23.42 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.773 178.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.8 m -102.65 4.18 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-N 116.146 -0.479 . . . . 0.0 112.139 -179.56 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.446 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.6 mm-40 -100.48 -48.62 4.49 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -179.088 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.4 p90 -148.02 1.89 0.67 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 113.379 0.881 . . . . 0.0 113.379 -178.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.09 63.39 70.08 Favored Pre-proline 0 CA--C 1.551 0.993 0 N-CA-C 111.723 0.268 . . . . 0.0 111.723 -179.236 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.51 175.2 11.37 Favored 'Trans proline' 0 C--N 1.37 1.683 0 C-N-CA 122.391 2.061 . . . . 0.0 112.644 179.287 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.5 m -79.75 140.74 36.82 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.559 179.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.89 -52.59 1.04 Allowed Pre-proline 0 N--CA 1.474 0.768 0 CA-C-O 119.057 -0.497 . . . . 0.0 111.975 -179.296 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -73.89 175.94 10.13 Favored 'Trans proline' 0 C--N 1.376 1.995 0 C-N-CA 122.148 1.899 . . . . 0.0 111.941 179.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.3 64.91 1.53 Allowed 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 122.322 2.014 . . . . 0.0 112.732 179.501 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 40.3 mt -127.43 161.58 28.36 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.744 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.409 ' HG1' ' N ' ' A' ' 21' ' ' CYS . 5.9 t -112.73 149.41 32.98 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.026 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.409 ' N ' ' HG1' ' A' ' 20' ' ' THR . 3.3 t -93.9 108.85 20.6 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.539 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.401 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -127.99 130.81 23.58 Favored Pre-proline 0 CA--C 1.541 0.626 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.264 -179.749 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -73.29 -39.02 1.56 Allowed 'Cis proline' 0 C--N 1.374 1.92 0 C-N-CA 124.692 -0.962 . . . . 0.0 113.439 -0.306 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.86 39.83 12.98 Favored Glycine 0 C--N 1.343 0.971 0 O-C-N 123.43 0.456 . . . . 0.0 113.073 -179.68 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.32 83.09 13.86 Favored Pre-proline 0 CA--C 1.547 0.861 0 C-N-CA 122.222 0.209 . . . . 0.0 111.299 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.91 -33.45 2.65 Favored 'Cis proline' 0 C--N 1.372 1.807 0 C-N-CA 125.345 -0.689 . . . . 0.0 112.755 -0.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.1 m-85 -106.89 156.51 18.62 Favored 'General case' 0 N--CA 1.465 0.313 0 O-C-N 123.593 0.558 . . . . 0.0 111.035 -179.424 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.05 -152.27 5.95 Favored Glycine 0 C--N 1.339 0.697 0 CA-C-N 115.866 -0.606 . . . . 0.0 112.603 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.503 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.3 mm -129.06 147.15 33.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.502 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 77.8 m -84.36 107.78 16.83 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.108 179.264 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.503 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -105.98 159.24 16.2 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.782 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.92 122.91 44.79 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.669 179.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.459 ' O ' HD13 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 1.014 0 CA-C-O 118.3 -0.857 . . . . 0.0 111.351 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.485 1.319 0 CA-C-O 119.579 -0.248 . . . . 0.0 111.081 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -83.87 -178.91 3.78 Favored 'Trans proline' 0 C--N 1.371 1.747 0 C-N-CA 122.536 2.157 . . . . 0.0 113.941 -179.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . 0.504 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.37 -152.36 6.45 Favored Glycine 0 C--N 1.341 0.857 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.077 179.601 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -73.17 113.85 10.69 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-O 121.015 0.435 . . . . 0.0 111.629 -179.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.22 32.46 10.54 Favored Glycine 0 C--N 1.342 0.913 0 CA-C-N 115.345 -0.843 . . . . 0.0 112.778 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.52 162.28 26.79 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-O 120.508 0.194 . . . . 0.0 111.327 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.493 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.1 127.28 32.13 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.864 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.76 150.69 50.96 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.631 -179.193 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.447 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.2 t70 -110.5 154.69 23.31 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.775 178.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.6 m -102.98 3.95 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.191 -179.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.447 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.6 mm-40 -99.61 -48.79 4.62 Favored 'General case' 0 C--O 1.234 0.288 0 N-CA-C 111.936 0.346 . . . . 0.0 111.936 -179.053 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.1 p90 -148.63 1.97 0.61 Allowed 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -178.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -131.12 63.83 71.56 Favored Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 111.748 0.277 . . . . 0.0 111.748 -179.37 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -74.66 175.93 10.44 Favored 'Trans proline' 0 C--N 1.37 1.705 0 C-N-CA 122.459 2.106 . . . . 0.0 112.574 179.283 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.8 m -79.62 140.92 36.96 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 123.257 0.348 . . . . 0.0 110.62 179.626 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.96 -52.57 1.03 Allowed Pre-proline 0 CA--C 1.544 0.731 0 CA-C-O 119.01 -0.519 . . . . 0.0 111.954 -179.286 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -73.94 175.97 10.1 Favored 'Trans proline' 0 C--N 1.375 1.955 0 C-N-CA 122.132 1.888 . . . . 0.0 112.002 179.27 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.35 64.92 1.56 Allowed 'Trans proline' 0 C--N 1.379 2.16 0 C-N-CA 122.402 2.068 . . . . 0.0 112.71 179.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 40.5 mt -127.63 161.3 29.17 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.799 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.8 t -112.36 149.59 32.25 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.06 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -93.93 108.89 20.64 Favored 'General case' 0 C--O 1.237 0.446 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.512 179.622 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.403 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -128.11 130.8 23.56 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.252 -179.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -73.45 -38.91 1.6 Allowed 'Cis proline' 0 C--N 1.374 1.9 0 C-N-CA 124.562 -1.016 . . . . 0.0 113.507 -0.288 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.93 39.84 12.72 Favored Glycine 0 C--N 1.344 1.009 0 O-C-N 123.437 0.46 . . . . 0.0 113.032 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -141.17 83.12 14.05 Favored Pre-proline 0 CA--C 1.547 0.84 0 CA-C-N 116.646 0.223 . . . . 0.0 111.271 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.77 -33.49 2.67 Favored 'Cis proline' 0 C--N 1.371 1.761 0 CA-C-N 119.062 0.701 . . . . 0.0 112.792 -0.272 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.8 m-85 -106.82 156.51 18.59 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.069 -179.412 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.85 -152.82 6.1 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.529 179.775 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.498 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.2 mm -128.56 147.18 33.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 -179.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.504 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.9 m -84.35 107.98 16.93 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.179 179.229 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.498 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -106.26 159.15 16.33 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.767 -179.031 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.76 122.81 44.55 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.523 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.622 179.65 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.46 ' O ' HD11 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.248 1.017 0 CA-C-O 118.442 -0.789 . . . . 0.0 111.405 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.361 0 CA-C-O 119.546 -0.264 . . . . 0.0 111.106 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_endo -83.77 -178.93 3.82 Favored 'Trans proline' 0 C--N 1.372 1.764 0 C-N-CA 122.502 2.134 . . . . 0.0 114.091 -179.197 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . 0.503 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.73 -152.34 6.55 Favored Glycine 0 C--N 1.342 0.872 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.989 179.505 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.79 114.0 11.57 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-O 120.924 0.392 . . . . 0.0 111.572 -179.43 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.72 32.21 10.39 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-N 115.456 -0.793 . . . . 0.0 112.759 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -127.61 162.26 26.92 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.705 0.288 . . . . 0.0 111.319 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.486 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -79.94 127.11 31.87 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.798 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.62 150.51 50.92 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.684 -179.34 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.451 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.21 154.65 23.08 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.847 178.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.6 m -102.7 4.1 10.63 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.203 -179.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.451 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -100.37 -48.51 4.55 Favored 'General case' 0 C--O 1.235 0.336 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.079 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.3 p90 -148.22 1.83 0.64 Allowed 'General case' 0 N--CA 1.476 0.862 0 N-CA-C 113.23 0.826 . . . . 0.0 113.23 -178.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.07 63.55 70.69 Favored Pre-proline 0 CA--C 1.549 0.928 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 -179.317 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.6 175.44 11.08 Favored 'Trans proline' 0 C--N 1.37 1.662 0 C-N-CA 122.434 2.089 . . . . 0.0 112.626 179.244 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.6 m -79.74 140.76 36.83 Favored 'General case' 0 CA--C 1.534 0.363 0 O-C-N 123.255 0.347 . . . . 0.0 110.541 179.69 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.91 -52.67 1.03 Allowed Pre-proline 0 CA--C 1.544 0.721 0 CA-C-O 119.017 -0.516 . . . . 0.0 112.007 -179.291 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -73.78 175.93 10.1 Favored 'Trans proline' 0 C--N 1.374 1.893 0 C-N-CA 122.118 1.879 . . . . 0.0 112.013 179.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.39 64.95 1.58 Allowed 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 122.347 2.031 . . . . 0.0 112.678 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 39.9 mt -127.49 161.39 28.87 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.751 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.8 t -112.51 149.42 32.68 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.89 -0.596 . . . . 0.0 111.081 179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -93.88 108.79 20.54 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.515 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.409 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.2 mt -128.03 130.84 23.57 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.279 -179.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.31 -39.02 1.55 Allowed 'Cis proline' 0 C--N 1.374 1.89 0 C-N-CA 124.651 -0.979 . . . . 0.0 113.427 -0.284 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.75 39.63 13.65 Favored Glycine 0 C--N 1.344 0.98 0 O-C-N 123.469 0.48 . . . . 0.0 113.15 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -141.26 83.26 13.8 Favored Pre-proline 0 CA--C 1.546 0.799 0 C-N-CA 122.169 0.187 . . . . 0.0 111.302 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -83.68 -33.54 2.67 Favored 'Cis proline' 0 C--N 1.373 1.859 0 CA-C-N 119.05 0.697 . . . . 0.0 112.801 -0.271 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -106.71 156.24 18.84 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.018 -179.429 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.486 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.63 -153.35 6.27 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 115.868 -0.606 . . . . 0.0 112.597 179.715 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.501 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.5 mm -128.38 147.08 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.503 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.6 m -84.33 107.88 16.86 Favored 'General case' 0 C--O 1.238 0.48 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.221 179.157 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.501 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -106.02 159.08 16.33 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.767 -178.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.91 122.99 44.84 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.662 179.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.459 HD13 ' OXT' ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.132 -0.937 . . . . 0.0 111.41 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.7 p . . . . . 0 N--CA 1.487 1.417 0 CA-C-O 119.66 -0.21 . . . . 0.0 111.102 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.433 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 91.9 Cg_endo -79.27 -178.87 4.93 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 122.586 2.191 . . . . 0.0 113.785 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -139.77 -144.69 4.57 Favored Glycine 0 C--N 1.339 0.713 0 CA-C-N 115.369 -0.832 . . . . 0.0 111.871 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -84.37 109.88 18.18 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 120.904 0.383 . . . . 0.0 110.81 179.478 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.15 36.88 6.46 Favored Glycine 0 C--N 1.34 0.76 0 CA-C-N 115.465 -0.789 . . . . 0.0 112.733 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.446 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 42.5 mt-10 -133.25 167.13 20.93 Favored 'General case' 0 N--CA 1.467 0.396 0 O-C-N 123.622 0.248 . . . . 0.0 110.909 -179.728 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.518 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.3 tt0 -80.32 124.54 28.94 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.637 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 20.6 p -127.64 143.57 51.15 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.494 -179.267 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.407 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 10.2 t70 -113.8 156.67 23.45 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.696 -0.683 . . . . 0.0 109.919 179.126 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 16.0 m -103.74 7.84 9.78 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 CA-C-N 116.02 -0.536 . . . . 0.0 112.078 -179.563 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.407 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.4 mt-10 -110.16 -49.34 3.08 Favored 'General case' 0 CA--C 1.533 0.298 0 N-CA-C 112.308 0.485 . . . . 0.0 112.308 -178.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 37.3 p90 -141.2 4.16 1.81 Allowed 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 113.236 0.828 . . . . 0.0 113.236 -178.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -132.29 65.73 75.62 Favored Pre-proline 0 CA--C 1.546 0.795 0 CA-C-O 120.525 0.203 . . . . 0.0 111.126 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.433 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 50.4 Cg_endo -73.85 161.98 40.34 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.451 2.1 . . . . 0.0 112.81 179.509 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 91.1 m -79.88 140.85 36.59 Favored 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.548 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -83.81 -52.4 0.58 Allowed Pre-proline 0 CA--C 1.544 0.742 0 CA-C-O 118.906 -0.569 . . . . 0.0 112.265 -179.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -75.55 172.89 15.45 Favored 'Trans proline' 0 C--N 1.375 1.953 0 C-N-CA 122.15 1.9 . . . . 0.0 112.48 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_exo -71.51 66.05 2.93 Favored 'Trans proline' 0 C--N 1.377 2.051 0 C-N-CA 122.409 2.072 . . . . 0.0 112.464 179.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.419 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 58.5 mt -125.43 166.7 16.12 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.818 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.581 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 9.8 t -115.05 143.96 44.37 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.102 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 6.1 t -92.27 109.3 20.68 Favored 'General case' 0 C--O 1.237 0.429 0 O-C-N 123.479 0.487 . . . . 0.0 110.725 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 6.8 mt -126.37 130.9 23.8 Favored Pre-proline 0 CA--C 1.542 0.637 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.991 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -74.18 -37.58 2.16 Favored 'Cis proline' 0 C--N 1.374 1.874 0 C-N-CA 124.565 -1.014 . . . . 0.0 113.567 -0.143 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.8 36.31 19.52 Favored Glycine 0 C--N 1.345 1.043 0 O-C-N 123.343 0.402 . . . . 0.0 113.029 -179.634 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -143.8 82.5 11.15 Favored Pre-proline 0 CA--C 1.55 0.945 0 CA-C-N 116.666 0.233 . . . . 0.0 111.089 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -85.99 -35.52 1.46 Allowed 'Cis proline' 0 C--N 1.373 1.843 0 CA-C-N 119.171 0.74 . . . . 0.0 112.834 -0.421 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 64.5 m-85 -109.85 158.81 17.79 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.991 -179.184 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -162.49 -152.68 6.85 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-N 115.886 -0.597 . . . . 0.0 112.356 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.446 ' HA ' ' O ' ' A' ' 6' ' ' GLU . 16.0 mm -126.71 144.78 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 179.711 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.581 ' HA ' ' O ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -91.44 117.82 30.02 Favored 'General case' 0 C--O 1.235 0.337 0 O-C-N 123.505 0.503 . . . . 0.0 111.13 -179.977 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -109.04 167.35 10.16 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.731 -178.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.6 tp -95.04 123.62 47.23 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.553 179.526 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.471 ' O ' HD13 ' A' ' 33' ' ' ILE . 1.4 pp . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.371 -0.823 . . . . 0.0 111.319 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.487 1.382 0 CA-C-O 119.658 -0.211 . . . . 0.0 111.098 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -83.37 -179.11 4.07 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.481 2.121 . . . . 0.0 114.087 -179.137 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . 0.483 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.98 -152.47 6.54 Favored Glycine 0 C--N 1.341 0.843 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.771 179.48 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.5 tt0 -73.34 111.85 8.85 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-O 120.83 0.348 . . . . 0.0 111.415 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.79 30.94 10.63 Favored Glycine 0 C--N 1.341 0.817 0 CA-C-N 115.485 -0.779 . . . . 0.0 112.715 -179.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.3 mt-10 -126.86 163.76 22.9 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-O 120.599 0.238 . . . . 0.0 111.21 -179.704 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.2 tt0 -79.97 128.67 33.75 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.067 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.481 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.4 p -127.11 142.61 51.47 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.627 -179.557 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -104.42 150.12 24.82 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.707 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.49 HG21 ' O ' ' A' ' 26' ' ' PRO . 9.0 m -101.61 5.38 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.904 -179.885 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -99.2 -47.52 5.17 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.929 -179.204 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -151.76 1.41 0.36 Allowed 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -178.855 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -131.65 64.44 72.9 Favored Pre-proline 0 CA--C 1.549 0.919 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -179.267 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -73.5 178.25 6.93 Favored 'Trans proline' 0 C--N 1.37 1.7 0 C-N-CA 122.538 2.159 . . . . 0.0 112.473 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.0 m -79.51 138.68 37.61 Favored 'General case' 0 N--CA 1.467 0.413 0 O-C-N 123.216 0.322 . . . . 0.0 110.706 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.02 -52.57 1.02 Allowed Pre-proline 0 CA--C 1.544 0.748 0 CA-C-O 118.983 -0.532 . . . . 0.0 112.089 -179.388 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -72.76 175.9 9.66 Favored 'Trans proline' 0 C--N 1.375 1.944 0 C-N-CA 122.163 1.908 . . . . 0.0 112.06 179.347 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -69.55 64.87 1.68 Allowed 'Trans proline' 0 C--N 1.378 2.124 0 C-N-CA 122.373 2.049 . . . . 0.0 112.747 179.399 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 32.9 mt -129.09 159.92 34.45 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.721 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.421 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -111.09 152.76 26.57 Favored 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.192 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.7 t -96.39 106.47 18.71 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.256 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.445 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.3 mt -125.89 131.51 24.02 Favored Pre-proline 0 CA--C 1.542 0.67 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.478 -179.532 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -71.26 -39.34 1.45 Allowed 'Cis proline' 0 C--N 1.375 1.952 0 C-N-CA 124.649 -0.98 . . . . 0.0 113.389 -0.117 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.59 31.15 46.3 Favored Glycine 0 C--N 1.343 0.947 0 O-C-N 123.408 0.442 . . . . 0.0 113.266 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -136.97 85.64 22.45 Favored Pre-proline 0 CA--C 1.545 0.781 0 C-N-CA 122.198 0.199 . . . . 0.0 111.096 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.49 ' O ' HG21 ' A' ' 10' ' ' VAL . 2.2 Cg_endo -83.13 -34.5 2.4 Favored 'Cis proline' 0 C--N 1.372 1.811 0 C-N-CA 125.246 -0.731 . . . . 0.0 112.94 -0.217 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.3 m-85 -98.66 153.94 18.33 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.02 -179.218 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.14 -171.5 18.58 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 116.072 -0.513 . . . . 0.0 113.06 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.473 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 42.5 mm -122.42 146.0 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.483 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.3 m -81.57 107.79 14.62 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.543 179.492 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.473 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.6 m-85 -108.29 158.6 17.33 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.612 -179.389 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 tp -92.1 123.32 44.17 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.662 179.618 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.446 ' OXT' HD11 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.124 -0.941 . . . . 0.0 111.402 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 119.546 -0.264 . . . . 0.0 111.116 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -83.55 -179.04 3.96 Favored 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.479 2.12 . . . . 0.0 114.029 -179.143 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . 0.521 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.68 -152.91 6.52 Favored Glycine 0 C--N 1.342 0.902 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.96 179.623 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -72.18 113.13 8.88 Favored 'General case' 0 N--CA 1.472 0.663 0 CA-C-O 120.941 0.4 . . . . 0.0 111.539 -179.44 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.7 33.32 10.15 Favored Glycine 0 C--N 1.342 0.873 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.761 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.435 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 8.6 mm-40 -127.65 163.55 23.99 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 120.607 0.241 . . . . 0.0 111.266 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.519 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.6 tt0 -80.15 127.93 32.91 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.837 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.422 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 8.6 p -130.86 148.77 52.67 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.75 -179.319 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.443 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.2 t70 -110.83 155.59 22.35 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.816 178.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.0 m -103.23 3.6 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 112.244 0.461 . . . . 0.0 112.244 -179.49 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.443 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -98.89 -48.79 4.78 Favored 'General case' 0 C--O 1.235 0.339 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -179.027 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -148.76 1.99 0.59 Allowed 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -178.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -131.02 63.7 71.26 Favored Pre-proline 0 CA--C 1.55 0.95 0 N-CA-C 111.757 0.28 . . . . 0.0 111.757 -179.371 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -74.81 175.66 10.88 Favored 'Trans proline' 0 C--N 1.37 1.708 0 C-N-CA 122.467 2.111 . . . . 0.0 112.571 179.133 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 38.4 m -79.74 140.1 37.07 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 116.55 -0.295 . . . . 0.0 110.561 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.98 -52.51 1.03 Allowed Pre-proline 0 CA--C 1.544 0.734 0 CA-C-O 119.082 -0.485 . . . . 0.0 112.037 -179.258 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -73.52 175.5 10.57 Favored 'Trans proline' 0 C--N 1.376 2.004 0 C-N-CA 122.087 1.858 . . . . 0.0 112.115 179.248 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -69.47 64.93 1.64 Allowed 'Trans proline' 0 C--N 1.377 2.072 0 C-N-CA 122.386 2.057 . . . . 0.0 112.707 179.465 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 36.7 mt -127.83 161.95 27.81 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.761 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.0 t -111.71 150.39 30.27 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.213 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 4.0 t -95.26 108.6 20.76 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.553 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.4 mt -127.66 130.99 23.6 Favored Pre-proline 0 CA--C 1.541 0.616 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.195 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.593 ' HB2' ' OD2' ' A' ' 25' ' ' ASP . 55.6 Cg_endo -72.48 -39.44 1.44 Allowed 'Cis proline' 0 C--N 1.373 1.854 0 C-N-CA 124.668 -0.972 . . . . 0.0 113.476 -0.272 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.56 38.82 11.55 Favored Glycine 0 C--N 1.344 0.998 0 O-C-N 123.483 0.49 . . . . 0.0 113.386 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.593 ' OD2' ' HB2' ' A' ' 23' ' ' PRO . 2.0 p30 -144.9 85.02 8.51 Favored Pre-proline 0 CA--C 1.55 0.952 0 CA-C-N 116.66 0.23 . . . . 0.0 111.473 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -83.88 -33.65 2.58 Favored 'Cis proline' 0 C--N 1.372 1.789 0 CA-C-N 118.985 0.673 . . . . 0.0 112.896 -0.466 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -109.69 156.72 19.9 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.977 -179.314 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.519 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.84 -151.17 5.67 Favored Glycine 0 C--N 1.338 0.661 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.507 179.78 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.478 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.7 mm -129.26 147.22 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.521 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 79.1 m -84.35 107.24 16.52 Favored 'General case' 0 CA--C 1.537 0.443 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.286 179.25 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.478 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.7 m-85 -105.14 157.84 16.99 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.544 -179.375 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 tt -94.23 124.42 46.7 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.704 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.453 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.247 0.95 0 CA-C-O 118.357 -0.83 . . . . 0.0 111.408 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.373 0 CA-C-O 119.67 -0.205 . . . . 0.0 111.09 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_endo -83.28 -179.13 4.11 Favored 'Trans proline' 0 C--N 1.373 1.822 0 C-N-CA 122.589 2.193 . . . . 0.0 114.054 -179.057 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . 0.484 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.0 -152.26 6.48 Favored Glycine 0 C--N 1.342 0.886 0 CA-C-N 115.41 -0.814 . . . . 0.0 111.777 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.5 tt0 -73.49 111.7 8.87 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 120.835 0.35 . . . . 0.0 111.452 -179.656 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.91 31.07 10.3 Favored Glycine 0 C--N 1.341 0.816 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.651 -179.752 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.1 mt-10 -126.94 163.85 22.75 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-O 120.534 0.207 . . . . 0.0 111.261 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -79.95 128.63 33.7 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.04 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.481 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.5 p -127.13 142.29 51.55 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.59 -179.549 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -104.29 150.03 24.81 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.737 179.407 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.493 HG21 ' O ' ' A' ' 26' ' ' PRO . 9.6 m -101.46 5.25 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.906 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -99.02 -47.45 5.23 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.928 -179.202 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -151.86 1.37 0.36 Allowed 'General case' 0 N--CA 1.478 0.947 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 -178.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -131.55 64.31 72.57 Favored Pre-proline 0 CA--C 1.548 0.89 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.273 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.46 178.24 6.93 Favored 'Trans proline' 0 C--N 1.371 1.731 0 C-N-CA 122.544 2.163 . . . . 0.0 112.484 179.034 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 49.3 m -79.49 138.75 37.66 Favored 'General case' 0 N--CA 1.467 0.42 0 O-C-N 123.224 0.328 . . . . 0.0 110.765 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.22 -52.58 0.98 Allowed Pre-proline 0 CA--C 1.544 0.736 0 CA-C-O 119.018 -0.515 . . . . 0.0 112.057 -179.301 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_endo -72.7 175.88 9.64 Favored 'Trans proline' 0 C--N 1.375 1.972 0 C-N-CA 122.16 1.906 . . . . 0.0 112.06 179.297 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.59 65.0 1.7 Allowed 'Trans proline' 0 C--N 1.378 2.093 0 C-N-CA 122.381 2.054 . . . . 0.0 112.591 179.475 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 33.2 mt -129.28 159.96 34.49 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.579 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.422 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -110.98 152.68 26.53 Favored 'General case' 0 CA--C 1.536 0.408 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.101 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.8 t -96.33 106.43 18.65 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.366 179.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.445 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.5 mt -125.81 131.56 24.04 Favored Pre-proline 0 CA--C 1.543 0.684 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.396 -179.458 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -71.08 -39.45 1.42 Allowed 'Cis proline' 0 C--N 1.375 1.923 0 C-N-CA 124.683 -0.965 . . . . 0.0 113.402 -0.225 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.65 30.69 47.66 Favored Glycine 0 C--N 1.345 1.043 0 O-C-N 123.463 0.477 . . . . 0.0 113.391 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -136.79 85.8 23.14 Favored Pre-proline 0 CA--C 1.546 0.82 0 C-N-CA 122.259 0.224 . . . . 0.0 111.049 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.493 ' O ' HG21 ' A' ' 10' ' ' VAL . 2.2 Cg_endo -83.07 -34.58 2.37 Favored 'Cis proline' 0 C--N 1.371 1.756 0 C-N-CA 125.273 -0.719 . . . . 0.0 112.95 -0.269 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 -98.64 153.9 18.34 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.044 -179.246 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.2 -171.8 18.9 Favored Glycine 0 C--N 1.339 0.729 0 O-C-N 123.542 0.526 . . . . 0.0 113.079 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.474 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 42.4 mm -122.17 145.91 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.484 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.5 m -81.44 107.73 14.45 Favored 'General case' 0 CA--C 1.537 0.469 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.517 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.474 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.6 m-85 -108.21 158.65 17.26 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.356 -0.383 . . . . 0.0 111.652 -179.447 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 tp -92.29 123.56 44.45 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.558 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.547 179.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.445 HD13 ' OXT' ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 0.983 0 CA-C-O 118.278 -0.868 . . . . 0.0 111.384 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.488 1.446 0 CA-C-O 119.624 -0.227 . . . . 0.0 111.156 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.433 ' HG2' ' SG ' ' A' ' 30' ' ' CYS . 87.3 Cg_endo -81.94 -179.65 4.94 Favored 'Trans proline' 0 C--N 1.372 1.782 0 C-N-CA 122.652 2.235 . . . . 0.0 113.997 -179.067 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . 0.479 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.27 -151.37 6.39 Favored Glycine 0 C--N 1.34 0.769 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.699 179.429 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -75.6 110.33 9.91 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-O 120.931 0.396 . . . . 0.0 111.288 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.38 29.82 10.7 Favored Glycine 0 C--N 1.341 0.833 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.524 -179.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -124.25 167.97 13.58 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-O 120.561 0.219 . . . . 0.0 111.133 -179.67 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 -79.9 137.39 36.89 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.072 -179.674 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -126.74 157.04 40.16 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.492 -0.777 . . . . 0.0 111.274 -179.283 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -131.18 140.04 49.84 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.289 179.076 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.508 HG22 ' O ' ' A' ' 26' ' ' PRO . 11.7 m -95.76 7.37 7.18 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 O-C-N 123.202 0.314 . . . . 0.0 111.757 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -99.73 -46.6 5.36 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.772 -179.274 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.0 p90 -154.58 1.17 0.2 Allowed 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 -178.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -132.72 65.61 74.74 Favored Pre-proline 0 CA--C 1.547 0.844 0 CA-C-N 117.931 0.332 . . . . 0.0 111.884 -179.237 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -74.14 177.57 8.06 Favored 'Trans proline' 0 C--N 1.369 1.628 0 C-N-CA 122.574 2.182 . . . . 0.0 112.252 178.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 56.9 m -79.35 139.64 37.71 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 116.705 -0.225 . . . . 0.0 110.898 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.35 -53.7 0.56 Allowed Pre-proline 0 CA--C 1.545 0.75 0 CA-C-O 119.014 -0.517 . . . . 0.0 112.342 -179.073 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -71.66 175.32 9.72 Favored 'Trans proline' 0 C--N 1.375 1.971 0 C-N-CA 122.09 1.86 . . . . 0.0 112.265 179.667 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_exo -69.6 65.06 1.71 Allowed 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 122.369 2.046 . . . . 0.0 112.615 179.456 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 47.4 mt -126.65 161.13 28.8 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.722 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.0 t -109.58 151.51 26.72 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.227 -179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.7 t -96.39 107.56 19.96 Favored 'General case' 0 C--O 1.238 0.47 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.398 179.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.44 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 3.8 mt -126.75 129.5 24.04 Favored Pre-proline 0 CA--C 1.541 0.615 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.761 -179.729 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -71.48 -39.14 1.5 Allowed 'Cis proline' 0 C--N 1.374 1.881 0 C-N-CA 124.591 -1.004 . . . . 0.0 113.305 -0.577 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.01 29.76 40.64 Favored Glycine 0 C--N 1.344 0.995 0 CA-C-N 116.158 -0.473 . . . . 0.0 113.429 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -144.13 89.55 7.06 Favored Pre-proline 0 CA--C 1.546 0.811 0 CA-C-N 116.702 0.251 . . . . 0.0 111.219 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.508 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.5 Cg_endo -83.77 -35.58 1.87 Allowed 'Cis proline' 0 C--N 1.371 1.738 0 CA-C-N 119.198 0.749 . . . . 0.0 112.846 -0.291 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 44.0 m-85 -103.01 156.95 17.32 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.717 -179.331 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -156.43 -164.98 14.0 Favored Glycine 0 C--N 1.339 0.743 0 C-N-CA 120.956 -0.64 . . . . 0.0 113.216 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.453 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 43.4 mm -127.24 147.53 32.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.479 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 72.3 m -82.89 109.41 16.99 Favored 'General case' 0 CA--C 1.537 0.478 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.401 179.282 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.453 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.4 m-85 -109.03 158.42 17.75 Favored 'General case' 0 N--CA 1.467 0.391 0 N-CA-C 112.038 0.384 . . . . 0.0 112.038 -179.024 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.1 tp -93.46 124.6 45.95 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.616 179.675 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.446 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.25 1.128 0 CA-C-O 118.185 -0.912 . . . . 0.0 111.44 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.374 0 CA-C-O 119.649 -0.215 . . . . 0.0 111.104 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -83.48 -179.07 4.0 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.467 2.111 . . . . 0.0 114.123 -179.157 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . 0.484 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.82 -152.77 6.64 Favored Glycine 0 C--N 1.341 0.849 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.809 179.433 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.46 111.91 9.04 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-O 120.896 0.379 . . . . 0.0 111.469 -179.753 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.27 30.74 10.46 Favored Glycine 0 C--N 1.341 0.832 0 CA-C-N 115.418 -0.81 . . . . 0.0 112.593 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -127.01 163.69 23.16 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-O 120.608 0.242 . . . . 0.0 111.194 -179.693 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -79.96 128.56 33.62 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.969 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.478 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.3 p -127.05 143.18 51.35 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.555 -179.6 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -104.56 150.28 24.77 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.345 -0.843 . . . . 0.0 109.74 179.469 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.486 HG21 ' O ' ' A' ' 26' ' ' PRO . 9.1 m -101.82 5.12 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.844 -179.854 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -99.17 -47.41 5.21 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.904 -179.126 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -151.84 1.53 0.36 Allowed 'General case' 0 N--CA 1.477 0.886 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -178.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -131.7 64.46 72.89 Favored Pre-proline 0 CA--C 1.549 0.927 0 N-CA-C 111.803 0.298 . . . . 0.0 111.803 -179.262 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.63 178.36 6.84 Favored 'Trans proline' 0 C--N 1.369 1.612 0 C-N-CA 122.56 2.173 . . . . 0.0 112.456 179.066 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 48.3 m -79.55 138.91 37.64 Favored 'General case' 0 C--N 1.344 0.367 0 O-C-N 123.163 0.29 . . . . 0.0 110.792 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.03 -52.66 1.01 Allowed Pre-proline 0 CA--C 1.543 0.697 0 CA-C-O 118.999 -0.525 . . . . 0.0 112.103 -179.319 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -72.78 175.88 9.7 Favored 'Trans proline' 0 C--N 1.375 1.964 0 C-N-CA 122.126 1.884 . . . . 0.0 112.036 179.337 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.44 64.82 1.62 Allowed 'Trans proline' 0 C--N 1.379 2.149 0 C-N-CA 122.38 2.053 . . . . 0.0 112.693 179.47 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 33.0 mt -129.11 159.96 34.34 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.698 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.425 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -111.22 152.88 26.6 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.149 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 t -96.37 106.75 19.03 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.298 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.447 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.5 mt -126.15 131.66 24.04 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.418 -179.538 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -71.12 -39.53 1.4 Allowed 'Cis proline' 0 C--N 1.374 1.895 0 C-N-CA 124.676 -0.969 . . . . 0.0 113.391 -0.326 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.67 31.54 44.52 Favored Glycine 0 C--N 1.342 0.9 0 O-C-N 123.49 0.494 . . . . 0.0 113.393 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -136.82 85.38 23.88 Favored Pre-proline 0 CA--C 1.545 0.783 0 C-N-CA 122.168 0.187 . . . . 0.0 111.072 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.486 ' O ' HG21 ' A' ' 10' ' ' VAL . 2.1 Cg_endo -83.3 -34.37 2.41 Favored 'Cis proline' 0 C--N 1.372 1.767 0 C-N-CA 125.17 -0.763 . . . . 0.0 112.993 -0.217 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 -98.56 153.9 18.31 Favored 'General case' 0 N--CA 1.466 0.369 0 O-C-N 123.586 0.554 . . . . 0.0 110.996 -179.238 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.15 -171.33 18.41 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 116.035 -0.529 . . . . 0.0 113.004 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.477 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 41.8 mm -122.38 146.16 28.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.484 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.5 m -81.7 107.92 14.83 Favored 'General case' 0 CA--C 1.537 0.477 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.509 179.562 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.477 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.6 m-85 -108.5 158.94 17.09 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.53 -179.45 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tp -91.57 122.75 43.29 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.61 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.448 ' OXT' HD11 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.116 -0.945 . . . . 0.0 111.326 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.5 p . . . . . 0 N--CA 1.486 1.359 0 CA-C-O 119.628 -0.225 . . . . 0.0 111.149 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.531 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 86.9 Cg_endo -78.26 -172.57 1.54 Allowed 'Trans proline' 0 C--N 1.37 1.7 0 C-N-CA 122.673 2.248 . . . . 0.0 113.83 -179.346 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.2 -144.21 4.24 Favored Glycine 0 C--N 1.339 0.698 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.588 179.755 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 13.3 tt0 -86.47 109.62 19.2 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-O 120.881 0.372 . . . . 0.0 110.705 179.476 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.53 35.88 6.74 Favored Glycine 0 C--N 1.34 0.774 0 CA-C-N 115.571 -0.74 . . . . 0.0 112.749 -179.664 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -131.85 167.68 19.16 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 122.335 0.254 . . . . 0.0 110.831 -179.709 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -79.9 120.56 24.28 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.715 179.746 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 11.8 p -120.17 135.6 54.91 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.288 -179.343 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -104.02 156.15 18.09 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 115.483 -0.78 . . . . 0.0 109.691 179.649 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.423 HG21 ' O ' ' A' ' 26' ' ' PRO . 8.0 m -107.82 14.29 8.14 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.905 -179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -120.54 -45.11 2.43 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.112 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 38.1 p90 -141.28 2.34 1.67 Allowed 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -178.753 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . 0.531 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 2.0 t30 -135.97 68.21 63.85 Favored Pre-proline 0 CA--C 1.543 0.71 0 CA-C-O 120.524 0.202 . . . . 0.0 111.377 -179.644 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.47 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 50.5 Cg_endo -74.46 164.36 34.13 Favored 'Trans proline' 0 C--N 1.368 1.602 0 C-N-CA 122.614 2.209 . . . . 0.0 112.581 179.009 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 94.1 m -79.6 140.42 37.14 Favored 'General case' 0 N--CA 1.47 0.538 0 O-C-N 123.441 0.463 . . . . 0.0 111.681 -179.455 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 m -84.9 -52.54 0.5 Allowed Pre-proline 0 CA--C 1.545 0.751 0 O-C-N 123.63 0.581 . . . . 0.0 112.168 -179.634 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -75.02 172.8 15.66 Favored 'Trans proline' 0 C--N 1.376 2.014 0 C-N-CA 122.066 1.844 . . . . 0.0 112.408 179.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo -71.31 66.16 2.76 Favored 'Trans proline' 0 C--N 1.379 2.149 0 C-N-CA 122.357 2.038 . . . . 0.0 112.511 179.613 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.425 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 55.5 mt -124.52 168.1 13.55 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.817 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.563 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 8.5 t -118.73 140.99 49.04 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.337 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 6.3 t -90.99 104.25 16.86 Favored 'General case' 0 CA--C 1.536 0.442 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.541 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mt -120.84 131.58 24.43 Favored Pre-proline 0 CA--C 1.543 0.692 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.325 -179.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -72.52 -36.9 2.4 Favored 'Cis proline' 0 C--N 1.374 1.888 0 C-N-CA 124.542 -1.024 . . . . 0.0 113.257 -0.264 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.47 30.57 48.88 Favored Glycine 0 C--N 1.343 0.925 0 CA-C-N 116.171 -0.468 . . . . 0.0 113.297 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -142.24 86.33 10.2 Favored Pre-proline 0 CA--C 1.545 0.783 0 C-N-CA 122.287 0.235 . . . . 0.0 111.161 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.423 ' O ' HG21 ' A' ' 10' ' ' VAL . 1.7 Cg_endo -85.24 -35.59 1.59 Allowed 'Cis proline' 0 C--N 1.373 1.826 0 CA-C-N 119.055 0.698 . . . . 0.0 112.987 -0.377 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 23.6 m-85 -104.45 154.52 19.77 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.906 -179.056 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -161.76 -172.83 29.66 Favored Glycine 0 C--N 1.34 0.761 0 CA-C-N 116.015 -0.538 . . . . 0.0 113.139 179.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 27.2 mm -116.87 145.2 22.94 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 179.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.563 ' HA ' ' O ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -89.4 119.56 29.97 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.484 -179.864 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -111.87 167.01 10.7 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.487 -179.111 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -95.42 122.93 47.33 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.464 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.554 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.467 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.5 pp . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.418 -0.801 . . . . 0.0 111.352 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 31.6 p . . . . . 0 N--CA 1.486 1.35 0 CA-C-O 119.48 -0.295 . . . . 0.0 111.027 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -84.61 -177.33 2.85 Favored 'Trans proline' 0 C--N 1.37 1.661 0 C-N-CA 122.161 1.908 . . . . 0.0 113.088 179.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . 0.565 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -146.93 -157.89 7.57 Favored Glycine 0 C--N 1.337 0.613 0 CA-C-N 115.74 -0.663 . . . . 0.0 112.027 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -65.66 110.3 2.72 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 121.042 0.448 . . . . 0.0 111.737 -179.251 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.33 31.57 10.48 Favored Glycine 0 C--N 1.339 0.745 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.723 -179.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.41 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 36.7 mt-10 -126.3 159.98 31.64 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.606 0.241 . . . . 0.0 111.275 -179.686 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.489 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.7 tt0 -80.04 121.92 26.12 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.566 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.409 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 7.9 p -124.83 149.29 47.61 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 115.795 -0.638 . . . . 0.0 111.673 -179.169 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.443 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.1 t70 -109.11 155.35 21.09 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.898 179.14 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.3 m -103.0 3.42 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 -179.543 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.443 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.9 mm-40 -98.6 -48.6 4.92 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 111.939 0.348 . . . . 0.0 111.939 -179.037 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -149.15 1.56 0.55 Allowed 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 113.325 0.861 . . . . 0.0 113.325 -178.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -130.73 63.73 70.97 Favored Pre-proline 0 CA--C 1.55 0.965 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 -179.333 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -76.61 172.7 15.75 Favored 'Trans proline' 0 C--N 1.369 1.656 0 C-N-CA 122.438 2.092 . . . . 0.0 112.618 179.115 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.409 ' SG ' ' SG ' ' A' ' 8' ' ' CYS . 21.9 m -79.56 133.33 36.45 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.3 179.623 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.521 ' SG ' ' HD3' ' A' ' 17' ' ' PRO . 0.8 OUTLIER -79.55 -45.46 1.6 Allowed Pre-proline 0 N--CA 1.475 0.782 0 N-CA-C 112.859 0.689 . . . . 0.0 112.859 -179.279 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.521 ' HD3' ' SG ' ' A' ' 16' ' ' CYS . 56.7 Cg_endo -70.69 174.37 10.43 Favored 'Trans proline' 0 C--N 1.374 1.876 0 C-N-CA 121.863 1.709 . . . . 0.0 111.879 178.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 14.2 Cg_exo -70.0 65.71 1.93 Allowed 'Trans proline' 0 C--N 1.377 2.046 0 C-N-CA 122.274 1.983 . . . . 0.0 112.366 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 25.8 mt -133.43 162.38 32.01 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.27 -0.877 . . . . 0.0 110.901 -179.56 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.494 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.6 t -112.28 155.32 24.26 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.244 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -98.37 108.41 21.1 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.307 179.618 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.423 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.1 mt -128.15 130.86 23.55 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.376 -179.831 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.86 -39.3 1.48 Allowed 'Cis proline' 0 C--N 1.373 1.849 0 C-N-CA 124.624 -0.99 . . . . 0.0 113.533 -0.342 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.29 38.37 18.39 Favored Glycine 0 C--N 1.345 1.049 0 CA-C-N 116.216 -0.447 . . . . 0.0 113.079 -179.725 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -141.23 84.13 13.06 Favored Pre-proline 0 CA--C 1.547 0.847 0 C-N-CA 122.225 0.21 . . . . 0.0 111.338 -179.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -83.16 -34.14 2.54 Favored 'Cis proline' 0 C--N 1.373 1.828 0 CA-C-N 119.047 0.695 . . . . 0.0 112.763 -0.189 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -106.14 156.41 18.46 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.892 -179.35 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.1 -156.24 7.49 Favored Glycine 0 C--N 1.337 0.622 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.622 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.47 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 23.3 mm -127.4 147.88 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 N-CA-C 110.051 -0.351 . . . . 0.0 110.051 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.565 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 76.7 m -84.74 110.13 18.56 Favored 'General case' 0 CA--C 1.537 0.455 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.114 179.228 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.47 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.4 m-85 -107.38 159.77 16.14 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.899 -178.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.0 tp -93.57 124.1 45.9 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.536 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.6 179.551 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.4 pt . . . . . 0 C--O 1.25 1.119 0 CA-C-O 118.489 -0.767 . . . . 0.0 111.328 179.988 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.487 1.375 0 CA-C-O 119.616 -0.23 . . . . 0.0 111.179 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -83.44 -179.15 4.07 Favored 'Trans proline' 0 C--N 1.371 1.733 0 C-N-CA 122.497 2.131 . . . . 0.0 114.082 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . 0.484 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.84 -152.53 6.58 Favored Glycine 0 C--N 1.341 0.843 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.81 179.41 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.65 111.83 9.16 Favored 'General case' 0 N--CA 1.472 0.63 0 CA-C-O 120.878 0.371 . . . . 0.0 111.385 -179.661 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.21 30.93 10.22 Favored Glycine 0 C--N 1.341 0.828 0 CA-C-N 115.502 -0.772 . . . . 0.0 112.638 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.3 mt-10 -127.14 163.75 23.12 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-O 120.559 0.219 . . . . 0.0 111.212 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -79.95 128.48 33.52 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.971 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.479 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.3 p -127.02 142.9 51.43 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.515 -179.644 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -104.46 150.04 24.91 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.808 179.439 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.49 HG22 ' O ' ' A' ' 26' ' ' PRO . 9.4 m -101.68 5.92 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 O-C-N 123.397 0.436 . . . . 0.0 111.947 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.6 tt0 -100.04 -48.0 4.8 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.522 -179.105 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 36.7 p90 -151.11 1.54 0.41 Allowed 'General case' 0 N--CA 1.477 0.918 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -178.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -131.55 64.3 72.54 Favored Pre-proline 0 CA--C 1.55 0.972 0 N-CA-C 111.854 0.316 . . . . 0.0 111.854 -179.281 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -73.54 177.79 7.53 Favored 'Trans proline' 0 C--N 1.37 1.658 0 C-N-CA 122.525 2.15 . . . . 0.0 112.429 179.047 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 47.3 m -79.53 138.7 37.59 Favored 'General case' 0 N--CA 1.467 0.385 0 O-C-N 123.188 0.305 . . . . 0.0 110.807 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.01 -52.64 1.01 Allowed Pre-proline 0 N--CA 1.474 0.727 0 CA-C-O 119.025 -0.512 . . . . 0.0 111.983 -179.22 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -72.73 175.88 9.66 Favored 'Trans proline' 0 C--N 1.375 1.951 0 C-N-CA 122.166 1.91 . . . . 0.0 112.051 179.372 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.3 Cg_exo -69.6 65.01 1.71 Allowed 'Trans proline' 0 C--N 1.378 2.126 0 C-N-CA 122.375 2.05 . . . . 0.0 112.642 179.458 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 32.6 mt -129.2 159.96 34.42 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.687 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.421 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -111.33 152.71 26.95 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.107 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.7 t -96.39 106.72 19.0 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.232 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.446 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.4 mt -125.99 131.63 24.05 Favored Pre-proline 0 CA--C 1.542 0.67 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.391 -179.482 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -71.1 -39.43 1.42 Allowed 'Cis proline' 0 C--N 1.375 1.944 0 C-N-CA 124.717 -0.951 . . . . 0.0 113.446 -0.289 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.51 31.39 45.86 Favored Glycine 0 C--N 1.344 0.997 0 CA-C-N 116.136 -0.484 . . . . 0.0 113.321 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -136.9 85.45 23.29 Favored Pre-proline 0 CA--C 1.545 0.762 0 C-N-CA 122.234 0.214 . . . . 0.0 111.04 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.49 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.2 Cg_endo -83.22 -34.42 2.41 Favored 'Cis proline' 0 C--N 1.373 1.827 0 C-N-CA 125.237 -0.734 . . . . 0.0 112.978 -0.257 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -98.57 154.15 18.13 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.061 -179.257 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.43 -171.56 18.83 Favored Glycine 0 C--N 1.338 0.681 0 CA-C-N 116.11 -0.495 . . . . 0.0 113.01 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.475 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 41.8 mm -122.3 146.05 28.08 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.484 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.4 m -81.49 107.94 14.68 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.582 179.463 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.475 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.8 m-85 -108.48 158.82 17.2 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.554 -179.389 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tp -91.68 122.84 43.49 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.668 179.622 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.446 ' O ' HD13 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.247 0.93 0 CA-C-O 118.44 -0.79 . . . . 0.0 111.405 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 31.7 p . . . . . 0 N--CA 1.488 1.474 0 CA-C-O 119.486 -0.292 . . . . 0.0 110.892 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -84.73 -177.32 2.82 Favored 'Trans proline' 0 C--N 1.37 1.687 0 C-N-CA 122.079 1.853 . . . . 0.0 113.092 179.406 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . 0.568 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -147.27 -158.6 7.92 Favored Glycine 0 C--N 1.337 0.589 0 CA-C-N 115.723 -0.671 . . . . 0.0 111.947 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -64.79 110.0 2.25 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-O 120.979 0.419 . . . . 0.0 111.713 -179.218 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.29 31.97 10.1 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-N 115.331 -0.849 . . . . 0.0 112.713 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.43 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 36.9 mt-10 -126.65 160.48 30.6 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 120.548 0.213 . . . . 0.0 111.238 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.499 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.5 tt0 -79.98 122.01 26.2 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.585 179.682 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 8.5 p -125.49 149.75 48.0 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.637 -179.062 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -109.69 155.53 21.4 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 115.507 -0.769 . . . . 0.0 109.844 179.104 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.4 m -104.14 4.2 10.54 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.222 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -99.24 -48.67 4.74 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 116.637 -0.256 . . . . 0.0 111.654 -179.056 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 37.9 p90 -148.85 0.97 0.56 Allowed 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -179.056 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -130.87 63.56 70.59 Favored Pre-proline 0 CA--C 1.551 0.99 0 N-CA-C 111.816 0.302 . . . . 0.0 111.816 -179.32 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -76.27 173.5 14.38 Favored 'Trans proline' 0 C--N 1.369 1.638 0 C-N-CA 122.53 2.153 . . . . 0.0 112.594 179.203 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 8' ' ' CYS . 23.6 m -79.75 133.5 36.33 Favored 'General case' 0 N--CA 1.466 0.352 0 O-C-N 123.373 0.421 . . . . 0.0 110.252 179.556 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.526 ' SG ' ' HD3' ' A' ' 17' ' ' PRO . 0.8 OUTLIER -79.59 -45.4 1.59 Allowed Pre-proline 0 N--CA 1.476 0.836 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -179.271 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.526 ' HD3' ' SG ' ' A' ' 16' ' ' CYS . 56.9 Cg_endo -70.6 174.42 10.26 Favored 'Trans proline' 0 C--N 1.374 1.913 0 C-N-CA 121.928 1.752 . . . . 0.0 111.922 178.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_exo -70.04 65.66 1.96 Allowed 'Trans proline' 0 C--N 1.376 2.015 0 C-N-CA 122.266 1.977 . . . . 0.0 112.354 179.341 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 26.5 mt -133.5 162.43 31.91 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.84 -179.52 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.497 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.6 t -112.01 155.69 23.37 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.16 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 t -98.83 108.53 21.24 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.314 179.59 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.43 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -128.09 130.87 23.56 Favored Pre-proline 0 CA--C 1.542 0.637 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.323 -179.805 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -73.17 -39.06 1.54 Allowed 'Cis proline' 0 C--N 1.373 1.859 0 C-N-CA 124.62 -0.992 . . . . 0.0 113.523 -0.265 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.14 39.48 15.99 Favored Glycine 0 C--N 1.344 1.018 0 O-C-N 123.459 0.475 . . . . 0.0 113.138 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.55 83.56 13.13 Favored Pre-proline 0 CA--C 1.547 0.855 0 C-N-CA 122.132 0.173 . . . . 0.0 111.253 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -83.51 -33.43 2.75 Favored 'Cis proline' 0 C--N 1.372 1.794 0 CA-C-N 119.056 0.698 . . . . 0.0 112.812 -0.312 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -107.27 155.75 19.61 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.95 -179.404 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.499 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.59 -154.1 6.55 Favored Glycine 0 C--N 1.338 0.672 0 CA-C-N 115.876 -0.602 . . . . 0.0 112.574 179.767 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.469 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 22.6 mm -128.37 148.22 32.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.568 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 77.9 m -84.68 110.22 18.6 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.239 179.286 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.469 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.6 m-85 -107.73 160.54 15.64 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.876 -178.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 tp -92.39 122.87 44.23 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.638 179.621 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.456 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.378 -0.82 . . . . 0.0 111.465 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 32.1 p . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 119.412 -0.328 . . . . 0.0 110.945 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -84.75 -177.55 2.91 Favored 'Trans proline' 0 C--N 1.369 1.612 0 C-N-CA 122.014 1.809 . . . . 0.0 113.202 179.582 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . 0.58 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -146.92 -161.51 9.39 Favored Glycine 0 C--N 1.338 0.683 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.882 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -62.01 111.13 1.8 Allowed 'General case' 0 N--CA 1.474 0.765 0 CA-C-O 121.069 0.462 . . . . 0.0 111.938 -179.209 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.32 31.66 13.52 Favored Glycine 0 C--N 1.341 0.817 0 CA-C-N 115.242 -0.89 . . . . 0.0 112.718 -179.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . 0.508 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 36.2 mt-10 -125.46 161.48 27.02 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-O 120.551 0.215 . . . . 0.0 111.328 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.478 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.7 tt0 -79.91 120.93 24.8 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.521 179.726 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.9 p -125.16 150.03 47.32 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.627 -179.062 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.463 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 7.9 t70 -110.59 154.67 23.44 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.804 179.257 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.1 m -104.06 3.93 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 CA-C-N 116.125 -0.488 . . . . 0.0 112.178 -179.589 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.463 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.3 mt-10 -98.39 -47.93 5.23 Favored 'General case' 0 C--O 1.234 0.24 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -179.163 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -150.07 0.39 0.46 Allowed 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 113.449 0.907 . . . . 0.0 113.449 -179.025 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -131.01 63.81 71.68 Favored Pre-proline 0 CA--C 1.549 0.928 0 N-CA-C 111.874 0.324 . . . . 0.0 111.874 -179.299 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -76.27 174.49 12.74 Favored 'Trans proline' 0 C--N 1.369 1.646 0 C-N-CA 122.513 2.142 . . . . 0.0 112.618 179.299 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 31.0 m -79.62 133.12 36.4 Favored 'General case' 0 N--CA 1.468 0.438 0 C-N-CA 122.574 0.35 . . . . 0.0 110.303 179.587 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.525 ' SG ' ' HD3' ' A' ' 17' ' ' PRO . 0.9 OUTLIER -79.66 -45.45 1.57 Allowed Pre-proline 0 N--CA 1.477 0.877 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -179.242 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.525 ' HD3' ' SG ' ' A' ' 16' ' ' CYS . 56.0 Cg_endo -69.98 174.81 9.15 Favored 'Trans proline' 0 C--N 1.373 1.856 0 C-N-CA 121.886 1.724 . . . . 0.0 111.956 179.054 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_exo -69.59 65.22 1.7 Allowed 'Trans proline' 0 C--N 1.378 2.127 0 C-N-CA 122.292 1.995 . . . . 0.0 112.534 179.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.406 ' HB3' ' O ' ' A' ' 31' ' ' TYR . 15.6 mt -136.12 162.04 34.04 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.673 -179.671 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.567 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 14.7 t -111.31 163.02 14.4 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.078 179.543 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.8 t -102.62 110.74 22.78 Favored 'General case' 0 C--O 1.239 0.538 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.294 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 4.8 mt -127.78 131.09 23.63 Favored Pre-proline 0 CA--C 1.542 0.669 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.339 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -74.55 -37.85 2.05 Favored 'Cis proline' 0 C--N 1.374 1.877 0 C-N-CA 124.461 -1.058 . . . . 0.0 113.242 -0.25 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.83 39.51 11.79 Favored Glycine 0 C--N 1.345 1.046 0 O-C-N 123.508 0.505 . . . . 0.0 113.076 -179.716 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -140.71 82.17 16.01 Favored Pre-proline 0 CA--C 1.55 0.978 0 C-N-CA 122.105 0.162 . . . . 0.0 110.911 -179.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -84.86 -33.7 2.35 Favored 'Cis proline' 0 C--N 1.371 1.761 0 CA-C-N 119.096 0.713 . . . . 0.0 112.972 -0.415 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -105.69 156.67 18.06 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.934 -179.256 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.478 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.31 -155.27 7.08 Favored Glycine 0 C--N 1.338 0.682 0 CA-C-N 115.868 -0.606 . . . . 0.0 112.553 179.75 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.508 ' HA ' ' O ' ' A' ' 6' ' ' GLU . 19.4 mm -128.57 149.24 33.18 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.58 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 63.6 m -84.42 110.67 18.81 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.274 179.196 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.406 ' O ' ' HB3' ' A' ' 19' ' ' LEU . 85.3 m-85 -106.24 160.95 14.96 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.128 -0.487 . . . . 0.0 112.056 -178.816 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.1 tp -90.1 126.52 42.95 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.611 179.569 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 38.2 mm . . . . . 0 C--O 1.25 1.124 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.088 -179.606 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.487 1.404 0 CA-C-O 119.528 -0.272 . . . . 0.0 111.164 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -83.78 -178.85 3.78 Favored 'Trans proline' 0 C--N 1.372 1.806 0 C-N-CA 122.47 2.113 . . . . 0.0 113.949 -179.099 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.503 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.27 -152.32 6.45 Favored Glycine 0 C--N 1.342 0.913 0 CA-C-N 115.613 -0.722 . . . . 0.0 112.04 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -73.25 113.76 10.67 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.916 0.389 . . . . 0.0 111.621 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.32 32.47 10.44 Favored Glycine 0 C--N 1.341 0.816 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.795 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.55 162.26 26.86 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-O 120.663 0.268 . . . . 0.0 111.251 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.486 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.8 tt0 -80.09 127.0 31.79 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.816 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.47 150.55 50.76 Favored 'General case' 0 C--O 1.233 0.237 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.664 -179.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.451 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.17 154.62 23.08 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.597 -0.729 . . . . 0.0 109.785 179.008 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.7 m -102.93 4.23 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 116.123 -0.49 . . . . 0.0 112.14 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.451 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.0 mt-10 -100.27 -48.57 4.55 Favored 'General case' 0 C--O 1.235 0.329 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.113 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.4 p90 -148.45 2.0 0.62 Allowed 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 113.293 0.849 . . . . 0.0 113.293 -178.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.08 63.46 70.34 Favored Pre-proline 0 CA--C 1.548 0.903 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -74.46 175.59 10.82 Favored 'Trans proline' 0 C--N 1.369 1.649 0 C-N-CA 122.493 2.128 . . . . 0.0 112.594 179.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.7 m -79.69 140.87 36.87 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.503 179.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -80.0 -52.58 1.02 Allowed Pre-proline 0 CA--C 1.543 0.702 0 CA-C-O 118.996 -0.526 . . . . 0.0 112.006 -179.326 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -73.79 175.98 10.04 Favored 'Trans proline' 0 C--N 1.375 1.928 0 C-N-CA 122.143 1.895 . . . . 0.0 111.963 179.258 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.38 64.78 1.58 Allowed 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 122.387 2.058 . . . . 0.0 112.731 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 39.7 mt -127.46 161.32 29.0 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.748 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.0 t -112.4 149.57 32.33 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.015 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.2 t -93.91 108.61 20.39 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.59 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.428 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -127.91 130.78 23.59 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.301 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -73.36 -38.99 1.56 Allowed 'Cis proline' 0 C--N 1.372 1.802 0 C-N-CA 124.671 -0.97 . . . . 0.0 113.464 -0.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.65 39.69 13.86 Favored Glycine 0 C--N 1.344 0.999 0 O-C-N 123.453 0.471 . . . . 0.0 113.047 -179.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -141.19 83.34 13.82 Favored Pre-proline 0 CA--C 1.546 0.791 0 C-N-CA 122.182 0.193 . . . . 0.0 111.315 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.56 -33.5 2.71 Favored 'Cis proline' 0 C--N 1.372 1.779 0 CA-C-N 119.061 0.7 . . . . 0.0 112.826 -0.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -106.69 156.32 18.75 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.932 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.486 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.78 -154.2 6.61 Favored Glycine 0 C--N 1.338 0.642 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.526 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.503 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.9 mm -127.62 147.17 32.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.503 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.1 m -84.38 107.93 16.92 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.13 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.503 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.4 m-85 -106.09 158.99 16.41 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.824 -179.073 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -93.29 122.99 45.23 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.6 179.664 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.3 pt . . . . . 0 C--O 1.251 1.141 0 CA-C-O 118.472 -0.775 . . . . 0.0 111.349 179.94 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.37 0 CA-C-O 119.533 -0.27 . . . . 0.0 111.133 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -83.89 -178.83 3.73 Favored 'Trans proline' 0 C--N 1.373 1.816 0 C-N-CA 122.458 2.105 . . . . 0.0 114.008 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.505 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.4 -152.35 6.44 Favored Glycine 0 C--N 1.343 0.922 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.961 179.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -73.08 113.89 10.63 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-O 120.789 0.328 . . . . 0.0 111.641 -179.49 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.06 32.63 10.46 Favored Glycine 0 C--N 1.34 0.757 0 CA-C-N 115.448 -0.796 . . . . 0.0 112.781 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.3 mt-10 -127.6 162.39 26.61 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.647 0.26 . . . . 0.0 111.282 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.498 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.6 tt0 -80.05 127.1 31.89 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.793 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.84 150.7 51.02 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.681 -179.262 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.448 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.54 154.71 23.32 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.775 179.024 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.9 m -102.85 4.07 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-N 116.18 -0.464 . . . . 0.0 112.156 -179.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.448 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.4 mt-10 -100.01 -48.65 4.58 Favored 'General case' 0 C--O 1.235 0.312 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.002 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -148.54 2.13 0.62 Allowed 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 113.407 0.891 . . . . 0.0 113.407 -178.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -131.17 63.68 70.95 Favored Pre-proline 0 CA--C 1.55 0.962 0 N-CA-C 111.678 0.251 . . . . 0.0 111.678 -179.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.65 175.71 10.75 Favored 'Trans proline' 0 C--N 1.369 1.641 0 C-N-CA 122.493 2.129 . . . . 0.0 112.663 179.235 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.5 m -79.66 140.87 36.91 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 123.288 0.368 . . . . 0.0 110.618 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.94 -52.58 1.03 Allowed Pre-proline 0 CA--C 1.543 0.705 0 CA-C-O 119.131 -0.462 . . . . 0.0 111.925 -179.212 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 66.4 Cg_endo -73.78 175.87 10.17 Favored 'Trans proline' 0 C--N 1.376 1.986 0 C-N-CA 122.105 1.87 . . . . 0.0 112.01 179.227 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -69.37 64.89 1.57 Allowed 'Trans proline' 0 C--N 1.377 2.068 0 C-N-CA 122.373 2.049 . . . . 0.0 112.721 179.478 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 41.1 mt -127.55 161.45 28.76 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.746 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.7 t -112.34 149.58 32.24 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.084 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -94.02 108.93 20.71 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.496 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mt -128.14 130.68 23.57 Favored Pre-proline 0 CA--C 1.541 0.612 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.314 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -73.55 -38.95 1.58 Allowed 'Cis proline' 0 C--N 1.374 1.872 0 C-N-CA 124.581 -1.008 . . . . 0.0 113.456 -0.181 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.85 39.84 12.98 Favored Glycine 0 C--N 1.345 1.08 0 O-C-N 123.483 0.489 . . . . 0.0 113.111 -179.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -140.98 82.88 14.56 Favored Pre-proline 0 CA--C 1.546 0.818 0 C-N-CA 122.205 0.202 . . . . 0.0 111.26 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -83.76 -33.54 2.65 Favored 'Cis proline' 0 C--N 1.372 1.766 0 CA-C-N 119.066 0.702 . . . . 0.0 112.857 -0.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -106.97 156.32 18.85 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.01 -179.324 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.498 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.76 -152.13 5.89 Favored Glycine 0 C--N 1.337 0.635 0 CA-C-N 115.869 -0.605 . . . . 0.0 112.554 179.815 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.493 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.2 mm -129.11 147.13 33.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.505 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.2 m -84.4 108.13 17.05 Favored 'General case' 0 C--O 1.238 0.48 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.174 179.198 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.493 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.0 m-85 -106.2 159.23 16.25 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.79 -179.056 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.91 123.25 44.94 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.641 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.459 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.173 -0.918 . . . . 0.0 111.495 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.37 0 CA-C-O 119.499 -0.286 . . . . 0.0 111.115 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -83.89 -178.81 3.73 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.424 2.083 . . . . 0.0 113.995 -179.161 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.504 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.31 -152.41 6.47 Favored Glycine 0 C--N 1.343 0.965 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.993 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -73.03 113.84 10.52 Favored 'General case' 0 N--CA 1.471 0.594 0 CA-C-O 120.961 0.41 . . . . 0.0 111.669 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.09 32.48 10.62 Favored Glycine 0 C--N 1.342 0.886 0 CA-C-N 115.415 -0.812 . . . . 0.0 112.78 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.54 162.34 26.66 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.63 0.252 . . . . 0.0 111.302 -179.731 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.486 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.15 127.31 32.18 Favored 'General case' 0 C--N 1.346 0.428 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.794 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.4 p -129.7 150.49 50.99 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 115.815 -0.629 . . . . 0.0 111.605 -179.234 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.451 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.1 t70 -110.2 154.58 23.17 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.831 178.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.5 m -102.88 3.94 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 CA-C-N 116.165 -0.47 . . . . 0.0 112.225 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.451 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -99.71 -48.76 4.6 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 111.981 0.363 . . . . 0.0 111.981 -179.046 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -148.64 2.18 0.61 Allowed 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 113.204 0.816 . . . . 0.0 113.204 -178.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.28 63.67 70.74 Favored Pre-proline 0 CA--C 1.548 0.903 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -74.55 176.11 10.17 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 122.434 2.089 . . . . 0.0 112.66 179.209 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 36.2 m -79.81 140.9 36.68 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.557 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.96 -52.64 1.02 Allowed Pre-proline 0 CA--C 1.544 0.75 0 CA-C-O 119.068 -0.491 . . . . 0.0 111.926 -179.197 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -73.76 175.96 10.04 Favored 'Trans proline' 0 C--N 1.376 1.99 0 C-N-CA 122.114 1.876 . . . . 0.0 112.039 179.26 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.36 64.89 1.57 Allowed 'Trans proline' 0 C--N 1.377 2.069 0 C-N-CA 122.327 2.018 . . . . 0.0 112.747 179.479 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 40.6 mt -127.6 161.42 28.88 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.736 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.9 t -112.34 149.57 32.25 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 115.888 -0.597 . . . . 0.0 111.068 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.2 t -94.06 108.76 20.56 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.551 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.1 mt -127.99 130.75 23.58 Favored Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.337 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.38 -39.02 1.55 Allowed 'Cis proline' 0 C--N 1.374 1.87 0 C-N-CA 124.583 -1.007 . . . . 0.0 113.444 -0.22 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.91 39.68 13.02 Favored Glycine 0 C--N 1.345 1.06 0 O-C-N 123.423 0.452 . . . . 0.0 113.069 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.23 83.39 13.73 Favored Pre-proline 0 CA--C 1.547 0.841 0 C-N-CA 122.116 0.166 . . . . 0.0 111.217 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.65 -33.41 2.73 Favored 'Cis proline' 0 C--N 1.372 1.772 0 C-N-CA 125.335 -0.694 . . . . 0.0 112.841 -0.364 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -106.79 156.2 18.92 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.018 -179.378 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.486 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.53 -153.88 6.46 Favored Glycine 0 C--N 1.338 0.639 0 CA-C-N 115.866 -0.606 . . . . 0.0 112.508 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.499 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.4 mm -127.85 147.11 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.504 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.6 m -84.3 107.9 16.85 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.142 179.26 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.499 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -106.03 159.25 16.2 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.785 -179.094 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -93.06 123.15 45.05 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.622 179.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.46 ' O ' HD11 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.295 -0.86 . . . . 0.0 111.519 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.37 0 CA-C-O 119.576 -0.25 . . . . 0.0 111.05 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -83.75 -178.86 3.8 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.53 2.153 . . . . 0.0 114.019 -179.129 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.503 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.04 -152.29 6.48 Favored Glycine 0 C--N 1.342 0.888 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.996 179.659 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -73.52 113.98 11.23 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-O 120.986 0.422 . . . . 0.0 111.561 -179.54 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.13 32.57 10.48 Favored Glycine 0 C--N 1.341 0.818 0 CA-C-N 115.418 -0.81 . . . . 0.0 112.8 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.44 162.3 26.68 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-O 120.476 0.179 . . . . 0.0 111.345 -179.645 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.494 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.07 127.27 32.1 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.795 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.78 150.38 51.11 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.631 -179.248 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.451 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.42 154.89 22.95 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.821 178.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.7 m -102.93 4.21 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 CA-C-N 116.174 -0.466 . . . . 0.0 112.137 -179.507 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.451 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.3 mt-10 -100.32 -48.57 4.54 Favored 'General case' 0 C--O 1.235 0.307 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -179.123 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.6 p90 -148.28 2.0 0.64 Allowed 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 113.279 0.844 . . . . 0.0 113.279 -178.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.12 63.58 70.7 Favored Pre-proline 0 CA--C 1.548 0.903 0 N-CA-C 111.73 0.27 . . . . 0.0 111.73 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.59 175.36 11.19 Favored 'Trans proline' 0 C--N 1.371 1.712 0 C-N-CA 122.461 2.107 . . . . 0.0 112.61 179.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.8 m -79.58 140.69 37.08 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.537 179.664 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.98 -52.57 1.03 Allowed Pre-proline 0 N--CA 1.473 0.687 0 CA-C-O 118.98 -0.533 . . . . 0.0 111.983 -179.367 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -73.88 175.93 10.14 Favored 'Trans proline' 0 C--N 1.375 1.951 0 C-N-CA 122.135 1.89 . . . . 0.0 111.984 179.287 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.43 64.91 1.61 Allowed 'Trans proline' 0 C--N 1.378 2.102 0 C-N-CA 122.277 1.985 . . . . 0.0 112.769 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 40.7 mt -127.35 161.6 28.26 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.782 179.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.7 t -112.65 149.38 32.93 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.009 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -93.88 108.81 20.56 Favored 'General case' 0 C--O 1.238 0.49 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.544 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mt -127.99 130.8 23.58 Favored Pre-proline 0 CA--C 1.542 0.665 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.247 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -73.47 -38.82 1.64 Allowed 'Cis proline' 0 C--N 1.374 1.872 0 C-N-CA 124.553 -1.019 . . . . 0.0 113.475 -0.296 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.95 39.66 12.96 Favored Glycine 0 C--N 1.345 1.042 0 O-C-N 123.38 0.425 . . . . 0.0 113.089 -179.743 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -141.24 83.16 13.92 Favored Pre-proline 0 CA--C 1.547 0.827 0 C-N-CA 122.161 0.185 . . . . 0.0 111.265 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -83.84 -33.52 2.64 Favored 'Cis proline' 0 C--N 1.373 1.823 0 CA-C-N 119.052 0.697 . . . . 0.0 112.829 -0.282 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.1 m-85 -106.96 156.42 18.74 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.928 -179.354 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.494 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.82 -152.47 5.99 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 115.85 -0.614 . . . . 0.0 112.603 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.496 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.5 mm -129.02 147.04 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 O-C-N 123.8 0.353 . . . . 0.0 110.08 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.503 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 76.6 m -84.18 107.79 16.7 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.262 179.2 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.496 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.1 m-85 -105.91 159.13 16.27 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.835 -179.044 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.9 123.25 44.92 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.627 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.458 ' O ' HD11 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.32 -0.848 . . . . 0.0 111.398 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.371 0 CA-C-O 119.586 -0.245 . . . . 0.0 111.171 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -83.8 -178.82 3.76 Favored 'Trans proline' 0 C--N 1.372 1.805 0 C-N-CA 122.445 2.097 . . . . 0.0 114.031 -179.137 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.503 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.87 -152.18 6.49 Favored Glycine 0 C--N 1.343 0.942 0 CA-C-N 115.539 -0.755 . . . . 0.0 112.002 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.46 114.24 11.46 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-O 120.891 0.377 . . . . 0.0 111.6 -179.569 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.69 32.6 11.08 Favored Glycine 0 C--N 1.34 0.801 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.838 -179.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -127.4 162.65 25.83 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 120.625 0.25 . . . . 0.0 111.255 -179.576 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.512 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.07 127.25 32.08 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.805 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.8 p -130.32 150.47 51.54 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.631 -179.372 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.496 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.4 t70 -110.65 154.93 23.12 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.876 178.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.543 HG23 ' OE2' ' A' ' 11' ' ' GLU . 9.6 m -102.9 3.31 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-N 116.172 -0.467 . . . . 0.0 112.152 -179.481 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.543 ' OE2' HG23 ' A' ' 10' ' ' VAL . 4.9 mp0 -97.85 -49.02 4.96 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.443 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 42.1 p90 -149.26 2.52 0.56 Allowed 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 113.375 0.88 . . . . 0.0 113.375 -178.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -130.69 63.67 70.71 Favored Pre-proline 0 CA--C 1.548 0.887 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -74.66 175.99 10.37 Favored 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 122.507 2.138 . . . . 0.0 112.604 179.3 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 34.8 m -79.7 140.92 36.83 Favored 'General case' 0 CA--C 1.534 0.352 0 O-C-N 123.271 0.357 . . . . 0.0 110.603 179.648 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.89 -52.76 1.03 Allowed Pre-proline 0 CA--C 1.545 0.752 0 CA-C-O 119.039 -0.505 . . . . 0.0 111.939 -179.283 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -73.53 175.72 10.28 Favored 'Trans proline' 0 C--N 1.374 1.893 0 C-N-CA 122.097 1.865 . . . . 0.0 112.006 179.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.35 64.94 1.56 Allowed 'Trans proline' 0 C--N 1.377 2.064 0 C-N-CA 122.347 2.031 . . . . 0.0 112.792 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 38.5 mt -127.6 161.84 27.89 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.741 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.2 t -112.57 149.74 32.31 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.076 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.4 t -94.14 109.05 20.86 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.555 179.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.6 mt -128.02 130.99 23.56 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.251 -179.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -73.44 -38.82 1.64 Allowed 'Cis proline' 0 C--N 1.374 1.878 0 C-N-CA 124.686 -0.964 . . . . 0.0 113.56 -0.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.37 42.05 10.88 Favored Glycine 0 C--N 1.344 1.009 0 O-C-N 123.379 0.424 . . . . 0.0 113.035 -179.584 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.07 80.68 16.75 Favored Pre-proline 0 CA--C 1.547 0.841 0 C-N-CA 122.194 0.198 . . . . 0.0 111.352 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -84.81 -32.77 2.73 Favored 'Cis proline' 0 C--N 1.372 1.804 0 C-N-CA 125.365 -0.681 . . . . 0.0 112.889 -0.359 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 83.2 m-85 -105.86 156.49 18.29 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.107 -179.173 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.512 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -154.31 -150.95 5.64 Favored Glycine 0 C--N 1.338 0.672 0 CA-C-N 115.883 -0.599 . . . . 0.0 112.452 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.476 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.8 mm -129.25 146.99 33.39 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.503 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.1 m -84.64 108.62 17.47 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.204 179.237 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.476 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.7 m-85 -106.1 158.83 16.53 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.874 -179.002 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tp -93.63 123.89 45.89 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.517 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.623 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.3 pt . . . . . 0 C--O 1.248 0.984 0 CA-C-O 118.115 -0.945 . . . . 0.0 111.279 179.987 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.348 0 CA-C-O 119.554 -0.26 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -83.71 -178.88 3.82 Favored 'Trans proline' 0 C--N 1.372 1.814 0 C-N-CA 122.496 2.131 . . . . 0.0 114.038 -179.088 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.502 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.04 -152.28 6.48 Favored Glycine 0 C--N 1.341 0.86 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.031 179.608 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.1 tt0 -73.45 113.75 10.9 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 120.932 0.396 . . . . 0.0 111.715 -179.66 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.45 32.62 10.14 Favored Glycine 0 C--N 1.34 0.8 0 CA-C-N 115.46 -0.791 . . . . 0.0 112.846 -179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.66 162.07 27.4 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-O 120.58 0.228 . . . . 0.0 111.314 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.492 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.8 tt0 -79.96 127.13 31.9 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.804 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.71 150.67 50.92 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.619 -179.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.449 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.1 t70 -110.36 154.9 22.88 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.811 178.834 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.5 m -102.79 4.27 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-N 116.186 -0.461 . . . . 0.0 112.132 -179.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.449 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -100.93 -48.51 4.42 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 112.084 0.401 . . . . 0.0 112.084 -179.052 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 39.9 p90 -147.78 1.8 0.69 Allowed 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 113.42 0.896 . . . . 0.0 113.42 -178.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.05 63.29 69.82 Favored Pre-proline 0 CA--C 1.55 0.97 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.344 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.48 175.06 11.55 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.381 2.054 . . . . 0.0 112.617 179.281 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.4 m -79.68 140.81 36.9 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.484 179.733 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.98 -52.56 1.03 Allowed Pre-proline 0 CA--C 1.543 0.7 0 CA-C-O 119.087 -0.483 . . . . 0.0 111.993 -179.368 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -73.85 175.94 10.11 Favored 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 122.071 1.848 . . . . 0.0 112.045 179.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -69.34 64.83 1.55 Allowed 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 122.384 2.056 . . . . 0.0 112.759 179.547 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 41.8 mt -127.28 161.59 28.23 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.818 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.9 t -112.81 149.26 33.3 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.995 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.2 t -93.78 108.76 20.48 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.551 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.425 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.4 mt -127.95 130.93 23.57 Favored Pre-proline 0 CA--C 1.541 0.626 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.226 -179.748 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -73.34 -39.02 1.56 Allowed 'Cis proline' 0 C--N 1.374 1.91 0 C-N-CA 124.705 -0.956 . . . . 0.0 113.468 -0.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.64 39.64 13.99 Favored Glycine 0 C--N 1.344 0.981 0 O-C-N 123.455 0.472 . . . . 0.0 113.075 -179.682 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -140.89 82.99 14.64 Favored Pre-proline 0 CA--C 1.549 0.925 0 C-N-CA 122.188 0.195 . . . . 0.0 110.956 -179.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -83.92 -33.75 2.53 Favored 'Cis proline' 0 C--N 1.372 1.777 0 CA-C-N 119.101 0.715 . . . . 0.0 112.877 -0.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.7 m-85 -106.6 156.25 18.79 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.025 -179.408 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.492 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.85 -152.74 6.08 Favored Glycine 0 C--N 1.338 0.67 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.538 179.741 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.506 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.2 mm -128.69 147.0 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -179.838 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.502 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 78.8 m -84.06 107.97 16.72 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.183 179.175 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.506 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.4 m-85 -106.17 159.3 16.19 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.805 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -93.02 122.81 44.81 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.681 179.552 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.458 ' O ' HD13 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.363 -0.827 . . . . 0.0 111.449 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.361 0 CA-C-O 119.522 -0.275 . . . . 0.0 111.098 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -83.7 -178.86 3.82 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.47 2.114 . . . . 0.0 113.967 -179.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.502 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.98 -152.23 6.48 Favored Glycine 0 C--N 1.343 0.945 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.031 179.53 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -73.53 113.84 11.09 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-O 120.833 0.349 . . . . 0.0 111.581 -179.504 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.33 32.69 10.15 Favored Glycine 0 C--N 1.339 0.747 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.793 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.62 162.22 27.0 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 120.564 0.221 . . . . 0.0 111.275 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.496 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -79.93 127.26 32.05 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.828 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.6 p -129.92 150.65 51.11 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.592 -179.278 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.446 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.64 154.71 23.42 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.773 178.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.8 m -102.65 4.18 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-N 116.146 -0.479 . . . . 0.0 112.139 -179.56 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.446 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.6 mm-40 -100.48 -48.62 4.49 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -179.088 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.4 p90 -148.02 1.89 0.67 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 113.379 0.881 . . . . 0.0 113.379 -178.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.09 63.39 70.08 Favored Pre-proline 0 CA--C 1.551 0.993 0 N-CA-C 111.723 0.268 . . . . 0.0 111.723 -179.236 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.51 175.2 11.37 Favored 'Trans proline' 0 C--N 1.37 1.683 0 C-N-CA 122.391 2.061 . . . . 0.0 112.644 179.287 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.5 m -79.75 140.74 36.82 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.559 179.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.89 -52.59 1.04 Allowed Pre-proline 0 N--CA 1.474 0.768 0 CA-C-O 119.057 -0.497 . . . . 0.0 111.975 -179.296 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -73.89 175.94 10.13 Favored 'Trans proline' 0 C--N 1.376 1.995 0 C-N-CA 122.148 1.899 . . . . 0.0 111.941 179.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.3 64.91 1.53 Allowed 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 122.322 2.014 . . . . 0.0 112.732 179.501 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 40.3 mt -127.43 161.58 28.36 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.744 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.409 ' HG1' ' N ' ' A' ' 21' ' ' CYS . 5.9 t -112.73 149.41 32.98 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.026 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.409 ' N ' ' HG1' ' A' ' 20' ' ' THR . 3.3 t -93.9 108.85 20.6 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.539 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.401 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -127.99 130.81 23.58 Favored Pre-proline 0 CA--C 1.541 0.626 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.264 -179.749 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -73.29 -39.02 1.56 Allowed 'Cis proline' 0 C--N 1.374 1.92 0 C-N-CA 124.692 -0.962 . . . . 0.0 113.439 -0.306 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.86 39.83 12.98 Favored Glycine 0 C--N 1.343 0.971 0 O-C-N 123.43 0.456 . . . . 0.0 113.073 -179.68 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.32 83.09 13.86 Favored Pre-proline 0 CA--C 1.547 0.861 0 C-N-CA 122.222 0.209 . . . . 0.0 111.299 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.91 -33.45 2.65 Favored 'Cis proline' 0 C--N 1.372 1.807 0 C-N-CA 125.345 -0.689 . . . . 0.0 112.755 -0.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.1 m-85 -106.89 156.51 18.62 Favored 'General case' 0 N--CA 1.465 0.313 0 O-C-N 123.593 0.558 . . . . 0.0 111.035 -179.424 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.05 -152.27 5.95 Favored Glycine 0 C--N 1.339 0.697 0 CA-C-N 115.866 -0.606 . . . . 0.0 112.603 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.503 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.3 mm -129.06 147.15 33.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.502 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 77.8 m -84.36 107.78 16.83 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.108 179.264 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.503 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -105.98 159.24 16.2 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.782 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.92 122.91 44.79 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.669 179.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.459 ' O ' HD13 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 1.014 0 CA-C-O 118.3 -0.857 . . . . 0.0 111.351 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.485 1.319 0 CA-C-O 119.579 -0.248 . . . . 0.0 111.081 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -83.87 -178.91 3.78 Favored 'Trans proline' 0 C--N 1.371 1.747 0 C-N-CA 122.536 2.157 . . . . 0.0 113.941 -179.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.504 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.37 -152.36 6.45 Favored Glycine 0 C--N 1.341 0.857 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.077 179.601 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -73.17 113.85 10.69 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-O 121.015 0.435 . . . . 0.0 111.629 -179.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.22 32.46 10.54 Favored Glycine 0 C--N 1.342 0.913 0 CA-C-N 115.345 -0.843 . . . . 0.0 112.778 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.52 162.28 26.79 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-O 120.508 0.194 . . . . 0.0 111.327 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.493 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.1 127.28 32.13 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.864 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.76 150.69 50.96 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.631 -179.193 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.447 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.2 t70 -110.5 154.69 23.31 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.775 178.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.6 m -102.98 3.95 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.191 -179.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.447 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.6 mm-40 -99.61 -48.79 4.62 Favored 'General case' 0 C--O 1.234 0.288 0 N-CA-C 111.936 0.346 . . . . 0.0 111.936 -179.053 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.1 p90 -148.63 1.97 0.61 Allowed 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -178.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -131.12 63.83 71.56 Favored Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 111.748 0.277 . . . . 0.0 111.748 -179.37 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -74.66 175.93 10.44 Favored 'Trans proline' 0 C--N 1.37 1.705 0 C-N-CA 122.459 2.106 . . . . 0.0 112.574 179.283 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.8 m -79.62 140.92 36.96 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 123.257 0.348 . . . . 0.0 110.62 179.626 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.96 -52.57 1.03 Allowed Pre-proline 0 CA--C 1.544 0.731 0 CA-C-O 119.01 -0.519 . . . . 0.0 111.954 -179.286 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -73.94 175.97 10.1 Favored 'Trans proline' 0 C--N 1.375 1.955 0 C-N-CA 122.132 1.888 . . . . 0.0 112.002 179.27 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.35 64.92 1.56 Allowed 'Trans proline' 0 C--N 1.379 2.16 0 C-N-CA 122.402 2.068 . . . . 0.0 112.71 179.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 40.5 mt -127.63 161.3 29.17 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.799 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.8 t -112.36 149.59 32.25 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.06 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -93.93 108.89 20.64 Favored 'General case' 0 C--O 1.237 0.446 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.512 179.622 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.403 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -128.11 130.8 23.56 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.252 -179.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -73.45 -38.91 1.6 Allowed 'Cis proline' 0 C--N 1.374 1.9 0 C-N-CA 124.562 -1.016 . . . . 0.0 113.507 -0.288 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.93 39.84 12.72 Favored Glycine 0 C--N 1.344 1.009 0 O-C-N 123.437 0.46 . . . . 0.0 113.032 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -141.17 83.12 14.05 Favored Pre-proline 0 CA--C 1.547 0.84 0 CA-C-N 116.646 0.223 . . . . 0.0 111.271 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.77 -33.49 2.67 Favored 'Cis proline' 0 C--N 1.371 1.761 0 CA-C-N 119.062 0.701 . . . . 0.0 112.792 -0.272 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.8 m-85 -106.82 156.51 18.59 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.069 -179.412 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.85 -152.82 6.1 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.529 179.775 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.498 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.2 mm -128.56 147.18 33.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 -179.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.504 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.9 m -84.35 107.98 16.93 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.179 179.229 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.498 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -106.26 159.15 16.33 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.767 -179.031 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.76 122.81 44.55 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.523 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.622 179.65 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.46 ' O ' HD11 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.248 1.017 0 CA-C-O 118.442 -0.789 . . . . 0.0 111.405 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.361 0 CA-C-O 119.546 -0.264 . . . . 0.0 111.106 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_endo -83.77 -178.93 3.82 Favored 'Trans proline' 0 C--N 1.372 1.764 0 C-N-CA 122.502 2.134 . . . . 0.0 114.091 -179.197 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.503 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.73 -152.34 6.55 Favored Glycine 0 C--N 1.342 0.872 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.989 179.505 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.79 114.0 11.57 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-O 120.924 0.392 . . . . 0.0 111.572 -179.43 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.72 32.21 10.39 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-N 115.456 -0.793 . . . . 0.0 112.759 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -127.61 162.26 26.92 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.705 0.288 . . . . 0.0 111.319 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.486 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -79.94 127.11 31.87 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.798 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.62 150.51 50.92 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.684 -179.34 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.451 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.21 154.65 23.08 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.847 178.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.6 m -102.7 4.1 10.63 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.203 -179.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.451 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -100.37 -48.51 4.55 Favored 'General case' 0 C--O 1.235 0.336 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.079 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.3 p90 -148.22 1.83 0.64 Allowed 'General case' 0 N--CA 1.476 0.862 0 N-CA-C 113.23 0.826 . . . . 0.0 113.23 -178.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.07 63.55 70.69 Favored Pre-proline 0 CA--C 1.549 0.928 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 -179.317 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.6 175.44 11.08 Favored 'Trans proline' 0 C--N 1.37 1.662 0 C-N-CA 122.434 2.089 . . . . 0.0 112.626 179.244 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.6 m -79.74 140.76 36.83 Favored 'General case' 0 CA--C 1.534 0.363 0 O-C-N 123.255 0.347 . . . . 0.0 110.541 179.69 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.91 -52.67 1.03 Allowed Pre-proline 0 CA--C 1.544 0.721 0 CA-C-O 119.017 -0.516 . . . . 0.0 112.007 -179.291 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -73.78 175.93 10.1 Favored 'Trans proline' 0 C--N 1.374 1.893 0 C-N-CA 122.118 1.879 . . . . 0.0 112.013 179.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.39 64.95 1.58 Allowed 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 122.347 2.031 . . . . 0.0 112.678 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 39.9 mt -127.49 161.39 28.87 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.751 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.8 t -112.51 149.42 32.68 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.89 -0.596 . . . . 0.0 111.081 179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -93.88 108.79 20.54 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.515 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.409 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.2 mt -128.03 130.84 23.57 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.279 -179.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.31 -39.02 1.55 Allowed 'Cis proline' 0 C--N 1.374 1.89 0 C-N-CA 124.651 -0.979 . . . . 0.0 113.427 -0.284 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.75 39.63 13.65 Favored Glycine 0 C--N 1.344 0.98 0 O-C-N 123.469 0.48 . . . . 0.0 113.15 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -141.26 83.26 13.8 Favored Pre-proline 0 CA--C 1.546 0.799 0 C-N-CA 122.169 0.187 . . . . 0.0 111.302 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -83.68 -33.54 2.67 Favored 'Cis proline' 0 C--N 1.373 1.859 0 CA-C-N 119.05 0.697 . . . . 0.0 112.801 -0.271 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -106.71 156.24 18.84 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.018 -179.429 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.486 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.63 -153.35 6.27 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 115.868 -0.606 . . . . 0.0 112.597 179.715 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.501 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.5 mm -128.38 147.08 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.503 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.6 m -84.33 107.88 16.86 Favored 'General case' 0 C--O 1.238 0.48 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.221 179.157 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.501 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -106.02 159.08 16.33 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.767 -178.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.91 122.99 44.84 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.662 179.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.459 HD13 ' OXT' ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.132 -0.937 . . . . 0.0 111.41 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.7 p . . . . . 0 N--CA 1.487 1.417 0 CA-C-O 119.66 -0.21 . . . . 0.0 111.102 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.433 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 91.9 Cg_endo -79.27 -178.87 4.93 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 122.586 2.191 . . . . 0.0 113.785 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -139.77 -144.69 4.57 Favored Glycine 0 C--N 1.339 0.713 0 CA-C-N 115.369 -0.832 . . . . 0.0 111.871 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -84.37 109.88 18.18 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 120.904 0.383 . . . . 0.0 110.81 179.478 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.15 36.88 6.46 Favored Glycine 0 C--N 1.34 0.76 0 CA-C-N 115.465 -0.789 . . . . 0.0 112.733 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.446 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 42.5 mt-10 -133.25 167.13 20.93 Favored 'General case' 0 N--CA 1.467 0.396 0 O-C-N 123.622 0.248 . . . . 0.0 110.909 -179.728 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.518 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.3 tt0 -80.32 124.54 28.94 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.637 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 20.6 p -127.64 143.57 51.15 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.494 -179.267 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.407 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 10.2 t70 -113.8 156.67 23.45 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.696 -0.683 . . . . 0.0 109.919 179.126 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 16.0 m -103.74 7.84 9.78 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 CA-C-N 116.02 -0.536 . . . . 0.0 112.078 -179.563 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.407 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.4 mt-10 -110.16 -49.34 3.08 Favored 'General case' 0 CA--C 1.533 0.298 0 N-CA-C 112.308 0.485 . . . . 0.0 112.308 -178.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 37.3 p90 -141.2 4.16 1.81 Allowed 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 113.236 0.828 . . . . 0.0 113.236 -178.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -132.29 65.73 75.62 Favored Pre-proline 0 CA--C 1.546 0.795 0 CA-C-O 120.525 0.203 . . . . 0.0 111.126 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.433 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 50.4 Cg_endo -73.85 161.98 40.34 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.451 2.1 . . . . 0.0 112.81 179.509 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 91.1 m -79.88 140.85 36.59 Favored 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.548 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -83.81 -52.4 0.58 Allowed Pre-proline 0 CA--C 1.544 0.742 0 CA-C-O 118.906 -0.569 . . . . 0.0 112.265 -179.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -75.55 172.89 15.45 Favored 'Trans proline' 0 C--N 1.375 1.953 0 C-N-CA 122.15 1.9 . . . . 0.0 112.48 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_exo -71.51 66.05 2.93 Favored 'Trans proline' 0 C--N 1.377 2.051 0 C-N-CA 122.409 2.072 . . . . 0.0 112.464 179.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.419 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 58.5 mt -125.43 166.7 16.12 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.818 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.581 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 9.8 t -115.05 143.96 44.37 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.102 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 6.1 t -92.27 109.3 20.68 Favored 'General case' 0 C--O 1.237 0.429 0 O-C-N 123.479 0.487 . . . . 0.0 110.725 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 6.8 mt -126.37 130.9 23.8 Favored Pre-proline 0 CA--C 1.542 0.637 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.991 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -74.18 -37.58 2.16 Favored 'Cis proline' 0 C--N 1.374 1.874 0 C-N-CA 124.565 -1.014 . . . . 0.0 113.567 -0.143 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.8 36.31 19.52 Favored Glycine 0 C--N 1.345 1.043 0 O-C-N 123.343 0.402 . . . . 0.0 113.029 -179.634 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -143.8 82.5 11.15 Favored Pre-proline 0 CA--C 1.55 0.945 0 CA-C-N 116.666 0.233 . . . . 0.0 111.089 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -85.99 -35.52 1.46 Allowed 'Cis proline' 0 C--N 1.373 1.843 0 CA-C-N 119.171 0.74 . . . . 0.0 112.834 -0.421 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 64.5 m-85 -109.85 158.81 17.79 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.991 -179.184 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -162.49 -152.68 6.85 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-N 115.886 -0.597 . . . . 0.0 112.356 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.446 ' HA ' ' O ' ' A' ' 6' ' ' GLU . 16.0 mm -126.71 144.78 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 179.711 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.581 ' HA ' ' O ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -91.44 117.82 30.02 Favored 'General case' 0 C--O 1.235 0.337 0 O-C-N 123.505 0.503 . . . . 0.0 111.13 -179.977 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -109.04 167.35 10.16 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.731 -178.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.6 tp -95.04 123.62 47.23 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.553 179.526 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.471 ' O ' HD13 ' A' ' 33' ' ' ILE . 1.4 pp . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.371 -0.823 . . . . 0.0 111.319 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.487 1.382 0 CA-C-O 119.658 -0.211 . . . . 0.0 111.098 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -83.37 -179.11 4.07 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.481 2.121 . . . . 0.0 114.087 -179.137 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.483 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.98 -152.47 6.54 Favored Glycine 0 C--N 1.341 0.843 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.771 179.48 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.5 tt0 -73.34 111.85 8.85 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-O 120.83 0.348 . . . . 0.0 111.415 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.79 30.94 10.63 Favored Glycine 0 C--N 1.341 0.817 0 CA-C-N 115.485 -0.779 . . . . 0.0 112.715 -179.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.3 mt-10 -126.86 163.76 22.9 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-O 120.599 0.238 . . . . 0.0 111.21 -179.704 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.2 tt0 -79.97 128.67 33.75 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.067 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.481 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.4 p -127.11 142.61 51.47 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.627 -179.557 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -104.42 150.12 24.82 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.707 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.49 HG21 ' O ' ' A' ' 26' ' ' PRO . 9.0 m -101.61 5.38 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.904 -179.885 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -99.2 -47.52 5.17 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.929 -179.204 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -151.76 1.41 0.36 Allowed 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -178.855 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -131.65 64.44 72.9 Favored Pre-proline 0 CA--C 1.549 0.919 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -179.267 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -73.5 178.25 6.93 Favored 'Trans proline' 0 C--N 1.37 1.7 0 C-N-CA 122.538 2.159 . . . . 0.0 112.473 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.0 m -79.51 138.68 37.61 Favored 'General case' 0 N--CA 1.467 0.413 0 O-C-N 123.216 0.322 . . . . 0.0 110.706 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.02 -52.57 1.02 Allowed Pre-proline 0 CA--C 1.544 0.748 0 CA-C-O 118.983 -0.532 . . . . 0.0 112.089 -179.388 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -72.76 175.9 9.66 Favored 'Trans proline' 0 C--N 1.375 1.944 0 C-N-CA 122.163 1.908 . . . . 0.0 112.06 179.347 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -69.55 64.87 1.68 Allowed 'Trans proline' 0 C--N 1.378 2.124 0 C-N-CA 122.373 2.049 . . . . 0.0 112.747 179.399 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 32.9 mt -129.09 159.92 34.45 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.721 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.421 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -111.09 152.76 26.57 Favored 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.192 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.7 t -96.39 106.47 18.71 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.256 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.445 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.3 mt -125.89 131.51 24.02 Favored Pre-proline 0 CA--C 1.542 0.67 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.478 -179.532 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -71.26 -39.34 1.45 Allowed 'Cis proline' 0 C--N 1.375 1.952 0 C-N-CA 124.649 -0.98 . . . . 0.0 113.389 -0.117 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.59 31.15 46.3 Favored Glycine 0 C--N 1.343 0.947 0 O-C-N 123.408 0.442 . . . . 0.0 113.266 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -136.97 85.64 22.45 Favored Pre-proline 0 CA--C 1.545 0.781 0 C-N-CA 122.198 0.199 . . . . 0.0 111.096 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.49 ' O ' HG21 ' A' ' 10' ' ' VAL . 2.2 Cg_endo -83.13 -34.5 2.4 Favored 'Cis proline' 0 C--N 1.372 1.811 0 C-N-CA 125.246 -0.731 . . . . 0.0 112.94 -0.217 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.3 m-85 -98.66 153.94 18.33 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.02 -179.218 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.14 -171.5 18.58 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 116.072 -0.513 . . . . 0.0 113.06 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.473 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 42.5 mm -122.42 146.0 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.483 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.3 m -81.57 107.79 14.62 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.543 179.492 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.473 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.6 m-85 -108.29 158.6 17.33 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.612 -179.389 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 tp -92.1 123.32 44.17 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.662 179.618 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.446 ' OXT' HD11 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.124 -0.941 . . . . 0.0 111.402 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 119.546 -0.264 . . . . 0.0 111.116 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -83.55 -179.04 3.96 Favored 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.479 2.12 . . . . 0.0 114.029 -179.143 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.521 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.68 -152.91 6.52 Favored Glycine 0 C--N 1.342 0.902 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.96 179.623 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -72.18 113.13 8.88 Favored 'General case' 0 N--CA 1.472 0.663 0 CA-C-O 120.941 0.4 . . . . 0.0 111.539 -179.44 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.7 33.32 10.15 Favored Glycine 0 C--N 1.342 0.873 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.761 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.435 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 8.6 mm-40 -127.65 163.55 23.99 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 120.607 0.241 . . . . 0.0 111.266 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.519 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.6 tt0 -80.15 127.93 32.91 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.837 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.422 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 8.6 p -130.86 148.77 52.67 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.75 -179.319 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.443 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.2 t70 -110.83 155.59 22.35 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.816 178.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.0 m -103.23 3.6 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 112.244 0.461 . . . . 0.0 112.244 -179.49 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.443 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -98.89 -48.79 4.78 Favored 'General case' 0 C--O 1.235 0.339 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -179.027 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -148.76 1.99 0.59 Allowed 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -178.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -131.02 63.7 71.26 Favored Pre-proline 0 CA--C 1.55 0.95 0 N-CA-C 111.757 0.28 . . . . 0.0 111.757 -179.371 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -74.81 175.66 10.88 Favored 'Trans proline' 0 C--N 1.37 1.708 0 C-N-CA 122.467 2.111 . . . . 0.0 112.571 179.133 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 38.4 m -79.74 140.1 37.07 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 116.55 -0.295 . . . . 0.0 110.561 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.98 -52.51 1.03 Allowed Pre-proline 0 CA--C 1.544 0.734 0 CA-C-O 119.082 -0.485 . . . . 0.0 112.037 -179.258 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -73.52 175.5 10.57 Favored 'Trans proline' 0 C--N 1.376 2.004 0 C-N-CA 122.087 1.858 . . . . 0.0 112.115 179.248 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -69.47 64.93 1.64 Allowed 'Trans proline' 0 C--N 1.377 2.072 0 C-N-CA 122.386 2.057 . . . . 0.0 112.707 179.465 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 36.7 mt -127.83 161.95 27.81 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.761 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.0 t -111.71 150.39 30.27 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.213 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 4.0 t -95.26 108.6 20.76 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.553 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.4 mt -127.66 130.99 23.6 Favored Pre-proline 0 CA--C 1.541 0.616 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.195 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.593 ' HB2' ' OD2' ' A' ' 25' ' ' ASP . 55.6 Cg_endo -72.48 -39.44 1.44 Allowed 'Cis proline' 0 C--N 1.373 1.854 0 C-N-CA 124.668 -0.972 . . . . 0.0 113.476 -0.272 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.56 38.82 11.55 Favored Glycine 0 C--N 1.344 0.998 0 O-C-N 123.483 0.49 . . . . 0.0 113.386 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.593 ' OD2' ' HB2' ' A' ' 23' ' ' PRO . 2.0 p30 -144.9 85.02 8.51 Favored Pre-proline 0 CA--C 1.55 0.952 0 CA-C-N 116.66 0.23 . . . . 0.0 111.473 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -83.88 -33.65 2.58 Favored 'Cis proline' 0 C--N 1.372 1.789 0 CA-C-N 118.985 0.673 . . . . 0.0 112.896 -0.466 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -109.69 156.72 19.9 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.977 -179.314 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.519 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.84 -151.17 5.67 Favored Glycine 0 C--N 1.338 0.661 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.507 179.78 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.478 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.7 mm -129.26 147.22 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.521 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 79.1 m -84.35 107.24 16.52 Favored 'General case' 0 CA--C 1.537 0.443 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.286 179.25 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.478 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.7 m-85 -105.14 157.84 16.99 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.544 -179.375 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 tt -94.23 124.42 46.7 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.704 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.453 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.247 0.95 0 CA-C-O 118.357 -0.83 . . . . 0.0 111.408 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.373 0 CA-C-O 119.67 -0.205 . . . . 0.0 111.09 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_endo -83.28 -179.13 4.11 Favored 'Trans proline' 0 C--N 1.373 1.822 0 C-N-CA 122.589 2.193 . . . . 0.0 114.054 -179.057 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.484 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.0 -152.26 6.48 Favored Glycine 0 C--N 1.342 0.886 0 CA-C-N 115.41 -0.814 . . . . 0.0 111.777 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.5 tt0 -73.49 111.7 8.87 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 120.835 0.35 . . . . 0.0 111.452 -179.656 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.91 31.07 10.3 Favored Glycine 0 C--N 1.341 0.816 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.651 -179.752 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.1 mt-10 -126.94 163.85 22.75 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-O 120.534 0.207 . . . . 0.0 111.261 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -79.95 128.63 33.7 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.04 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.481 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.5 p -127.13 142.29 51.55 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.59 -179.549 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -104.29 150.03 24.81 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.737 179.407 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.493 HG21 ' O ' ' A' ' 26' ' ' PRO . 9.6 m -101.46 5.25 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.906 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -99.02 -47.45 5.23 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.928 -179.202 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -151.86 1.37 0.36 Allowed 'General case' 0 N--CA 1.478 0.947 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 -178.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -131.55 64.31 72.57 Favored Pre-proline 0 CA--C 1.548 0.89 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.273 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.46 178.24 6.93 Favored 'Trans proline' 0 C--N 1.371 1.731 0 C-N-CA 122.544 2.163 . . . . 0.0 112.484 179.034 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 49.3 m -79.49 138.75 37.66 Favored 'General case' 0 N--CA 1.467 0.42 0 O-C-N 123.224 0.328 . . . . 0.0 110.765 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.22 -52.58 0.98 Allowed Pre-proline 0 CA--C 1.544 0.736 0 CA-C-O 119.018 -0.515 . . . . 0.0 112.057 -179.301 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_endo -72.7 175.88 9.64 Favored 'Trans proline' 0 C--N 1.375 1.972 0 C-N-CA 122.16 1.906 . . . . 0.0 112.06 179.297 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.59 65.0 1.7 Allowed 'Trans proline' 0 C--N 1.378 2.093 0 C-N-CA 122.381 2.054 . . . . 0.0 112.591 179.475 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 33.2 mt -129.28 159.96 34.49 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.579 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.422 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -110.98 152.68 26.53 Favored 'General case' 0 CA--C 1.536 0.408 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.101 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.8 t -96.33 106.43 18.65 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.366 179.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.445 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.5 mt -125.81 131.56 24.04 Favored Pre-proline 0 CA--C 1.543 0.684 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.396 -179.458 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -71.08 -39.45 1.42 Allowed 'Cis proline' 0 C--N 1.375 1.923 0 C-N-CA 124.683 -0.965 . . . . 0.0 113.402 -0.225 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.65 30.69 47.66 Favored Glycine 0 C--N 1.345 1.043 0 O-C-N 123.463 0.477 . . . . 0.0 113.391 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -136.79 85.8 23.14 Favored Pre-proline 0 CA--C 1.546 0.82 0 C-N-CA 122.259 0.224 . . . . 0.0 111.049 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.493 ' O ' HG21 ' A' ' 10' ' ' VAL . 2.2 Cg_endo -83.07 -34.58 2.37 Favored 'Cis proline' 0 C--N 1.371 1.756 0 C-N-CA 125.273 -0.719 . . . . 0.0 112.95 -0.269 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 -98.64 153.9 18.34 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.044 -179.246 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.2 -171.8 18.9 Favored Glycine 0 C--N 1.339 0.729 0 O-C-N 123.542 0.526 . . . . 0.0 113.079 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.474 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 42.4 mm -122.17 145.91 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.484 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.5 m -81.44 107.73 14.45 Favored 'General case' 0 CA--C 1.537 0.469 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.517 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.474 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.6 m-85 -108.21 158.65 17.26 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.356 -0.383 . . . . 0.0 111.652 -179.447 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 tp -92.29 123.56 44.45 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.558 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.547 179.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.445 HD13 ' OXT' ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 0.983 0 CA-C-O 118.278 -0.868 . . . . 0.0 111.384 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.488 1.446 0 CA-C-O 119.624 -0.227 . . . . 0.0 111.156 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.433 ' HG2' ' SG ' ' A' ' 30' ' ' CYS . 87.3 Cg_endo -81.94 -179.65 4.94 Favored 'Trans proline' 0 C--N 1.372 1.782 0 C-N-CA 122.652 2.235 . . . . 0.0 113.997 -179.067 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.479 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.27 -151.37 6.39 Favored Glycine 0 C--N 1.34 0.769 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.699 179.429 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -75.6 110.33 9.91 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-O 120.931 0.396 . . . . 0.0 111.288 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.38 29.82 10.7 Favored Glycine 0 C--N 1.341 0.833 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.524 -179.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -124.25 167.97 13.58 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-O 120.561 0.219 . . . . 0.0 111.133 -179.67 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 -79.9 137.39 36.89 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.072 -179.674 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -126.74 157.04 40.16 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.492 -0.777 . . . . 0.0 111.274 -179.283 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -131.18 140.04 49.84 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.289 179.076 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.508 HG22 ' O ' ' A' ' 26' ' ' PRO . 11.7 m -95.76 7.37 7.18 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 O-C-N 123.202 0.314 . . . . 0.0 111.757 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -99.73 -46.6 5.36 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.772 -179.274 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.0 p90 -154.58 1.17 0.2 Allowed 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 -178.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -132.72 65.61 74.74 Favored Pre-proline 0 CA--C 1.547 0.844 0 CA-C-N 117.931 0.332 . . . . 0.0 111.884 -179.237 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -74.14 177.57 8.06 Favored 'Trans proline' 0 C--N 1.369 1.628 0 C-N-CA 122.574 2.182 . . . . 0.0 112.252 178.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 56.9 m -79.35 139.64 37.71 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 116.705 -0.225 . . . . 0.0 110.898 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.35 -53.7 0.56 Allowed Pre-proline 0 CA--C 1.545 0.75 0 CA-C-O 119.014 -0.517 . . . . 0.0 112.342 -179.073 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -71.66 175.32 9.72 Favored 'Trans proline' 0 C--N 1.375 1.971 0 C-N-CA 122.09 1.86 . . . . 0.0 112.265 179.667 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_exo -69.6 65.06 1.71 Allowed 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 122.369 2.046 . . . . 0.0 112.615 179.456 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 47.4 mt -126.65 161.13 28.8 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.722 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.0 t -109.58 151.51 26.72 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.227 -179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.7 t -96.39 107.56 19.96 Favored 'General case' 0 C--O 1.238 0.47 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.398 179.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.44 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 3.8 mt -126.75 129.5 24.04 Favored Pre-proline 0 CA--C 1.541 0.615 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.761 -179.729 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -71.48 -39.14 1.5 Allowed 'Cis proline' 0 C--N 1.374 1.881 0 C-N-CA 124.591 -1.004 . . . . 0.0 113.305 -0.577 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.01 29.76 40.64 Favored Glycine 0 C--N 1.344 0.995 0 CA-C-N 116.158 -0.473 . . . . 0.0 113.429 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -144.13 89.55 7.06 Favored Pre-proline 0 CA--C 1.546 0.811 0 CA-C-N 116.702 0.251 . . . . 0.0 111.219 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.508 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.5 Cg_endo -83.77 -35.58 1.87 Allowed 'Cis proline' 0 C--N 1.371 1.738 0 CA-C-N 119.198 0.749 . . . . 0.0 112.846 -0.291 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 44.0 m-85 -103.01 156.95 17.32 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.717 -179.331 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -156.43 -164.98 14.0 Favored Glycine 0 C--N 1.339 0.743 0 C-N-CA 120.956 -0.64 . . . . 0.0 113.216 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.453 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 43.4 mm -127.24 147.53 32.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.479 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 72.3 m -82.89 109.41 16.99 Favored 'General case' 0 CA--C 1.537 0.478 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.401 179.282 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.453 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.4 m-85 -109.03 158.42 17.75 Favored 'General case' 0 N--CA 1.467 0.391 0 N-CA-C 112.038 0.384 . . . . 0.0 112.038 -179.024 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.1 tp -93.46 124.6 45.95 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.616 179.675 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.446 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.25 1.128 0 CA-C-O 118.185 -0.912 . . . . 0.0 111.44 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.374 0 CA-C-O 119.649 -0.215 . . . . 0.0 111.104 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -83.48 -179.07 4.0 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.467 2.111 . . . . 0.0 114.123 -179.157 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.484 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.82 -152.77 6.64 Favored Glycine 0 C--N 1.341 0.849 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.809 179.433 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.46 111.91 9.04 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-O 120.896 0.379 . . . . 0.0 111.469 -179.753 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.27 30.74 10.46 Favored Glycine 0 C--N 1.341 0.832 0 CA-C-N 115.418 -0.81 . . . . 0.0 112.593 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -127.01 163.69 23.16 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-O 120.608 0.242 . . . . 0.0 111.194 -179.693 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -79.96 128.56 33.62 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.969 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.478 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.3 p -127.05 143.18 51.35 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.555 -179.6 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -104.56 150.28 24.77 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.345 -0.843 . . . . 0.0 109.74 179.469 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.486 HG21 ' O ' ' A' ' 26' ' ' PRO . 9.1 m -101.82 5.12 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.844 -179.854 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -99.17 -47.41 5.21 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.904 -179.126 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -151.84 1.53 0.36 Allowed 'General case' 0 N--CA 1.477 0.886 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -178.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -131.7 64.46 72.89 Favored Pre-proline 0 CA--C 1.549 0.927 0 N-CA-C 111.803 0.298 . . . . 0.0 111.803 -179.262 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.63 178.36 6.84 Favored 'Trans proline' 0 C--N 1.369 1.612 0 C-N-CA 122.56 2.173 . . . . 0.0 112.456 179.066 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 48.3 m -79.55 138.91 37.64 Favored 'General case' 0 C--N 1.344 0.367 0 O-C-N 123.163 0.29 . . . . 0.0 110.792 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.03 -52.66 1.01 Allowed Pre-proline 0 CA--C 1.543 0.697 0 CA-C-O 118.999 -0.525 . . . . 0.0 112.103 -179.319 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 63.9 Cg_endo -72.78 175.88 9.7 Favored 'Trans proline' 0 C--N 1.375 1.964 0 C-N-CA 122.126 1.884 . . . . 0.0 112.036 179.337 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.44 64.82 1.62 Allowed 'Trans proline' 0 C--N 1.379 2.149 0 C-N-CA 122.38 2.053 . . . . 0.0 112.693 179.47 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 33.0 mt -129.11 159.96 34.34 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.698 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.425 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -111.22 152.88 26.6 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.149 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 t -96.37 106.75 19.03 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.298 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.447 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.5 mt -126.15 131.66 24.04 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.418 -179.538 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -71.12 -39.53 1.4 Allowed 'Cis proline' 0 C--N 1.374 1.895 0 C-N-CA 124.676 -0.969 . . . . 0.0 113.391 -0.326 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.67 31.54 44.52 Favored Glycine 0 C--N 1.342 0.9 0 O-C-N 123.49 0.494 . . . . 0.0 113.393 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -136.82 85.38 23.88 Favored Pre-proline 0 CA--C 1.545 0.783 0 C-N-CA 122.168 0.187 . . . . 0.0 111.072 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.486 ' O ' HG21 ' A' ' 10' ' ' VAL . 2.1 Cg_endo -83.3 -34.37 2.41 Favored 'Cis proline' 0 C--N 1.372 1.767 0 C-N-CA 125.17 -0.763 . . . . 0.0 112.993 -0.217 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 -98.56 153.9 18.31 Favored 'General case' 0 N--CA 1.466 0.369 0 O-C-N 123.586 0.554 . . . . 0.0 110.996 -179.238 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.15 -171.33 18.41 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 116.035 -0.529 . . . . 0.0 113.004 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.477 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 41.8 mm -122.38 146.16 28.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.484 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.5 m -81.7 107.92 14.83 Favored 'General case' 0 CA--C 1.537 0.477 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.509 179.562 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.477 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.6 m-85 -108.5 158.94 17.09 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.53 -179.45 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tp -91.57 122.75 43.29 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.61 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.448 ' OXT' HD11 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.116 -0.945 . . . . 0.0 111.326 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.5 p . . . . . 0 N--CA 1.486 1.359 0 CA-C-O 119.628 -0.225 . . . . 0.0 111.149 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.531 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 86.9 Cg_endo -78.26 -172.57 1.54 Allowed 'Trans proline' 0 C--N 1.37 1.7 0 C-N-CA 122.673 2.248 . . . . 0.0 113.83 -179.346 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.2 -144.21 4.24 Favored Glycine 0 C--N 1.339 0.698 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.588 179.755 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 13.3 tt0 -86.47 109.62 19.2 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-O 120.881 0.372 . . . . 0.0 110.705 179.476 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.53 35.88 6.74 Favored Glycine 0 C--N 1.34 0.774 0 CA-C-N 115.571 -0.74 . . . . 0.0 112.749 -179.664 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -131.85 167.68 19.16 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 122.335 0.254 . . . . 0.0 110.831 -179.709 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -79.9 120.56 24.28 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.715 179.746 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 11.8 p -120.17 135.6 54.91 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.288 -179.343 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -104.02 156.15 18.09 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 115.483 -0.78 . . . . 0.0 109.691 179.649 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.423 HG21 ' O ' ' A' ' 26' ' ' PRO . 8.0 m -107.82 14.29 8.14 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.905 -179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -120.54 -45.11 2.43 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.112 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 38.1 p90 -141.28 2.34 1.67 Allowed 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -178.753 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . 0.531 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 2.0 t30 -135.97 68.21 63.85 Favored Pre-proline 0 CA--C 1.543 0.71 0 CA-C-O 120.524 0.202 . . . . 0.0 111.377 -179.644 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.47 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 50.5 Cg_endo -74.46 164.36 34.13 Favored 'Trans proline' 0 C--N 1.368 1.602 0 C-N-CA 122.614 2.209 . . . . 0.0 112.581 179.009 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 94.1 m -79.6 140.42 37.14 Favored 'General case' 0 N--CA 1.47 0.538 0 O-C-N 123.441 0.463 . . . . 0.0 111.681 -179.455 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 m -84.9 -52.54 0.5 Allowed Pre-proline 0 CA--C 1.545 0.751 0 O-C-N 123.63 0.581 . . . . 0.0 112.168 -179.634 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -75.02 172.8 15.66 Favored 'Trans proline' 0 C--N 1.376 2.014 0 C-N-CA 122.066 1.844 . . . . 0.0 112.408 179.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo -71.31 66.16 2.76 Favored 'Trans proline' 0 C--N 1.379 2.149 0 C-N-CA 122.357 2.038 . . . . 0.0 112.511 179.613 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.425 ' HB2' ' SG ' ' A' ' 30' ' ' CYS . 55.5 mt -124.52 168.1 13.55 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.817 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.563 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 8.5 t -118.73 140.99 49.04 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.337 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 6.3 t -90.99 104.25 16.86 Favored 'General case' 0 CA--C 1.536 0.442 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.541 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mt -120.84 131.58 24.43 Favored Pre-proline 0 CA--C 1.543 0.692 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.325 -179.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -72.52 -36.9 2.4 Favored 'Cis proline' 0 C--N 1.374 1.888 0 C-N-CA 124.542 -1.024 . . . . 0.0 113.257 -0.264 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.47 30.57 48.88 Favored Glycine 0 C--N 1.343 0.925 0 CA-C-N 116.171 -0.468 . . . . 0.0 113.297 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -142.24 86.33 10.2 Favored Pre-proline 0 CA--C 1.545 0.783 0 C-N-CA 122.287 0.235 . . . . 0.0 111.161 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.423 ' O ' HG21 ' A' ' 10' ' ' VAL . 1.7 Cg_endo -85.24 -35.59 1.59 Allowed 'Cis proline' 0 C--N 1.373 1.826 0 CA-C-N 119.055 0.698 . . . . 0.0 112.987 -0.377 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 23.6 m-85 -104.45 154.52 19.77 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.906 -179.056 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -161.76 -172.83 29.66 Favored Glycine 0 C--N 1.34 0.761 0 CA-C-N 116.015 -0.538 . . . . 0.0 113.139 179.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 27.2 mm -116.87 145.2 22.94 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 179.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.563 ' HA ' ' O ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -89.4 119.56 29.97 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.484 -179.864 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -111.87 167.01 10.7 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.487 -179.111 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -95.42 122.93 47.33 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.464 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.554 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.467 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.5 pp . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.418 -0.801 . . . . 0.0 111.352 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 31.6 p . . . . . 0 N--CA 1.486 1.35 0 CA-C-O 119.48 -0.295 . . . . 0.0 111.027 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -84.61 -177.33 2.85 Favored 'Trans proline' 0 C--N 1.37 1.661 0 C-N-CA 122.161 1.908 . . . . 0.0 113.088 179.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.565 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -146.93 -157.89 7.57 Favored Glycine 0 C--N 1.337 0.613 0 CA-C-N 115.74 -0.663 . . . . 0.0 112.027 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -65.66 110.3 2.72 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 121.042 0.448 . . . . 0.0 111.737 -179.251 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.33 31.57 10.48 Favored Glycine 0 C--N 1.339 0.745 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.723 -179.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.41 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 36.7 mt-10 -126.3 159.98 31.64 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.606 0.241 . . . . 0.0 111.275 -179.686 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.489 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.7 tt0 -80.04 121.92 26.12 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.566 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.409 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 7.9 p -124.83 149.29 47.61 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 115.795 -0.638 . . . . 0.0 111.673 -179.169 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.443 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.1 t70 -109.11 155.35 21.09 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.898 179.14 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.3 m -103.0 3.42 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 -179.543 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.443 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.9 mm-40 -98.6 -48.6 4.92 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 111.939 0.348 . . . . 0.0 111.939 -179.037 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -149.15 1.56 0.55 Allowed 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 113.325 0.861 . . . . 0.0 113.325 -178.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -130.73 63.73 70.97 Favored Pre-proline 0 CA--C 1.55 0.965 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 -179.333 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -76.61 172.7 15.75 Favored 'Trans proline' 0 C--N 1.369 1.656 0 C-N-CA 122.438 2.092 . . . . 0.0 112.618 179.115 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.409 ' SG ' ' SG ' ' A' ' 8' ' ' CYS . 21.9 m -79.56 133.33 36.45 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.3 179.623 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.521 ' SG ' ' HD3' ' A' ' 17' ' ' PRO . 0.8 OUTLIER -79.55 -45.46 1.6 Allowed Pre-proline 0 N--CA 1.475 0.782 0 N-CA-C 112.859 0.689 . . . . 0.0 112.859 -179.279 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.521 ' HD3' ' SG ' ' A' ' 16' ' ' CYS . 56.7 Cg_endo -70.69 174.37 10.43 Favored 'Trans proline' 0 C--N 1.374 1.876 0 C-N-CA 121.863 1.709 . . . . 0.0 111.879 178.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 14.2 Cg_exo -70.0 65.71 1.93 Allowed 'Trans proline' 0 C--N 1.377 2.046 0 C-N-CA 122.274 1.983 . . . . 0.0 112.366 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 25.8 mt -133.43 162.38 32.01 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.27 -0.877 . . . . 0.0 110.901 -179.56 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.494 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.6 t -112.28 155.32 24.26 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.244 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -98.37 108.41 21.1 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.307 179.618 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.423 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.1 mt -128.15 130.86 23.55 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.376 -179.831 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.86 -39.3 1.48 Allowed 'Cis proline' 0 C--N 1.373 1.849 0 C-N-CA 124.624 -0.99 . . . . 0.0 113.533 -0.342 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.29 38.37 18.39 Favored Glycine 0 C--N 1.345 1.049 0 CA-C-N 116.216 -0.447 . . . . 0.0 113.079 -179.725 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -141.23 84.13 13.06 Favored Pre-proline 0 CA--C 1.547 0.847 0 C-N-CA 122.225 0.21 . . . . 0.0 111.338 -179.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -83.16 -34.14 2.54 Favored 'Cis proline' 0 C--N 1.373 1.828 0 CA-C-N 119.047 0.695 . . . . 0.0 112.763 -0.189 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -106.14 156.41 18.46 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.892 -179.35 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.1 -156.24 7.49 Favored Glycine 0 C--N 1.337 0.622 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.622 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.47 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 23.3 mm -127.4 147.88 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 N-CA-C 110.051 -0.351 . . . . 0.0 110.051 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.565 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 76.7 m -84.74 110.13 18.56 Favored 'General case' 0 CA--C 1.537 0.455 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.114 179.228 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.47 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.4 m-85 -107.38 159.77 16.14 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.899 -178.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.0 tp -93.57 124.1 45.9 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.536 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.6 179.551 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.4 pt . . . . . 0 C--O 1.25 1.119 0 CA-C-O 118.489 -0.767 . . . . 0.0 111.328 179.988 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.487 1.375 0 CA-C-O 119.616 -0.23 . . . . 0.0 111.179 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -83.44 -179.15 4.07 Favored 'Trans proline' 0 C--N 1.371 1.733 0 C-N-CA 122.497 2.131 . . . . 0.0 114.082 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.484 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.84 -152.53 6.58 Favored Glycine 0 C--N 1.341 0.843 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.81 179.41 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.65 111.83 9.16 Favored 'General case' 0 N--CA 1.472 0.63 0 CA-C-O 120.878 0.371 . . . . 0.0 111.385 -179.661 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.21 30.93 10.22 Favored Glycine 0 C--N 1.341 0.828 0 CA-C-N 115.502 -0.772 . . . . 0.0 112.638 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.3 mt-10 -127.14 163.75 23.12 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-O 120.559 0.219 . . . . 0.0 111.212 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -79.95 128.48 33.52 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.971 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.479 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.3 p -127.02 142.9 51.43 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.515 -179.644 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -104.46 150.04 24.91 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.808 179.439 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.49 HG22 ' O ' ' A' ' 26' ' ' PRO . 9.4 m -101.68 5.92 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 O-C-N 123.397 0.436 . . . . 0.0 111.947 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.6 tt0 -100.04 -48.0 4.8 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.522 -179.105 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 36.7 p90 -151.11 1.54 0.41 Allowed 'General case' 0 N--CA 1.477 0.918 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -178.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -131.55 64.3 72.54 Favored Pre-proline 0 CA--C 1.55 0.972 0 N-CA-C 111.854 0.316 . . . . 0.0 111.854 -179.281 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -73.54 177.79 7.53 Favored 'Trans proline' 0 C--N 1.37 1.658 0 C-N-CA 122.525 2.15 . . . . 0.0 112.429 179.047 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 47.3 m -79.53 138.7 37.59 Favored 'General case' 0 N--CA 1.467 0.385 0 O-C-N 123.188 0.305 . . . . 0.0 110.807 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.01 -52.64 1.01 Allowed Pre-proline 0 N--CA 1.474 0.727 0 CA-C-O 119.025 -0.512 . . . . 0.0 111.983 -179.22 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -72.73 175.88 9.66 Favored 'Trans proline' 0 C--N 1.375 1.951 0 C-N-CA 122.166 1.91 . . . . 0.0 112.051 179.372 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.3 Cg_exo -69.6 65.01 1.71 Allowed 'Trans proline' 0 C--N 1.378 2.126 0 C-N-CA 122.375 2.05 . . . . 0.0 112.642 179.458 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 32.6 mt -129.2 159.96 34.42 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.687 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.421 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -111.33 152.71 26.95 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.107 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.7 t -96.39 106.72 19.0 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.232 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.446 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.4 mt -125.99 131.63 24.05 Favored Pre-proline 0 CA--C 1.542 0.67 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.391 -179.482 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -71.1 -39.43 1.42 Allowed 'Cis proline' 0 C--N 1.375 1.944 0 C-N-CA 124.717 -0.951 . . . . 0.0 113.446 -0.289 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.51 31.39 45.86 Favored Glycine 0 C--N 1.344 0.997 0 CA-C-N 116.136 -0.484 . . . . 0.0 113.321 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -136.9 85.45 23.29 Favored Pre-proline 0 CA--C 1.545 0.762 0 C-N-CA 122.234 0.214 . . . . 0.0 111.04 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.49 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.2 Cg_endo -83.22 -34.42 2.41 Favored 'Cis proline' 0 C--N 1.373 1.827 0 C-N-CA 125.237 -0.734 . . . . 0.0 112.978 -0.257 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -98.57 154.15 18.13 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.061 -179.257 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.43 -171.56 18.83 Favored Glycine 0 C--N 1.338 0.681 0 CA-C-N 116.11 -0.495 . . . . 0.0 113.01 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.475 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 41.8 mm -122.3 146.05 28.08 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.484 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.4 m -81.49 107.94 14.68 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.582 179.463 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.475 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.8 m-85 -108.48 158.82 17.2 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.554 -179.389 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tp -91.68 122.84 43.49 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.668 179.622 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.446 ' O ' HD13 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.247 0.93 0 CA-C-O 118.44 -0.79 . . . . 0.0 111.405 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 31.7 p . . . . . 0 N--CA 1.488 1.474 0 CA-C-O 119.486 -0.292 . . . . 0.0 110.892 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -84.73 -177.32 2.82 Favored 'Trans proline' 0 C--N 1.37 1.687 0 C-N-CA 122.079 1.853 . . . . 0.0 113.092 179.406 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.568 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -147.27 -158.6 7.92 Favored Glycine 0 C--N 1.337 0.589 0 CA-C-N 115.723 -0.671 . . . . 0.0 111.947 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -64.79 110.0 2.25 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-O 120.979 0.419 . . . . 0.0 111.713 -179.218 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.29 31.97 10.1 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-N 115.331 -0.849 . . . . 0.0 112.713 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.43 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 36.9 mt-10 -126.65 160.48 30.6 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 120.548 0.213 . . . . 0.0 111.238 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.499 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.5 tt0 -79.98 122.01 26.2 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.585 179.682 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 8.5 p -125.49 149.75 48.0 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.637 -179.062 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -109.69 155.53 21.4 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 115.507 -0.769 . . . . 0.0 109.844 179.104 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.4 m -104.14 4.2 10.54 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.222 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -99.24 -48.67 4.74 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 116.637 -0.256 . . . . 0.0 111.654 -179.056 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 37.9 p90 -148.85 0.97 0.56 Allowed 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -179.056 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -130.87 63.56 70.59 Favored Pre-proline 0 CA--C 1.551 0.99 0 N-CA-C 111.816 0.302 . . . . 0.0 111.816 -179.32 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -76.27 173.5 14.38 Favored 'Trans proline' 0 C--N 1.369 1.638 0 C-N-CA 122.53 2.153 . . . . 0.0 112.594 179.203 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 8' ' ' CYS . 23.6 m -79.75 133.5 36.33 Favored 'General case' 0 N--CA 1.466 0.352 0 O-C-N 123.373 0.421 . . . . 0.0 110.252 179.556 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.526 ' SG ' ' HD3' ' A' ' 17' ' ' PRO . 0.8 OUTLIER -79.59 -45.4 1.59 Allowed Pre-proline 0 N--CA 1.476 0.836 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -179.271 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.526 ' HD3' ' SG ' ' A' ' 16' ' ' CYS . 56.9 Cg_endo -70.6 174.42 10.26 Favored 'Trans proline' 0 C--N 1.374 1.913 0 C-N-CA 121.928 1.752 . . . . 0.0 111.922 178.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_exo -70.04 65.66 1.96 Allowed 'Trans proline' 0 C--N 1.376 2.015 0 C-N-CA 122.266 1.977 . . . . 0.0 112.354 179.341 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 26.5 mt -133.5 162.43 31.91 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.84 -179.52 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.497 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.6 t -112.01 155.69 23.37 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.16 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 t -98.83 108.53 21.24 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.314 179.59 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.43 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -128.09 130.87 23.56 Favored Pre-proline 0 CA--C 1.542 0.637 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.323 -179.805 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -73.17 -39.06 1.54 Allowed 'Cis proline' 0 C--N 1.373 1.859 0 C-N-CA 124.62 -0.992 . . . . 0.0 113.523 -0.265 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.14 39.48 15.99 Favored Glycine 0 C--N 1.344 1.018 0 O-C-N 123.459 0.475 . . . . 0.0 113.138 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.55 83.56 13.13 Favored Pre-proline 0 CA--C 1.547 0.855 0 C-N-CA 122.132 0.173 . . . . 0.0 111.253 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -83.51 -33.43 2.75 Favored 'Cis proline' 0 C--N 1.372 1.794 0 CA-C-N 119.056 0.698 . . . . 0.0 112.812 -0.312 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -107.27 155.75 19.61 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.95 -179.404 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.499 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.59 -154.1 6.55 Favored Glycine 0 C--N 1.338 0.672 0 CA-C-N 115.876 -0.602 . . . . 0.0 112.574 179.767 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.469 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 22.6 mm -128.37 148.22 32.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.568 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 77.9 m -84.68 110.22 18.6 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.239 179.286 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.469 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.6 m-85 -107.73 160.54 15.64 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.876 -178.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 tp -92.39 122.87 44.23 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.638 179.621 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.456 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.378 -0.82 . . . . 0.0 111.465 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 32.1 p . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 119.412 -0.328 . . . . 0.0 110.945 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -84.75 -177.55 2.91 Favored 'Trans proline' 0 C--N 1.369 1.612 0 C-N-CA 122.014 1.809 . . . . 0.0 113.202 179.582 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.58 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -146.92 -161.51 9.39 Favored Glycine 0 C--N 1.338 0.683 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.882 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -62.01 111.13 1.8 Allowed 'General case' 0 N--CA 1.474 0.765 0 CA-C-O 121.069 0.462 . . . . 0.0 111.938 -179.209 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.32 31.66 13.52 Favored Glycine 0 C--N 1.341 0.817 0 CA-C-N 115.242 -0.89 . . . . 0.0 112.718 -179.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.508 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 36.2 mt-10 -125.46 161.48 27.02 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-O 120.551 0.215 . . . . 0.0 111.328 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.478 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.7 tt0 -79.91 120.93 24.8 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.521 179.726 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.9 p -125.16 150.03 47.32 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.627 -179.062 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.463 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 7.9 t70 -110.59 154.67 23.44 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.804 179.257 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.1 m -104.06 3.93 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 CA-C-N 116.125 -0.488 . . . . 0.0 112.178 -179.589 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.463 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.3 mt-10 -98.39 -47.93 5.23 Favored 'General case' 0 C--O 1.234 0.24 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -179.163 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -150.07 0.39 0.46 Allowed 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 113.449 0.907 . . . . 0.0 113.449 -179.025 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -131.01 63.81 71.68 Favored Pre-proline 0 CA--C 1.549 0.928 0 N-CA-C 111.874 0.324 . . . . 0.0 111.874 -179.299 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -76.27 174.49 12.74 Favored 'Trans proline' 0 C--N 1.369 1.646 0 C-N-CA 122.513 2.142 . . . . 0.0 112.618 179.299 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 31.0 m -79.62 133.12 36.4 Favored 'General case' 0 N--CA 1.468 0.438 0 C-N-CA 122.574 0.35 . . . . 0.0 110.303 179.587 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.525 ' SG ' ' HD3' ' A' ' 17' ' ' PRO . 0.9 OUTLIER -79.66 -45.45 1.57 Allowed Pre-proline 0 N--CA 1.477 0.877 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -179.242 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.525 ' HD3' ' SG ' ' A' ' 16' ' ' CYS . 56.0 Cg_endo -69.98 174.81 9.15 Favored 'Trans proline' 0 C--N 1.373 1.856 0 C-N-CA 121.886 1.724 . . . . 0.0 111.956 179.054 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_exo -69.59 65.22 1.7 Allowed 'Trans proline' 0 C--N 1.378 2.127 0 C-N-CA 122.292 1.995 . . . . 0.0 112.534 179.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.406 ' HB3' ' O ' ' A' ' 31' ' ' TYR . 15.6 mt -136.12 162.04 34.04 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.673 -179.671 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.567 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 14.7 t -111.31 163.02 14.4 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.078 179.543 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.8 t -102.62 110.74 22.78 Favored 'General case' 0 C--O 1.239 0.538 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.294 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 4.8 mt -127.78 131.09 23.63 Favored Pre-proline 0 CA--C 1.542 0.669 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.339 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -74.55 -37.85 2.05 Favored 'Cis proline' 0 C--N 1.374 1.877 0 C-N-CA 124.461 -1.058 . . . . 0.0 113.242 -0.25 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.83 39.51 11.79 Favored Glycine 0 C--N 1.345 1.046 0 O-C-N 123.508 0.505 . . . . 0.0 113.076 -179.716 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -140.71 82.17 16.01 Favored Pre-proline 0 CA--C 1.55 0.978 0 C-N-CA 122.105 0.162 . . . . 0.0 110.911 -179.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -84.86 -33.7 2.35 Favored 'Cis proline' 0 C--N 1.371 1.761 0 CA-C-N 119.096 0.713 . . . . 0.0 112.972 -0.415 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -105.69 156.67 18.06 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.934 -179.256 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.478 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.31 -155.27 7.08 Favored Glycine 0 C--N 1.338 0.682 0 CA-C-N 115.868 -0.606 . . . . 0.0 112.553 179.75 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.508 ' HA ' ' O ' ' A' ' 6' ' ' GLU . 19.4 mm -128.57 149.24 33.18 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.58 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 63.6 m -84.42 110.67 18.81 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.274 179.196 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.406 ' O ' ' HB3' ' A' ' 19' ' ' LEU . 85.3 m-85 -106.24 160.95 14.96 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.128 -0.487 . . . . 0.0 112.056 -178.816 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.1 tp -90.1 126.52 42.95 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.611 179.569 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 38.2 mm . . . . . 0 C--O 1.25 1.124 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.088 -179.606 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.487 1.404 0 CA-C-O 119.528 -0.272 . . . . 0.0 111.164 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -83.78 -178.85 3.78 Favored 'Trans proline' 0 C--N 1.372 1.806 0 C-N-CA 122.47 2.113 . . . . 0.0 113.949 -179.099 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' GLY . . . . . 0.511 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.27 -152.32 6.45 Favored Glycine 0 C--N 1.342 0.913 0 CA-C-N 115.613 -0.722 . . . . 0.0 112.04 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -73.25 113.76 10.67 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.916 0.389 . . . . 0.0 111.621 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.32 32.47 10.44 Favored Glycine 0 C--N 1.341 0.816 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.795 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.55 162.26 26.86 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-O 120.663 0.268 . . . . 0.0 111.251 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.502 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.8 tt0 -80.09 127.0 31.79 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.816 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.47 150.55 50.76 Favored 'General case' 0 C--O 1.233 0.237 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.664 -179.252 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.451 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.17 154.62 23.08 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.597 -0.729 . . . . 0.0 109.785 179.008 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.7 m -102.93 4.23 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 116.123 -0.49 . . . . 0.0 112.14 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.451 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.0 mt-10 -100.27 -48.57 4.55 Favored 'General case' 0 C--O 1.235 0.329 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.113 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.4 p90 -148.45 2.0 0.62 Allowed 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 113.293 0.849 . . . . 0.0 113.293 -178.877 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.08 63.46 70.34 Favored Pre-proline 0 CA--C 1.548 0.903 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -74.46 175.59 10.82 Favored 'Trans proline' 0 C--N 1.369 1.649 0 C-N-CA 122.493 2.128 . . . . 0.0 112.594 179.281 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.7 m -79.69 140.87 36.87 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.503 179.706 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -80.0 -52.58 1.02 Allowed Pre-proline 0 CA--C 1.543 0.702 0 CA-C-O 118.996 -0.526 . . . . 0.0 112.006 -179.326 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.429 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.6 Cg_endo -73.79 175.98 10.04 Favored 'Trans proline' 0 C--N 1.375 1.928 0 C-N-CA 122.143 1.895 . . . . 0.0 111.963 179.258 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.38 64.78 1.58 Allowed 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 122.387 2.058 . . . . 0.0 112.731 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.429 HD12 ' HG2' ' A' ' 17' ' ' PRO . 39.7 mt -127.46 161.32 29.0 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.748 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.0 t -112.4 149.57 32.33 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.015 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.2 t -93.91 108.61 20.39 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.59 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.426 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -127.91 130.78 23.59 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.301 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -73.36 -38.99 1.56 Allowed 'Cis proline' 0 C--N 1.372 1.802 0 C-N-CA 124.671 -0.97 . . . . 0.0 113.464 -0.232 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.65 39.69 13.86 Favored Glycine 0 C--N 1.344 0.999 0 O-C-N 123.453 0.471 . . . . 0.0 113.047 -179.722 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -141.19 83.34 13.82 Favored Pre-proline 0 CA--C 1.546 0.791 0 C-N-CA 122.182 0.193 . . . . 0.0 111.315 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.56 -33.5 2.71 Favored 'Cis proline' 0 C--N 1.372 1.779 0 CA-C-N 119.061 0.7 . . . . 0.0 112.826 -0.369 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -106.69 156.32 18.75 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.932 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.502 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.78 -154.2 6.61 Favored Glycine 0 C--N 1.338 0.642 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.526 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.511 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.9 mm -127.62 147.17 32.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.511 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.1 m -84.38 107.93 16.92 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.13 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.511 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.4 m-85 -106.09 158.99 16.41 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.824 -179.073 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -93.29 122.99 45.23 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.6 179.664 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.3 pt . . . . . 0 C--O 1.251 1.141 0 CA-C-O 118.472 -0.775 . . . . 0.0 111.349 179.94 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.37 0 CA-C-O 119.533 -0.27 . . . . 0.0 111.133 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -83.89 -178.83 3.73 Favored 'Trans proline' 0 C--N 1.373 1.816 0 C-N-CA 122.458 2.105 . . . . 0.0 114.008 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' GLY . . . . . 0.513 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.4 -152.35 6.44 Favored Glycine 0 C--N 1.343 0.922 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.961 179.68 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -73.08 113.89 10.63 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-O 120.789 0.328 . . . . 0.0 111.641 -179.49 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.06 32.63 10.46 Favored Glycine 0 C--N 1.34 0.757 0 CA-C-N 115.448 -0.796 . . . . 0.0 112.781 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.3 mt-10 -127.6 162.39 26.61 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.647 0.26 . . . . 0.0 111.282 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.514 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.6 tt0 -80.05 127.1 31.89 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.793 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.84 150.7 51.02 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.681 -179.262 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.447 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.54 154.71 23.32 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.775 179.024 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.9 m -102.85 4.07 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-N 116.18 -0.464 . . . . 0.0 112.156 -179.605 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.447 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.4 mt-10 -100.01 -48.65 4.58 Favored 'General case' 0 C--O 1.235 0.312 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.002 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -148.54 2.13 0.62 Allowed 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 113.407 0.891 . . . . 0.0 113.407 -178.912 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -131.17 63.68 70.95 Favored Pre-proline 0 CA--C 1.55 0.962 0 N-CA-C 111.678 0.251 . . . . 0.0 111.678 -179.432 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.65 175.71 10.75 Favored 'Trans proline' 0 C--N 1.369 1.641 0 C-N-CA 122.493 2.129 . . . . 0.0 112.663 179.235 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.5 m -79.66 140.87 36.91 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 123.288 0.368 . . . . 0.0 110.618 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.94 -52.58 1.03 Allowed Pre-proline 0 CA--C 1.543 0.705 0 CA-C-O 119.131 -0.462 . . . . 0.0 111.925 -179.212 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.426 ' HG2' HD12 ' A' ' 19' ' ' LEU . 66.4 Cg_endo -73.78 175.87 10.17 Favored 'Trans proline' 0 C--N 1.376 1.986 0 C-N-CA 122.105 1.87 . . . . 0.0 112.01 179.227 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -69.37 64.89 1.57 Allowed 'Trans proline' 0 C--N 1.377 2.068 0 C-N-CA 122.373 2.049 . . . . 0.0 112.721 179.478 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.426 HD12 ' HG2' ' A' ' 17' ' ' PRO . 41.1 mt -127.55 161.45 28.76 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.746 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.7 t -112.34 149.58 32.24 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.084 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -94.02 108.93 20.71 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.496 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mt -128.14 130.68 23.57 Favored Pre-proline 0 CA--C 1.541 0.612 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.314 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -73.55 -38.95 1.58 Allowed 'Cis proline' 0 C--N 1.374 1.872 0 C-N-CA 124.581 -1.008 . . . . 0.0 113.456 -0.181 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.85 39.84 12.98 Favored Glycine 0 C--N 1.345 1.08 0 O-C-N 123.483 0.489 . . . . 0.0 113.111 -179.644 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -140.98 82.88 14.56 Favored Pre-proline 0 CA--C 1.546 0.818 0 C-N-CA 122.205 0.202 . . . . 0.0 111.26 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -83.76 -33.54 2.65 Favored 'Cis proline' 0 C--N 1.372 1.766 0 CA-C-N 119.066 0.702 . . . . 0.0 112.857 -0.409 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -106.97 156.32 18.85 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.01 -179.324 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.514 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.76 -152.13 5.89 Favored Glycine 0 C--N 1.337 0.635 0 CA-C-N 115.869 -0.605 . . . . 0.0 112.554 179.815 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.501 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.2 mm -129.11 147.13 33.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.513 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.2 m -84.4 108.13 17.05 Favored 'General case' 0 C--O 1.238 0.48 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.174 179.198 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.501 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.0 m-85 -106.2 159.23 16.25 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.79 -179.056 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.91 123.25 44.94 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.641 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.465 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.173 -0.918 . . . . 0.0 111.495 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.37 0 CA-C-O 119.499 -0.286 . . . . 0.0 111.115 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -83.89 -178.81 3.73 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.424 2.083 . . . . 0.0 113.995 -179.161 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' GLY . . . . . 0.513 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.31 -152.41 6.47 Favored Glycine 0 C--N 1.343 0.965 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.993 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -73.03 113.84 10.52 Favored 'General case' 0 N--CA 1.471 0.594 0 CA-C-O 120.961 0.41 . . . . 0.0 111.669 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.09 32.48 10.62 Favored Glycine 0 C--N 1.342 0.886 0 CA-C-N 115.415 -0.812 . . . . 0.0 112.78 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.54 162.34 26.66 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.63 0.252 . . . . 0.0 111.302 -179.731 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.502 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.15 127.31 32.18 Favored 'General case' 0 C--N 1.346 0.428 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.794 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.4 p -129.7 150.49 50.99 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 115.815 -0.629 . . . . 0.0 111.605 -179.234 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.452 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.1 t70 -110.2 154.58 23.17 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.831 178.922 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.5 m -102.88 3.94 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 CA-C-N 116.165 -0.47 . . . . 0.0 112.225 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.452 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -99.71 -48.76 4.6 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 111.981 0.363 . . . . 0.0 111.981 -179.046 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -148.64 2.18 0.61 Allowed 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 113.204 0.816 . . . . 0.0 113.204 -178.847 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.28 63.67 70.74 Favored Pre-proline 0 CA--C 1.548 0.903 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -74.55 176.11 10.17 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 122.434 2.089 . . . . 0.0 112.66 179.209 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 36.2 m -79.81 140.9 36.68 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.557 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.96 -52.64 1.02 Allowed Pre-proline 0 CA--C 1.544 0.75 0 CA-C-O 119.068 -0.491 . . . . 0.0 111.926 -179.197 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.43 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.6 Cg_endo -73.76 175.96 10.04 Favored 'Trans proline' 0 C--N 1.376 1.99 0 C-N-CA 122.114 1.876 . . . . 0.0 112.039 179.26 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.36 64.89 1.57 Allowed 'Trans proline' 0 C--N 1.377 2.069 0 C-N-CA 122.327 2.018 . . . . 0.0 112.747 179.479 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.43 HD12 ' HG2' ' A' ' 17' ' ' PRO . 40.6 mt -127.6 161.42 28.88 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.736 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.9 t -112.34 149.57 32.25 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 115.888 -0.597 . . . . 0.0 111.068 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.2 t -94.06 108.76 20.56 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.551 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.1 mt -127.99 130.75 23.58 Favored Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.337 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.38 -39.02 1.55 Allowed 'Cis proline' 0 C--N 1.374 1.87 0 C-N-CA 124.583 -1.007 . . . . 0.0 113.444 -0.22 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.91 39.68 13.02 Favored Glycine 0 C--N 1.345 1.06 0 O-C-N 123.423 0.452 . . . . 0.0 113.069 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.23 83.39 13.73 Favored Pre-proline 0 CA--C 1.547 0.841 0 C-N-CA 122.116 0.166 . . . . 0.0 111.217 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.65 -33.41 2.73 Favored 'Cis proline' 0 C--N 1.372 1.772 0 C-N-CA 125.335 -0.694 . . . . 0.0 112.841 -0.364 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -106.79 156.2 18.92 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.018 -179.378 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.502 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.53 -153.88 6.46 Favored Glycine 0 C--N 1.338 0.639 0 CA-C-N 115.866 -0.606 . . . . 0.0 112.508 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.507 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.4 mm -127.85 147.11 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.513 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.6 m -84.3 107.9 16.85 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.142 179.26 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.507 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -106.03 159.25 16.2 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.785 -179.094 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -93.06 123.15 45.05 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.622 179.646 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.466 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.295 -0.86 . . . . 0.0 111.519 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.37 0 CA-C-O 119.576 -0.25 . . . . 0.0 111.05 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -83.75 -178.86 3.8 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.53 2.153 . . . . 0.0 114.019 -179.129 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' GLY . . . . . 0.513 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.04 -152.29 6.48 Favored Glycine 0 C--N 1.342 0.888 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.996 179.659 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -73.52 113.98 11.23 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-O 120.986 0.422 . . . . 0.0 111.561 -179.54 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.13 32.57 10.48 Favored Glycine 0 C--N 1.341 0.818 0 CA-C-N 115.418 -0.81 . . . . 0.0 112.8 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.44 162.3 26.68 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-O 120.476 0.179 . . . . 0.0 111.345 -179.645 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.511 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.07 127.27 32.1 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.795 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.78 150.38 51.11 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.631 -179.248 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.448 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.42 154.89 22.95 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.821 178.94 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.7 m -102.93 4.21 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 CA-C-N 116.174 -0.466 . . . . 0.0 112.137 -179.507 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.448 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.3 mt-10 -100.32 -48.57 4.54 Favored 'General case' 0 C--O 1.235 0.307 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -179.123 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.6 p90 -148.28 2.0 0.64 Allowed 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 113.279 0.844 . . . . 0.0 113.279 -178.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.12 63.58 70.7 Favored Pre-proline 0 CA--C 1.548 0.903 0 N-CA-C 111.73 0.27 . . . . 0.0 111.73 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.59 175.36 11.19 Favored 'Trans proline' 0 C--N 1.371 1.712 0 C-N-CA 122.461 2.107 . . . . 0.0 112.61 179.208 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.8 m -79.58 140.69 37.08 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.537 179.664 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.98 -52.57 1.03 Allowed Pre-proline 0 N--CA 1.473 0.687 0 CA-C-O 118.98 -0.533 . . . . 0.0 111.983 -179.367 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.426 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.1 Cg_endo -73.88 175.93 10.14 Favored 'Trans proline' 0 C--N 1.375 1.951 0 C-N-CA 122.135 1.89 . . . . 0.0 111.984 179.287 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.43 64.91 1.61 Allowed 'Trans proline' 0 C--N 1.378 2.102 0 C-N-CA 122.277 1.985 . . . . 0.0 112.769 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.426 HD12 ' HG2' ' A' ' 17' ' ' PRO . 40.7 mt -127.35 161.6 28.26 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.782 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.7 t -112.65 149.38 32.93 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.009 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -93.88 108.81 20.56 Favored 'General case' 0 C--O 1.238 0.49 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.544 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mt -127.99 130.8 23.58 Favored Pre-proline 0 CA--C 1.542 0.665 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.247 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -73.47 -38.82 1.64 Allowed 'Cis proline' 0 C--N 1.374 1.872 0 C-N-CA 124.553 -1.019 . . . . 0.0 113.475 -0.296 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.95 39.66 12.96 Favored Glycine 0 C--N 1.345 1.042 0 O-C-N 123.38 0.425 . . . . 0.0 113.089 -179.743 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -141.24 83.16 13.92 Favored Pre-proline 0 CA--C 1.547 0.827 0 C-N-CA 122.161 0.185 . . . . 0.0 111.265 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -83.84 -33.52 2.64 Favored 'Cis proline' 0 C--N 1.373 1.823 0 CA-C-N 119.052 0.697 . . . . 0.0 112.829 -0.282 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.1 m-85 -106.96 156.42 18.74 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.928 -179.354 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.82 -152.47 5.99 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 115.85 -0.614 . . . . 0.0 112.603 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.505 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.5 mm -129.02 147.04 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 O-C-N 123.8 0.353 . . . . 0.0 110.08 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.513 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 76.6 m -84.18 107.79 16.7 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.262 179.2 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.505 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.1 m-85 -105.91 159.13 16.27 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.835 -179.044 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.9 123.25 44.92 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.627 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.466 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.32 -0.848 . . . . 0.0 111.398 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.371 0 CA-C-O 119.586 -0.245 . . . . 0.0 111.171 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -83.8 -178.82 3.76 Favored 'Trans proline' 0 C--N 1.372 1.805 0 C-N-CA 122.445 2.097 . . . . 0.0 114.031 -179.137 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' GLY . . . . . 0.51 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.87 -152.18 6.49 Favored Glycine 0 C--N 1.343 0.942 0 CA-C-N 115.539 -0.755 . . . . 0.0 112.002 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.46 114.24 11.46 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-O 120.891 0.377 . . . . 0.0 111.6 -179.569 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.69 32.6 11.08 Favored Glycine 0 C--N 1.34 0.801 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.838 -179.761 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.403 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 33.5 mt-10 -127.4 162.65 25.83 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 120.625 0.25 . . . . 0.0 111.255 -179.576 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.528 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.07 127.25 32.08 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.805 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.8 p -130.32 150.47 51.54 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.631 -179.372 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.499 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.4 t70 -110.65 154.93 23.12 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.876 178.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.543 HG23 ' OE2' ' A' ' 11' ' ' GLU . 9.6 m -102.9 3.31 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-N 116.172 -0.467 . . . . 0.0 112.152 -179.481 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.543 ' OE2' HG23 ' A' ' 10' ' ' VAL . 4.9 mp0 -97.85 -49.02 4.96 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.443 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 42.1 p90 -149.26 2.52 0.56 Allowed 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 113.375 0.88 . . . . 0.0 113.375 -178.85 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -130.69 63.67 70.71 Favored Pre-proline 0 CA--C 1.548 0.887 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -74.66 175.99 10.37 Favored 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 122.507 2.138 . . . . 0.0 112.604 179.3 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 34.8 m -79.7 140.92 36.83 Favored 'General case' 0 CA--C 1.534 0.352 0 O-C-N 123.271 0.357 . . . . 0.0 110.603 179.648 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.89 -52.76 1.03 Allowed Pre-proline 0 CA--C 1.545 0.752 0 CA-C-O 119.039 -0.505 . . . . 0.0 111.939 -179.283 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.426 ' HG2' HD12 ' A' ' 19' ' ' LEU . 63.1 Cg_endo -73.53 175.72 10.28 Favored 'Trans proline' 0 C--N 1.374 1.893 0 C-N-CA 122.097 1.865 . . . . 0.0 112.006 179.251 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.35 64.94 1.56 Allowed 'Trans proline' 0 C--N 1.377 2.064 0 C-N-CA 122.347 2.031 . . . . 0.0 112.792 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.426 HD12 ' HG2' ' A' ' 17' ' ' PRO . 38.5 mt -127.6 161.84 27.89 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.741 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.2 t -112.57 149.74 32.31 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.076 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.4 t -94.14 109.05 20.86 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.555 179.595 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.6 mt -128.02 130.99 23.56 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.251 -179.766 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -73.44 -38.82 1.64 Allowed 'Cis proline' 0 C--N 1.374 1.878 0 C-N-CA 124.686 -0.964 . . . . 0.0 113.56 -0.301 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.37 42.05 10.88 Favored Glycine 0 C--N 1.344 1.009 0 O-C-N 123.379 0.424 . . . . 0.0 113.035 -179.584 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.07 80.68 16.75 Favored Pre-proline 0 CA--C 1.547 0.841 0 C-N-CA 122.194 0.198 . . . . 0.0 111.352 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -84.81 -32.77 2.73 Favored 'Cis proline' 0 C--N 1.372 1.804 0 C-N-CA 125.365 -0.681 . . . . 0.0 112.889 -0.359 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 83.2 m-85 -105.86 156.49 18.29 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.107 -179.173 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.528 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -154.31 -150.95 5.64 Favored Glycine 0 C--N 1.338 0.672 0 CA-C-N 115.883 -0.599 . . . . 0.0 112.452 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.485 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.8 mm -129.25 146.99 33.39 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.51 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.1 m -84.64 108.62 17.47 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.204 179.237 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.485 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.7 m-85 -106.1 158.83 16.53 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.874 -179.002 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tp -93.63 123.89 45.89 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.517 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.623 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.3 pt . . . . . 0 C--O 1.248 0.984 0 CA-C-O 118.115 -0.945 . . . . 0.0 111.279 179.987 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.348 0 CA-C-O 119.554 -0.26 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -83.71 -178.88 3.82 Favored 'Trans proline' 0 C--N 1.372 1.814 0 C-N-CA 122.496 2.131 . . . . 0.0 114.038 -179.088 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' GLY . . . . . 0.511 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.04 -152.28 6.48 Favored Glycine 0 C--N 1.341 0.86 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.031 179.608 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.1 tt0 -73.45 113.75 10.9 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 120.932 0.396 . . . . 0.0 111.715 -179.66 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.45 32.62 10.14 Favored Glycine 0 C--N 1.34 0.8 0 CA-C-N 115.46 -0.791 . . . . 0.0 112.846 -179.792 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.66 162.07 27.4 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-O 120.58 0.228 . . . . 0.0 111.314 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.508 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.8 tt0 -79.96 127.13 31.9 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.804 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.71 150.67 50.92 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.619 -179.282 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.449 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.1 t70 -110.36 154.9 22.88 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.811 178.834 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.5 m -102.79 4.27 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-N 116.186 -0.461 . . . . 0.0 112.132 -179.534 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.449 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -100.93 -48.51 4.42 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 112.084 0.401 . . . . 0.0 112.084 -179.052 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 39.9 p90 -147.78 1.8 0.69 Allowed 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 113.42 0.896 . . . . 0.0 113.42 -178.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.05 63.29 69.82 Favored Pre-proline 0 CA--C 1.55 0.97 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.344 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.48 175.06 11.55 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.381 2.054 . . . . 0.0 112.617 179.281 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.4 m -79.68 140.81 36.9 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.484 179.733 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.98 -52.56 1.03 Allowed Pre-proline 0 CA--C 1.543 0.7 0 CA-C-O 119.087 -0.483 . . . . 0.0 111.993 -179.368 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.43 ' HG2' HD12 ' A' ' 19' ' ' LEU . 66.6 Cg_endo -73.85 175.94 10.11 Favored 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 122.071 1.848 . . . . 0.0 112.045 179.165 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -69.34 64.83 1.55 Allowed 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 122.384 2.056 . . . . 0.0 112.759 179.547 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.43 HD12 ' HG2' ' A' ' 17' ' ' PRO . 41.8 mt -127.28 161.59 28.23 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.818 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.9 t -112.81 149.26 33.3 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.995 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.2 t -93.78 108.76 20.48 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.551 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.424 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.4 mt -127.95 130.93 23.57 Favored Pre-proline 0 CA--C 1.541 0.626 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.226 -179.748 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -73.34 -39.02 1.56 Allowed 'Cis proline' 0 C--N 1.374 1.91 0 C-N-CA 124.705 -0.956 . . . . 0.0 113.468 -0.389 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.64 39.64 13.99 Favored Glycine 0 C--N 1.344 0.981 0 O-C-N 123.455 0.472 . . . . 0.0 113.075 -179.682 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -140.89 82.99 14.64 Favored Pre-proline 0 CA--C 1.549 0.925 0 C-N-CA 122.188 0.195 . . . . 0.0 110.956 -179.765 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -83.92 -33.75 2.53 Favored 'Cis proline' 0 C--N 1.372 1.777 0 CA-C-N 119.101 0.715 . . . . 0.0 112.877 -0.436 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.7 m-85 -106.6 156.25 18.79 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.025 -179.408 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.508 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.85 -152.74 6.08 Favored Glycine 0 C--N 1.338 0.67 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.538 179.741 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.515 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.2 mm -128.69 147.0 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -179.838 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.511 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 78.8 m -84.06 107.97 16.72 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.183 179.175 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.515 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.4 m-85 -106.17 159.3 16.19 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.805 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -93.02 122.81 44.81 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.681 179.552 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.466 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.363 -0.827 . . . . 0.0 111.449 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.361 0 CA-C-O 119.522 -0.275 . . . . 0.0 111.098 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -83.7 -178.86 3.82 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.47 2.114 . . . . 0.0 113.967 -179.068 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' GLY . . . . . 0.512 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.98 -152.23 6.48 Favored Glycine 0 C--N 1.343 0.945 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.031 179.53 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -73.53 113.84 11.09 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-O 120.833 0.349 . . . . 0.0 111.581 -179.504 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.33 32.69 10.15 Favored Glycine 0 C--N 1.339 0.747 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.793 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.62 162.22 27.0 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 120.564 0.221 . . . . 0.0 111.275 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.513 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -79.93 127.26 32.05 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.828 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.6 p -129.92 150.65 51.11 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.592 -179.278 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.445 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.64 154.71 23.42 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.773 178.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.8 m -102.65 4.18 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-N 116.146 -0.479 . . . . 0.0 112.139 -179.56 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.445 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.6 mm-40 -100.48 -48.62 4.49 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -179.088 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.4 p90 -148.02 1.89 0.67 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 113.379 0.881 . . . . 0.0 113.379 -178.854 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.09 63.39 70.08 Favored Pre-proline 0 CA--C 1.551 0.993 0 N-CA-C 111.723 0.268 . . . . 0.0 111.723 -179.236 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.51 175.2 11.37 Favored 'Trans proline' 0 C--N 1.37 1.683 0 C-N-CA 122.391 2.061 . . . . 0.0 112.644 179.287 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.5 m -79.75 140.74 36.82 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.559 179.631 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.89 -52.59 1.04 Allowed Pre-proline 0 N--CA 1.474 0.768 0 CA-C-O 119.057 -0.497 . . . . 0.0 111.975 -179.296 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.426 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.1 Cg_endo -73.89 175.94 10.13 Favored 'Trans proline' 0 C--N 1.376 1.995 0 C-N-CA 122.148 1.899 . . . . 0.0 111.941 179.342 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.3 64.91 1.53 Allowed 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 122.322 2.014 . . . . 0.0 112.732 179.501 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.426 HD12 ' HG2' ' A' ' 17' ' ' PRO . 40.3 mt -127.43 161.58 28.36 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.744 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.9 t -112.73 149.41 32.98 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.026 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -93.9 108.85 20.6 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.539 179.568 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.401 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -127.99 130.81 23.58 Favored Pre-proline 0 CA--C 1.541 0.626 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.264 -179.749 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -73.29 -39.02 1.56 Allowed 'Cis proline' 0 C--N 1.374 1.92 0 C-N-CA 124.692 -0.962 . . . . 0.0 113.439 -0.306 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.86 39.83 12.98 Favored Glycine 0 C--N 1.343 0.971 0 O-C-N 123.43 0.456 . . . . 0.0 113.073 -179.68 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.32 83.09 13.86 Favored Pre-proline 0 CA--C 1.547 0.861 0 C-N-CA 122.222 0.209 . . . . 0.0 111.299 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.91 -33.45 2.65 Favored 'Cis proline' 0 C--N 1.372 1.807 0 C-N-CA 125.345 -0.689 . . . . 0.0 112.755 -0.251 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.1 m-85 -106.89 156.51 18.62 Favored 'General case' 0 N--CA 1.465 0.313 0 O-C-N 123.593 0.558 . . . . 0.0 111.035 -179.424 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.513 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.05 -152.27 5.95 Favored Glycine 0 C--N 1.339 0.697 0 CA-C-N 115.866 -0.606 . . . . 0.0 112.603 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.512 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.3 mm -129.06 147.15 33.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.512 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 77.8 m -84.36 107.78 16.83 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.108 179.264 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.512 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -105.98 159.24 16.2 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.782 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.92 122.91 44.79 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.669 179.562 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.467 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 1.014 0 CA-C-O 118.3 -0.857 . . . . 0.0 111.351 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.485 1.319 0 CA-C-O 119.579 -0.248 . . . . 0.0 111.081 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -83.87 -178.91 3.78 Favored 'Trans proline' 0 C--N 1.371 1.747 0 C-N-CA 122.536 2.157 . . . . 0.0 113.941 -179.057 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' GLY . . . . . 0.512 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.37 -152.36 6.45 Favored Glycine 0 C--N 1.341 0.857 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.077 179.601 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -73.17 113.85 10.69 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-O 121.015 0.435 . . . . 0.0 111.629 -179.548 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.22 32.46 10.54 Favored Glycine 0 C--N 1.342 0.913 0 CA-C-N 115.345 -0.843 . . . . 0.0 112.778 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.52 162.28 26.79 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-O 120.508 0.194 . . . . 0.0 111.327 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.51 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.1 127.28 32.13 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.864 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.76 150.69 50.96 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.631 -179.193 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.447 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.2 t70 -110.5 154.69 23.31 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.775 178.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.6 m -102.98 3.95 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.191 -179.564 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.447 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.6 mm-40 -99.61 -48.79 4.62 Favored 'General case' 0 C--O 1.234 0.288 0 N-CA-C 111.936 0.346 . . . . 0.0 111.936 -179.053 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.1 p90 -148.63 1.97 0.61 Allowed 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -178.81 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -131.12 63.83 71.56 Favored Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 111.748 0.277 . . . . 0.0 111.748 -179.37 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -74.66 175.93 10.44 Favored 'Trans proline' 0 C--N 1.37 1.705 0 C-N-CA 122.459 2.106 . . . . 0.0 112.574 179.283 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.8 m -79.62 140.92 36.96 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 123.257 0.348 . . . . 0.0 110.62 179.626 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.96 -52.57 1.03 Allowed Pre-proline 0 CA--C 1.544 0.731 0 CA-C-O 119.01 -0.519 . . . . 0.0 111.954 -179.286 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.426 ' HG2' HD12 ' A' ' 19' ' ' LEU . 66.2 Cg_endo -73.94 175.97 10.1 Favored 'Trans proline' 0 C--N 1.375 1.955 0 C-N-CA 122.132 1.888 . . . . 0.0 112.002 179.27 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.35 64.92 1.56 Allowed 'Trans proline' 0 C--N 1.379 2.16 0 C-N-CA 122.402 2.068 . . . . 0.0 112.71 179.517 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.426 HD12 ' HG2' ' A' ' 17' ' ' PRO . 40.5 mt -127.63 161.3 29.17 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.799 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.8 t -112.36 149.59 32.25 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.06 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -93.93 108.89 20.64 Favored 'General case' 0 C--O 1.237 0.446 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.512 179.622 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.401 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -128.11 130.8 23.56 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.252 -179.82 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -73.45 -38.91 1.6 Allowed 'Cis proline' 0 C--N 1.374 1.9 0 C-N-CA 124.562 -1.016 . . . . 0.0 113.507 -0.288 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.93 39.84 12.72 Favored Glycine 0 C--N 1.344 1.009 0 O-C-N 123.437 0.46 . . . . 0.0 113.032 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -141.17 83.12 14.05 Favored Pre-proline 0 CA--C 1.547 0.84 0 CA-C-N 116.646 0.223 . . . . 0.0 111.271 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.77 -33.49 2.67 Favored 'Cis proline' 0 C--N 1.371 1.761 0 CA-C-N 119.062 0.701 . . . . 0.0 112.792 -0.272 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.8 m-85 -106.82 156.51 18.59 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.069 -179.412 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.51 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.85 -152.82 6.1 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.529 179.775 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.509 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.2 mm -128.56 147.18 33.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 -179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.512 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.9 m -84.35 107.98 16.93 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.179 179.229 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.509 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -106.26 159.15 16.33 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.767 -179.031 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.76 122.81 44.55 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.523 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.622 179.65 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.467 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.248 1.017 0 CA-C-O 118.442 -0.789 . . . . 0.0 111.405 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.361 0 CA-C-O 119.546 -0.264 . . . . 0.0 111.106 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_endo -83.77 -178.93 3.82 Favored 'Trans proline' 0 C--N 1.372 1.764 0 C-N-CA 122.502 2.134 . . . . 0.0 114.091 -179.197 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' GLY . . . . . 0.512 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.73 -152.34 6.55 Favored Glycine 0 C--N 1.342 0.872 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.989 179.505 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.79 114.0 11.57 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-O 120.924 0.392 . . . . 0.0 111.572 -179.43 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.72 32.21 10.39 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-N 115.456 -0.793 . . . . 0.0 112.759 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -127.61 162.26 26.92 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.705 0.288 . . . . 0.0 111.319 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.504 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -79.94 127.11 31.87 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.798 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.62 150.51 50.92 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.684 -179.34 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.451 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.21 154.65 23.08 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.847 178.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.6 m -102.7 4.1 10.63 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.203 -179.544 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.451 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -100.37 -48.51 4.55 Favored 'General case' 0 C--O 1.235 0.336 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.079 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.3 p90 -148.22 1.83 0.64 Allowed 'General case' 0 N--CA 1.476 0.862 0 N-CA-C 113.23 0.826 . . . . 0.0 113.23 -178.79 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.07 63.55 70.69 Favored Pre-proline 0 CA--C 1.549 0.928 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 -179.317 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.6 175.44 11.08 Favored 'Trans proline' 0 C--N 1.37 1.662 0 C-N-CA 122.434 2.089 . . . . 0.0 112.626 179.244 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.6 m -79.74 140.76 36.83 Favored 'General case' 0 CA--C 1.534 0.363 0 O-C-N 123.255 0.347 . . . . 0.0 110.541 179.69 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.91 -52.67 1.03 Allowed Pre-proline 0 CA--C 1.544 0.721 0 CA-C-O 119.017 -0.516 . . . . 0.0 112.007 -179.291 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.428 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.9 Cg_endo -73.78 175.93 10.1 Favored 'Trans proline' 0 C--N 1.374 1.893 0 C-N-CA 122.118 1.879 . . . . 0.0 112.013 179.212 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.39 64.95 1.58 Allowed 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 122.347 2.031 . . . . 0.0 112.678 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.428 HD12 ' HG2' ' A' ' 17' ' ' PRO . 39.9 mt -127.49 161.39 28.87 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.751 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.8 t -112.51 149.42 32.68 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.89 -0.596 . . . . 0.0 111.081 179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -93.88 108.79 20.54 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.515 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.409 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.2 mt -128.03 130.84 23.57 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.279 -179.783 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.31 -39.02 1.55 Allowed 'Cis proline' 0 C--N 1.374 1.89 0 C-N-CA 124.651 -0.979 . . . . 0.0 113.427 -0.284 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.75 39.63 13.65 Favored Glycine 0 C--N 1.344 0.98 0 O-C-N 123.469 0.48 . . . . 0.0 113.15 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -141.26 83.26 13.8 Favored Pre-proline 0 CA--C 1.546 0.799 0 C-N-CA 122.169 0.187 . . . . 0.0 111.302 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -83.68 -33.54 2.67 Favored 'Cis proline' 0 C--N 1.373 1.859 0 CA-C-N 119.05 0.697 . . . . 0.0 112.801 -0.271 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -106.71 156.24 18.84 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.018 -179.429 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.504 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.63 -153.35 6.27 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 115.868 -0.606 . . . . 0.0 112.597 179.715 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.51 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.5 mm -128.38 147.08 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.512 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.6 m -84.33 107.88 16.86 Favored 'General case' 0 C--O 1.238 0.48 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.221 179.157 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.51 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -106.02 159.08 16.33 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.767 -178.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.91 122.99 44.84 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.662 179.584 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.465 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.132 -0.937 . . . . 0.0 111.41 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.7 p . . . . . 0 N--CA 1.487 1.417 0 CA-C-O 119.66 -0.21 . . . . 0.0 111.102 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.453 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 91.9 Cg_endo -79.27 -178.87 4.93 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 122.586 2.191 . . . . 0.0 113.785 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -139.77 -144.69 4.57 Favored Glycine 0 C--N 1.339 0.713 0 CA-C-N 115.369 -0.832 . . . . 0.0 111.871 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -84.37 109.88 18.18 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 120.904 0.383 . . . . 0.0 110.81 179.478 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.15 36.88 6.46 Favored Glycine 0 C--N 1.34 0.76 0 CA-C-N 115.465 -0.789 . . . . 0.0 112.733 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.451 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 42.5 mt-10 -133.25 167.13 20.93 Favored 'General case' 0 N--CA 1.467 0.396 0 O-C-N 123.622 0.248 . . . . 0.0 110.909 -179.728 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.532 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.3 tt0 -80.32 124.54 28.94 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.637 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 20.6 p -127.64 143.57 51.15 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.494 -179.267 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.407 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 10.2 t70 -113.8 156.67 23.45 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.696 -0.683 . . . . 0.0 109.919 179.126 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 16.0 m -103.74 7.84 9.78 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 CA-C-N 116.02 -0.536 . . . . 0.0 112.078 -179.563 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.407 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.4 mt-10 -110.16 -49.34 3.08 Favored 'General case' 0 CA--C 1.533 0.298 0 N-CA-C 112.308 0.485 . . . . 0.0 112.308 -178.882 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.468 ' HZ ' ' HH ' ' A' ' 27' ' ' TYR . 37.3 p90 -141.2 4.16 1.81 Allowed 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 113.236 0.828 . . . . 0.0 113.236 -178.737 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -132.29 65.73 75.62 Favored Pre-proline 0 CA--C 1.546 0.795 0 CA-C-O 120.525 0.203 . . . . 0.0 111.126 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.453 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 50.4 Cg_endo -73.85 161.98 40.34 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.451 2.1 . . . . 0.0 112.81 179.509 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 91.1 m -79.88 140.85 36.59 Favored 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.548 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -83.81 -52.4 0.58 Allowed Pre-proline 0 CA--C 1.544 0.742 0 CA-C-O 118.906 -0.569 . . . . 0.0 112.265 -179.798 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.471 ' HG2' HD12 ' A' ' 19' ' ' LEU . 72.5 Cg_endo -75.55 172.89 15.45 Favored 'Trans proline' 0 C--N 1.375 1.953 0 C-N-CA 122.15 1.9 . . . . 0.0 112.48 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_exo -71.51 66.05 2.93 Favored 'Trans proline' 0 C--N 1.377 2.051 0 C-N-CA 122.409 2.072 . . . . 0.0 112.464 179.588 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.471 HD12 ' HG2' ' A' ' 17' ' ' PRO . 58.5 mt -125.43 166.7 16.12 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.818 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.596 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 9.8 t -115.05 143.96 44.37 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.102 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 6.1 t -92.27 109.3 20.68 Favored 'General case' 0 C--O 1.237 0.429 0 O-C-N 123.479 0.487 . . . . 0.0 110.725 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 6.8 mt -126.37 130.9 23.8 Favored Pre-proline 0 CA--C 1.542 0.637 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.991 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -74.18 -37.58 2.16 Favored 'Cis proline' 0 C--N 1.374 1.874 0 C-N-CA 124.565 -1.014 . . . . 0.0 113.567 -0.143 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.8 36.31 19.52 Favored Glycine 0 C--N 1.345 1.043 0 O-C-N 123.343 0.402 . . . . 0.0 113.029 -179.634 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -143.8 82.5 11.15 Favored Pre-proline 0 CA--C 1.55 0.945 0 CA-C-N 116.666 0.233 . . . . 0.0 111.089 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -85.99 -35.52 1.46 Allowed 'Cis proline' 0 C--N 1.373 1.843 0 CA-C-N 119.171 0.74 . . . . 0.0 112.834 -0.421 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.468 ' HH ' ' HZ ' ' A' ' 12' ' ' PHE . 64.5 m-85 -109.85 158.81 17.79 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.991 -179.184 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.532 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -162.49 -152.68 6.85 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-N 115.886 -0.597 . . . . 0.0 112.356 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.451 ' HA ' ' O ' ' A' ' 6' ' ' GLU . 16.0 mm -126.71 144.78 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 179.711 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.596 ' HA ' ' O ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -91.44 117.82 30.02 Favored 'General case' 0 C--O 1.235 0.337 0 O-C-N 123.505 0.503 . . . . 0.0 111.13 -179.977 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -109.04 167.35 10.16 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.731 -178.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.6 tp -95.04 123.62 47.23 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.553 179.526 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.478 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.4 pp . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.371 -0.823 . . . . 0.0 111.319 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.487 1.382 0 CA-C-O 119.658 -0.211 . . . . 0.0 111.098 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -83.37 -179.11 4.07 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.481 2.121 . . . . 0.0 114.087 -179.137 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' GLY . . . . . 0.495 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.98 -152.47 6.54 Favored Glycine 0 C--N 1.341 0.843 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.771 179.48 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.5 tt0 -73.34 111.85 8.85 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-O 120.83 0.348 . . . . 0.0 111.415 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.79 30.94 10.63 Favored Glycine 0 C--N 1.341 0.817 0 CA-C-N 115.485 -0.779 . . . . 0.0 112.715 -179.728 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.3 mt-10 -126.86 163.76 22.9 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-O 120.599 0.238 . . . . 0.0 111.21 -179.704 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.2 tt0 -79.97 128.67 33.75 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.067 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.474 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.4 p -127.11 142.61 51.47 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.627 -179.557 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -104.42 150.12 24.82 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.707 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.489 HG22 ' O ' ' A' ' 26' ' ' PRO . 9.0 m -101.61 5.38 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.904 -179.885 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -99.2 -47.52 5.17 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.929 -179.204 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -151.76 1.41 0.36 Allowed 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -178.855 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -131.65 64.44 72.9 Favored Pre-proline 0 CA--C 1.549 0.919 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -179.267 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -73.5 178.25 6.93 Favored 'Trans proline' 0 C--N 1.37 1.7 0 C-N-CA 122.538 2.159 . . . . 0.0 112.473 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.0 m -79.51 138.68 37.61 Favored 'General case' 0 N--CA 1.467 0.413 0 O-C-N 123.216 0.322 . . . . 0.0 110.706 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.02 -52.57 1.02 Allowed Pre-proline 0 CA--C 1.544 0.748 0 CA-C-O 118.983 -0.532 . . . . 0.0 112.089 -179.388 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.413 ' HG2' HD12 ' A' ' 19' ' ' LEU . 64.3 Cg_endo -72.76 175.9 9.66 Favored 'Trans proline' 0 C--N 1.375 1.944 0 C-N-CA 122.163 1.908 . . . . 0.0 112.06 179.347 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -69.55 64.87 1.68 Allowed 'Trans proline' 0 C--N 1.378 2.124 0 C-N-CA 122.373 2.049 . . . . 0.0 112.747 179.399 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.413 HD12 ' HG2' ' A' ' 17' ' ' PRO . 32.9 mt -129.09 159.92 34.45 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.721 179.889 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.431 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -111.09 152.76 26.57 Favored 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.192 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.7 t -96.39 106.47 18.71 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.256 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.443 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.3 mt -125.89 131.51 24.02 Favored Pre-proline 0 CA--C 1.542 0.67 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.478 -179.532 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -71.26 -39.34 1.45 Allowed 'Cis proline' 0 C--N 1.375 1.952 0 C-N-CA 124.649 -0.98 . . . . 0.0 113.389 -0.117 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.59 31.15 46.3 Favored Glycine 0 C--N 1.343 0.947 0 O-C-N 123.408 0.442 . . . . 0.0 113.266 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -136.97 85.64 22.45 Favored Pre-proline 0 CA--C 1.545 0.781 0 C-N-CA 122.198 0.199 . . . . 0.0 111.096 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.489 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.2 Cg_endo -83.13 -34.5 2.4 Favored 'Cis proline' 0 C--N 1.372 1.811 0 C-N-CA 125.246 -0.731 . . . . 0.0 112.94 -0.217 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.3 m-85 -98.66 153.94 18.33 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.02 -179.218 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.14 -171.5 18.58 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 116.072 -0.513 . . . . 0.0 113.06 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.479 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 42.5 mm -122.42 146.0 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.495 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.3 m -81.57 107.79 14.62 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.543 179.492 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.479 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.6 m-85 -108.29 158.6 17.33 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.612 -179.389 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 tp -92.1 123.32 44.17 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.662 179.618 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.453 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.124 -0.941 . . . . 0.0 111.402 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 119.546 -0.264 . . . . 0.0 111.116 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -83.55 -179.04 3.96 Favored 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.479 2.12 . . . . 0.0 114.029 -179.143 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' GLY . . . . . 0.528 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.68 -152.91 6.52 Favored Glycine 0 C--N 1.342 0.902 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.96 179.623 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -72.18 113.13 8.88 Favored 'General case' 0 N--CA 1.472 0.663 0 CA-C-O 120.941 0.4 . . . . 0.0 111.539 -179.44 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.7 33.32 10.15 Favored Glycine 0 C--N 1.342 0.873 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.761 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.441 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 8.6 mm-40 -127.65 163.55 23.99 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 120.607 0.241 . . . . 0.0 111.266 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.535 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.6 tt0 -80.15 127.93 32.91 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.837 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.412 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 8.6 p -130.86 148.77 52.67 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.75 -179.319 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.44 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.2 t70 -110.83 155.59 22.35 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.816 178.958 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.0 m -103.23 3.6 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 112.244 0.461 . . . . 0.0 112.244 -179.49 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.44 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -98.89 -48.79 4.78 Favored 'General case' 0 C--O 1.235 0.339 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -179.027 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -148.76 1.99 0.59 Allowed 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -178.874 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -131.02 63.7 71.26 Favored Pre-proline 0 CA--C 1.55 0.95 0 N-CA-C 111.757 0.28 . . . . 0.0 111.757 -179.371 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -74.81 175.66 10.88 Favored 'Trans proline' 0 C--N 1.37 1.708 0 C-N-CA 122.467 2.111 . . . . 0.0 112.571 179.133 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 38.4 m -79.74 140.1 37.07 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 116.55 -0.295 . . . . 0.0 110.561 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.98 -52.51 1.03 Allowed Pre-proline 0 CA--C 1.544 0.734 0 CA-C-O 119.082 -0.485 . . . . 0.0 112.037 -179.258 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.428 ' HG2' HD12 ' A' ' 19' ' ' LEU . 64.6 Cg_endo -73.52 175.5 10.57 Favored 'Trans proline' 0 C--N 1.376 2.004 0 C-N-CA 122.087 1.858 . . . . 0.0 112.115 179.248 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -69.47 64.93 1.64 Allowed 'Trans proline' 0 C--N 1.377 2.072 0 C-N-CA 122.386 2.057 . . . . 0.0 112.707 179.465 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.428 HD12 ' HG2' ' A' ' 17' ' ' PRO . 36.7 mt -127.83 161.95 27.81 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.761 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.0 t -111.71 150.39 30.27 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.213 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 4.0 t -95.26 108.6 20.76 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.553 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.4 mt -127.66 130.99 23.6 Favored Pre-proline 0 CA--C 1.541 0.616 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.195 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.599 ' HB2' ' OD2' ' A' ' 25' ' ' ASP . 55.6 Cg_endo -72.48 -39.44 1.44 Allowed 'Cis proline' 0 C--N 1.373 1.854 0 C-N-CA 124.668 -0.972 . . . . 0.0 113.476 -0.272 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.56 38.82 11.55 Favored Glycine 0 C--N 1.344 0.998 0 O-C-N 123.483 0.49 . . . . 0.0 113.386 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.599 ' OD2' ' HB2' ' A' ' 23' ' ' PRO . 2.0 p30 -144.9 85.02 8.51 Favored Pre-proline 0 CA--C 1.55 0.952 0 CA-C-N 116.66 0.23 . . . . 0.0 111.473 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -83.88 -33.65 2.58 Favored 'Cis proline' 0 C--N 1.372 1.789 0 CA-C-N 118.985 0.673 . . . . 0.0 112.896 -0.466 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -109.69 156.72 19.9 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.977 -179.314 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.535 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.84 -151.17 5.67 Favored Glycine 0 C--N 1.338 0.661 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.507 179.78 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.487 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.7 mm -129.26 147.22 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.528 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 79.1 m -84.35 107.24 16.52 Favored 'General case' 0 CA--C 1.537 0.443 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.286 179.25 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.487 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.7 m-85 -105.14 157.84 16.99 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.544 -179.375 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 tt -94.23 124.42 46.7 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.704 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.459 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.247 0.95 0 CA-C-O 118.357 -0.83 . . . . 0.0 111.408 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.373 0 CA-C-O 119.67 -0.205 . . . . 0.0 111.09 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_endo -83.28 -179.13 4.11 Favored 'Trans proline' 0 C--N 1.373 1.822 0 C-N-CA 122.589 2.193 . . . . 0.0 114.054 -179.057 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' GLY . . . . . 0.495 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.0 -152.26 6.48 Favored Glycine 0 C--N 1.342 0.886 0 CA-C-N 115.41 -0.814 . . . . 0.0 111.777 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.5 tt0 -73.49 111.7 8.87 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 120.835 0.35 . . . . 0.0 111.452 -179.656 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.91 31.07 10.3 Favored Glycine 0 C--N 1.341 0.816 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.651 -179.752 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.1 mt-10 -126.94 163.85 22.75 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-O 120.534 0.207 . . . . 0.0 111.261 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -79.95 128.63 33.7 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.04 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.474 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.5 p -127.13 142.29 51.55 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.59 -179.549 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -104.29 150.03 24.81 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.737 179.407 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.491 HG22 ' O ' ' A' ' 26' ' ' PRO . 9.6 m -101.46 5.25 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.906 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -99.02 -47.45 5.23 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.928 -179.202 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -151.86 1.37 0.36 Allowed 'General case' 0 N--CA 1.478 0.947 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 -178.893 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 -131.55 64.31 72.57 Favored Pre-proline 0 CA--C 1.548 0.89 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.273 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.46 178.24 6.93 Favored 'Trans proline' 0 C--N 1.371 1.731 0 C-N-CA 122.544 2.163 . . . . 0.0 112.484 179.034 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 49.3 m -79.49 138.75 37.66 Favored 'General case' 0 N--CA 1.467 0.42 0 O-C-N 123.224 0.328 . . . . 0.0 110.765 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.22 -52.58 0.98 Allowed Pre-proline 0 CA--C 1.544 0.736 0 CA-C-O 119.018 -0.515 . . . . 0.0 112.057 -179.301 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.409 ' HG2' HD12 ' A' ' 19' ' ' LEU . 64.5 Cg_endo -72.7 175.88 9.64 Favored 'Trans proline' 0 C--N 1.375 1.972 0 C-N-CA 122.16 1.906 . . . . 0.0 112.06 179.297 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.59 65.0 1.7 Allowed 'Trans proline' 0 C--N 1.378 2.093 0 C-N-CA 122.381 2.054 . . . . 0.0 112.591 179.475 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.409 HD12 ' HG2' ' A' ' 17' ' ' PRO . 33.2 mt -129.28 159.96 34.49 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.579 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.432 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -110.98 152.68 26.53 Favored 'General case' 0 CA--C 1.536 0.408 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.101 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.8 t -96.33 106.43 18.65 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.366 179.679 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.444 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.5 mt -125.81 131.56 24.04 Favored Pre-proline 0 CA--C 1.543 0.684 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.396 -179.458 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -71.08 -39.45 1.42 Allowed 'Cis proline' 0 C--N 1.375 1.923 0 C-N-CA 124.683 -0.965 . . . . 0.0 113.402 -0.225 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.65 30.69 47.66 Favored Glycine 0 C--N 1.345 1.043 0 O-C-N 123.463 0.477 . . . . 0.0 113.391 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -136.79 85.8 23.14 Favored Pre-proline 0 CA--C 1.546 0.82 0 C-N-CA 122.259 0.224 . . . . 0.0 111.049 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.491 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.2 Cg_endo -83.07 -34.58 2.37 Favored 'Cis proline' 0 C--N 1.371 1.756 0 C-N-CA 125.273 -0.719 . . . . 0.0 112.95 -0.269 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 -98.64 153.9 18.34 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.044 -179.246 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.2 -171.8 18.9 Favored Glycine 0 C--N 1.339 0.729 0 O-C-N 123.542 0.526 . . . . 0.0 113.079 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.48 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 42.4 mm -122.17 145.91 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.495 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.5 m -81.44 107.73 14.45 Favored 'General case' 0 CA--C 1.537 0.469 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.517 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.48 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.6 m-85 -108.21 158.65 17.26 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.356 -0.383 . . . . 0.0 111.652 -179.447 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 tp -92.29 123.56 44.45 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.558 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.547 179.694 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.45 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 0.983 0 CA-C-O 118.278 -0.868 . . . . 0.0 111.384 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.488 1.446 0 CA-C-O 119.624 -0.227 . . . . 0.0 111.156 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.439 ' HG2' ' SG ' ' A' ' 30' ' ' CYS . 87.3 Cg_endo -81.94 -179.65 4.94 Favored 'Trans proline' 0 C--N 1.372 1.782 0 C-N-CA 122.652 2.235 . . . . 0.0 113.997 -179.067 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 3' ' ' GLY . . . . . 0.495 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.27 -151.37 6.39 Favored Glycine 0 C--N 1.34 0.769 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.699 179.429 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -75.6 110.33 9.91 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-O 120.931 0.396 . . . . 0.0 111.288 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.38 29.82 10.7 Favored Glycine 0 C--N 1.341 0.833 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.524 -179.687 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -124.25 167.97 13.58 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-O 120.561 0.219 . . . . 0.0 111.133 -179.67 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 -79.9 137.39 36.89 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.072 -179.674 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -126.74 157.04 40.16 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.492 -0.777 . . . . 0.0 111.274 -179.283 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -131.18 140.04 49.84 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.289 179.076 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.521 HG22 ' O ' ' A' ' 26' ' ' PRO . 11.7 m -95.76 7.37 7.18 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 O-C-N 123.202 0.314 . . . . 0.0 111.757 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -99.73 -46.6 5.36 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.772 -179.274 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.0 p90 -154.58 1.17 0.2 Allowed 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 -178.91 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -132.72 65.61 74.74 Favored Pre-proline 0 CA--C 1.547 0.844 0 CA-C-N 117.931 0.332 . . . . 0.0 111.884 -179.237 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.407 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 55.3 Cg_endo -74.14 177.57 8.06 Favored 'Trans proline' 0 C--N 1.369 1.628 0 C-N-CA 122.574 2.182 . . . . 0.0 112.252 178.906 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 56.9 m -79.35 139.64 37.71 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 116.705 -0.225 . . . . 0.0 110.898 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.35 -53.7 0.56 Allowed Pre-proline 0 CA--C 1.545 0.75 0 CA-C-O 119.014 -0.517 . . . . 0.0 112.342 -179.073 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.43 ' HG2' HD12 ' A' ' 19' ' ' LEU . 60.0 Cg_endo -71.66 175.32 9.72 Favored 'Trans proline' 0 C--N 1.375 1.971 0 C-N-CA 122.09 1.86 . . . . 0.0 112.265 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_exo -69.6 65.06 1.71 Allowed 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 122.369 2.046 . . . . 0.0 112.615 179.456 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.43 HD12 ' HG2' ' A' ' 17' ' ' PRO . 47.4 mt -126.65 161.13 28.8 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.722 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.0 t -109.58 151.51 26.72 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.227 -179.901 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.7 t -96.39 107.56 19.96 Favored 'General case' 0 C--O 1.238 0.47 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.398 179.541 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.438 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 3.8 mt -126.75 129.5 24.04 Favored Pre-proline 0 CA--C 1.541 0.615 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.761 -179.729 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -71.48 -39.14 1.5 Allowed 'Cis proline' 0 C--N 1.374 1.881 0 C-N-CA 124.591 -1.004 . . . . 0.0 113.305 -0.577 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.01 29.76 40.64 Favored Glycine 0 C--N 1.344 0.995 0 CA-C-N 116.158 -0.473 . . . . 0.0 113.429 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -144.13 89.55 7.06 Favored Pre-proline 0 CA--C 1.546 0.811 0 CA-C-N 116.702 0.251 . . . . 0.0 111.219 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.521 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.5 Cg_endo -83.77 -35.58 1.87 Allowed 'Cis proline' 0 C--N 1.371 1.738 0 CA-C-N 119.198 0.749 . . . . 0.0 112.846 -0.291 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 44.0 m-85 -103.01 156.95 17.32 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.717 -179.331 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -156.43 -164.98 14.0 Favored Glycine 0 C--N 1.339 0.743 0 C-N-CA 120.956 -0.64 . . . . 0.0 113.216 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.461 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 43.4 mm -127.24 147.53 32.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.495 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 72.3 m -82.89 109.41 16.99 Favored 'General case' 0 CA--C 1.537 0.478 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.401 179.282 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.461 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.4 m-85 -109.03 158.42 17.75 Favored 'General case' 0 N--CA 1.467 0.391 0 N-CA-C 112.038 0.384 . . . . 0.0 112.038 -179.024 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.1 tp -93.46 124.6 45.95 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.616 179.675 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.453 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.25 1.128 0 CA-C-O 118.185 -0.912 . . . . 0.0 111.44 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.374 0 CA-C-O 119.649 -0.215 . . . . 0.0 111.104 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -83.48 -179.07 4.0 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.467 2.111 . . . . 0.0 114.123 -179.157 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' GLY . . . . . 0.493 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.82 -152.77 6.64 Favored Glycine 0 C--N 1.341 0.849 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.809 179.433 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.46 111.91 9.04 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-O 120.896 0.379 . . . . 0.0 111.469 -179.753 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.27 30.74 10.46 Favored Glycine 0 C--N 1.341 0.832 0 CA-C-N 115.418 -0.81 . . . . 0.0 112.593 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -127.01 163.69 23.16 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-O 120.608 0.242 . . . . 0.0 111.194 -179.693 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -79.96 128.56 33.62 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.969 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.47 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.3 p -127.05 143.18 51.35 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.555 -179.6 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -104.56 150.28 24.77 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.345 -0.843 . . . . 0.0 109.74 179.469 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.485 HG22 ' O ' ' A' ' 26' ' ' PRO . 9.1 m -101.82 5.12 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.844 -179.854 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -99.17 -47.41 5.21 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.904 -179.126 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -151.84 1.53 0.36 Allowed 'General case' 0 N--CA 1.477 0.886 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -178.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -131.7 64.46 72.89 Favored Pre-proline 0 CA--C 1.549 0.927 0 N-CA-C 111.803 0.298 . . . . 0.0 111.803 -179.262 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.63 178.36 6.84 Favored 'Trans proline' 0 C--N 1.369 1.612 0 C-N-CA 122.56 2.173 . . . . 0.0 112.456 179.066 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 48.3 m -79.55 138.91 37.64 Favored 'General case' 0 C--N 1.344 0.367 0 O-C-N 123.163 0.29 . . . . 0.0 110.792 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.03 -52.66 1.01 Allowed Pre-proline 0 CA--C 1.543 0.697 0 CA-C-O 118.999 -0.525 . . . . 0.0 112.103 -179.319 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.416 ' HG2' HD12 ' A' ' 19' ' ' LEU . 63.9 Cg_endo -72.78 175.88 9.7 Favored 'Trans proline' 0 C--N 1.375 1.964 0 C-N-CA 122.126 1.884 . . . . 0.0 112.036 179.337 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.44 64.82 1.62 Allowed 'Trans proline' 0 C--N 1.379 2.149 0 C-N-CA 122.38 2.053 . . . . 0.0 112.693 179.47 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.416 HD12 ' HG2' ' A' ' 17' ' ' PRO . 33.0 mt -129.11 159.96 34.34 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.698 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.435 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -111.22 152.88 26.6 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.149 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 t -96.37 106.75 19.03 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.298 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.447 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.5 mt -126.15 131.66 24.04 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.418 -179.538 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -71.12 -39.53 1.4 Allowed 'Cis proline' 0 C--N 1.374 1.895 0 C-N-CA 124.676 -0.969 . . . . 0.0 113.391 -0.326 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.67 31.54 44.52 Favored Glycine 0 C--N 1.342 0.9 0 O-C-N 123.49 0.494 . . . . 0.0 113.393 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -136.82 85.38 23.88 Favored Pre-proline 0 CA--C 1.545 0.783 0 C-N-CA 122.168 0.187 . . . . 0.0 111.072 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.485 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.1 Cg_endo -83.3 -34.37 2.41 Favored 'Cis proline' 0 C--N 1.372 1.767 0 C-N-CA 125.17 -0.763 . . . . 0.0 112.993 -0.217 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 -98.56 153.9 18.31 Favored 'General case' 0 N--CA 1.466 0.369 0 O-C-N 123.586 0.554 . . . . 0.0 110.996 -179.238 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.15 -171.33 18.41 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 116.035 -0.529 . . . . 0.0 113.004 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.483 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 41.8 mm -122.38 146.16 28.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.493 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.5 m -81.7 107.92 14.83 Favored 'General case' 0 CA--C 1.537 0.477 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.509 179.562 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.483 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.6 m-85 -108.5 158.94 17.09 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.53 -179.45 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tp -91.57 122.75 43.29 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.61 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.457 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.116 -0.945 . . . . 0.0 111.326 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.5 p . . . . . 0 N--CA 1.486 1.359 0 CA-C-O 119.628 -0.225 . . . . 0.0 111.149 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.492 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 86.9 Cg_endo -78.26 -172.57 1.54 Allowed 'Trans proline' 0 C--N 1.37 1.7 0 C-N-CA 122.673 2.248 . . . . 0.0 113.83 -179.346 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.2 -144.21 4.24 Favored Glycine 0 C--N 1.339 0.698 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.588 179.755 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 13.3 tt0 -86.47 109.62 19.2 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-O 120.881 0.372 . . . . 0.0 110.705 179.476 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.53 35.88 6.74 Favored Glycine 0 C--N 1.34 0.774 0 CA-C-N 115.571 -0.74 . . . . 0.0 112.749 -179.664 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -131.85 167.68 19.16 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 122.335 0.254 . . . . 0.0 110.831 -179.709 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -79.9 120.56 24.28 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.715 179.746 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 11.8 p -120.17 135.6 54.91 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.288 -179.343 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -104.02 156.15 18.09 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 115.483 -0.78 . . . . 0.0 109.691 179.649 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.428 HG22 ' O ' ' A' ' 26' ' ' PRO . 8.0 m -107.82 14.29 8.14 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.905 -179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -120.54 -45.11 2.43 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.112 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 38.1 p90 -141.28 2.34 1.67 Allowed 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -178.753 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -135.97 68.21 63.85 Favored Pre-proline 0 CA--C 1.543 0.71 0 CA-C-O 120.524 0.202 . . . . 0.0 111.377 -179.644 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.492 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 50.5 Cg_endo -74.46 164.36 34.13 Favored 'Trans proline' 0 C--N 1.368 1.602 0 C-N-CA 122.614 2.209 . . . . 0.0 112.581 179.009 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 94.1 m -79.6 140.42 37.14 Favored 'General case' 0 N--CA 1.47 0.538 0 O-C-N 123.441 0.463 . . . . 0.0 111.681 -179.455 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 m -84.9 -52.54 0.5 Allowed Pre-proline 0 CA--C 1.545 0.751 0 O-C-N 123.63 0.581 . . . . 0.0 112.168 -179.634 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.482 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.3 Cg_endo -75.02 172.8 15.66 Favored 'Trans proline' 0 C--N 1.376 2.014 0 C-N-CA 122.066 1.844 . . . . 0.0 112.408 179.741 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo -71.31 66.16 2.76 Favored 'Trans proline' 0 C--N 1.379 2.149 0 C-N-CA 122.357 2.038 . . . . 0.0 112.511 179.613 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.482 HD12 ' HG2' ' A' ' 17' ' ' PRO . 55.5 mt -124.52 168.1 13.55 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.817 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.579 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 8.5 t -118.73 140.99 49.04 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.337 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 6.3 t -90.99 104.25 16.86 Favored 'General case' 0 CA--C 1.536 0.442 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.541 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mt -120.84 131.58 24.43 Favored Pre-proline 0 CA--C 1.543 0.692 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.325 -179.598 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -72.52 -36.9 2.4 Favored 'Cis proline' 0 C--N 1.374 1.888 0 C-N-CA 124.542 -1.024 . . . . 0.0 113.257 -0.264 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.47 30.57 48.88 Favored Glycine 0 C--N 1.343 0.925 0 CA-C-N 116.171 -0.468 . . . . 0.0 113.297 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -142.24 86.33 10.2 Favored Pre-proline 0 CA--C 1.545 0.783 0 C-N-CA 122.287 0.235 . . . . 0.0 111.161 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.428 ' O ' HG22 ' A' ' 10' ' ' VAL . 1.7 Cg_endo -85.24 -35.59 1.59 Allowed 'Cis proline' 0 C--N 1.373 1.826 0 CA-C-N 119.055 0.698 . . . . 0.0 112.987 -0.377 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 23.6 m-85 -104.45 154.52 19.77 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.906 -179.056 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -161.76 -172.83 29.66 Favored Glycine 0 C--N 1.34 0.761 0 CA-C-N 116.015 -0.538 . . . . 0.0 113.139 179.6 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 27.2 mm -116.87 145.2 22.94 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 179.747 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.579 ' HA ' ' O ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -89.4 119.56 29.97 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.484 -179.864 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -111.87 167.01 10.7 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.487 -179.111 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -95.42 122.93 47.33 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.464 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.554 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.475 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.5 pp . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.418 -0.801 . . . . 0.0 111.352 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 31.6 p . . . . . 0 N--CA 1.486 1.35 0 CA-C-O 119.48 -0.295 . . . . 0.0 111.027 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -84.61 -177.33 2.85 Favored 'Trans proline' 0 C--N 1.37 1.661 0 C-N-CA 122.161 1.908 . . . . 0.0 113.088 179.407 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' GLY . . . . . 0.576 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -146.93 -157.89 7.57 Favored Glycine 0 C--N 1.337 0.613 0 CA-C-N 115.74 -0.663 . . . . 0.0 112.027 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -65.66 110.3 2.72 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 121.042 0.448 . . . . 0.0 111.737 -179.251 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.33 31.57 10.48 Favored Glycine 0 C--N 1.339 0.745 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.723 -179.865 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.447 ' HB2' ' H ' ' A' ' 3' ' ' GLY . 36.7 mt-10 -126.3 159.98 31.64 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.606 0.241 . . . . 0.0 111.275 -179.686 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.507 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.7 tt0 -80.04 121.92 26.12 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.566 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.409 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 7.9 p -124.83 149.29 47.61 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 115.795 -0.638 . . . . 0.0 111.673 -179.169 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.441 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.1 t70 -109.11 155.35 21.09 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.898 179.14 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.3 m -103.0 3.42 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 -179.543 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.441 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.9 mm-40 -98.6 -48.6 4.92 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 111.939 0.348 . . . . 0.0 111.939 -179.037 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -149.15 1.56 0.55 Allowed 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 113.325 0.861 . . . . 0.0 113.325 -178.902 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -130.73 63.73 70.97 Favored Pre-proline 0 CA--C 1.55 0.965 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 -179.333 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -76.61 172.7 15.75 Favored 'Trans proline' 0 C--N 1.369 1.656 0 C-N-CA 122.438 2.092 . . . . 0.0 112.618 179.115 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.409 ' SG ' ' SG ' ' A' ' 8' ' ' CYS . 21.9 m -79.56 133.33 36.45 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.3 179.623 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.545 ' SG ' ' HD3' ' A' ' 17' ' ' PRO . 0.8 OUTLIER -79.55 -45.46 1.6 Allowed Pre-proline 0 N--CA 1.475 0.782 0 N-CA-C 112.859 0.689 . . . . 0.0 112.859 -179.279 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.545 ' HD3' ' SG ' ' A' ' 16' ' ' CYS . 56.7 Cg_endo -70.69 174.37 10.43 Favored 'Trans proline' 0 C--N 1.374 1.876 0 C-N-CA 121.863 1.709 . . . . 0.0 111.879 178.892 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 14.2 Cg_exo -70.0 65.71 1.93 Allowed 'Trans proline' 0 C--N 1.377 2.046 0 C-N-CA 122.274 1.983 . . . . 0.0 112.366 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.527 HD12 ' HG2' ' A' ' 17' ' ' PRO . 25.8 mt -133.43 162.38 32.01 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.27 -0.877 . . . . 0.0 110.901 -179.56 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.507 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.6 t -112.28 155.32 24.26 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.244 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -98.37 108.41 21.1 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.307 179.618 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.422 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.1 mt -128.15 130.86 23.55 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.376 -179.831 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.86 -39.3 1.48 Allowed 'Cis proline' 0 C--N 1.373 1.849 0 C-N-CA 124.624 -0.99 . . . . 0.0 113.533 -0.342 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.29 38.37 18.39 Favored Glycine 0 C--N 1.345 1.049 0 CA-C-N 116.216 -0.447 . . . . 0.0 113.079 -179.725 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -141.23 84.13 13.06 Favored Pre-proline 0 CA--C 1.547 0.847 0 C-N-CA 122.225 0.21 . . . . 0.0 111.338 -179.832 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -83.16 -34.14 2.54 Favored 'Cis proline' 0 C--N 1.373 1.828 0 CA-C-N 119.047 0.695 . . . . 0.0 112.763 -0.189 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -106.14 156.41 18.46 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.892 -179.35 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.507 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.1 -156.24 7.49 Favored Glycine 0 C--N 1.337 0.622 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.622 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.479 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 23.3 mm -127.4 147.88 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 N-CA-C 110.051 -0.351 . . . . 0.0 110.051 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.576 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 76.7 m -84.74 110.13 18.56 Favored 'General case' 0 CA--C 1.537 0.455 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.114 179.228 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.479 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.4 m-85 -107.38 159.77 16.14 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.899 -178.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.0 tp -93.57 124.1 45.9 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.536 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.6 179.551 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.4 pt . . . . . 0 C--O 1.25 1.119 0 CA-C-O 118.489 -0.767 . . . . 0.0 111.328 179.988 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.487 1.375 0 CA-C-O 119.616 -0.23 . . . . 0.0 111.179 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -83.44 -179.15 4.07 Favored 'Trans proline' 0 C--N 1.371 1.733 0 C-N-CA 122.497 2.131 . . . . 0.0 114.082 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' GLY . . . . . 0.494 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.84 -152.53 6.58 Favored Glycine 0 C--N 1.341 0.843 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.81 179.41 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.65 111.83 9.16 Favored 'General case' 0 N--CA 1.472 0.63 0 CA-C-O 120.878 0.371 . . . . 0.0 111.385 -179.661 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.21 30.93 10.22 Favored Glycine 0 C--N 1.341 0.828 0 CA-C-N 115.502 -0.772 . . . . 0.0 112.638 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.3 mt-10 -127.14 163.75 23.12 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-O 120.559 0.219 . . . . 0.0 111.212 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -79.95 128.48 33.52 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.971 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.472 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.3 p -127.02 142.9 51.43 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.515 -179.644 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.404 ' OD1' ' HB3' ' A' ' 13' ' ' ASN . 1.3 m-20 -104.46 150.04 24.91 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.808 179.439 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.488 HG22 ' O ' ' A' ' 26' ' ' PRO . 9.4 m -101.68 5.92 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 O-C-N 123.397 0.436 . . . . 0.0 111.947 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.6 tt0 -100.04 -48.0 4.8 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.522 -179.105 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 36.7 p90 -151.11 1.54 0.41 Allowed 'General case' 0 N--CA 1.477 0.918 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -178.861 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ASN . . . . . 0.404 ' HB3' ' OD1' ' A' ' 9' ' ' ASP . 2.3 t-20 -131.55 64.3 72.54 Favored Pre-proline 0 CA--C 1.55 0.972 0 N-CA-C 111.854 0.316 . . . . 0.0 111.854 -179.281 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -73.54 177.79 7.53 Favored 'Trans proline' 0 C--N 1.37 1.658 0 C-N-CA 122.525 2.15 . . . . 0.0 112.429 179.047 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 47.3 m -79.53 138.7 37.59 Favored 'General case' 0 N--CA 1.467 0.385 0 O-C-N 123.188 0.305 . . . . 0.0 110.807 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.01 -52.64 1.01 Allowed Pre-proline 0 N--CA 1.474 0.727 0 CA-C-O 119.025 -0.512 . . . . 0.0 111.983 -179.22 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.41 ' HG2' HD12 ' A' ' 19' ' ' LEU . 64.4 Cg_endo -72.73 175.88 9.66 Favored 'Trans proline' 0 C--N 1.375 1.951 0 C-N-CA 122.166 1.91 . . . . 0.0 112.051 179.372 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.3 Cg_exo -69.6 65.01 1.71 Allowed 'Trans proline' 0 C--N 1.378 2.126 0 C-N-CA 122.375 2.05 . . . . 0.0 112.642 179.458 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.41 HD12 ' HG2' ' A' ' 17' ' ' PRO . 32.6 mt -129.2 159.96 34.42 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.687 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.432 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -111.33 152.71 26.95 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.107 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.7 t -96.39 106.72 19.0 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.232 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.445 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.4 mt -125.99 131.63 24.05 Favored Pre-proline 0 CA--C 1.542 0.67 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.391 -179.482 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -71.1 -39.43 1.42 Allowed 'Cis proline' 0 C--N 1.375 1.944 0 C-N-CA 124.717 -0.951 . . . . 0.0 113.446 -0.289 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.51 31.39 45.86 Favored Glycine 0 C--N 1.344 0.997 0 CA-C-N 116.136 -0.484 . . . . 0.0 113.321 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -136.9 85.45 23.29 Favored Pre-proline 0 CA--C 1.545 0.762 0 C-N-CA 122.234 0.214 . . . . 0.0 111.04 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.488 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.2 Cg_endo -83.22 -34.42 2.41 Favored 'Cis proline' 0 C--N 1.373 1.827 0 C-N-CA 125.237 -0.734 . . . . 0.0 112.978 -0.257 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -98.57 154.15 18.13 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.061 -179.257 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.43 -171.56 18.83 Favored Glycine 0 C--N 1.338 0.681 0 CA-C-N 116.11 -0.495 . . . . 0.0 113.01 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.481 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 41.8 mm -122.3 146.05 28.08 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.494 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.4 m -81.49 107.94 14.68 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.582 179.463 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.481 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.8 m-85 -108.48 158.82 17.2 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.554 -179.389 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tp -91.68 122.84 43.49 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.668 179.622 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.455 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.247 0.93 0 CA-C-O 118.44 -0.79 . . . . 0.0 111.405 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 31.7 p . . . . . 0 N--CA 1.488 1.474 0 CA-C-O 119.486 -0.292 . . . . 0.0 110.892 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -84.73 -177.32 2.82 Favored 'Trans proline' 0 C--N 1.37 1.687 0 C-N-CA 122.079 1.853 . . . . 0.0 113.092 179.406 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' GLY . . . . . 0.578 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -147.27 -158.6 7.92 Favored Glycine 0 C--N 1.337 0.589 0 CA-C-N 115.723 -0.671 . . . . 0.0 111.947 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -64.79 110.0 2.25 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-O 120.979 0.419 . . . . 0.0 111.713 -179.218 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.29 31.97 10.1 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-N 115.331 -0.849 . . . . 0.0 112.713 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.451 ' HB2' ' H ' ' A' ' 3' ' ' GLY . 36.9 mt-10 -126.65 160.48 30.6 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 120.548 0.213 . . . . 0.0 111.238 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.517 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.5 tt0 -79.98 122.01 26.2 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.585 179.682 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 8.5 p -125.49 149.75 48.0 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.637 -179.062 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -109.69 155.53 21.4 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 115.507 -0.769 . . . . 0.0 109.844 179.104 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.4 m -104.14 4.2 10.54 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.222 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -99.24 -48.67 4.74 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 116.637 -0.256 . . . . 0.0 111.654 -179.056 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 37.9 p90 -148.85 0.97 0.56 Allowed 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -179.056 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -130.87 63.56 70.59 Favored Pre-proline 0 CA--C 1.551 0.99 0 N-CA-C 111.816 0.302 . . . . 0.0 111.816 -179.32 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -76.27 173.5 14.38 Favored 'Trans proline' 0 C--N 1.369 1.638 0 C-N-CA 122.53 2.153 . . . . 0.0 112.594 179.203 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 8' ' ' CYS . 23.6 m -79.75 133.5 36.33 Favored 'General case' 0 N--CA 1.466 0.352 0 O-C-N 123.373 0.421 . . . . 0.0 110.252 179.556 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.55 ' SG ' ' HD3' ' A' ' 17' ' ' PRO . 0.8 OUTLIER -79.59 -45.4 1.59 Allowed Pre-proline 0 N--CA 1.476 0.836 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -179.271 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.55 ' HD3' ' SG ' ' A' ' 16' ' ' CYS . 56.9 Cg_endo -70.6 174.42 10.26 Favored 'Trans proline' 0 C--N 1.374 1.913 0 C-N-CA 121.928 1.752 . . . . 0.0 111.922 178.91 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_exo -70.04 65.66 1.96 Allowed 'Trans proline' 0 C--N 1.376 2.015 0 C-N-CA 122.266 1.977 . . . . 0.0 112.354 179.341 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.526 HD12 ' HG2' ' A' ' 17' ' ' PRO . 26.5 mt -133.5 162.43 31.91 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.84 -179.52 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.507 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.6 t -112.01 155.69 23.37 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.16 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 t -98.83 108.53 21.24 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.314 179.59 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.43 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -128.09 130.87 23.56 Favored Pre-proline 0 CA--C 1.542 0.637 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.323 -179.805 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -73.17 -39.06 1.54 Allowed 'Cis proline' 0 C--N 1.373 1.859 0 C-N-CA 124.62 -0.992 . . . . 0.0 113.523 -0.265 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.14 39.48 15.99 Favored Glycine 0 C--N 1.344 1.018 0 O-C-N 123.459 0.475 . . . . 0.0 113.138 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.55 83.56 13.13 Favored Pre-proline 0 CA--C 1.547 0.855 0 C-N-CA 122.132 0.173 . . . . 0.0 111.253 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -83.51 -33.43 2.75 Favored 'Cis proline' 0 C--N 1.372 1.794 0 CA-C-N 119.056 0.698 . . . . 0.0 112.812 -0.312 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -107.27 155.75 19.61 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.95 -179.404 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.517 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.59 -154.1 6.55 Favored Glycine 0 C--N 1.338 0.672 0 CA-C-N 115.876 -0.602 . . . . 0.0 112.574 179.767 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.481 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 22.6 mm -128.37 148.22 32.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.578 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 77.9 m -84.68 110.22 18.6 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.239 179.286 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.481 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.6 m-85 -107.73 160.54 15.64 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.876 -178.964 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 tp -92.39 122.87 44.23 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.638 179.621 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.463 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.378 -0.82 . . . . 0.0 111.465 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 32.1 p . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 119.412 -0.328 . . . . 0.0 110.945 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -84.75 -177.55 2.91 Favored 'Trans proline' 0 C--N 1.369 1.612 0 C-N-CA 122.014 1.809 . . . . 0.0 113.202 179.582 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' GLY . . . . . 0.584 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -146.92 -161.51 9.39 Favored Glycine 0 C--N 1.338 0.683 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.882 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -62.01 111.13 1.8 Allowed 'General case' 0 N--CA 1.474 0.765 0 CA-C-O 121.069 0.462 . . . . 0.0 111.938 -179.209 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.32 31.66 13.52 Favored Glycine 0 C--N 1.341 0.817 0 CA-C-N 115.242 -0.89 . . . . 0.0 112.718 -179.918 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.508 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 36.2 mt-10 -125.46 161.48 27.02 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-O 120.551 0.215 . . . . 0.0 111.328 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.493 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.7 tt0 -79.91 120.93 24.8 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.521 179.726 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.9 p -125.16 150.03 47.32 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.627 -179.062 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.461 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 7.9 t70 -110.59 154.67 23.44 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.804 179.257 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.1 m -104.06 3.93 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 CA-C-N 116.125 -0.488 . . . . 0.0 112.178 -179.589 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.461 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.3 mt-10 -98.39 -47.93 5.23 Favored 'General case' 0 C--O 1.234 0.24 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -179.163 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -150.07 0.39 0.46 Allowed 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 113.449 0.907 . . . . 0.0 113.449 -179.025 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -131.01 63.81 71.68 Favored Pre-proline 0 CA--C 1.549 0.928 0 N-CA-C 111.874 0.324 . . . . 0.0 111.874 -179.299 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -76.27 174.49 12.74 Favored 'Trans proline' 0 C--N 1.369 1.646 0 C-N-CA 122.513 2.142 . . . . 0.0 112.618 179.299 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 31.0 m -79.62 133.12 36.4 Favored 'General case' 0 N--CA 1.468 0.438 0 C-N-CA 122.574 0.35 . . . . 0.0 110.303 179.587 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.548 ' SG ' ' HD3' ' A' ' 17' ' ' PRO . 0.9 OUTLIER -79.66 -45.45 1.57 Allowed Pre-proline 0 N--CA 1.477 0.877 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -179.242 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.548 ' HD3' ' SG ' ' A' ' 16' ' ' CYS . 56.0 Cg_endo -69.98 174.81 9.15 Favored 'Trans proline' 0 C--N 1.373 1.856 0 C-N-CA 121.886 1.724 . . . . 0.0 111.956 179.054 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_exo -69.59 65.22 1.7 Allowed 'Trans proline' 0 C--N 1.378 2.127 0 C-N-CA 122.292 1.995 . . . . 0.0 112.534 179.396 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.52 HD12 ' HG2' ' A' ' 17' ' ' PRO . 15.6 mt -136.12 162.04 34.04 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.673 -179.671 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.579 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 14.7 t -111.31 163.02 14.4 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.078 179.543 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.8 t -102.62 110.74 22.78 Favored 'General case' 0 C--O 1.239 0.538 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.294 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 4.8 mt -127.78 131.09 23.63 Favored Pre-proline 0 CA--C 1.542 0.669 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.339 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -74.55 -37.85 2.05 Favored 'Cis proline' 0 C--N 1.374 1.877 0 C-N-CA 124.461 -1.058 . . . . 0.0 113.242 -0.25 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.83 39.51 11.79 Favored Glycine 0 C--N 1.345 1.046 0 O-C-N 123.508 0.505 . . . . 0.0 113.076 -179.716 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -140.71 82.17 16.01 Favored Pre-proline 0 CA--C 1.55 0.978 0 C-N-CA 122.105 0.162 . . . . 0.0 110.911 -179.782 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -84.86 -33.7 2.35 Favored 'Cis proline' 0 C--N 1.371 1.761 0 CA-C-N 119.096 0.713 . . . . 0.0 112.972 -0.415 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -105.69 156.67 18.06 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.934 -179.256 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.31 -155.27 7.08 Favored Glycine 0 C--N 1.338 0.682 0 CA-C-N 115.868 -0.606 . . . . 0.0 112.553 179.75 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.508 ' HA ' ' O ' ' A' ' 6' ' ' GLU . 19.4 mm -128.57 149.24 33.18 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.584 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 63.6 m -84.42 110.67 18.81 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.274 179.196 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.41 ' O ' ' HB3' ' A' ' 19' ' ' LEU . 85.3 m-85 -106.24 160.95 14.96 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.128 -0.487 . . . . 0.0 112.056 -178.816 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.1 tp -90.1 126.52 42.95 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.611 179.569 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 38.2 mm . . . . . 0 C--O 1.25 1.124 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.088 -179.606 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.487 1.404 0 CA-C-O 119.528 -0.272 . . . . 0.0 111.164 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -83.78 -178.85 3.78 Favored 'Trans proline' 0 C--N 1.372 1.806 0 C-N-CA 122.47 2.113 . . . . 0.0 113.949 -179.099 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.511 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.27 -152.32 6.45 Favored Glycine 0 C--N 1.342 0.913 0 CA-C-N 115.613 -0.722 . . . . 0.0 112.04 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -73.25 113.76 10.67 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.916 0.389 . . . . 0.0 111.621 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.32 32.47 10.44 Favored Glycine 0 C--N 1.341 0.816 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.795 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.55 162.26 26.86 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-O 120.663 0.268 . . . . 0.0 111.251 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.502 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.8 tt0 -80.09 127.0 31.79 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.816 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.47 150.55 50.76 Favored 'General case' 0 C--O 1.233 0.237 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.664 -179.252 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.451 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.17 154.62 23.08 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.597 -0.729 . . . . 0.0 109.785 179.008 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.7 m -102.93 4.23 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 116.123 -0.49 . . . . 0.0 112.14 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.451 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.0 mt-10 -100.27 -48.57 4.55 Favored 'General case' 0 C--O 1.235 0.329 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.113 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.4 p90 -148.45 2.0 0.62 Allowed 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 113.293 0.849 . . . . 0.0 113.293 -178.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.08 63.46 70.34 Favored Pre-proline 0 CA--C 1.548 0.903 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -74.46 175.59 10.82 Favored 'Trans proline' 0 C--N 1.369 1.649 0 C-N-CA 122.493 2.128 . . . . 0.0 112.594 179.281 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.7 m -79.69 140.87 36.87 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.503 179.706 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -80.0 -52.58 1.02 Allowed Pre-proline 0 CA--C 1.543 0.702 0 CA-C-O 118.996 -0.526 . . . . 0.0 112.006 -179.326 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.429 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.6 Cg_endo -73.79 175.98 10.04 Favored 'Trans proline' 0 C--N 1.375 1.928 0 C-N-CA 122.143 1.895 . . . . 0.0 111.963 179.258 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.38 64.78 1.58 Allowed 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 122.387 2.058 . . . . 0.0 112.731 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.429 HD12 ' HG2' ' A' ' 17' ' ' PRO . 39.7 mt -127.46 161.32 29.0 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.748 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.0 t -112.4 149.57 32.33 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.015 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.2 t -93.91 108.61 20.39 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.59 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.426 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -127.91 130.78 23.59 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.301 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -73.36 -38.99 1.56 Allowed 'Cis proline' 0 C--N 1.372 1.802 0 C-N-CA 124.671 -0.97 . . . . 0.0 113.464 -0.232 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.65 39.69 13.86 Favored Glycine 0 C--N 1.344 0.999 0 O-C-N 123.453 0.471 . . . . 0.0 113.047 -179.722 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -141.19 83.34 13.82 Favored Pre-proline 0 CA--C 1.546 0.791 0 C-N-CA 122.182 0.193 . . . . 0.0 111.315 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.56 -33.5 2.71 Favored 'Cis proline' 0 C--N 1.372 1.779 0 CA-C-N 119.061 0.7 . . . . 0.0 112.826 -0.369 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -106.69 156.32 18.75 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.932 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.502 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.78 -154.2 6.61 Favored Glycine 0 C--N 1.338 0.642 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.526 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.511 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.9 mm -127.62 147.17 32.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.511 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.1 m -84.38 107.93 16.92 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.13 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.511 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.4 m-85 -106.09 158.99 16.41 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.824 -179.073 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -93.29 122.99 45.23 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.6 179.664 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.3 pt . . . . . 0 C--O 1.251 1.141 0 CA-C-O 118.472 -0.775 . . . . 0.0 111.349 179.94 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.37 0 CA-C-O 119.533 -0.27 . . . . 0.0 111.133 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -83.89 -178.83 3.73 Favored 'Trans proline' 0 C--N 1.373 1.816 0 C-N-CA 122.458 2.105 . . . . 0.0 114.008 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.513 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.4 -152.35 6.44 Favored Glycine 0 C--N 1.343 0.922 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.961 179.68 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -73.08 113.89 10.63 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-O 120.789 0.328 . . . . 0.0 111.641 -179.49 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.06 32.63 10.46 Favored Glycine 0 C--N 1.34 0.757 0 CA-C-N 115.448 -0.796 . . . . 0.0 112.781 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.3 mt-10 -127.6 162.39 26.61 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.647 0.26 . . . . 0.0 111.282 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.514 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.6 tt0 -80.05 127.1 31.89 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.793 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.84 150.7 51.02 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.681 -179.262 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.447 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.54 154.71 23.32 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.775 179.024 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.9 m -102.85 4.07 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-N 116.18 -0.464 . . . . 0.0 112.156 -179.605 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.447 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.4 mt-10 -100.01 -48.65 4.58 Favored 'General case' 0 C--O 1.235 0.312 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.002 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -148.54 2.13 0.62 Allowed 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 113.407 0.891 . . . . 0.0 113.407 -178.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -131.17 63.68 70.95 Favored Pre-proline 0 CA--C 1.55 0.962 0 N-CA-C 111.678 0.251 . . . . 0.0 111.678 -179.432 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.65 175.71 10.75 Favored 'Trans proline' 0 C--N 1.369 1.641 0 C-N-CA 122.493 2.129 . . . . 0.0 112.663 179.235 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.5 m -79.66 140.87 36.91 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 123.288 0.368 . . . . 0.0 110.618 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.94 -52.58 1.03 Allowed Pre-proline 0 CA--C 1.543 0.705 0 CA-C-O 119.131 -0.462 . . . . 0.0 111.925 -179.212 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.426 ' HG2' HD12 ' A' ' 19' ' ' LEU . 66.4 Cg_endo -73.78 175.87 10.17 Favored 'Trans proline' 0 C--N 1.376 1.986 0 C-N-CA 122.105 1.87 . . . . 0.0 112.01 179.227 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -69.37 64.89 1.57 Allowed 'Trans proline' 0 C--N 1.377 2.068 0 C-N-CA 122.373 2.049 . . . . 0.0 112.721 179.478 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.426 HD12 ' HG2' ' A' ' 17' ' ' PRO . 41.1 mt -127.55 161.45 28.76 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.746 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.7 t -112.34 149.58 32.24 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.084 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -94.02 108.93 20.71 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.496 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mt -128.14 130.68 23.57 Favored Pre-proline 0 CA--C 1.541 0.612 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.314 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -73.55 -38.95 1.58 Allowed 'Cis proline' 0 C--N 1.374 1.872 0 C-N-CA 124.581 -1.008 . . . . 0.0 113.456 -0.181 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.85 39.84 12.98 Favored Glycine 0 C--N 1.345 1.08 0 O-C-N 123.483 0.489 . . . . 0.0 113.111 -179.644 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -140.98 82.88 14.56 Favored Pre-proline 0 CA--C 1.546 0.818 0 C-N-CA 122.205 0.202 . . . . 0.0 111.26 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -83.76 -33.54 2.65 Favored 'Cis proline' 0 C--N 1.372 1.766 0 CA-C-N 119.066 0.702 . . . . 0.0 112.857 -0.409 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -106.97 156.32 18.85 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.01 -179.324 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.514 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.76 -152.13 5.89 Favored Glycine 0 C--N 1.337 0.635 0 CA-C-N 115.869 -0.605 . . . . 0.0 112.554 179.815 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.501 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.2 mm -129.11 147.13 33.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.513 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.2 m -84.4 108.13 17.05 Favored 'General case' 0 C--O 1.238 0.48 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.174 179.198 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.501 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.0 m-85 -106.2 159.23 16.25 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.79 -179.056 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.91 123.25 44.94 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.641 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.465 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.173 -0.918 . . . . 0.0 111.495 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.37 0 CA-C-O 119.499 -0.286 . . . . 0.0 111.115 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -83.89 -178.81 3.73 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.424 2.083 . . . . 0.0 113.995 -179.161 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.513 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.31 -152.41 6.47 Favored Glycine 0 C--N 1.343 0.965 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.993 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -73.03 113.84 10.52 Favored 'General case' 0 N--CA 1.471 0.594 0 CA-C-O 120.961 0.41 . . . . 0.0 111.669 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.09 32.48 10.62 Favored Glycine 0 C--N 1.342 0.886 0 CA-C-N 115.415 -0.812 . . . . 0.0 112.78 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.54 162.34 26.66 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.63 0.252 . . . . 0.0 111.302 -179.731 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.502 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.15 127.31 32.18 Favored 'General case' 0 C--N 1.346 0.428 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.794 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.4 p -129.7 150.49 50.99 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 115.815 -0.629 . . . . 0.0 111.605 -179.234 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.452 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.1 t70 -110.2 154.58 23.17 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.831 178.922 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.5 m -102.88 3.94 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 CA-C-N 116.165 -0.47 . . . . 0.0 112.225 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.452 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -99.71 -48.76 4.6 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 111.981 0.363 . . . . 0.0 111.981 -179.046 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -148.64 2.18 0.61 Allowed 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 113.204 0.816 . . . . 0.0 113.204 -178.847 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.28 63.67 70.74 Favored Pre-proline 0 CA--C 1.548 0.903 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -74.55 176.11 10.17 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 122.434 2.089 . . . . 0.0 112.66 179.209 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 36.2 m -79.81 140.9 36.68 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.557 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.96 -52.64 1.02 Allowed Pre-proline 0 CA--C 1.544 0.75 0 CA-C-O 119.068 -0.491 . . . . 0.0 111.926 -179.197 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.43 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.6 Cg_endo -73.76 175.96 10.04 Favored 'Trans proline' 0 C--N 1.376 1.99 0 C-N-CA 122.114 1.876 . . . . 0.0 112.039 179.26 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.36 64.89 1.57 Allowed 'Trans proline' 0 C--N 1.377 2.069 0 C-N-CA 122.327 2.018 . . . . 0.0 112.747 179.479 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.43 HD12 ' HG2' ' A' ' 17' ' ' PRO . 40.6 mt -127.6 161.42 28.88 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.736 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.9 t -112.34 149.57 32.25 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 115.888 -0.597 . . . . 0.0 111.068 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.2 t -94.06 108.76 20.56 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.551 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.1 mt -127.99 130.75 23.58 Favored Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.337 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.38 -39.02 1.55 Allowed 'Cis proline' 0 C--N 1.374 1.87 0 C-N-CA 124.583 -1.007 . . . . 0.0 113.444 -0.22 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.91 39.68 13.02 Favored Glycine 0 C--N 1.345 1.06 0 O-C-N 123.423 0.452 . . . . 0.0 113.069 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.23 83.39 13.73 Favored Pre-proline 0 CA--C 1.547 0.841 0 C-N-CA 122.116 0.166 . . . . 0.0 111.217 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.65 -33.41 2.73 Favored 'Cis proline' 0 C--N 1.372 1.772 0 C-N-CA 125.335 -0.694 . . . . 0.0 112.841 -0.364 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -106.79 156.2 18.92 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.018 -179.378 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.502 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.53 -153.88 6.46 Favored Glycine 0 C--N 1.338 0.639 0 CA-C-N 115.866 -0.606 . . . . 0.0 112.508 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.507 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.4 mm -127.85 147.11 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.513 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.6 m -84.3 107.9 16.85 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.142 179.26 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.507 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -106.03 159.25 16.2 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.785 -179.094 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -93.06 123.15 45.05 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.622 179.646 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.466 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.295 -0.86 . . . . 0.0 111.519 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.37 0 CA-C-O 119.576 -0.25 . . . . 0.0 111.05 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -83.75 -178.86 3.8 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.53 2.153 . . . . 0.0 114.019 -179.129 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.513 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.04 -152.29 6.48 Favored Glycine 0 C--N 1.342 0.888 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.996 179.659 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -73.52 113.98 11.23 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-O 120.986 0.422 . . . . 0.0 111.561 -179.54 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.13 32.57 10.48 Favored Glycine 0 C--N 1.341 0.818 0 CA-C-N 115.418 -0.81 . . . . 0.0 112.8 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.44 162.3 26.68 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-O 120.476 0.179 . . . . 0.0 111.345 -179.645 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.511 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.07 127.27 32.1 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.795 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.78 150.38 51.11 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.631 -179.248 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.448 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.42 154.89 22.95 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.821 178.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.7 m -102.93 4.21 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 CA-C-N 116.174 -0.466 . . . . 0.0 112.137 -179.507 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.448 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.3 mt-10 -100.32 -48.57 4.54 Favored 'General case' 0 C--O 1.235 0.307 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -179.123 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.6 p90 -148.28 2.0 0.64 Allowed 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 113.279 0.844 . . . . 0.0 113.279 -178.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.12 63.58 70.7 Favored Pre-proline 0 CA--C 1.548 0.903 0 N-CA-C 111.73 0.27 . . . . 0.0 111.73 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.59 175.36 11.19 Favored 'Trans proline' 0 C--N 1.371 1.712 0 C-N-CA 122.461 2.107 . . . . 0.0 112.61 179.208 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.8 m -79.58 140.69 37.08 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.537 179.664 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.98 -52.57 1.03 Allowed Pre-proline 0 N--CA 1.473 0.687 0 CA-C-O 118.98 -0.533 . . . . 0.0 111.983 -179.367 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.426 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.1 Cg_endo -73.88 175.93 10.14 Favored 'Trans proline' 0 C--N 1.375 1.951 0 C-N-CA 122.135 1.89 . . . . 0.0 111.984 179.287 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.43 64.91 1.61 Allowed 'Trans proline' 0 C--N 1.378 2.102 0 C-N-CA 122.277 1.985 . . . . 0.0 112.769 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.426 HD12 ' HG2' ' A' ' 17' ' ' PRO . 40.7 mt -127.35 161.6 28.26 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.782 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.7 t -112.65 149.38 32.93 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.009 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -93.88 108.81 20.56 Favored 'General case' 0 C--O 1.238 0.49 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.544 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mt -127.99 130.8 23.58 Favored Pre-proline 0 CA--C 1.542 0.665 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.247 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -73.47 -38.82 1.64 Allowed 'Cis proline' 0 C--N 1.374 1.872 0 C-N-CA 124.553 -1.019 . . . . 0.0 113.475 -0.296 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.95 39.66 12.96 Favored Glycine 0 C--N 1.345 1.042 0 O-C-N 123.38 0.425 . . . . 0.0 113.089 -179.743 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -141.24 83.16 13.92 Favored Pre-proline 0 CA--C 1.547 0.827 0 C-N-CA 122.161 0.185 . . . . 0.0 111.265 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -83.84 -33.52 2.64 Favored 'Cis proline' 0 C--N 1.373 1.823 0 CA-C-N 119.052 0.697 . . . . 0.0 112.829 -0.282 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.1 m-85 -106.96 156.42 18.74 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.928 -179.354 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.82 -152.47 5.99 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 115.85 -0.614 . . . . 0.0 112.603 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.505 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.5 mm -129.02 147.04 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 O-C-N 123.8 0.353 . . . . 0.0 110.08 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.513 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 76.6 m -84.18 107.79 16.7 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.262 179.2 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.505 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.1 m-85 -105.91 159.13 16.27 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.835 -179.044 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.9 123.25 44.92 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.627 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.466 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.32 -0.848 . . . . 0.0 111.398 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.371 0 CA-C-O 119.586 -0.245 . . . . 0.0 111.171 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -83.8 -178.82 3.76 Favored 'Trans proline' 0 C--N 1.372 1.805 0 C-N-CA 122.445 2.097 . . . . 0.0 114.031 -179.137 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.51 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.87 -152.18 6.49 Favored Glycine 0 C--N 1.343 0.942 0 CA-C-N 115.539 -0.755 . . . . 0.0 112.002 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.46 114.24 11.46 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-O 120.891 0.377 . . . . 0.0 111.6 -179.569 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.69 32.6 11.08 Favored Glycine 0 C--N 1.34 0.801 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.838 -179.761 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.403 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 33.5 mt-10 -127.4 162.65 25.83 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 120.625 0.25 . . . . 0.0 111.255 -179.576 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.528 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.07 127.25 32.08 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.805 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.8 p -130.32 150.47 51.54 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.631 -179.372 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.499 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.4 t70 -110.65 154.93 23.12 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.876 178.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.543 HG23 ' OE2' ' A' ' 11' ' ' GLU . 9.6 m -102.9 3.31 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-N 116.172 -0.467 . . . . 0.0 112.152 -179.481 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.543 ' OE2' HG23 ' A' ' 10' ' ' VAL . 4.9 mp0 -97.85 -49.02 4.96 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.443 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 42.1 p90 -149.26 2.52 0.56 Allowed 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 113.375 0.88 . . . . 0.0 113.375 -178.85 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -130.69 63.67 70.71 Favored Pre-proline 0 CA--C 1.548 0.887 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -74.66 175.99 10.37 Favored 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 122.507 2.138 . . . . 0.0 112.604 179.3 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 34.8 m -79.7 140.92 36.83 Favored 'General case' 0 CA--C 1.534 0.352 0 O-C-N 123.271 0.357 . . . . 0.0 110.603 179.648 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.89 -52.76 1.03 Allowed Pre-proline 0 CA--C 1.545 0.752 0 CA-C-O 119.039 -0.505 . . . . 0.0 111.939 -179.283 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.426 ' HG2' HD12 ' A' ' 19' ' ' LEU . 63.1 Cg_endo -73.53 175.72 10.28 Favored 'Trans proline' 0 C--N 1.374 1.893 0 C-N-CA 122.097 1.865 . . . . 0.0 112.006 179.251 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.35 64.94 1.56 Allowed 'Trans proline' 0 C--N 1.377 2.064 0 C-N-CA 122.347 2.031 . . . . 0.0 112.792 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.426 HD12 ' HG2' ' A' ' 17' ' ' PRO . 38.5 mt -127.6 161.84 27.89 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.741 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.2 t -112.57 149.74 32.31 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.076 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.4 t -94.14 109.05 20.86 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.555 179.595 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.6 mt -128.02 130.99 23.56 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.251 -179.766 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -73.44 -38.82 1.64 Allowed 'Cis proline' 0 C--N 1.374 1.878 0 C-N-CA 124.686 -0.964 . . . . 0.0 113.56 -0.301 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.37 42.05 10.88 Favored Glycine 0 C--N 1.344 1.009 0 O-C-N 123.379 0.424 . . . . 0.0 113.035 -179.584 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.07 80.68 16.75 Favored Pre-proline 0 CA--C 1.547 0.841 0 C-N-CA 122.194 0.198 . . . . 0.0 111.352 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -84.81 -32.77 2.73 Favored 'Cis proline' 0 C--N 1.372 1.804 0 C-N-CA 125.365 -0.681 . . . . 0.0 112.889 -0.359 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 83.2 m-85 -105.86 156.49 18.29 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.107 -179.173 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.528 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -154.31 -150.95 5.64 Favored Glycine 0 C--N 1.338 0.672 0 CA-C-N 115.883 -0.599 . . . . 0.0 112.452 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.485 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.8 mm -129.25 146.99 33.39 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.51 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.1 m -84.64 108.62 17.47 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.204 179.237 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.485 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.7 m-85 -106.1 158.83 16.53 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.874 -179.002 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tp -93.63 123.89 45.89 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.517 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.623 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.3 pt . . . . . 0 C--O 1.248 0.984 0 CA-C-O 118.115 -0.945 . . . . 0.0 111.279 179.987 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.348 0 CA-C-O 119.554 -0.26 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -83.71 -178.88 3.82 Favored 'Trans proline' 0 C--N 1.372 1.814 0 C-N-CA 122.496 2.131 . . . . 0.0 114.038 -179.088 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.511 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.04 -152.28 6.48 Favored Glycine 0 C--N 1.341 0.86 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.031 179.608 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.1 tt0 -73.45 113.75 10.9 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 120.932 0.396 . . . . 0.0 111.715 -179.66 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.45 32.62 10.14 Favored Glycine 0 C--N 1.34 0.8 0 CA-C-N 115.46 -0.791 . . . . 0.0 112.846 -179.792 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.66 162.07 27.4 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-O 120.58 0.228 . . . . 0.0 111.314 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.508 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.8 tt0 -79.96 127.13 31.9 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.804 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.71 150.67 50.92 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.619 -179.282 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.449 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.1 t70 -110.36 154.9 22.88 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.811 178.834 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.5 m -102.79 4.27 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-N 116.186 -0.461 . . . . 0.0 112.132 -179.534 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.449 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -100.93 -48.51 4.42 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 112.084 0.401 . . . . 0.0 112.084 -179.052 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 39.9 p90 -147.78 1.8 0.69 Allowed 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 113.42 0.896 . . . . 0.0 113.42 -178.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.05 63.29 69.82 Favored Pre-proline 0 CA--C 1.55 0.97 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.344 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.48 175.06 11.55 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.381 2.054 . . . . 0.0 112.617 179.281 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.4 m -79.68 140.81 36.9 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.484 179.733 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.98 -52.56 1.03 Allowed Pre-proline 0 CA--C 1.543 0.7 0 CA-C-O 119.087 -0.483 . . . . 0.0 111.993 -179.368 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.43 ' HG2' HD12 ' A' ' 19' ' ' LEU . 66.6 Cg_endo -73.85 175.94 10.11 Favored 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 122.071 1.848 . . . . 0.0 112.045 179.165 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -69.34 64.83 1.55 Allowed 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 122.384 2.056 . . . . 0.0 112.759 179.547 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.43 HD12 ' HG2' ' A' ' 17' ' ' PRO . 41.8 mt -127.28 161.59 28.23 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.818 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.9 t -112.81 149.26 33.3 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.995 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.2 t -93.78 108.76 20.48 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.551 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.424 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.4 mt -127.95 130.93 23.57 Favored Pre-proline 0 CA--C 1.541 0.626 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.226 -179.748 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -73.34 -39.02 1.56 Allowed 'Cis proline' 0 C--N 1.374 1.91 0 C-N-CA 124.705 -0.956 . . . . 0.0 113.468 -0.389 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.64 39.64 13.99 Favored Glycine 0 C--N 1.344 0.981 0 O-C-N 123.455 0.472 . . . . 0.0 113.075 -179.682 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -140.89 82.99 14.64 Favored Pre-proline 0 CA--C 1.549 0.925 0 C-N-CA 122.188 0.195 . . . . 0.0 110.956 -179.765 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -83.92 -33.75 2.53 Favored 'Cis proline' 0 C--N 1.372 1.777 0 CA-C-N 119.101 0.715 . . . . 0.0 112.877 -0.436 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.7 m-85 -106.6 156.25 18.79 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.025 -179.408 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.508 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.85 -152.74 6.08 Favored Glycine 0 C--N 1.338 0.67 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.538 179.741 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.515 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.2 mm -128.69 147.0 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -179.838 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.511 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 78.8 m -84.06 107.97 16.72 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.183 179.175 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.515 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.4 m-85 -106.17 159.3 16.19 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.805 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -93.02 122.81 44.81 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.681 179.552 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.466 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.363 -0.827 . . . . 0.0 111.449 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.361 0 CA-C-O 119.522 -0.275 . . . . 0.0 111.098 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -83.7 -178.86 3.82 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.47 2.114 . . . . 0.0 113.967 -179.068 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.512 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.98 -152.23 6.48 Favored Glycine 0 C--N 1.343 0.945 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.031 179.53 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -73.53 113.84 11.09 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-O 120.833 0.349 . . . . 0.0 111.581 -179.504 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.33 32.69 10.15 Favored Glycine 0 C--N 1.339 0.747 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.793 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.62 162.22 27.0 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 120.564 0.221 . . . . 0.0 111.275 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.513 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -79.93 127.26 32.05 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.828 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.6 p -129.92 150.65 51.11 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.592 -179.278 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.445 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.64 154.71 23.42 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.773 178.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.8 m -102.65 4.18 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-N 116.146 -0.479 . . . . 0.0 112.139 -179.56 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.445 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.6 mm-40 -100.48 -48.62 4.49 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -179.088 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.4 p90 -148.02 1.89 0.67 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 113.379 0.881 . . . . 0.0 113.379 -178.854 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.09 63.39 70.08 Favored Pre-proline 0 CA--C 1.551 0.993 0 N-CA-C 111.723 0.268 . . . . 0.0 111.723 -179.236 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.51 175.2 11.37 Favored 'Trans proline' 0 C--N 1.37 1.683 0 C-N-CA 122.391 2.061 . . . . 0.0 112.644 179.287 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.5 m -79.75 140.74 36.82 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.559 179.631 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.89 -52.59 1.04 Allowed Pre-proline 0 N--CA 1.474 0.768 0 CA-C-O 119.057 -0.497 . . . . 0.0 111.975 -179.296 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.426 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.1 Cg_endo -73.89 175.94 10.13 Favored 'Trans proline' 0 C--N 1.376 1.995 0 C-N-CA 122.148 1.899 . . . . 0.0 111.941 179.342 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.3 64.91 1.53 Allowed 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 122.322 2.014 . . . . 0.0 112.732 179.501 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.426 HD12 ' HG2' ' A' ' 17' ' ' PRO . 40.3 mt -127.43 161.58 28.36 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.744 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.9 t -112.73 149.41 32.98 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.026 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -93.9 108.85 20.6 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.539 179.568 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.401 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -127.99 130.81 23.58 Favored Pre-proline 0 CA--C 1.541 0.626 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.264 -179.749 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -73.29 -39.02 1.56 Allowed 'Cis proline' 0 C--N 1.374 1.92 0 C-N-CA 124.692 -0.962 . . . . 0.0 113.439 -0.306 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.86 39.83 12.98 Favored Glycine 0 C--N 1.343 0.971 0 O-C-N 123.43 0.456 . . . . 0.0 113.073 -179.68 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.32 83.09 13.86 Favored Pre-proline 0 CA--C 1.547 0.861 0 C-N-CA 122.222 0.209 . . . . 0.0 111.299 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.91 -33.45 2.65 Favored 'Cis proline' 0 C--N 1.372 1.807 0 C-N-CA 125.345 -0.689 . . . . 0.0 112.755 -0.251 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.1 m-85 -106.89 156.51 18.62 Favored 'General case' 0 N--CA 1.465 0.313 0 O-C-N 123.593 0.558 . . . . 0.0 111.035 -179.424 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.513 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.05 -152.27 5.95 Favored Glycine 0 C--N 1.339 0.697 0 CA-C-N 115.866 -0.606 . . . . 0.0 112.603 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.512 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.3 mm -129.06 147.15 33.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.512 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 77.8 m -84.36 107.78 16.83 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.108 179.264 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.512 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -105.98 159.24 16.2 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.782 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.92 122.91 44.79 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.669 179.562 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.467 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 1.014 0 CA-C-O 118.3 -0.857 . . . . 0.0 111.351 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.485 1.319 0 CA-C-O 119.579 -0.248 . . . . 0.0 111.081 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -83.87 -178.91 3.78 Favored 'Trans proline' 0 C--N 1.371 1.747 0 C-N-CA 122.536 2.157 . . . . 0.0 113.941 -179.057 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.512 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.37 -152.36 6.45 Favored Glycine 0 C--N 1.341 0.857 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.077 179.601 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -73.17 113.85 10.69 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-O 121.015 0.435 . . . . 0.0 111.629 -179.548 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.22 32.46 10.54 Favored Glycine 0 C--N 1.342 0.913 0 CA-C-N 115.345 -0.843 . . . . 0.0 112.778 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.52 162.28 26.79 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-O 120.508 0.194 . . . . 0.0 111.327 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.51 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.1 127.28 32.13 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.864 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.76 150.69 50.96 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.631 -179.193 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.447 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.2 t70 -110.5 154.69 23.31 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.775 178.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.6 m -102.98 3.95 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.191 -179.564 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.447 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.6 mm-40 -99.61 -48.79 4.62 Favored 'General case' 0 C--O 1.234 0.288 0 N-CA-C 111.936 0.346 . . . . 0.0 111.936 -179.053 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.1 p90 -148.63 1.97 0.61 Allowed 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -178.81 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -131.12 63.83 71.56 Favored Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 111.748 0.277 . . . . 0.0 111.748 -179.37 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -74.66 175.93 10.44 Favored 'Trans proline' 0 C--N 1.37 1.705 0 C-N-CA 122.459 2.106 . . . . 0.0 112.574 179.283 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.8 m -79.62 140.92 36.96 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 123.257 0.348 . . . . 0.0 110.62 179.626 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.96 -52.57 1.03 Allowed Pre-proline 0 CA--C 1.544 0.731 0 CA-C-O 119.01 -0.519 . . . . 0.0 111.954 -179.286 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.426 ' HG2' HD12 ' A' ' 19' ' ' LEU . 66.2 Cg_endo -73.94 175.97 10.1 Favored 'Trans proline' 0 C--N 1.375 1.955 0 C-N-CA 122.132 1.888 . . . . 0.0 112.002 179.27 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.35 64.92 1.56 Allowed 'Trans proline' 0 C--N 1.379 2.16 0 C-N-CA 122.402 2.068 . . . . 0.0 112.71 179.517 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.426 HD12 ' HG2' ' A' ' 17' ' ' PRO . 40.5 mt -127.63 161.3 29.17 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.799 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.8 t -112.36 149.59 32.25 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.06 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -93.93 108.89 20.64 Favored 'General case' 0 C--O 1.237 0.446 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.512 179.622 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.401 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -128.11 130.8 23.56 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.252 -179.82 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -73.45 -38.91 1.6 Allowed 'Cis proline' 0 C--N 1.374 1.9 0 C-N-CA 124.562 -1.016 . . . . 0.0 113.507 -0.288 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.93 39.84 12.72 Favored Glycine 0 C--N 1.344 1.009 0 O-C-N 123.437 0.46 . . . . 0.0 113.032 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -141.17 83.12 14.05 Favored Pre-proline 0 CA--C 1.547 0.84 0 CA-C-N 116.646 0.223 . . . . 0.0 111.271 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.77 -33.49 2.67 Favored 'Cis proline' 0 C--N 1.371 1.761 0 CA-C-N 119.062 0.701 . . . . 0.0 112.792 -0.272 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.8 m-85 -106.82 156.51 18.59 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.069 -179.412 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.51 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.85 -152.82 6.1 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.529 179.775 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.509 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.2 mm -128.56 147.18 33.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 -179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.512 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.9 m -84.35 107.98 16.93 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.179 179.229 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.509 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -106.26 159.15 16.33 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.767 -179.031 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.76 122.81 44.55 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.523 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.622 179.65 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.467 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.248 1.017 0 CA-C-O 118.442 -0.789 . . . . 0.0 111.405 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.361 0 CA-C-O 119.546 -0.264 . . . . 0.0 111.106 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_endo -83.77 -178.93 3.82 Favored 'Trans proline' 0 C--N 1.372 1.764 0 C-N-CA 122.502 2.134 . . . . 0.0 114.091 -179.197 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.512 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.73 -152.34 6.55 Favored Glycine 0 C--N 1.342 0.872 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.989 179.505 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.79 114.0 11.57 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-O 120.924 0.392 . . . . 0.0 111.572 -179.43 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.72 32.21 10.39 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-N 115.456 -0.793 . . . . 0.0 112.759 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -127.61 162.26 26.92 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.705 0.288 . . . . 0.0 111.319 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.504 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -79.94 127.11 31.87 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.798 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.62 150.51 50.92 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.684 -179.34 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.451 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.21 154.65 23.08 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.847 178.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.6 m -102.7 4.1 10.63 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.203 -179.544 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.451 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -100.37 -48.51 4.55 Favored 'General case' 0 C--O 1.235 0.336 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.079 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.3 p90 -148.22 1.83 0.64 Allowed 'General case' 0 N--CA 1.476 0.862 0 N-CA-C 113.23 0.826 . . . . 0.0 113.23 -178.79 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.07 63.55 70.69 Favored Pre-proline 0 CA--C 1.549 0.928 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 -179.317 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.6 175.44 11.08 Favored 'Trans proline' 0 C--N 1.37 1.662 0 C-N-CA 122.434 2.089 . . . . 0.0 112.626 179.244 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.6 m -79.74 140.76 36.83 Favored 'General case' 0 CA--C 1.534 0.363 0 O-C-N 123.255 0.347 . . . . 0.0 110.541 179.69 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.91 -52.67 1.03 Allowed Pre-proline 0 CA--C 1.544 0.721 0 CA-C-O 119.017 -0.516 . . . . 0.0 112.007 -179.291 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.428 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.9 Cg_endo -73.78 175.93 10.1 Favored 'Trans proline' 0 C--N 1.374 1.893 0 C-N-CA 122.118 1.879 . . . . 0.0 112.013 179.212 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.39 64.95 1.58 Allowed 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 122.347 2.031 . . . . 0.0 112.678 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.428 HD12 ' HG2' ' A' ' 17' ' ' PRO . 39.9 mt -127.49 161.39 28.87 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.751 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.8 t -112.51 149.42 32.68 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.89 -0.596 . . . . 0.0 111.081 179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -93.88 108.79 20.54 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.515 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.409 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.2 mt -128.03 130.84 23.57 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.279 -179.783 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.31 -39.02 1.55 Allowed 'Cis proline' 0 C--N 1.374 1.89 0 C-N-CA 124.651 -0.979 . . . . 0.0 113.427 -0.284 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.75 39.63 13.65 Favored Glycine 0 C--N 1.344 0.98 0 O-C-N 123.469 0.48 . . . . 0.0 113.15 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -141.26 83.26 13.8 Favored Pre-proline 0 CA--C 1.546 0.799 0 C-N-CA 122.169 0.187 . . . . 0.0 111.302 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -83.68 -33.54 2.67 Favored 'Cis proline' 0 C--N 1.373 1.859 0 CA-C-N 119.05 0.697 . . . . 0.0 112.801 -0.271 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -106.71 156.24 18.84 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.018 -179.429 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.504 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.63 -153.35 6.27 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 115.868 -0.606 . . . . 0.0 112.597 179.715 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.51 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.5 mm -128.38 147.08 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.512 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.6 m -84.33 107.88 16.86 Favored 'General case' 0 C--O 1.238 0.48 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.221 179.157 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.51 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -106.02 159.08 16.33 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.767 -178.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.91 122.99 44.84 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.662 179.584 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.465 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.132 -0.937 . . . . 0.0 111.41 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.7 p . . . . . 0 N--CA 1.487 1.417 0 CA-C-O 119.66 -0.21 . . . . 0.0 111.102 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.453 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 91.9 Cg_endo -79.27 -178.87 4.93 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 122.586 2.191 . . . . 0.0 113.785 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -139.77 -144.69 4.57 Favored Glycine 0 C--N 1.339 0.713 0 CA-C-N 115.369 -0.832 . . . . 0.0 111.871 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -84.37 109.88 18.18 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 120.904 0.383 . . . . 0.0 110.81 179.478 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.15 36.88 6.46 Favored Glycine 0 C--N 1.34 0.76 0 CA-C-N 115.465 -0.789 . . . . 0.0 112.733 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.451 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 42.5 mt-10 -133.25 167.13 20.93 Favored 'General case' 0 N--CA 1.467 0.396 0 O-C-N 123.622 0.248 . . . . 0.0 110.909 -179.728 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.532 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.3 tt0 -80.32 124.54 28.94 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.637 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 20.6 p -127.64 143.57 51.15 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.494 -179.267 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.407 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 10.2 t70 -113.8 156.67 23.45 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.696 -0.683 . . . . 0.0 109.919 179.126 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 16.0 m -103.74 7.84 9.78 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 CA-C-N 116.02 -0.536 . . . . 0.0 112.078 -179.563 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.407 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.4 mt-10 -110.16 -49.34 3.08 Favored 'General case' 0 CA--C 1.533 0.298 0 N-CA-C 112.308 0.485 . . . . 0.0 112.308 -178.882 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.468 ' HZ ' ' HH ' ' A' ' 27' ' ' TYR . 37.3 p90 -141.2 4.16 1.81 Allowed 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 113.236 0.828 . . . . 0.0 113.236 -178.737 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -132.29 65.73 75.62 Favored Pre-proline 0 CA--C 1.546 0.795 0 CA-C-O 120.525 0.203 . . . . 0.0 111.126 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.453 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 50.4 Cg_endo -73.85 161.98 40.34 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.451 2.1 . . . . 0.0 112.81 179.509 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 91.1 m -79.88 140.85 36.59 Favored 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.548 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -83.81 -52.4 0.58 Allowed Pre-proline 0 CA--C 1.544 0.742 0 CA-C-O 118.906 -0.569 . . . . 0.0 112.265 -179.798 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.471 ' HG2' HD12 ' A' ' 19' ' ' LEU . 72.5 Cg_endo -75.55 172.89 15.45 Favored 'Trans proline' 0 C--N 1.375 1.953 0 C-N-CA 122.15 1.9 . . . . 0.0 112.48 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_exo -71.51 66.05 2.93 Favored 'Trans proline' 0 C--N 1.377 2.051 0 C-N-CA 122.409 2.072 . . . . 0.0 112.464 179.588 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.471 HD12 ' HG2' ' A' ' 17' ' ' PRO . 58.5 mt -125.43 166.7 16.12 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.818 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.596 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 9.8 t -115.05 143.96 44.37 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.102 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 6.1 t -92.27 109.3 20.68 Favored 'General case' 0 C--O 1.237 0.429 0 O-C-N 123.479 0.487 . . . . 0.0 110.725 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 6.8 mt -126.37 130.9 23.8 Favored Pre-proline 0 CA--C 1.542 0.637 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.991 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -74.18 -37.58 2.16 Favored 'Cis proline' 0 C--N 1.374 1.874 0 C-N-CA 124.565 -1.014 . . . . 0.0 113.567 -0.143 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.8 36.31 19.52 Favored Glycine 0 C--N 1.345 1.043 0 O-C-N 123.343 0.402 . . . . 0.0 113.029 -179.634 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -143.8 82.5 11.15 Favored Pre-proline 0 CA--C 1.55 0.945 0 CA-C-N 116.666 0.233 . . . . 0.0 111.089 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -85.99 -35.52 1.46 Allowed 'Cis proline' 0 C--N 1.373 1.843 0 CA-C-N 119.171 0.74 . . . . 0.0 112.834 -0.421 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.468 ' HH ' ' HZ ' ' A' ' 12' ' ' PHE . 64.5 m-85 -109.85 158.81 17.79 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.991 -179.184 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.532 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -162.49 -152.68 6.85 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-N 115.886 -0.597 . . . . 0.0 112.356 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.451 ' HA ' ' O ' ' A' ' 6' ' ' GLU . 16.0 mm -126.71 144.78 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 179.711 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.596 ' HA ' ' O ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -91.44 117.82 30.02 Favored 'General case' 0 C--O 1.235 0.337 0 O-C-N 123.505 0.503 . . . . 0.0 111.13 -179.977 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -109.04 167.35 10.16 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.731 -178.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.6 tp -95.04 123.62 47.23 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.553 179.526 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.478 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.4 pp . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.371 -0.823 . . . . 0.0 111.319 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.487 1.382 0 CA-C-O 119.658 -0.211 . . . . 0.0 111.098 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -83.37 -179.11 4.07 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.481 2.121 . . . . 0.0 114.087 -179.137 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.495 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.98 -152.47 6.54 Favored Glycine 0 C--N 1.341 0.843 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.771 179.48 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.5 tt0 -73.34 111.85 8.85 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-O 120.83 0.348 . . . . 0.0 111.415 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.79 30.94 10.63 Favored Glycine 0 C--N 1.341 0.817 0 CA-C-N 115.485 -0.779 . . . . 0.0 112.715 -179.728 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.3 mt-10 -126.86 163.76 22.9 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-O 120.599 0.238 . . . . 0.0 111.21 -179.704 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.2 tt0 -79.97 128.67 33.75 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.067 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.474 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.4 p -127.11 142.61 51.47 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.627 -179.557 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -104.42 150.12 24.82 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.707 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.489 HG22 ' O ' ' A' ' 26' ' ' PRO . 9.0 m -101.61 5.38 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.904 -179.885 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -99.2 -47.52 5.17 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.929 -179.204 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -151.76 1.41 0.36 Allowed 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -178.855 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -131.65 64.44 72.9 Favored Pre-proline 0 CA--C 1.549 0.919 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -179.267 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -73.5 178.25 6.93 Favored 'Trans proline' 0 C--N 1.37 1.7 0 C-N-CA 122.538 2.159 . . . . 0.0 112.473 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.0 m -79.51 138.68 37.61 Favored 'General case' 0 N--CA 1.467 0.413 0 O-C-N 123.216 0.322 . . . . 0.0 110.706 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.02 -52.57 1.02 Allowed Pre-proline 0 CA--C 1.544 0.748 0 CA-C-O 118.983 -0.532 . . . . 0.0 112.089 -179.388 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.413 ' HG2' HD12 ' A' ' 19' ' ' LEU . 64.3 Cg_endo -72.76 175.9 9.66 Favored 'Trans proline' 0 C--N 1.375 1.944 0 C-N-CA 122.163 1.908 . . . . 0.0 112.06 179.347 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -69.55 64.87 1.68 Allowed 'Trans proline' 0 C--N 1.378 2.124 0 C-N-CA 122.373 2.049 . . . . 0.0 112.747 179.399 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.413 HD12 ' HG2' ' A' ' 17' ' ' PRO . 32.9 mt -129.09 159.92 34.45 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.721 179.889 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.431 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -111.09 152.76 26.57 Favored 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.192 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.7 t -96.39 106.47 18.71 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.256 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.443 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.3 mt -125.89 131.51 24.02 Favored Pre-proline 0 CA--C 1.542 0.67 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.478 -179.532 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -71.26 -39.34 1.45 Allowed 'Cis proline' 0 C--N 1.375 1.952 0 C-N-CA 124.649 -0.98 . . . . 0.0 113.389 -0.117 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.59 31.15 46.3 Favored Glycine 0 C--N 1.343 0.947 0 O-C-N 123.408 0.442 . . . . 0.0 113.266 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -136.97 85.64 22.45 Favored Pre-proline 0 CA--C 1.545 0.781 0 C-N-CA 122.198 0.199 . . . . 0.0 111.096 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.489 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.2 Cg_endo -83.13 -34.5 2.4 Favored 'Cis proline' 0 C--N 1.372 1.811 0 C-N-CA 125.246 -0.731 . . . . 0.0 112.94 -0.217 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.3 m-85 -98.66 153.94 18.33 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.02 -179.218 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.14 -171.5 18.58 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 116.072 -0.513 . . . . 0.0 113.06 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.479 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 42.5 mm -122.42 146.0 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.495 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.3 m -81.57 107.79 14.62 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.543 179.492 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.479 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.6 m-85 -108.29 158.6 17.33 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.612 -179.389 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 tp -92.1 123.32 44.17 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.662 179.618 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.453 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.124 -0.941 . . . . 0.0 111.402 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 119.546 -0.264 . . . . 0.0 111.116 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -83.55 -179.04 3.96 Favored 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.479 2.12 . . . . 0.0 114.029 -179.143 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.528 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.68 -152.91 6.52 Favored Glycine 0 C--N 1.342 0.902 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.96 179.623 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -72.18 113.13 8.88 Favored 'General case' 0 N--CA 1.472 0.663 0 CA-C-O 120.941 0.4 . . . . 0.0 111.539 -179.44 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.7 33.32 10.15 Favored Glycine 0 C--N 1.342 0.873 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.761 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.441 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 8.6 mm-40 -127.65 163.55 23.99 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 120.607 0.241 . . . . 0.0 111.266 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.535 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.6 tt0 -80.15 127.93 32.91 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.837 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.412 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 8.6 p -130.86 148.77 52.67 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.75 -179.319 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.44 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.2 t70 -110.83 155.59 22.35 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.816 178.958 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.0 m -103.23 3.6 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 112.244 0.461 . . . . 0.0 112.244 -179.49 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.44 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -98.89 -48.79 4.78 Favored 'General case' 0 C--O 1.235 0.339 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -179.027 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -148.76 1.99 0.59 Allowed 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -178.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -131.02 63.7 71.26 Favored Pre-proline 0 CA--C 1.55 0.95 0 N-CA-C 111.757 0.28 . . . . 0.0 111.757 -179.371 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -74.81 175.66 10.88 Favored 'Trans proline' 0 C--N 1.37 1.708 0 C-N-CA 122.467 2.111 . . . . 0.0 112.571 179.133 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 38.4 m -79.74 140.1 37.07 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 116.55 -0.295 . . . . 0.0 110.561 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.98 -52.51 1.03 Allowed Pre-proline 0 CA--C 1.544 0.734 0 CA-C-O 119.082 -0.485 . . . . 0.0 112.037 -179.258 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.428 ' HG2' HD12 ' A' ' 19' ' ' LEU . 64.6 Cg_endo -73.52 175.5 10.57 Favored 'Trans proline' 0 C--N 1.376 2.004 0 C-N-CA 122.087 1.858 . . . . 0.0 112.115 179.248 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -69.47 64.93 1.64 Allowed 'Trans proline' 0 C--N 1.377 2.072 0 C-N-CA 122.386 2.057 . . . . 0.0 112.707 179.465 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.428 HD12 ' HG2' ' A' ' 17' ' ' PRO . 36.7 mt -127.83 161.95 27.81 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.761 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.0 t -111.71 150.39 30.27 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.213 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 4.0 t -95.26 108.6 20.76 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.553 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.4 mt -127.66 130.99 23.6 Favored Pre-proline 0 CA--C 1.541 0.616 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.195 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.599 ' HB2' ' OD2' ' A' ' 25' ' ' ASP . 55.6 Cg_endo -72.48 -39.44 1.44 Allowed 'Cis proline' 0 C--N 1.373 1.854 0 C-N-CA 124.668 -0.972 . . . . 0.0 113.476 -0.272 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.56 38.82 11.55 Favored Glycine 0 C--N 1.344 0.998 0 O-C-N 123.483 0.49 . . . . 0.0 113.386 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.599 ' OD2' ' HB2' ' A' ' 23' ' ' PRO . 2.0 p30 -144.9 85.02 8.51 Favored Pre-proline 0 CA--C 1.55 0.952 0 CA-C-N 116.66 0.23 . . . . 0.0 111.473 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -83.88 -33.65 2.58 Favored 'Cis proline' 0 C--N 1.372 1.789 0 CA-C-N 118.985 0.673 . . . . 0.0 112.896 -0.466 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -109.69 156.72 19.9 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.977 -179.314 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.535 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.84 -151.17 5.67 Favored Glycine 0 C--N 1.338 0.661 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.507 179.78 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.487 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.7 mm -129.26 147.22 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.528 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 79.1 m -84.35 107.24 16.52 Favored 'General case' 0 CA--C 1.537 0.443 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.286 179.25 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.487 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.7 m-85 -105.14 157.84 16.99 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.544 -179.375 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 tt -94.23 124.42 46.7 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.704 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.459 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.247 0.95 0 CA-C-O 118.357 -0.83 . . . . 0.0 111.408 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.373 0 CA-C-O 119.67 -0.205 . . . . 0.0 111.09 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_endo -83.28 -179.13 4.11 Favored 'Trans proline' 0 C--N 1.373 1.822 0 C-N-CA 122.589 2.193 . . . . 0.0 114.054 -179.057 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.495 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.0 -152.26 6.48 Favored Glycine 0 C--N 1.342 0.886 0 CA-C-N 115.41 -0.814 . . . . 0.0 111.777 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.5 tt0 -73.49 111.7 8.87 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 120.835 0.35 . . . . 0.0 111.452 -179.656 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.91 31.07 10.3 Favored Glycine 0 C--N 1.341 0.816 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.651 -179.752 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.1 mt-10 -126.94 163.85 22.75 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-O 120.534 0.207 . . . . 0.0 111.261 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -79.95 128.63 33.7 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.04 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.474 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.5 p -127.13 142.29 51.55 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.59 -179.549 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -104.29 150.03 24.81 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.737 179.407 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.491 HG22 ' O ' ' A' ' 26' ' ' PRO . 9.6 m -101.46 5.25 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.906 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -99.02 -47.45 5.23 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.928 -179.202 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -151.86 1.37 0.36 Allowed 'General case' 0 N--CA 1.478 0.947 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 -178.893 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 -131.55 64.31 72.57 Favored Pre-proline 0 CA--C 1.548 0.89 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.273 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.46 178.24 6.93 Favored 'Trans proline' 0 C--N 1.371 1.731 0 C-N-CA 122.544 2.163 . . . . 0.0 112.484 179.034 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 49.3 m -79.49 138.75 37.66 Favored 'General case' 0 N--CA 1.467 0.42 0 O-C-N 123.224 0.328 . . . . 0.0 110.765 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.22 -52.58 0.98 Allowed Pre-proline 0 CA--C 1.544 0.736 0 CA-C-O 119.018 -0.515 . . . . 0.0 112.057 -179.301 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.409 ' HG2' HD12 ' A' ' 19' ' ' LEU . 64.5 Cg_endo -72.7 175.88 9.64 Favored 'Trans proline' 0 C--N 1.375 1.972 0 C-N-CA 122.16 1.906 . . . . 0.0 112.06 179.297 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.59 65.0 1.7 Allowed 'Trans proline' 0 C--N 1.378 2.093 0 C-N-CA 122.381 2.054 . . . . 0.0 112.591 179.475 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.409 HD12 ' HG2' ' A' ' 17' ' ' PRO . 33.2 mt -129.28 159.96 34.49 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.579 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.432 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -110.98 152.68 26.53 Favored 'General case' 0 CA--C 1.536 0.408 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.101 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.8 t -96.33 106.43 18.65 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.366 179.679 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.444 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.5 mt -125.81 131.56 24.04 Favored Pre-proline 0 CA--C 1.543 0.684 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.396 -179.458 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -71.08 -39.45 1.42 Allowed 'Cis proline' 0 C--N 1.375 1.923 0 C-N-CA 124.683 -0.965 . . . . 0.0 113.402 -0.225 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.65 30.69 47.66 Favored Glycine 0 C--N 1.345 1.043 0 O-C-N 123.463 0.477 . . . . 0.0 113.391 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -136.79 85.8 23.14 Favored Pre-proline 0 CA--C 1.546 0.82 0 C-N-CA 122.259 0.224 . . . . 0.0 111.049 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.491 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.2 Cg_endo -83.07 -34.58 2.37 Favored 'Cis proline' 0 C--N 1.371 1.756 0 C-N-CA 125.273 -0.719 . . . . 0.0 112.95 -0.269 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 -98.64 153.9 18.34 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.044 -179.246 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.2 -171.8 18.9 Favored Glycine 0 C--N 1.339 0.729 0 O-C-N 123.542 0.526 . . . . 0.0 113.079 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.48 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 42.4 mm -122.17 145.91 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.495 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.5 m -81.44 107.73 14.45 Favored 'General case' 0 CA--C 1.537 0.469 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.517 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.48 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.6 m-85 -108.21 158.65 17.26 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.356 -0.383 . . . . 0.0 111.652 -179.447 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 tp -92.29 123.56 44.45 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.558 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.547 179.694 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.45 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 0.983 0 CA-C-O 118.278 -0.868 . . . . 0.0 111.384 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.488 1.446 0 CA-C-O 119.624 -0.227 . . . . 0.0 111.156 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.439 ' HG2' ' SG ' ' A' ' 30' ' ' CYS . 87.3 Cg_endo -81.94 -179.65 4.94 Favored 'Trans proline' 0 C--N 1.372 1.782 0 C-N-CA 122.652 2.235 . . . . 0.0 113.997 -179.067 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.495 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.27 -151.37 6.39 Favored Glycine 0 C--N 1.34 0.769 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.699 179.429 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -75.6 110.33 9.91 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-O 120.931 0.396 . . . . 0.0 111.288 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.38 29.82 10.7 Favored Glycine 0 C--N 1.341 0.833 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.524 -179.687 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -124.25 167.97 13.58 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-O 120.561 0.219 . . . . 0.0 111.133 -179.67 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 -79.9 137.39 36.89 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.072 -179.674 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -126.74 157.04 40.16 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.492 -0.777 . . . . 0.0 111.274 -179.283 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -131.18 140.04 49.84 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.289 179.076 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.521 HG22 ' O ' ' A' ' 26' ' ' PRO . 11.7 m -95.76 7.37 7.18 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 O-C-N 123.202 0.314 . . . . 0.0 111.757 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -99.73 -46.6 5.36 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.772 -179.274 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.0 p90 -154.58 1.17 0.2 Allowed 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 -178.91 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -132.72 65.61 74.74 Favored Pre-proline 0 CA--C 1.547 0.844 0 CA-C-N 117.931 0.332 . . . . 0.0 111.884 -179.237 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.407 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 55.3 Cg_endo -74.14 177.57 8.06 Favored 'Trans proline' 0 C--N 1.369 1.628 0 C-N-CA 122.574 2.182 . . . . 0.0 112.252 178.906 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 56.9 m -79.35 139.64 37.71 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 116.705 -0.225 . . . . 0.0 110.898 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.35 -53.7 0.56 Allowed Pre-proline 0 CA--C 1.545 0.75 0 CA-C-O 119.014 -0.517 . . . . 0.0 112.342 -179.073 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.43 ' HG2' HD12 ' A' ' 19' ' ' LEU . 60.0 Cg_endo -71.66 175.32 9.72 Favored 'Trans proline' 0 C--N 1.375 1.971 0 C-N-CA 122.09 1.86 . . . . 0.0 112.265 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_exo -69.6 65.06 1.71 Allowed 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 122.369 2.046 . . . . 0.0 112.615 179.456 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.43 HD12 ' HG2' ' A' ' 17' ' ' PRO . 47.4 mt -126.65 161.13 28.8 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.722 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.0 t -109.58 151.51 26.72 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.227 -179.901 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.7 t -96.39 107.56 19.96 Favored 'General case' 0 C--O 1.238 0.47 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.398 179.541 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.438 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 3.8 mt -126.75 129.5 24.04 Favored Pre-proline 0 CA--C 1.541 0.615 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.761 -179.729 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -71.48 -39.14 1.5 Allowed 'Cis proline' 0 C--N 1.374 1.881 0 C-N-CA 124.591 -1.004 . . . . 0.0 113.305 -0.577 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.01 29.76 40.64 Favored Glycine 0 C--N 1.344 0.995 0 CA-C-N 116.158 -0.473 . . . . 0.0 113.429 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -144.13 89.55 7.06 Favored Pre-proline 0 CA--C 1.546 0.811 0 CA-C-N 116.702 0.251 . . . . 0.0 111.219 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.521 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.5 Cg_endo -83.77 -35.58 1.87 Allowed 'Cis proline' 0 C--N 1.371 1.738 0 CA-C-N 119.198 0.749 . . . . 0.0 112.846 -0.291 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 44.0 m-85 -103.01 156.95 17.32 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.717 -179.331 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -156.43 -164.98 14.0 Favored Glycine 0 C--N 1.339 0.743 0 C-N-CA 120.956 -0.64 . . . . 0.0 113.216 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.461 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 43.4 mm -127.24 147.53 32.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.495 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 72.3 m -82.89 109.41 16.99 Favored 'General case' 0 CA--C 1.537 0.478 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.401 179.282 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.461 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.4 m-85 -109.03 158.42 17.75 Favored 'General case' 0 N--CA 1.467 0.391 0 N-CA-C 112.038 0.384 . . . . 0.0 112.038 -179.024 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.1 tp -93.46 124.6 45.95 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.616 179.675 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.453 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.25 1.128 0 CA-C-O 118.185 -0.912 . . . . 0.0 111.44 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.374 0 CA-C-O 119.649 -0.215 . . . . 0.0 111.104 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -83.48 -179.07 4.0 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.467 2.111 . . . . 0.0 114.123 -179.157 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.493 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.82 -152.77 6.64 Favored Glycine 0 C--N 1.341 0.849 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.809 179.433 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.46 111.91 9.04 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-O 120.896 0.379 . . . . 0.0 111.469 -179.753 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.27 30.74 10.46 Favored Glycine 0 C--N 1.341 0.832 0 CA-C-N 115.418 -0.81 . . . . 0.0 112.593 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -127.01 163.69 23.16 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-O 120.608 0.242 . . . . 0.0 111.194 -179.693 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -79.96 128.56 33.62 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.969 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.47 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.3 p -127.05 143.18 51.35 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.555 -179.6 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -104.56 150.28 24.77 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.345 -0.843 . . . . 0.0 109.74 179.469 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.485 HG22 ' O ' ' A' ' 26' ' ' PRO . 9.1 m -101.82 5.12 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.844 -179.854 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -99.17 -47.41 5.21 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.904 -179.126 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -151.84 1.53 0.36 Allowed 'General case' 0 N--CA 1.477 0.886 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -178.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -131.7 64.46 72.89 Favored Pre-proline 0 CA--C 1.549 0.927 0 N-CA-C 111.803 0.298 . . . . 0.0 111.803 -179.262 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.63 178.36 6.84 Favored 'Trans proline' 0 C--N 1.369 1.612 0 C-N-CA 122.56 2.173 . . . . 0.0 112.456 179.066 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 48.3 m -79.55 138.91 37.64 Favored 'General case' 0 C--N 1.344 0.367 0 O-C-N 123.163 0.29 . . . . 0.0 110.792 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.03 -52.66 1.01 Allowed Pre-proline 0 CA--C 1.543 0.697 0 CA-C-O 118.999 -0.525 . . . . 0.0 112.103 -179.319 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.416 ' HG2' HD12 ' A' ' 19' ' ' LEU . 63.9 Cg_endo -72.78 175.88 9.7 Favored 'Trans proline' 0 C--N 1.375 1.964 0 C-N-CA 122.126 1.884 . . . . 0.0 112.036 179.337 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.44 64.82 1.62 Allowed 'Trans proline' 0 C--N 1.379 2.149 0 C-N-CA 122.38 2.053 . . . . 0.0 112.693 179.47 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.416 HD12 ' HG2' ' A' ' 17' ' ' PRO . 33.0 mt -129.11 159.96 34.34 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.698 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.435 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -111.22 152.88 26.6 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.149 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 t -96.37 106.75 19.03 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.298 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.447 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.5 mt -126.15 131.66 24.04 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.418 -179.538 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -71.12 -39.53 1.4 Allowed 'Cis proline' 0 C--N 1.374 1.895 0 C-N-CA 124.676 -0.969 . . . . 0.0 113.391 -0.326 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.67 31.54 44.52 Favored Glycine 0 C--N 1.342 0.9 0 O-C-N 123.49 0.494 . . . . 0.0 113.393 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -136.82 85.38 23.88 Favored Pre-proline 0 CA--C 1.545 0.783 0 C-N-CA 122.168 0.187 . . . . 0.0 111.072 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.485 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.1 Cg_endo -83.3 -34.37 2.41 Favored 'Cis proline' 0 C--N 1.372 1.767 0 C-N-CA 125.17 -0.763 . . . . 0.0 112.993 -0.217 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 -98.56 153.9 18.31 Favored 'General case' 0 N--CA 1.466 0.369 0 O-C-N 123.586 0.554 . . . . 0.0 110.996 -179.238 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.15 -171.33 18.41 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 116.035 -0.529 . . . . 0.0 113.004 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.483 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 41.8 mm -122.38 146.16 28.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.493 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.5 m -81.7 107.92 14.83 Favored 'General case' 0 CA--C 1.537 0.477 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.509 179.562 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.483 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.6 m-85 -108.5 158.94 17.09 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.53 -179.45 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tp -91.57 122.75 43.29 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.61 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.457 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.116 -0.945 . . . . 0.0 111.326 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.5 p . . . . . 0 N--CA 1.486 1.359 0 CA-C-O 119.628 -0.225 . . . . 0.0 111.149 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.492 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 86.9 Cg_endo -78.26 -172.57 1.54 Allowed 'Trans proline' 0 C--N 1.37 1.7 0 C-N-CA 122.673 2.248 . . . . 0.0 113.83 -179.346 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.2 -144.21 4.24 Favored Glycine 0 C--N 1.339 0.698 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.588 179.755 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 13.3 tt0 -86.47 109.62 19.2 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-O 120.881 0.372 . . . . 0.0 110.705 179.476 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.53 35.88 6.74 Favored Glycine 0 C--N 1.34 0.774 0 CA-C-N 115.571 -0.74 . . . . 0.0 112.749 -179.664 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -131.85 167.68 19.16 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 122.335 0.254 . . . . 0.0 110.831 -179.709 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -79.9 120.56 24.28 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.715 179.746 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 11.8 p -120.17 135.6 54.91 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.288 -179.343 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -104.02 156.15 18.09 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 115.483 -0.78 . . . . 0.0 109.691 179.649 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.428 HG22 ' O ' ' A' ' 26' ' ' PRO . 8.0 m -107.82 14.29 8.14 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.905 -179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -120.54 -45.11 2.43 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.112 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 38.1 p90 -141.28 2.34 1.67 Allowed 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -178.753 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -135.97 68.21 63.85 Favored Pre-proline 0 CA--C 1.543 0.71 0 CA-C-O 120.524 0.202 . . . . 0.0 111.377 -179.644 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.492 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 50.5 Cg_endo -74.46 164.36 34.13 Favored 'Trans proline' 0 C--N 1.368 1.602 0 C-N-CA 122.614 2.209 . . . . 0.0 112.581 179.009 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 94.1 m -79.6 140.42 37.14 Favored 'General case' 0 N--CA 1.47 0.538 0 O-C-N 123.441 0.463 . . . . 0.0 111.681 -179.455 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 m -84.9 -52.54 0.5 Allowed Pre-proline 0 CA--C 1.545 0.751 0 O-C-N 123.63 0.581 . . . . 0.0 112.168 -179.634 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.482 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.3 Cg_endo -75.02 172.8 15.66 Favored 'Trans proline' 0 C--N 1.376 2.014 0 C-N-CA 122.066 1.844 . . . . 0.0 112.408 179.741 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo -71.31 66.16 2.76 Favored 'Trans proline' 0 C--N 1.379 2.149 0 C-N-CA 122.357 2.038 . . . . 0.0 112.511 179.613 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.482 HD12 ' HG2' ' A' ' 17' ' ' PRO . 55.5 mt -124.52 168.1 13.55 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.817 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.579 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 8.5 t -118.73 140.99 49.04 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.337 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 6.3 t -90.99 104.25 16.86 Favored 'General case' 0 CA--C 1.536 0.442 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.541 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mt -120.84 131.58 24.43 Favored Pre-proline 0 CA--C 1.543 0.692 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.325 -179.598 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -72.52 -36.9 2.4 Favored 'Cis proline' 0 C--N 1.374 1.888 0 C-N-CA 124.542 -1.024 . . . . 0.0 113.257 -0.264 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.47 30.57 48.88 Favored Glycine 0 C--N 1.343 0.925 0 CA-C-N 116.171 -0.468 . . . . 0.0 113.297 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -142.24 86.33 10.2 Favored Pre-proline 0 CA--C 1.545 0.783 0 C-N-CA 122.287 0.235 . . . . 0.0 111.161 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.428 ' O ' HG22 ' A' ' 10' ' ' VAL . 1.7 Cg_endo -85.24 -35.59 1.59 Allowed 'Cis proline' 0 C--N 1.373 1.826 0 CA-C-N 119.055 0.698 . . . . 0.0 112.987 -0.377 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 23.6 m-85 -104.45 154.52 19.77 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.906 -179.056 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -161.76 -172.83 29.66 Favored Glycine 0 C--N 1.34 0.761 0 CA-C-N 116.015 -0.538 . . . . 0.0 113.139 179.6 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 27.2 mm -116.87 145.2 22.94 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 179.747 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.579 ' HA ' ' O ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -89.4 119.56 29.97 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.484 -179.864 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -111.87 167.01 10.7 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.487 -179.111 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -95.42 122.93 47.33 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.464 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.554 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.475 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.5 pp . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.418 -0.801 . . . . 0.0 111.352 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 31.6 p . . . . . 0 N--CA 1.486 1.35 0 CA-C-O 119.48 -0.295 . . . . 0.0 111.027 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -84.61 -177.33 2.85 Favored 'Trans proline' 0 C--N 1.37 1.661 0 C-N-CA 122.161 1.908 . . . . 0.0 113.088 179.407 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.576 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -146.93 -157.89 7.57 Favored Glycine 0 C--N 1.337 0.613 0 CA-C-N 115.74 -0.663 . . . . 0.0 112.027 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -65.66 110.3 2.72 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 121.042 0.448 . . . . 0.0 111.737 -179.251 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.33 31.57 10.48 Favored Glycine 0 C--N 1.339 0.745 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.723 -179.865 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.447 ' HB2' ' H ' ' A' ' 3' ' ' GLY . 36.7 mt-10 -126.3 159.98 31.64 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.606 0.241 . . . . 0.0 111.275 -179.686 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.507 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.7 tt0 -80.04 121.92 26.12 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.566 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.409 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 7.9 p -124.83 149.29 47.61 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 115.795 -0.638 . . . . 0.0 111.673 -179.169 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.441 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.1 t70 -109.11 155.35 21.09 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.898 179.14 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.3 m -103.0 3.42 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 -179.543 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.441 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.9 mm-40 -98.6 -48.6 4.92 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 111.939 0.348 . . . . 0.0 111.939 -179.037 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -149.15 1.56 0.55 Allowed 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 113.325 0.861 . . . . 0.0 113.325 -178.902 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -130.73 63.73 70.97 Favored Pre-proline 0 CA--C 1.55 0.965 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 -179.333 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -76.61 172.7 15.75 Favored 'Trans proline' 0 C--N 1.369 1.656 0 C-N-CA 122.438 2.092 . . . . 0.0 112.618 179.115 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.409 ' SG ' ' SG ' ' A' ' 8' ' ' CYS . 21.9 m -79.56 133.33 36.45 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.3 179.623 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.545 ' SG ' ' HD3' ' A' ' 17' ' ' PRO . 0.8 OUTLIER -79.55 -45.46 1.6 Allowed Pre-proline 0 N--CA 1.475 0.782 0 N-CA-C 112.859 0.689 . . . . 0.0 112.859 -179.279 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.545 ' HD3' ' SG ' ' A' ' 16' ' ' CYS . 56.7 Cg_endo -70.69 174.37 10.43 Favored 'Trans proline' 0 C--N 1.374 1.876 0 C-N-CA 121.863 1.709 . . . . 0.0 111.879 178.892 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 14.2 Cg_exo -70.0 65.71 1.93 Allowed 'Trans proline' 0 C--N 1.377 2.046 0 C-N-CA 122.274 1.983 . . . . 0.0 112.366 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.527 HD12 ' HG2' ' A' ' 17' ' ' PRO . 25.8 mt -133.43 162.38 32.01 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.27 -0.877 . . . . 0.0 110.901 -179.56 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.507 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.6 t -112.28 155.32 24.26 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.244 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -98.37 108.41 21.1 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.307 179.618 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.422 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.1 mt -128.15 130.86 23.55 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.376 -179.831 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.86 -39.3 1.48 Allowed 'Cis proline' 0 C--N 1.373 1.849 0 C-N-CA 124.624 -0.99 . . . . 0.0 113.533 -0.342 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.29 38.37 18.39 Favored Glycine 0 C--N 1.345 1.049 0 CA-C-N 116.216 -0.447 . . . . 0.0 113.079 -179.725 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -141.23 84.13 13.06 Favored Pre-proline 0 CA--C 1.547 0.847 0 C-N-CA 122.225 0.21 . . . . 0.0 111.338 -179.832 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -83.16 -34.14 2.54 Favored 'Cis proline' 0 C--N 1.373 1.828 0 CA-C-N 119.047 0.695 . . . . 0.0 112.763 -0.189 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -106.14 156.41 18.46 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.892 -179.35 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.507 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.1 -156.24 7.49 Favored Glycine 0 C--N 1.337 0.622 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.622 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.479 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 23.3 mm -127.4 147.88 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 N-CA-C 110.051 -0.351 . . . . 0.0 110.051 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.576 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 76.7 m -84.74 110.13 18.56 Favored 'General case' 0 CA--C 1.537 0.455 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.114 179.228 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.479 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.4 m-85 -107.38 159.77 16.14 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.899 -178.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.0 tp -93.57 124.1 45.9 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.536 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.6 179.551 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.4 pt . . . . . 0 C--O 1.25 1.119 0 CA-C-O 118.489 -0.767 . . . . 0.0 111.328 179.988 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.487 1.375 0 CA-C-O 119.616 -0.23 . . . . 0.0 111.179 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -83.44 -179.15 4.07 Favored 'Trans proline' 0 C--N 1.371 1.733 0 C-N-CA 122.497 2.131 . . . . 0.0 114.082 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.494 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.84 -152.53 6.58 Favored Glycine 0 C--N 1.341 0.843 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.81 179.41 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.65 111.83 9.16 Favored 'General case' 0 N--CA 1.472 0.63 0 CA-C-O 120.878 0.371 . . . . 0.0 111.385 -179.661 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.21 30.93 10.22 Favored Glycine 0 C--N 1.341 0.828 0 CA-C-N 115.502 -0.772 . . . . 0.0 112.638 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.3 mt-10 -127.14 163.75 23.12 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-O 120.559 0.219 . . . . 0.0 111.212 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -79.95 128.48 33.52 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.971 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.472 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.3 p -127.02 142.9 51.43 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.515 -179.644 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.404 ' OD1' ' HB3' ' A' ' 13' ' ' ASN . 1.3 m-20 -104.46 150.04 24.91 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.808 179.439 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.488 HG22 ' O ' ' A' ' 26' ' ' PRO . 9.4 m -101.68 5.92 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 O-C-N 123.397 0.436 . . . . 0.0 111.947 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.6 tt0 -100.04 -48.0 4.8 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.522 -179.105 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 36.7 p90 -151.11 1.54 0.41 Allowed 'General case' 0 N--CA 1.477 0.918 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -178.861 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ASN . . . . . 0.404 ' HB3' ' OD1' ' A' ' 9' ' ' ASP . 2.3 t-20 -131.55 64.3 72.54 Favored Pre-proline 0 CA--C 1.55 0.972 0 N-CA-C 111.854 0.316 . . . . 0.0 111.854 -179.281 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -73.54 177.79 7.53 Favored 'Trans proline' 0 C--N 1.37 1.658 0 C-N-CA 122.525 2.15 . . . . 0.0 112.429 179.047 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 47.3 m -79.53 138.7 37.59 Favored 'General case' 0 N--CA 1.467 0.385 0 O-C-N 123.188 0.305 . . . . 0.0 110.807 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.01 -52.64 1.01 Allowed Pre-proline 0 N--CA 1.474 0.727 0 CA-C-O 119.025 -0.512 . . . . 0.0 111.983 -179.22 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.41 ' HG2' HD12 ' A' ' 19' ' ' LEU . 64.4 Cg_endo -72.73 175.88 9.66 Favored 'Trans proline' 0 C--N 1.375 1.951 0 C-N-CA 122.166 1.91 . . . . 0.0 112.051 179.372 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.3 Cg_exo -69.6 65.01 1.71 Allowed 'Trans proline' 0 C--N 1.378 2.126 0 C-N-CA 122.375 2.05 . . . . 0.0 112.642 179.458 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.41 HD12 ' HG2' ' A' ' 17' ' ' PRO . 32.6 mt -129.2 159.96 34.42 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.687 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.432 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -111.33 152.71 26.95 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.107 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.7 t -96.39 106.72 19.0 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.232 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.445 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.4 mt -125.99 131.63 24.05 Favored Pre-proline 0 CA--C 1.542 0.67 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.391 -179.482 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -71.1 -39.43 1.42 Allowed 'Cis proline' 0 C--N 1.375 1.944 0 C-N-CA 124.717 -0.951 . . . . 0.0 113.446 -0.289 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.51 31.39 45.86 Favored Glycine 0 C--N 1.344 0.997 0 CA-C-N 116.136 -0.484 . . . . 0.0 113.321 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -136.9 85.45 23.29 Favored Pre-proline 0 CA--C 1.545 0.762 0 C-N-CA 122.234 0.214 . . . . 0.0 111.04 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.488 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.2 Cg_endo -83.22 -34.42 2.41 Favored 'Cis proline' 0 C--N 1.373 1.827 0 C-N-CA 125.237 -0.734 . . . . 0.0 112.978 -0.257 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -98.57 154.15 18.13 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.061 -179.257 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.43 -171.56 18.83 Favored Glycine 0 C--N 1.338 0.681 0 CA-C-N 116.11 -0.495 . . . . 0.0 113.01 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.481 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 41.8 mm -122.3 146.05 28.08 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.494 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.4 m -81.49 107.94 14.68 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.582 179.463 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.481 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.8 m-85 -108.48 158.82 17.2 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.554 -179.389 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tp -91.68 122.84 43.49 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.668 179.622 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.455 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.247 0.93 0 CA-C-O 118.44 -0.79 . . . . 0.0 111.405 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 31.7 p . . . . . 0 N--CA 1.488 1.474 0 CA-C-O 119.486 -0.292 . . . . 0.0 110.892 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -84.73 -177.32 2.82 Favored 'Trans proline' 0 C--N 1.37 1.687 0 C-N-CA 122.079 1.853 . . . . 0.0 113.092 179.406 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.578 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -147.27 -158.6 7.92 Favored Glycine 0 C--N 1.337 0.589 0 CA-C-N 115.723 -0.671 . . . . 0.0 111.947 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -64.79 110.0 2.25 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-O 120.979 0.419 . . . . 0.0 111.713 -179.218 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.29 31.97 10.1 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-N 115.331 -0.849 . . . . 0.0 112.713 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.451 ' HB2' ' H ' ' A' ' 3' ' ' GLY . 36.9 mt-10 -126.65 160.48 30.6 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 120.548 0.213 . . . . 0.0 111.238 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.517 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.5 tt0 -79.98 122.01 26.2 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.585 179.682 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 8.5 p -125.49 149.75 48.0 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.637 -179.062 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -109.69 155.53 21.4 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 115.507 -0.769 . . . . 0.0 109.844 179.104 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.4 m -104.14 4.2 10.54 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.222 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -99.24 -48.67 4.74 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 116.637 -0.256 . . . . 0.0 111.654 -179.056 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 37.9 p90 -148.85 0.97 0.56 Allowed 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -179.056 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -130.87 63.56 70.59 Favored Pre-proline 0 CA--C 1.551 0.99 0 N-CA-C 111.816 0.302 . . . . 0.0 111.816 -179.32 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -76.27 173.5 14.38 Favored 'Trans proline' 0 C--N 1.369 1.638 0 C-N-CA 122.53 2.153 . . . . 0.0 112.594 179.203 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 8' ' ' CYS . 23.6 m -79.75 133.5 36.33 Favored 'General case' 0 N--CA 1.466 0.352 0 O-C-N 123.373 0.421 . . . . 0.0 110.252 179.556 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.55 ' SG ' ' HD3' ' A' ' 17' ' ' PRO . 0.8 OUTLIER -79.59 -45.4 1.59 Allowed Pre-proline 0 N--CA 1.476 0.836 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -179.271 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.55 ' HD3' ' SG ' ' A' ' 16' ' ' CYS . 56.9 Cg_endo -70.6 174.42 10.26 Favored 'Trans proline' 0 C--N 1.374 1.913 0 C-N-CA 121.928 1.752 . . . . 0.0 111.922 178.91 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_exo -70.04 65.66 1.96 Allowed 'Trans proline' 0 C--N 1.376 2.015 0 C-N-CA 122.266 1.977 . . . . 0.0 112.354 179.341 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.526 HD12 ' HG2' ' A' ' 17' ' ' PRO . 26.5 mt -133.5 162.43 31.91 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.84 -179.52 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.507 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.6 t -112.01 155.69 23.37 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.16 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 t -98.83 108.53 21.24 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.314 179.59 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.43 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -128.09 130.87 23.56 Favored Pre-proline 0 CA--C 1.542 0.637 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.323 -179.805 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -73.17 -39.06 1.54 Allowed 'Cis proline' 0 C--N 1.373 1.859 0 C-N-CA 124.62 -0.992 . . . . 0.0 113.523 -0.265 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.14 39.48 15.99 Favored Glycine 0 C--N 1.344 1.018 0 O-C-N 123.459 0.475 . . . . 0.0 113.138 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.55 83.56 13.13 Favored Pre-proline 0 CA--C 1.547 0.855 0 C-N-CA 122.132 0.173 . . . . 0.0 111.253 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -83.51 -33.43 2.75 Favored 'Cis proline' 0 C--N 1.372 1.794 0 CA-C-N 119.056 0.698 . . . . 0.0 112.812 -0.312 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -107.27 155.75 19.61 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.95 -179.404 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.517 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.59 -154.1 6.55 Favored Glycine 0 C--N 1.338 0.672 0 CA-C-N 115.876 -0.602 . . . . 0.0 112.574 179.767 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.481 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 22.6 mm -128.37 148.22 32.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.578 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 77.9 m -84.68 110.22 18.6 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.239 179.286 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.481 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.6 m-85 -107.73 160.54 15.64 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.876 -178.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 tp -92.39 122.87 44.23 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.638 179.621 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.463 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.378 -0.82 . . . . 0.0 111.465 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 32.1 p . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 119.412 -0.328 . . . . 0.0 110.945 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -84.75 -177.55 2.91 Favored 'Trans proline' 0 C--N 1.369 1.612 0 C-N-CA 122.014 1.809 . . . . 0.0 113.202 179.582 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.584 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -146.92 -161.51 9.39 Favored Glycine 0 C--N 1.338 0.683 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.882 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -62.01 111.13 1.8 Allowed 'General case' 0 N--CA 1.474 0.765 0 CA-C-O 121.069 0.462 . . . . 0.0 111.938 -179.209 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.32 31.66 13.52 Favored Glycine 0 C--N 1.341 0.817 0 CA-C-N 115.242 -0.89 . . . . 0.0 112.718 -179.918 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.508 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 36.2 mt-10 -125.46 161.48 27.02 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-O 120.551 0.215 . . . . 0.0 111.328 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.493 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.7 tt0 -79.91 120.93 24.8 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.521 179.726 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.9 p -125.16 150.03 47.32 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.627 -179.062 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.461 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 7.9 t70 -110.59 154.67 23.44 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.804 179.257 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.1 m -104.06 3.93 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 CA-C-N 116.125 -0.488 . . . . 0.0 112.178 -179.589 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.461 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.3 mt-10 -98.39 -47.93 5.23 Favored 'General case' 0 C--O 1.234 0.24 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -179.163 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -150.07 0.39 0.46 Allowed 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 113.449 0.907 . . . . 0.0 113.449 -179.025 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -131.01 63.81 71.68 Favored Pre-proline 0 CA--C 1.549 0.928 0 N-CA-C 111.874 0.324 . . . . 0.0 111.874 -179.299 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -76.27 174.49 12.74 Favored 'Trans proline' 0 C--N 1.369 1.646 0 C-N-CA 122.513 2.142 . . . . 0.0 112.618 179.299 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 31.0 m -79.62 133.12 36.4 Favored 'General case' 0 N--CA 1.468 0.438 0 C-N-CA 122.574 0.35 . . . . 0.0 110.303 179.587 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.548 ' SG ' ' HD3' ' A' ' 17' ' ' PRO . 0.9 OUTLIER -79.66 -45.45 1.57 Allowed Pre-proline 0 N--CA 1.477 0.877 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -179.242 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.548 ' HD3' ' SG ' ' A' ' 16' ' ' CYS . 56.0 Cg_endo -69.98 174.81 9.15 Favored 'Trans proline' 0 C--N 1.373 1.856 0 C-N-CA 121.886 1.724 . . . . 0.0 111.956 179.054 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_exo -69.59 65.22 1.7 Allowed 'Trans proline' 0 C--N 1.378 2.127 0 C-N-CA 122.292 1.995 . . . . 0.0 112.534 179.396 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.52 HD12 ' HG2' ' A' ' 17' ' ' PRO . 15.6 mt -136.12 162.04 34.04 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.673 -179.671 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.579 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 14.7 t -111.31 163.02 14.4 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.078 179.543 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.8 t -102.62 110.74 22.78 Favored 'General case' 0 C--O 1.239 0.538 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.294 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 4.8 mt -127.78 131.09 23.63 Favored Pre-proline 0 CA--C 1.542 0.669 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.339 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -74.55 -37.85 2.05 Favored 'Cis proline' 0 C--N 1.374 1.877 0 C-N-CA 124.461 -1.058 . . . . 0.0 113.242 -0.25 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.83 39.51 11.79 Favored Glycine 0 C--N 1.345 1.046 0 O-C-N 123.508 0.505 . . . . 0.0 113.076 -179.716 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -140.71 82.17 16.01 Favored Pre-proline 0 CA--C 1.55 0.978 0 C-N-CA 122.105 0.162 . . . . 0.0 110.911 -179.782 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -84.86 -33.7 2.35 Favored 'Cis proline' 0 C--N 1.371 1.761 0 CA-C-N 119.096 0.713 . . . . 0.0 112.972 -0.415 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -105.69 156.67 18.06 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.934 -179.256 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.31 -155.27 7.08 Favored Glycine 0 C--N 1.338 0.682 0 CA-C-N 115.868 -0.606 . . . . 0.0 112.553 179.75 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.508 ' HA ' ' O ' ' A' ' 6' ' ' GLU . 19.4 mm -128.57 149.24 33.18 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.584 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 63.6 m -84.42 110.67 18.81 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.274 179.196 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.41 ' O ' ' HB3' ' A' ' 19' ' ' LEU . 85.3 m-85 -106.24 160.95 14.96 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.128 -0.487 . . . . 0.0 112.056 -178.816 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.1 tp -90.1 126.52 42.95 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.611 179.569 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 38.2 mm . . . . . 0 C--O 1.25 1.124 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.088 -179.606 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.487 1.404 0 CA-C-O 119.528 -0.272 . . . . 0.0 111.164 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -83.78 -178.85 3.78 Favored 'Trans proline' 0 C--N 1.372 1.806 0 C-N-CA 122.47 2.113 . . . . 0.0 113.949 -179.099 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . 0.511 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.27 -152.32 6.45 Favored Glycine 0 C--N 1.342 0.913 0 CA-C-N 115.613 -0.722 . . . . 0.0 112.04 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -73.25 113.76 10.67 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.916 0.389 . . . . 0.0 111.621 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.32 32.47 10.44 Favored Glycine 0 C--N 1.341 0.816 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.795 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.55 162.26 26.86 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-O 120.663 0.268 . . . . 0.0 111.251 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.502 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.8 tt0 -80.09 127.0 31.79 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.816 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.47 150.55 50.76 Favored 'General case' 0 C--O 1.233 0.237 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.664 -179.252 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.451 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.17 154.62 23.08 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.597 -0.729 . . . . 0.0 109.785 179.008 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.7 m -102.93 4.23 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 116.123 -0.49 . . . . 0.0 112.14 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.451 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.0 mt-10 -100.27 -48.57 4.55 Favored 'General case' 0 C--O 1.235 0.329 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.113 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.4 p90 -148.45 2.0 0.62 Allowed 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 113.293 0.849 . . . . 0.0 113.293 -178.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.08 63.46 70.34 Favored Pre-proline 0 CA--C 1.548 0.903 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -74.46 175.59 10.82 Favored 'Trans proline' 0 C--N 1.369 1.649 0 C-N-CA 122.493 2.128 . . . . 0.0 112.594 179.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.7 m -79.69 140.87 36.87 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.503 179.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -80.0 -52.58 1.02 Allowed Pre-proline 0 CA--C 1.543 0.702 0 CA-C-O 118.996 -0.526 . . . . 0.0 112.006 -179.326 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.429 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.6 Cg_endo -73.79 175.98 10.04 Favored 'Trans proline' 0 C--N 1.375 1.928 0 C-N-CA 122.143 1.895 . . . . 0.0 111.963 179.258 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.38 64.78 1.58 Allowed 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 122.387 2.058 . . . . 0.0 112.731 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.429 HD12 ' HG2' ' A' ' 17' ' ' PRO . 39.7 mt -127.46 161.32 29.0 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.748 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.0 t -112.4 149.57 32.33 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.015 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.2 t -93.91 108.61 20.39 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.59 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.426 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -127.91 130.78 23.59 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.301 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -73.36 -38.99 1.56 Allowed 'Cis proline' 0 C--N 1.372 1.802 0 C-N-CA 124.671 -0.97 . . . . 0.0 113.464 -0.232 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.65 39.69 13.86 Favored Glycine 0 C--N 1.344 0.999 0 O-C-N 123.453 0.471 . . . . 0.0 113.047 -179.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -141.19 83.34 13.82 Favored Pre-proline 0 CA--C 1.546 0.791 0 C-N-CA 122.182 0.193 . . . . 0.0 111.315 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.56 -33.5 2.71 Favored 'Cis proline' 0 C--N 1.372 1.779 0 CA-C-N 119.061 0.7 . . . . 0.0 112.826 -0.369 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -106.69 156.32 18.75 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.932 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.502 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.78 -154.2 6.61 Favored Glycine 0 C--N 1.338 0.642 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.526 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.511 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.9 mm -127.62 147.17 32.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.511 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.1 m -84.38 107.93 16.92 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.13 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.511 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.4 m-85 -106.09 158.99 16.41 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.824 -179.073 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -93.29 122.99 45.23 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.6 179.664 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.3 pt . . . . . 0 C--O 1.251 1.141 0 CA-C-O 118.472 -0.775 . . . . 0.0 111.349 179.94 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.37 0 CA-C-O 119.533 -0.27 . . . . 0.0 111.133 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -83.89 -178.83 3.73 Favored 'Trans proline' 0 C--N 1.373 1.816 0 C-N-CA 122.458 2.105 . . . . 0.0 114.008 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . 0.513 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.4 -152.35 6.44 Favored Glycine 0 C--N 1.343 0.922 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.961 179.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -73.08 113.89 10.63 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-O 120.789 0.328 . . . . 0.0 111.641 -179.49 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.06 32.63 10.46 Favored Glycine 0 C--N 1.34 0.757 0 CA-C-N 115.448 -0.796 . . . . 0.0 112.781 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.3 mt-10 -127.6 162.39 26.61 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.647 0.26 . . . . 0.0 111.282 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.514 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.6 tt0 -80.05 127.1 31.89 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.793 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.84 150.7 51.02 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.681 -179.262 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.447 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.54 154.71 23.32 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.775 179.024 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.9 m -102.85 4.07 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-N 116.18 -0.464 . . . . 0.0 112.156 -179.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.447 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.4 mt-10 -100.01 -48.65 4.58 Favored 'General case' 0 C--O 1.235 0.312 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.002 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -148.54 2.13 0.62 Allowed 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 113.407 0.891 . . . . 0.0 113.407 -178.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -131.17 63.68 70.95 Favored Pre-proline 0 CA--C 1.55 0.962 0 N-CA-C 111.678 0.251 . . . . 0.0 111.678 -179.432 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.65 175.71 10.75 Favored 'Trans proline' 0 C--N 1.369 1.641 0 C-N-CA 122.493 2.129 . . . . 0.0 112.663 179.235 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.5 m -79.66 140.87 36.91 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 123.288 0.368 . . . . 0.0 110.618 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.94 -52.58 1.03 Allowed Pre-proline 0 CA--C 1.543 0.705 0 CA-C-O 119.131 -0.462 . . . . 0.0 111.925 -179.212 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.426 ' HG2' HD12 ' A' ' 19' ' ' LEU . 66.4 Cg_endo -73.78 175.87 10.17 Favored 'Trans proline' 0 C--N 1.376 1.986 0 C-N-CA 122.105 1.87 . . . . 0.0 112.01 179.227 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -69.37 64.89 1.57 Allowed 'Trans proline' 0 C--N 1.377 2.068 0 C-N-CA 122.373 2.049 . . . . 0.0 112.721 179.478 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.426 HD12 ' HG2' ' A' ' 17' ' ' PRO . 41.1 mt -127.55 161.45 28.76 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.746 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.7 t -112.34 149.58 32.24 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.084 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -94.02 108.93 20.71 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.496 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mt -128.14 130.68 23.57 Favored Pre-proline 0 CA--C 1.541 0.612 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.314 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -73.55 -38.95 1.58 Allowed 'Cis proline' 0 C--N 1.374 1.872 0 C-N-CA 124.581 -1.008 . . . . 0.0 113.456 -0.181 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.85 39.84 12.98 Favored Glycine 0 C--N 1.345 1.08 0 O-C-N 123.483 0.489 . . . . 0.0 113.111 -179.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -140.98 82.88 14.56 Favored Pre-proline 0 CA--C 1.546 0.818 0 C-N-CA 122.205 0.202 . . . . 0.0 111.26 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -83.76 -33.54 2.65 Favored 'Cis proline' 0 C--N 1.372 1.766 0 CA-C-N 119.066 0.702 . . . . 0.0 112.857 -0.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -106.97 156.32 18.85 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.01 -179.324 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.514 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.76 -152.13 5.89 Favored Glycine 0 C--N 1.337 0.635 0 CA-C-N 115.869 -0.605 . . . . 0.0 112.554 179.815 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.501 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.2 mm -129.11 147.13 33.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.513 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.2 m -84.4 108.13 17.05 Favored 'General case' 0 C--O 1.238 0.48 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.174 179.198 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.501 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.0 m-85 -106.2 159.23 16.25 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.79 -179.056 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.91 123.25 44.94 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.641 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.465 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.173 -0.918 . . . . 0.0 111.495 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.37 0 CA-C-O 119.499 -0.286 . . . . 0.0 111.115 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -83.89 -178.81 3.73 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.424 2.083 . . . . 0.0 113.995 -179.161 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . 0.513 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.31 -152.41 6.47 Favored Glycine 0 C--N 1.343 0.965 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.993 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -73.03 113.84 10.52 Favored 'General case' 0 N--CA 1.471 0.594 0 CA-C-O 120.961 0.41 . . . . 0.0 111.669 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.09 32.48 10.62 Favored Glycine 0 C--N 1.342 0.886 0 CA-C-N 115.415 -0.812 . . . . 0.0 112.78 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.54 162.34 26.66 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.63 0.252 . . . . 0.0 111.302 -179.731 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.502 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.15 127.31 32.18 Favored 'General case' 0 C--N 1.346 0.428 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.794 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.4 p -129.7 150.49 50.99 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 115.815 -0.629 . . . . 0.0 111.605 -179.234 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.452 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.1 t70 -110.2 154.58 23.17 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.831 178.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.5 m -102.88 3.94 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 CA-C-N 116.165 -0.47 . . . . 0.0 112.225 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.452 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -99.71 -48.76 4.6 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 111.981 0.363 . . . . 0.0 111.981 -179.046 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -148.64 2.18 0.61 Allowed 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 113.204 0.816 . . . . 0.0 113.204 -178.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.28 63.67 70.74 Favored Pre-proline 0 CA--C 1.548 0.903 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -74.55 176.11 10.17 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 122.434 2.089 . . . . 0.0 112.66 179.209 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 36.2 m -79.81 140.9 36.68 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.557 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.96 -52.64 1.02 Allowed Pre-proline 0 CA--C 1.544 0.75 0 CA-C-O 119.068 -0.491 . . . . 0.0 111.926 -179.197 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.43 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.6 Cg_endo -73.76 175.96 10.04 Favored 'Trans proline' 0 C--N 1.376 1.99 0 C-N-CA 122.114 1.876 . . . . 0.0 112.039 179.26 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.36 64.89 1.57 Allowed 'Trans proline' 0 C--N 1.377 2.069 0 C-N-CA 122.327 2.018 . . . . 0.0 112.747 179.479 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.43 HD12 ' HG2' ' A' ' 17' ' ' PRO . 40.6 mt -127.6 161.42 28.88 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.736 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.9 t -112.34 149.57 32.25 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 115.888 -0.597 . . . . 0.0 111.068 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.2 t -94.06 108.76 20.56 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.551 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.1 mt -127.99 130.75 23.58 Favored Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.337 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.38 -39.02 1.55 Allowed 'Cis proline' 0 C--N 1.374 1.87 0 C-N-CA 124.583 -1.007 . . . . 0.0 113.444 -0.22 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.91 39.68 13.02 Favored Glycine 0 C--N 1.345 1.06 0 O-C-N 123.423 0.452 . . . . 0.0 113.069 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.23 83.39 13.73 Favored Pre-proline 0 CA--C 1.547 0.841 0 C-N-CA 122.116 0.166 . . . . 0.0 111.217 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.65 -33.41 2.73 Favored 'Cis proline' 0 C--N 1.372 1.772 0 C-N-CA 125.335 -0.694 . . . . 0.0 112.841 -0.364 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -106.79 156.2 18.92 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.018 -179.378 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.502 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.53 -153.88 6.46 Favored Glycine 0 C--N 1.338 0.639 0 CA-C-N 115.866 -0.606 . . . . 0.0 112.508 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.507 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.4 mm -127.85 147.11 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.513 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.6 m -84.3 107.9 16.85 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.142 179.26 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.507 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -106.03 159.25 16.2 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.785 -179.094 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -93.06 123.15 45.05 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.622 179.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.466 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.295 -0.86 . . . . 0.0 111.519 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.37 0 CA-C-O 119.576 -0.25 . . . . 0.0 111.05 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -83.75 -178.86 3.8 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.53 2.153 . . . . 0.0 114.019 -179.129 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . 0.513 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.04 -152.29 6.48 Favored Glycine 0 C--N 1.342 0.888 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.996 179.659 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -73.52 113.98 11.23 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-O 120.986 0.422 . . . . 0.0 111.561 -179.54 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.13 32.57 10.48 Favored Glycine 0 C--N 1.341 0.818 0 CA-C-N 115.418 -0.81 . . . . 0.0 112.8 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.44 162.3 26.68 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-O 120.476 0.179 . . . . 0.0 111.345 -179.645 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.511 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.07 127.27 32.1 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.795 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.78 150.38 51.11 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.631 -179.248 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.448 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.42 154.89 22.95 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.821 178.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.7 m -102.93 4.21 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 CA-C-N 116.174 -0.466 . . . . 0.0 112.137 -179.507 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.448 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.3 mt-10 -100.32 -48.57 4.54 Favored 'General case' 0 C--O 1.235 0.307 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -179.123 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.6 p90 -148.28 2.0 0.64 Allowed 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 113.279 0.844 . . . . 0.0 113.279 -178.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.12 63.58 70.7 Favored Pre-proline 0 CA--C 1.548 0.903 0 N-CA-C 111.73 0.27 . . . . 0.0 111.73 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.59 175.36 11.19 Favored 'Trans proline' 0 C--N 1.371 1.712 0 C-N-CA 122.461 2.107 . . . . 0.0 112.61 179.208 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.8 m -79.58 140.69 37.08 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.537 179.664 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.98 -52.57 1.03 Allowed Pre-proline 0 N--CA 1.473 0.687 0 CA-C-O 118.98 -0.533 . . . . 0.0 111.983 -179.367 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.426 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.1 Cg_endo -73.88 175.93 10.14 Favored 'Trans proline' 0 C--N 1.375 1.951 0 C-N-CA 122.135 1.89 . . . . 0.0 111.984 179.287 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.43 64.91 1.61 Allowed 'Trans proline' 0 C--N 1.378 2.102 0 C-N-CA 122.277 1.985 . . . . 0.0 112.769 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.426 HD12 ' HG2' ' A' ' 17' ' ' PRO . 40.7 mt -127.35 161.6 28.26 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.782 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.7 t -112.65 149.38 32.93 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.009 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -93.88 108.81 20.56 Favored 'General case' 0 C--O 1.238 0.49 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.544 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mt -127.99 130.8 23.58 Favored Pre-proline 0 CA--C 1.542 0.665 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.247 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -73.47 -38.82 1.64 Allowed 'Cis proline' 0 C--N 1.374 1.872 0 C-N-CA 124.553 -1.019 . . . . 0.0 113.475 -0.296 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.95 39.66 12.96 Favored Glycine 0 C--N 1.345 1.042 0 O-C-N 123.38 0.425 . . . . 0.0 113.089 -179.743 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -141.24 83.16 13.92 Favored Pre-proline 0 CA--C 1.547 0.827 0 C-N-CA 122.161 0.185 . . . . 0.0 111.265 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -83.84 -33.52 2.64 Favored 'Cis proline' 0 C--N 1.373 1.823 0 CA-C-N 119.052 0.697 . . . . 0.0 112.829 -0.282 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.1 m-85 -106.96 156.42 18.74 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.928 -179.354 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.82 -152.47 5.99 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 115.85 -0.614 . . . . 0.0 112.603 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.505 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.5 mm -129.02 147.04 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 O-C-N 123.8 0.353 . . . . 0.0 110.08 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.513 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 76.6 m -84.18 107.79 16.7 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.262 179.2 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.505 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.1 m-85 -105.91 159.13 16.27 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.835 -179.044 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.9 123.25 44.92 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.627 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.466 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.32 -0.848 . . . . 0.0 111.398 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.371 0 CA-C-O 119.586 -0.245 . . . . 0.0 111.171 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -83.8 -178.82 3.76 Favored 'Trans proline' 0 C--N 1.372 1.805 0 C-N-CA 122.445 2.097 . . . . 0.0 114.031 -179.137 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . 0.51 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.87 -152.18 6.49 Favored Glycine 0 C--N 1.343 0.942 0 CA-C-N 115.539 -0.755 . . . . 0.0 112.002 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.46 114.24 11.46 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-O 120.891 0.377 . . . . 0.0 111.6 -179.569 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.69 32.6 11.08 Favored Glycine 0 C--N 1.34 0.801 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.838 -179.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.403 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 33.5 mt-10 -127.4 162.65 25.83 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 120.625 0.25 . . . . 0.0 111.255 -179.576 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.528 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.07 127.25 32.08 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.805 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.8 p -130.32 150.47 51.54 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.631 -179.372 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.499 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.4 t70 -110.65 154.93 23.12 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.876 178.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.543 HG23 ' OE2' ' A' ' 11' ' ' GLU . 9.6 m -102.9 3.31 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-N 116.172 -0.467 . . . . 0.0 112.152 -179.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.543 ' OE2' HG23 ' A' ' 10' ' ' VAL . 4.9 mp0 -97.85 -49.02 4.96 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.443 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 42.1 p90 -149.26 2.52 0.56 Allowed 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 113.375 0.88 . . . . 0.0 113.375 -178.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -130.69 63.67 70.71 Favored Pre-proline 0 CA--C 1.548 0.887 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -74.66 175.99 10.37 Favored 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 122.507 2.138 . . . . 0.0 112.604 179.3 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 34.8 m -79.7 140.92 36.83 Favored 'General case' 0 CA--C 1.534 0.352 0 O-C-N 123.271 0.357 . . . . 0.0 110.603 179.648 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.89 -52.76 1.03 Allowed Pre-proline 0 CA--C 1.545 0.752 0 CA-C-O 119.039 -0.505 . . . . 0.0 111.939 -179.283 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.426 ' HG2' HD12 ' A' ' 19' ' ' LEU . 63.1 Cg_endo -73.53 175.72 10.28 Favored 'Trans proline' 0 C--N 1.374 1.893 0 C-N-CA 122.097 1.865 . . . . 0.0 112.006 179.251 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.35 64.94 1.56 Allowed 'Trans proline' 0 C--N 1.377 2.064 0 C-N-CA 122.347 2.031 . . . . 0.0 112.792 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.426 HD12 ' HG2' ' A' ' 17' ' ' PRO . 38.5 mt -127.6 161.84 27.89 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.741 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.2 t -112.57 149.74 32.31 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.076 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.4 t -94.14 109.05 20.86 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.555 179.595 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.6 mt -128.02 130.99 23.56 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.251 -179.766 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -73.44 -38.82 1.64 Allowed 'Cis proline' 0 C--N 1.374 1.878 0 C-N-CA 124.686 -0.964 . . . . 0.0 113.56 -0.301 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.37 42.05 10.88 Favored Glycine 0 C--N 1.344 1.009 0 O-C-N 123.379 0.424 . . . . 0.0 113.035 -179.584 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.07 80.68 16.75 Favored Pre-proline 0 CA--C 1.547 0.841 0 C-N-CA 122.194 0.198 . . . . 0.0 111.352 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -84.81 -32.77 2.73 Favored 'Cis proline' 0 C--N 1.372 1.804 0 C-N-CA 125.365 -0.681 . . . . 0.0 112.889 -0.359 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 83.2 m-85 -105.86 156.49 18.29 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.107 -179.173 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.528 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -154.31 -150.95 5.64 Favored Glycine 0 C--N 1.338 0.672 0 CA-C-N 115.883 -0.599 . . . . 0.0 112.452 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.485 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.8 mm -129.25 146.99 33.39 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.51 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.1 m -84.64 108.62 17.47 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.204 179.237 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.485 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.7 m-85 -106.1 158.83 16.53 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.874 -179.002 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tp -93.63 123.89 45.89 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.517 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.623 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.3 pt . . . . . 0 C--O 1.248 0.984 0 CA-C-O 118.115 -0.945 . . . . 0.0 111.279 179.987 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.348 0 CA-C-O 119.554 -0.26 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -83.71 -178.88 3.82 Favored 'Trans proline' 0 C--N 1.372 1.814 0 C-N-CA 122.496 2.131 . . . . 0.0 114.038 -179.088 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . 0.511 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.04 -152.28 6.48 Favored Glycine 0 C--N 1.341 0.86 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.031 179.608 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.1 tt0 -73.45 113.75 10.9 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 120.932 0.396 . . . . 0.0 111.715 -179.66 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.45 32.62 10.14 Favored Glycine 0 C--N 1.34 0.8 0 CA-C-N 115.46 -0.791 . . . . 0.0 112.846 -179.792 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.66 162.07 27.4 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-O 120.58 0.228 . . . . 0.0 111.314 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.508 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.8 tt0 -79.96 127.13 31.9 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.804 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.71 150.67 50.92 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.619 -179.282 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.449 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.1 t70 -110.36 154.9 22.88 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.811 178.834 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.5 m -102.79 4.27 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-N 116.186 -0.461 . . . . 0.0 112.132 -179.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.449 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -100.93 -48.51 4.42 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 112.084 0.401 . . . . 0.0 112.084 -179.052 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 39.9 p90 -147.78 1.8 0.69 Allowed 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 113.42 0.896 . . . . 0.0 113.42 -178.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.05 63.29 69.82 Favored Pre-proline 0 CA--C 1.55 0.97 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.344 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.48 175.06 11.55 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.381 2.054 . . . . 0.0 112.617 179.281 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.4 m -79.68 140.81 36.9 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.484 179.733 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.98 -52.56 1.03 Allowed Pre-proline 0 CA--C 1.543 0.7 0 CA-C-O 119.087 -0.483 . . . . 0.0 111.993 -179.368 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.43 ' HG2' HD12 ' A' ' 19' ' ' LEU . 66.6 Cg_endo -73.85 175.94 10.11 Favored 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 122.071 1.848 . . . . 0.0 112.045 179.165 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -69.34 64.83 1.55 Allowed 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 122.384 2.056 . . . . 0.0 112.759 179.547 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.43 HD12 ' HG2' ' A' ' 17' ' ' PRO . 41.8 mt -127.28 161.59 28.23 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.818 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.9 t -112.81 149.26 33.3 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.995 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.2 t -93.78 108.76 20.48 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.551 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.424 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.4 mt -127.95 130.93 23.57 Favored Pre-proline 0 CA--C 1.541 0.626 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.226 -179.748 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -73.34 -39.02 1.56 Allowed 'Cis proline' 0 C--N 1.374 1.91 0 C-N-CA 124.705 -0.956 . . . . 0.0 113.468 -0.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.64 39.64 13.99 Favored Glycine 0 C--N 1.344 0.981 0 O-C-N 123.455 0.472 . . . . 0.0 113.075 -179.682 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -140.89 82.99 14.64 Favored Pre-proline 0 CA--C 1.549 0.925 0 C-N-CA 122.188 0.195 . . . . 0.0 110.956 -179.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -83.92 -33.75 2.53 Favored 'Cis proline' 0 C--N 1.372 1.777 0 CA-C-N 119.101 0.715 . . . . 0.0 112.877 -0.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.7 m-85 -106.6 156.25 18.79 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.025 -179.408 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.508 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.85 -152.74 6.08 Favored Glycine 0 C--N 1.338 0.67 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.538 179.741 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.515 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.2 mm -128.69 147.0 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -179.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.511 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 78.8 m -84.06 107.97 16.72 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.183 179.175 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.515 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.4 m-85 -106.17 159.3 16.19 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.805 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -93.02 122.81 44.81 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.681 179.552 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.466 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.363 -0.827 . . . . 0.0 111.449 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.361 0 CA-C-O 119.522 -0.275 . . . . 0.0 111.098 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -83.7 -178.86 3.82 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.47 2.114 . . . . 0.0 113.967 -179.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . 0.512 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.98 -152.23 6.48 Favored Glycine 0 C--N 1.343 0.945 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.031 179.53 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -73.53 113.84 11.09 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-O 120.833 0.349 . . . . 0.0 111.581 -179.504 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.33 32.69 10.15 Favored Glycine 0 C--N 1.339 0.747 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.793 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.62 162.22 27.0 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 120.564 0.221 . . . . 0.0 111.275 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.513 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -79.93 127.26 32.05 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.828 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.6 p -129.92 150.65 51.11 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.592 -179.278 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.445 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.64 154.71 23.42 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.773 178.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.8 m -102.65 4.18 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-N 116.146 -0.479 . . . . 0.0 112.139 -179.56 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.445 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.6 mm-40 -100.48 -48.62 4.49 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -179.088 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.4 p90 -148.02 1.89 0.67 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 113.379 0.881 . . . . 0.0 113.379 -178.854 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.09 63.39 70.08 Favored Pre-proline 0 CA--C 1.551 0.993 0 N-CA-C 111.723 0.268 . . . . 0.0 111.723 -179.236 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.51 175.2 11.37 Favored 'Trans proline' 0 C--N 1.37 1.683 0 C-N-CA 122.391 2.061 . . . . 0.0 112.644 179.287 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.5 m -79.75 140.74 36.82 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.559 179.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.89 -52.59 1.04 Allowed Pre-proline 0 N--CA 1.474 0.768 0 CA-C-O 119.057 -0.497 . . . . 0.0 111.975 -179.296 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.426 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.1 Cg_endo -73.89 175.94 10.13 Favored 'Trans proline' 0 C--N 1.376 1.995 0 C-N-CA 122.148 1.899 . . . . 0.0 111.941 179.342 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.3 64.91 1.53 Allowed 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 122.322 2.014 . . . . 0.0 112.732 179.501 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.426 HD12 ' HG2' ' A' ' 17' ' ' PRO . 40.3 mt -127.43 161.58 28.36 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.744 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.9 t -112.73 149.41 32.98 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.026 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -93.9 108.85 20.6 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.539 179.568 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.401 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -127.99 130.81 23.58 Favored Pre-proline 0 CA--C 1.541 0.626 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.264 -179.749 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -73.29 -39.02 1.56 Allowed 'Cis proline' 0 C--N 1.374 1.92 0 C-N-CA 124.692 -0.962 . . . . 0.0 113.439 -0.306 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.86 39.83 12.98 Favored Glycine 0 C--N 1.343 0.971 0 O-C-N 123.43 0.456 . . . . 0.0 113.073 -179.68 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.32 83.09 13.86 Favored Pre-proline 0 CA--C 1.547 0.861 0 C-N-CA 122.222 0.209 . . . . 0.0 111.299 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.91 -33.45 2.65 Favored 'Cis proline' 0 C--N 1.372 1.807 0 C-N-CA 125.345 -0.689 . . . . 0.0 112.755 -0.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.1 m-85 -106.89 156.51 18.62 Favored 'General case' 0 N--CA 1.465 0.313 0 O-C-N 123.593 0.558 . . . . 0.0 111.035 -179.424 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.513 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.05 -152.27 5.95 Favored Glycine 0 C--N 1.339 0.697 0 CA-C-N 115.866 -0.606 . . . . 0.0 112.603 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.512 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.3 mm -129.06 147.15 33.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.512 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 77.8 m -84.36 107.78 16.83 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.108 179.264 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.512 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -105.98 159.24 16.2 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.782 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.92 122.91 44.79 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.669 179.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.467 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 1.014 0 CA-C-O 118.3 -0.857 . . . . 0.0 111.351 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.485 1.319 0 CA-C-O 119.579 -0.248 . . . . 0.0 111.081 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -83.87 -178.91 3.78 Favored 'Trans proline' 0 C--N 1.371 1.747 0 C-N-CA 122.536 2.157 . . . . 0.0 113.941 -179.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . 0.512 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.37 -152.36 6.45 Favored Glycine 0 C--N 1.341 0.857 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.077 179.601 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -73.17 113.85 10.69 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-O 121.015 0.435 . . . . 0.0 111.629 -179.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.22 32.46 10.54 Favored Glycine 0 C--N 1.342 0.913 0 CA-C-N 115.345 -0.843 . . . . 0.0 112.778 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.52 162.28 26.79 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-O 120.508 0.194 . . . . 0.0 111.327 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.51 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.1 127.28 32.13 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.864 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.76 150.69 50.96 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.631 -179.193 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.447 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.2 t70 -110.5 154.69 23.31 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.775 178.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.6 m -102.98 3.95 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.191 -179.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.447 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.6 mm-40 -99.61 -48.79 4.62 Favored 'General case' 0 C--O 1.234 0.288 0 N-CA-C 111.936 0.346 . . . . 0.0 111.936 -179.053 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.1 p90 -148.63 1.97 0.61 Allowed 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -178.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -131.12 63.83 71.56 Favored Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 111.748 0.277 . . . . 0.0 111.748 -179.37 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -74.66 175.93 10.44 Favored 'Trans proline' 0 C--N 1.37 1.705 0 C-N-CA 122.459 2.106 . . . . 0.0 112.574 179.283 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.8 m -79.62 140.92 36.96 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 123.257 0.348 . . . . 0.0 110.62 179.626 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.96 -52.57 1.03 Allowed Pre-proline 0 CA--C 1.544 0.731 0 CA-C-O 119.01 -0.519 . . . . 0.0 111.954 -179.286 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.426 ' HG2' HD12 ' A' ' 19' ' ' LEU . 66.2 Cg_endo -73.94 175.97 10.1 Favored 'Trans proline' 0 C--N 1.375 1.955 0 C-N-CA 122.132 1.888 . . . . 0.0 112.002 179.27 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.35 64.92 1.56 Allowed 'Trans proline' 0 C--N 1.379 2.16 0 C-N-CA 122.402 2.068 . . . . 0.0 112.71 179.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.426 HD12 ' HG2' ' A' ' 17' ' ' PRO . 40.5 mt -127.63 161.3 29.17 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.799 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.8 t -112.36 149.59 32.25 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.06 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -93.93 108.89 20.64 Favored 'General case' 0 C--O 1.237 0.446 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.512 179.622 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.401 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -128.11 130.8 23.56 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.252 -179.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -73.45 -38.91 1.6 Allowed 'Cis proline' 0 C--N 1.374 1.9 0 C-N-CA 124.562 -1.016 . . . . 0.0 113.507 -0.288 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.93 39.84 12.72 Favored Glycine 0 C--N 1.344 1.009 0 O-C-N 123.437 0.46 . . . . 0.0 113.032 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -141.17 83.12 14.05 Favored Pre-proline 0 CA--C 1.547 0.84 0 CA-C-N 116.646 0.223 . . . . 0.0 111.271 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.77 -33.49 2.67 Favored 'Cis proline' 0 C--N 1.371 1.761 0 CA-C-N 119.062 0.701 . . . . 0.0 112.792 -0.272 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.8 m-85 -106.82 156.51 18.59 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.069 -179.412 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.51 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.85 -152.82 6.1 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.529 179.775 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.509 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.2 mm -128.56 147.18 33.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 -179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.512 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.9 m -84.35 107.98 16.93 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.179 179.229 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.509 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -106.26 159.15 16.33 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.767 -179.031 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.76 122.81 44.55 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.523 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.622 179.65 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.467 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.248 1.017 0 CA-C-O 118.442 -0.789 . . . . 0.0 111.405 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.361 0 CA-C-O 119.546 -0.264 . . . . 0.0 111.106 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_endo -83.77 -178.93 3.82 Favored 'Trans proline' 0 C--N 1.372 1.764 0 C-N-CA 122.502 2.134 . . . . 0.0 114.091 -179.197 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . 0.512 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.73 -152.34 6.55 Favored Glycine 0 C--N 1.342 0.872 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.989 179.505 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.79 114.0 11.57 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-O 120.924 0.392 . . . . 0.0 111.572 -179.43 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.72 32.21 10.39 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-N 115.456 -0.793 . . . . 0.0 112.759 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -127.61 162.26 26.92 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.705 0.288 . . . . 0.0 111.319 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.504 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -79.94 127.11 31.87 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.798 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.62 150.51 50.92 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.684 -179.34 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.451 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.21 154.65 23.08 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.847 178.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.6 m -102.7 4.1 10.63 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.203 -179.544 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.451 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -100.37 -48.51 4.55 Favored 'General case' 0 C--O 1.235 0.336 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.079 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.3 p90 -148.22 1.83 0.64 Allowed 'General case' 0 N--CA 1.476 0.862 0 N-CA-C 113.23 0.826 . . . . 0.0 113.23 -178.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.07 63.55 70.69 Favored Pre-proline 0 CA--C 1.549 0.928 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 -179.317 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.6 175.44 11.08 Favored 'Trans proline' 0 C--N 1.37 1.662 0 C-N-CA 122.434 2.089 . . . . 0.0 112.626 179.244 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.6 m -79.74 140.76 36.83 Favored 'General case' 0 CA--C 1.534 0.363 0 O-C-N 123.255 0.347 . . . . 0.0 110.541 179.69 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.91 -52.67 1.03 Allowed Pre-proline 0 CA--C 1.544 0.721 0 CA-C-O 119.017 -0.516 . . . . 0.0 112.007 -179.291 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.428 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.9 Cg_endo -73.78 175.93 10.1 Favored 'Trans proline' 0 C--N 1.374 1.893 0 C-N-CA 122.118 1.879 . . . . 0.0 112.013 179.212 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.39 64.95 1.58 Allowed 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 122.347 2.031 . . . . 0.0 112.678 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.428 HD12 ' HG2' ' A' ' 17' ' ' PRO . 39.9 mt -127.49 161.39 28.87 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.751 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.8 t -112.51 149.42 32.68 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.89 -0.596 . . . . 0.0 111.081 179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -93.88 108.79 20.54 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.515 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.409 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.2 mt -128.03 130.84 23.57 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.279 -179.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.31 -39.02 1.55 Allowed 'Cis proline' 0 C--N 1.374 1.89 0 C-N-CA 124.651 -0.979 . . . . 0.0 113.427 -0.284 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.75 39.63 13.65 Favored Glycine 0 C--N 1.344 0.98 0 O-C-N 123.469 0.48 . . . . 0.0 113.15 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -141.26 83.26 13.8 Favored Pre-proline 0 CA--C 1.546 0.799 0 C-N-CA 122.169 0.187 . . . . 0.0 111.302 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -83.68 -33.54 2.67 Favored 'Cis proline' 0 C--N 1.373 1.859 0 CA-C-N 119.05 0.697 . . . . 0.0 112.801 -0.271 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -106.71 156.24 18.84 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.018 -179.429 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.504 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.63 -153.35 6.27 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 115.868 -0.606 . . . . 0.0 112.597 179.715 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.51 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.5 mm -128.38 147.08 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.512 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.6 m -84.33 107.88 16.86 Favored 'General case' 0 C--O 1.238 0.48 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.221 179.157 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.51 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -106.02 159.08 16.33 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.767 -178.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.91 122.99 44.84 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.662 179.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.465 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.132 -0.937 . . . . 0.0 111.41 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.7 p . . . . . 0 N--CA 1.487 1.417 0 CA-C-O 119.66 -0.21 . . . . 0.0 111.102 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.453 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 91.9 Cg_endo -79.27 -178.87 4.93 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 122.586 2.191 . . . . 0.0 113.785 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -139.77 -144.69 4.57 Favored Glycine 0 C--N 1.339 0.713 0 CA-C-N 115.369 -0.832 . . . . 0.0 111.871 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -84.37 109.88 18.18 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 120.904 0.383 . . . . 0.0 110.81 179.478 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.15 36.88 6.46 Favored Glycine 0 C--N 1.34 0.76 0 CA-C-N 115.465 -0.789 . . . . 0.0 112.733 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.451 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 42.5 mt-10 -133.25 167.13 20.93 Favored 'General case' 0 N--CA 1.467 0.396 0 O-C-N 123.622 0.248 . . . . 0.0 110.909 -179.728 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.532 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.3 tt0 -80.32 124.54 28.94 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.637 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 20.6 p -127.64 143.57 51.15 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.494 -179.267 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.407 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 10.2 t70 -113.8 156.67 23.45 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.696 -0.683 . . . . 0.0 109.919 179.126 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 16.0 m -103.74 7.84 9.78 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 CA-C-N 116.02 -0.536 . . . . 0.0 112.078 -179.563 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.407 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.4 mt-10 -110.16 -49.34 3.08 Favored 'General case' 0 CA--C 1.533 0.298 0 N-CA-C 112.308 0.485 . . . . 0.0 112.308 -178.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . 0.468 ' HZ ' ' HH ' ' A' ' 27' ' ' TYR . 37.3 p90 -141.2 4.16 1.81 Allowed 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 113.236 0.828 . . . . 0.0 113.236 -178.737 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -132.29 65.73 75.62 Favored Pre-proline 0 CA--C 1.546 0.795 0 CA-C-O 120.525 0.203 . . . . 0.0 111.126 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.453 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 50.4 Cg_endo -73.85 161.98 40.34 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.451 2.1 . . . . 0.0 112.81 179.509 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 91.1 m -79.88 140.85 36.59 Favored 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.548 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -83.81 -52.4 0.58 Allowed Pre-proline 0 CA--C 1.544 0.742 0 CA-C-O 118.906 -0.569 . . . . 0.0 112.265 -179.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.471 ' HG2' HD12 ' A' ' 19' ' ' LEU . 72.5 Cg_endo -75.55 172.89 15.45 Favored 'Trans proline' 0 C--N 1.375 1.953 0 C-N-CA 122.15 1.9 . . . . 0.0 112.48 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_exo -71.51 66.05 2.93 Favored 'Trans proline' 0 C--N 1.377 2.051 0 C-N-CA 122.409 2.072 . . . . 0.0 112.464 179.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.471 HD12 ' HG2' ' A' ' 17' ' ' PRO . 58.5 mt -125.43 166.7 16.12 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.818 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.596 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 9.8 t -115.05 143.96 44.37 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.102 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 6.1 t -92.27 109.3 20.68 Favored 'General case' 0 C--O 1.237 0.429 0 O-C-N 123.479 0.487 . . . . 0.0 110.725 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 6.8 mt -126.37 130.9 23.8 Favored Pre-proline 0 CA--C 1.542 0.637 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.991 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -74.18 -37.58 2.16 Favored 'Cis proline' 0 C--N 1.374 1.874 0 C-N-CA 124.565 -1.014 . . . . 0.0 113.567 -0.143 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.8 36.31 19.52 Favored Glycine 0 C--N 1.345 1.043 0 O-C-N 123.343 0.402 . . . . 0.0 113.029 -179.634 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -143.8 82.5 11.15 Favored Pre-proline 0 CA--C 1.55 0.945 0 CA-C-N 116.666 0.233 . . . . 0.0 111.089 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -85.99 -35.52 1.46 Allowed 'Cis proline' 0 C--N 1.373 1.843 0 CA-C-N 119.171 0.74 . . . . 0.0 112.834 -0.421 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.468 ' HH ' ' HZ ' ' A' ' 12' ' ' PHE . 64.5 m-85 -109.85 158.81 17.79 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.991 -179.184 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.532 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -162.49 -152.68 6.85 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-N 115.886 -0.597 . . . . 0.0 112.356 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.451 ' HA ' ' O ' ' A' ' 6' ' ' GLU . 16.0 mm -126.71 144.78 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 179.711 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.596 ' HA ' ' O ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -91.44 117.82 30.02 Favored 'General case' 0 C--O 1.235 0.337 0 O-C-N 123.505 0.503 . . . . 0.0 111.13 -179.977 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -109.04 167.35 10.16 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.731 -178.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.6 tp -95.04 123.62 47.23 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.553 179.526 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.478 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.4 pp . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.371 -0.823 . . . . 0.0 111.319 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.487 1.382 0 CA-C-O 119.658 -0.211 . . . . 0.0 111.098 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -83.37 -179.11 4.07 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.481 2.121 . . . . 0.0 114.087 -179.137 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . 0.495 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.98 -152.47 6.54 Favored Glycine 0 C--N 1.341 0.843 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.771 179.48 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.5 tt0 -73.34 111.85 8.85 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-O 120.83 0.348 . . . . 0.0 111.415 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.79 30.94 10.63 Favored Glycine 0 C--N 1.341 0.817 0 CA-C-N 115.485 -0.779 . . . . 0.0 112.715 -179.728 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.3 mt-10 -126.86 163.76 22.9 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-O 120.599 0.238 . . . . 0.0 111.21 -179.704 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.2 tt0 -79.97 128.67 33.75 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.067 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.474 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.4 p -127.11 142.61 51.47 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.627 -179.557 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -104.42 150.12 24.82 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.707 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.489 HG22 ' O ' ' A' ' 26' ' ' PRO . 9.0 m -101.61 5.38 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.904 -179.885 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -99.2 -47.52 5.17 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.929 -179.204 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -151.76 1.41 0.36 Allowed 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -178.855 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -131.65 64.44 72.9 Favored Pre-proline 0 CA--C 1.549 0.919 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -179.267 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -73.5 178.25 6.93 Favored 'Trans proline' 0 C--N 1.37 1.7 0 C-N-CA 122.538 2.159 . . . . 0.0 112.473 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.0 m -79.51 138.68 37.61 Favored 'General case' 0 N--CA 1.467 0.413 0 O-C-N 123.216 0.322 . . . . 0.0 110.706 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.02 -52.57 1.02 Allowed Pre-proline 0 CA--C 1.544 0.748 0 CA-C-O 118.983 -0.532 . . . . 0.0 112.089 -179.388 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.413 ' HG2' HD12 ' A' ' 19' ' ' LEU . 64.3 Cg_endo -72.76 175.9 9.66 Favored 'Trans proline' 0 C--N 1.375 1.944 0 C-N-CA 122.163 1.908 . . . . 0.0 112.06 179.347 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -69.55 64.87 1.68 Allowed 'Trans proline' 0 C--N 1.378 2.124 0 C-N-CA 122.373 2.049 . . . . 0.0 112.747 179.399 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.413 HD12 ' HG2' ' A' ' 17' ' ' PRO . 32.9 mt -129.09 159.92 34.45 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.721 179.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.431 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -111.09 152.76 26.57 Favored 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.192 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.7 t -96.39 106.47 18.71 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.256 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.443 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.3 mt -125.89 131.51 24.02 Favored Pre-proline 0 CA--C 1.542 0.67 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.478 -179.532 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -71.26 -39.34 1.45 Allowed 'Cis proline' 0 C--N 1.375 1.952 0 C-N-CA 124.649 -0.98 . . . . 0.0 113.389 -0.117 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.59 31.15 46.3 Favored Glycine 0 C--N 1.343 0.947 0 O-C-N 123.408 0.442 . . . . 0.0 113.266 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -136.97 85.64 22.45 Favored Pre-proline 0 CA--C 1.545 0.781 0 C-N-CA 122.198 0.199 . . . . 0.0 111.096 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.489 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.2 Cg_endo -83.13 -34.5 2.4 Favored 'Cis proline' 0 C--N 1.372 1.811 0 C-N-CA 125.246 -0.731 . . . . 0.0 112.94 -0.217 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.3 m-85 -98.66 153.94 18.33 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.02 -179.218 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.14 -171.5 18.58 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 116.072 -0.513 . . . . 0.0 113.06 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.479 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 42.5 mm -122.42 146.0 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.495 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.3 m -81.57 107.79 14.62 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.543 179.492 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.479 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.6 m-85 -108.29 158.6 17.33 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.612 -179.389 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 tp -92.1 123.32 44.17 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.662 179.618 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.453 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.124 -0.941 . . . . 0.0 111.402 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 119.546 -0.264 . . . . 0.0 111.116 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -83.55 -179.04 3.96 Favored 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.479 2.12 . . . . 0.0 114.029 -179.143 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . 0.528 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.68 -152.91 6.52 Favored Glycine 0 C--N 1.342 0.902 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.96 179.623 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -72.18 113.13 8.88 Favored 'General case' 0 N--CA 1.472 0.663 0 CA-C-O 120.941 0.4 . . . . 0.0 111.539 -179.44 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.7 33.32 10.15 Favored Glycine 0 C--N 1.342 0.873 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.761 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.441 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 8.6 mm-40 -127.65 163.55 23.99 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 120.607 0.241 . . . . 0.0 111.266 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.535 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.6 tt0 -80.15 127.93 32.91 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.837 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.412 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 8.6 p -130.86 148.77 52.67 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.75 -179.319 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.44 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.2 t70 -110.83 155.59 22.35 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.816 178.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.0 m -103.23 3.6 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 112.244 0.461 . . . . 0.0 112.244 -179.49 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.44 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -98.89 -48.79 4.78 Favored 'General case' 0 C--O 1.235 0.339 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -179.027 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -148.76 1.99 0.59 Allowed 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -178.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -131.02 63.7 71.26 Favored Pre-proline 0 CA--C 1.55 0.95 0 N-CA-C 111.757 0.28 . . . . 0.0 111.757 -179.371 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -74.81 175.66 10.88 Favored 'Trans proline' 0 C--N 1.37 1.708 0 C-N-CA 122.467 2.111 . . . . 0.0 112.571 179.133 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 38.4 m -79.74 140.1 37.07 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 116.55 -0.295 . . . . 0.0 110.561 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.98 -52.51 1.03 Allowed Pre-proline 0 CA--C 1.544 0.734 0 CA-C-O 119.082 -0.485 . . . . 0.0 112.037 -179.258 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.428 ' HG2' HD12 ' A' ' 19' ' ' LEU . 64.6 Cg_endo -73.52 175.5 10.57 Favored 'Trans proline' 0 C--N 1.376 2.004 0 C-N-CA 122.087 1.858 . . . . 0.0 112.115 179.248 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -69.47 64.93 1.64 Allowed 'Trans proline' 0 C--N 1.377 2.072 0 C-N-CA 122.386 2.057 . . . . 0.0 112.707 179.465 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.428 HD12 ' HG2' ' A' ' 17' ' ' PRO . 36.7 mt -127.83 161.95 27.81 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.761 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.0 t -111.71 150.39 30.27 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.213 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 4.0 t -95.26 108.6 20.76 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.553 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.4 mt -127.66 130.99 23.6 Favored Pre-proline 0 CA--C 1.541 0.616 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.195 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.599 ' HB2' ' OD2' ' A' ' 25' ' ' ASP . 55.6 Cg_endo -72.48 -39.44 1.44 Allowed 'Cis proline' 0 C--N 1.373 1.854 0 C-N-CA 124.668 -0.972 . . . . 0.0 113.476 -0.272 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.56 38.82 11.55 Favored Glycine 0 C--N 1.344 0.998 0 O-C-N 123.483 0.49 . . . . 0.0 113.386 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.599 ' OD2' ' HB2' ' A' ' 23' ' ' PRO . 2.0 p30 -144.9 85.02 8.51 Favored Pre-proline 0 CA--C 1.55 0.952 0 CA-C-N 116.66 0.23 . . . . 0.0 111.473 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -83.88 -33.65 2.58 Favored 'Cis proline' 0 C--N 1.372 1.789 0 CA-C-N 118.985 0.673 . . . . 0.0 112.896 -0.466 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -109.69 156.72 19.9 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.977 -179.314 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.535 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.84 -151.17 5.67 Favored Glycine 0 C--N 1.338 0.661 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.507 179.78 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.487 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.7 mm -129.26 147.22 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.528 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 79.1 m -84.35 107.24 16.52 Favored 'General case' 0 CA--C 1.537 0.443 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.286 179.25 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.487 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.7 m-85 -105.14 157.84 16.99 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.544 -179.375 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 tt -94.23 124.42 46.7 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.704 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.459 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.247 0.95 0 CA-C-O 118.357 -0.83 . . . . 0.0 111.408 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.373 0 CA-C-O 119.67 -0.205 . . . . 0.0 111.09 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_endo -83.28 -179.13 4.11 Favored 'Trans proline' 0 C--N 1.373 1.822 0 C-N-CA 122.589 2.193 . . . . 0.0 114.054 -179.057 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . 0.495 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.0 -152.26 6.48 Favored Glycine 0 C--N 1.342 0.886 0 CA-C-N 115.41 -0.814 . . . . 0.0 111.777 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.5 tt0 -73.49 111.7 8.87 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 120.835 0.35 . . . . 0.0 111.452 -179.656 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.91 31.07 10.3 Favored Glycine 0 C--N 1.341 0.816 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.651 -179.752 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.1 mt-10 -126.94 163.85 22.75 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-O 120.534 0.207 . . . . 0.0 111.261 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -79.95 128.63 33.7 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.04 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.474 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.5 p -127.13 142.29 51.55 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.59 -179.549 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -104.29 150.03 24.81 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.737 179.407 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.491 HG22 ' O ' ' A' ' 26' ' ' PRO . 9.6 m -101.46 5.25 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.906 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -99.02 -47.45 5.23 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.928 -179.202 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -151.86 1.37 0.36 Allowed 'General case' 0 N--CA 1.478 0.947 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 -178.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -131.55 64.31 72.57 Favored Pre-proline 0 CA--C 1.548 0.89 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.273 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.46 178.24 6.93 Favored 'Trans proline' 0 C--N 1.371 1.731 0 C-N-CA 122.544 2.163 . . . . 0.0 112.484 179.034 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 49.3 m -79.49 138.75 37.66 Favored 'General case' 0 N--CA 1.467 0.42 0 O-C-N 123.224 0.328 . . . . 0.0 110.765 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.22 -52.58 0.98 Allowed Pre-proline 0 CA--C 1.544 0.736 0 CA-C-O 119.018 -0.515 . . . . 0.0 112.057 -179.301 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.409 ' HG2' HD12 ' A' ' 19' ' ' LEU . 64.5 Cg_endo -72.7 175.88 9.64 Favored 'Trans proline' 0 C--N 1.375 1.972 0 C-N-CA 122.16 1.906 . . . . 0.0 112.06 179.297 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.59 65.0 1.7 Allowed 'Trans proline' 0 C--N 1.378 2.093 0 C-N-CA 122.381 2.054 . . . . 0.0 112.591 179.475 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.409 HD12 ' HG2' ' A' ' 17' ' ' PRO . 33.2 mt -129.28 159.96 34.49 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.579 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.432 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -110.98 152.68 26.53 Favored 'General case' 0 CA--C 1.536 0.408 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.101 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.8 t -96.33 106.43 18.65 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.366 179.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.444 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.5 mt -125.81 131.56 24.04 Favored Pre-proline 0 CA--C 1.543 0.684 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.396 -179.458 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -71.08 -39.45 1.42 Allowed 'Cis proline' 0 C--N 1.375 1.923 0 C-N-CA 124.683 -0.965 . . . . 0.0 113.402 -0.225 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.65 30.69 47.66 Favored Glycine 0 C--N 1.345 1.043 0 O-C-N 123.463 0.477 . . . . 0.0 113.391 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -136.79 85.8 23.14 Favored Pre-proline 0 CA--C 1.546 0.82 0 C-N-CA 122.259 0.224 . . . . 0.0 111.049 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.491 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.2 Cg_endo -83.07 -34.58 2.37 Favored 'Cis proline' 0 C--N 1.371 1.756 0 C-N-CA 125.273 -0.719 . . . . 0.0 112.95 -0.269 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 -98.64 153.9 18.34 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.044 -179.246 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.2 -171.8 18.9 Favored Glycine 0 C--N 1.339 0.729 0 O-C-N 123.542 0.526 . . . . 0.0 113.079 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.48 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 42.4 mm -122.17 145.91 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.495 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.5 m -81.44 107.73 14.45 Favored 'General case' 0 CA--C 1.537 0.469 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.517 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.48 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.6 m-85 -108.21 158.65 17.26 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.356 -0.383 . . . . 0.0 111.652 -179.447 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 tp -92.29 123.56 44.45 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.558 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.547 179.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.45 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 0.983 0 CA-C-O 118.278 -0.868 . . . . 0.0 111.384 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.488 1.446 0 CA-C-O 119.624 -0.227 . . . . 0.0 111.156 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.439 ' HG2' ' SG ' ' A' ' 30' ' ' CYS . 87.3 Cg_endo -81.94 -179.65 4.94 Favored 'Trans proline' 0 C--N 1.372 1.782 0 C-N-CA 122.652 2.235 . . . . 0.0 113.997 -179.067 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . 0.495 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.27 -151.37 6.39 Favored Glycine 0 C--N 1.34 0.769 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.699 179.429 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -75.6 110.33 9.91 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-O 120.931 0.396 . . . . 0.0 111.288 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.38 29.82 10.7 Favored Glycine 0 C--N 1.341 0.833 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.524 -179.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -124.25 167.97 13.58 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-O 120.561 0.219 . . . . 0.0 111.133 -179.67 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 -79.9 137.39 36.89 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.072 -179.674 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -126.74 157.04 40.16 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.492 -0.777 . . . . 0.0 111.274 -179.283 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -131.18 140.04 49.84 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.289 179.076 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.521 HG22 ' O ' ' A' ' 26' ' ' PRO . 11.7 m -95.76 7.37 7.18 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 O-C-N 123.202 0.314 . . . . 0.0 111.757 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -99.73 -46.6 5.36 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.772 -179.274 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.0 p90 -154.58 1.17 0.2 Allowed 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 -178.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -132.72 65.61 74.74 Favored Pre-proline 0 CA--C 1.547 0.844 0 CA-C-N 117.931 0.332 . . . . 0.0 111.884 -179.237 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.407 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 55.3 Cg_endo -74.14 177.57 8.06 Favored 'Trans proline' 0 C--N 1.369 1.628 0 C-N-CA 122.574 2.182 . . . . 0.0 112.252 178.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 56.9 m -79.35 139.64 37.71 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 116.705 -0.225 . . . . 0.0 110.898 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.35 -53.7 0.56 Allowed Pre-proline 0 CA--C 1.545 0.75 0 CA-C-O 119.014 -0.517 . . . . 0.0 112.342 -179.073 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.43 ' HG2' HD12 ' A' ' 19' ' ' LEU . 60.0 Cg_endo -71.66 175.32 9.72 Favored 'Trans proline' 0 C--N 1.375 1.971 0 C-N-CA 122.09 1.86 . . . . 0.0 112.265 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_exo -69.6 65.06 1.71 Allowed 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 122.369 2.046 . . . . 0.0 112.615 179.456 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.43 HD12 ' HG2' ' A' ' 17' ' ' PRO . 47.4 mt -126.65 161.13 28.8 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.722 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.0 t -109.58 151.51 26.72 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.227 -179.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.7 t -96.39 107.56 19.96 Favored 'General case' 0 C--O 1.238 0.47 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.398 179.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.438 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 3.8 mt -126.75 129.5 24.04 Favored Pre-proline 0 CA--C 1.541 0.615 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.761 -179.729 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -71.48 -39.14 1.5 Allowed 'Cis proline' 0 C--N 1.374 1.881 0 C-N-CA 124.591 -1.004 . . . . 0.0 113.305 -0.577 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.01 29.76 40.64 Favored Glycine 0 C--N 1.344 0.995 0 CA-C-N 116.158 -0.473 . . . . 0.0 113.429 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -144.13 89.55 7.06 Favored Pre-proline 0 CA--C 1.546 0.811 0 CA-C-N 116.702 0.251 . . . . 0.0 111.219 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.521 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.5 Cg_endo -83.77 -35.58 1.87 Allowed 'Cis proline' 0 C--N 1.371 1.738 0 CA-C-N 119.198 0.749 . . . . 0.0 112.846 -0.291 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 44.0 m-85 -103.01 156.95 17.32 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.717 -179.331 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -156.43 -164.98 14.0 Favored Glycine 0 C--N 1.339 0.743 0 C-N-CA 120.956 -0.64 . . . . 0.0 113.216 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.461 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 43.4 mm -127.24 147.53 32.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.495 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 72.3 m -82.89 109.41 16.99 Favored 'General case' 0 CA--C 1.537 0.478 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.401 179.282 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.461 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.4 m-85 -109.03 158.42 17.75 Favored 'General case' 0 N--CA 1.467 0.391 0 N-CA-C 112.038 0.384 . . . . 0.0 112.038 -179.024 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.1 tp -93.46 124.6 45.95 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.616 179.675 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.453 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.25 1.128 0 CA-C-O 118.185 -0.912 . . . . 0.0 111.44 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.374 0 CA-C-O 119.649 -0.215 . . . . 0.0 111.104 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -83.48 -179.07 4.0 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.467 2.111 . . . . 0.0 114.123 -179.157 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . 0.493 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.82 -152.77 6.64 Favored Glycine 0 C--N 1.341 0.849 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.809 179.433 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.46 111.91 9.04 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-O 120.896 0.379 . . . . 0.0 111.469 -179.753 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.27 30.74 10.46 Favored Glycine 0 C--N 1.341 0.832 0 CA-C-N 115.418 -0.81 . . . . 0.0 112.593 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -127.01 163.69 23.16 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-O 120.608 0.242 . . . . 0.0 111.194 -179.693 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -79.96 128.56 33.62 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.969 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.47 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.3 p -127.05 143.18 51.35 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.555 -179.6 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -104.56 150.28 24.77 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.345 -0.843 . . . . 0.0 109.74 179.469 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.485 HG22 ' O ' ' A' ' 26' ' ' PRO . 9.1 m -101.82 5.12 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.844 -179.854 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -99.17 -47.41 5.21 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.904 -179.126 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -151.84 1.53 0.36 Allowed 'General case' 0 N--CA 1.477 0.886 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -178.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -131.7 64.46 72.89 Favored Pre-proline 0 CA--C 1.549 0.927 0 N-CA-C 111.803 0.298 . . . . 0.0 111.803 -179.262 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.63 178.36 6.84 Favored 'Trans proline' 0 C--N 1.369 1.612 0 C-N-CA 122.56 2.173 . . . . 0.0 112.456 179.066 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 48.3 m -79.55 138.91 37.64 Favored 'General case' 0 C--N 1.344 0.367 0 O-C-N 123.163 0.29 . . . . 0.0 110.792 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.03 -52.66 1.01 Allowed Pre-proline 0 CA--C 1.543 0.697 0 CA-C-O 118.999 -0.525 . . . . 0.0 112.103 -179.319 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.416 ' HG2' HD12 ' A' ' 19' ' ' LEU . 63.9 Cg_endo -72.78 175.88 9.7 Favored 'Trans proline' 0 C--N 1.375 1.964 0 C-N-CA 122.126 1.884 . . . . 0.0 112.036 179.337 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.44 64.82 1.62 Allowed 'Trans proline' 0 C--N 1.379 2.149 0 C-N-CA 122.38 2.053 . . . . 0.0 112.693 179.47 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.416 HD12 ' HG2' ' A' ' 17' ' ' PRO . 33.0 mt -129.11 159.96 34.34 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.698 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.435 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -111.22 152.88 26.6 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.149 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 t -96.37 106.75 19.03 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.298 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.447 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.5 mt -126.15 131.66 24.04 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.418 -179.538 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -71.12 -39.53 1.4 Allowed 'Cis proline' 0 C--N 1.374 1.895 0 C-N-CA 124.676 -0.969 . . . . 0.0 113.391 -0.326 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.67 31.54 44.52 Favored Glycine 0 C--N 1.342 0.9 0 O-C-N 123.49 0.494 . . . . 0.0 113.393 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -136.82 85.38 23.88 Favored Pre-proline 0 CA--C 1.545 0.783 0 C-N-CA 122.168 0.187 . . . . 0.0 111.072 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.485 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.1 Cg_endo -83.3 -34.37 2.41 Favored 'Cis proline' 0 C--N 1.372 1.767 0 C-N-CA 125.17 -0.763 . . . . 0.0 112.993 -0.217 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 -98.56 153.9 18.31 Favored 'General case' 0 N--CA 1.466 0.369 0 O-C-N 123.586 0.554 . . . . 0.0 110.996 -179.238 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.15 -171.33 18.41 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 116.035 -0.529 . . . . 0.0 113.004 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.483 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 41.8 mm -122.38 146.16 28.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.493 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.5 m -81.7 107.92 14.83 Favored 'General case' 0 CA--C 1.537 0.477 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.509 179.562 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.483 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.6 m-85 -108.5 158.94 17.09 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.53 -179.45 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tp -91.57 122.75 43.29 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.61 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.457 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.116 -0.945 . . . . 0.0 111.326 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.5 p . . . . . 0 N--CA 1.486 1.359 0 CA-C-O 119.628 -0.225 . . . . 0.0 111.149 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.532 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 86.9 Cg_endo -78.26 -172.57 1.54 Allowed 'Trans proline' 0 C--N 1.37 1.7 0 C-N-CA 122.673 2.248 . . . . 0.0 113.83 -179.346 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.2 -144.21 4.24 Favored Glycine 0 C--N 1.339 0.698 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.588 179.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 13.3 tt0 -86.47 109.62 19.2 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-O 120.881 0.372 . . . . 0.0 110.705 179.476 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.53 35.88 6.74 Favored Glycine 0 C--N 1.34 0.774 0 CA-C-N 115.571 -0.74 . . . . 0.0 112.749 -179.664 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -131.85 167.68 19.16 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 122.335 0.254 . . . . 0.0 110.831 -179.709 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -79.9 120.56 24.28 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.715 179.746 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 11.8 p -120.17 135.6 54.91 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.288 -179.343 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -104.02 156.15 18.09 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 115.483 -0.78 . . . . 0.0 109.691 179.649 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.428 HG22 ' O ' ' A' ' 26' ' ' PRO . 8.0 m -107.82 14.29 8.14 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.905 -179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -120.54 -45.11 2.43 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.112 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 38.1 p90 -141.28 2.34 1.67 Allowed 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -178.753 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.532 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 2.0 t30 -135.97 68.21 63.85 Favored Pre-proline 0 CA--C 1.543 0.71 0 CA-C-O 120.524 0.202 . . . . 0.0 111.377 -179.644 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.492 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 50.5 Cg_endo -74.46 164.36 34.13 Favored 'Trans proline' 0 C--N 1.368 1.602 0 C-N-CA 122.614 2.209 . . . . 0.0 112.581 179.009 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 94.1 m -79.6 140.42 37.14 Favored 'General case' 0 N--CA 1.47 0.538 0 O-C-N 123.441 0.463 . . . . 0.0 111.681 -179.455 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 m -84.9 -52.54 0.5 Allowed Pre-proline 0 CA--C 1.545 0.751 0 O-C-N 123.63 0.581 . . . . 0.0 112.168 -179.634 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.482 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.3 Cg_endo -75.02 172.8 15.66 Favored 'Trans proline' 0 C--N 1.376 2.014 0 C-N-CA 122.066 1.844 . . . . 0.0 112.408 179.741 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo -71.31 66.16 2.76 Favored 'Trans proline' 0 C--N 1.379 2.149 0 C-N-CA 122.357 2.038 . . . . 0.0 112.511 179.613 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.482 HD12 ' HG2' ' A' ' 17' ' ' PRO . 55.5 mt -124.52 168.1 13.55 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.817 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.579 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 8.5 t -118.73 140.99 49.04 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.337 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 6.3 t -90.99 104.25 16.86 Favored 'General case' 0 CA--C 1.536 0.442 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.541 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mt -120.84 131.58 24.43 Favored Pre-proline 0 CA--C 1.543 0.692 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.325 -179.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -72.52 -36.9 2.4 Favored 'Cis proline' 0 C--N 1.374 1.888 0 C-N-CA 124.542 -1.024 . . . . 0.0 113.257 -0.264 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.47 30.57 48.88 Favored Glycine 0 C--N 1.343 0.925 0 CA-C-N 116.171 -0.468 . . . . 0.0 113.297 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -142.24 86.33 10.2 Favored Pre-proline 0 CA--C 1.545 0.783 0 C-N-CA 122.287 0.235 . . . . 0.0 111.161 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.428 ' O ' HG22 ' A' ' 10' ' ' VAL . 1.7 Cg_endo -85.24 -35.59 1.59 Allowed 'Cis proline' 0 C--N 1.373 1.826 0 CA-C-N 119.055 0.698 . . . . 0.0 112.987 -0.377 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 23.6 m-85 -104.45 154.52 19.77 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.906 -179.056 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -161.76 -172.83 29.66 Favored Glycine 0 C--N 1.34 0.761 0 CA-C-N 116.015 -0.538 . . . . 0.0 113.139 179.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 27.2 mm -116.87 145.2 22.94 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 179.747 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.579 ' HA ' ' O ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -89.4 119.56 29.97 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.484 -179.864 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -111.87 167.01 10.7 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.487 -179.111 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -95.42 122.93 47.33 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.464 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.554 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.475 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.5 pp . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.418 -0.801 . . . . 0.0 111.352 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 31.6 p . . . . . 0 N--CA 1.486 1.35 0 CA-C-O 119.48 -0.295 . . . . 0.0 111.027 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -84.61 -177.33 2.85 Favored 'Trans proline' 0 C--N 1.37 1.661 0 C-N-CA 122.161 1.908 . . . . 0.0 113.088 179.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . 0.576 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -146.93 -157.89 7.57 Favored Glycine 0 C--N 1.337 0.613 0 CA-C-N 115.74 -0.663 . . . . 0.0 112.027 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -65.66 110.3 2.72 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 121.042 0.448 . . . . 0.0 111.737 -179.251 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.33 31.57 10.48 Favored Glycine 0 C--N 1.339 0.745 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.723 -179.865 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.447 ' HB2' ' H ' ' A' ' 3' ' ' GLY . 36.7 mt-10 -126.3 159.98 31.64 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.606 0.241 . . . . 0.0 111.275 -179.686 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.507 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.7 tt0 -80.04 121.92 26.12 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.566 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.409 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 7.9 p -124.83 149.29 47.61 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 115.795 -0.638 . . . . 0.0 111.673 -179.169 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.441 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.1 t70 -109.11 155.35 21.09 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.898 179.14 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.3 m -103.0 3.42 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 -179.543 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.441 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.9 mm-40 -98.6 -48.6 4.92 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 111.939 0.348 . . . . 0.0 111.939 -179.037 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -149.15 1.56 0.55 Allowed 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 113.325 0.861 . . . . 0.0 113.325 -178.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -130.73 63.73 70.97 Favored Pre-proline 0 CA--C 1.55 0.965 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 -179.333 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -76.61 172.7 15.75 Favored 'Trans proline' 0 C--N 1.369 1.656 0 C-N-CA 122.438 2.092 . . . . 0.0 112.618 179.115 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.409 ' SG ' ' SG ' ' A' ' 8' ' ' CYS . 21.9 m -79.56 133.33 36.45 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.3 179.623 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.545 ' SG ' ' HD3' ' A' ' 17' ' ' PRO . 0.8 OUTLIER -79.55 -45.46 1.6 Allowed Pre-proline 0 N--CA 1.475 0.782 0 N-CA-C 112.859 0.689 . . . . 0.0 112.859 -179.279 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.545 ' HD3' ' SG ' ' A' ' 16' ' ' CYS . 56.7 Cg_endo -70.69 174.37 10.43 Favored 'Trans proline' 0 C--N 1.374 1.876 0 C-N-CA 121.863 1.709 . . . . 0.0 111.879 178.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 14.2 Cg_exo -70.0 65.71 1.93 Allowed 'Trans proline' 0 C--N 1.377 2.046 0 C-N-CA 122.274 1.983 . . . . 0.0 112.366 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.527 HD12 ' HG2' ' A' ' 17' ' ' PRO . 25.8 mt -133.43 162.38 32.01 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.27 -0.877 . . . . 0.0 110.901 -179.56 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.507 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.6 t -112.28 155.32 24.26 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.244 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -98.37 108.41 21.1 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.307 179.618 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.422 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.1 mt -128.15 130.86 23.55 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.376 -179.831 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.86 -39.3 1.48 Allowed 'Cis proline' 0 C--N 1.373 1.849 0 C-N-CA 124.624 -0.99 . . . . 0.0 113.533 -0.342 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.29 38.37 18.39 Favored Glycine 0 C--N 1.345 1.049 0 CA-C-N 116.216 -0.447 . . . . 0.0 113.079 -179.725 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -141.23 84.13 13.06 Favored Pre-proline 0 CA--C 1.547 0.847 0 C-N-CA 122.225 0.21 . . . . 0.0 111.338 -179.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -83.16 -34.14 2.54 Favored 'Cis proline' 0 C--N 1.373 1.828 0 CA-C-N 119.047 0.695 . . . . 0.0 112.763 -0.189 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -106.14 156.41 18.46 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.892 -179.35 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.507 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.1 -156.24 7.49 Favored Glycine 0 C--N 1.337 0.622 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.622 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.479 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 23.3 mm -127.4 147.88 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 N-CA-C 110.051 -0.351 . . . . 0.0 110.051 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.576 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 76.7 m -84.74 110.13 18.56 Favored 'General case' 0 CA--C 1.537 0.455 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.114 179.228 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.479 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.4 m-85 -107.38 159.77 16.14 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.899 -178.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.0 tp -93.57 124.1 45.9 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.536 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.6 179.551 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.4 pt . . . . . 0 C--O 1.25 1.119 0 CA-C-O 118.489 -0.767 . . . . 0.0 111.328 179.988 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.487 1.375 0 CA-C-O 119.616 -0.23 . . . . 0.0 111.179 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -83.44 -179.15 4.07 Favored 'Trans proline' 0 C--N 1.371 1.733 0 C-N-CA 122.497 2.131 . . . . 0.0 114.082 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . 0.494 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.84 -152.53 6.58 Favored Glycine 0 C--N 1.341 0.843 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.81 179.41 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.65 111.83 9.16 Favored 'General case' 0 N--CA 1.472 0.63 0 CA-C-O 120.878 0.371 . . . . 0.0 111.385 -179.661 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.21 30.93 10.22 Favored Glycine 0 C--N 1.341 0.828 0 CA-C-N 115.502 -0.772 . . . . 0.0 112.638 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.3 mt-10 -127.14 163.75 23.12 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-O 120.559 0.219 . . . . 0.0 111.212 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -79.95 128.48 33.52 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.971 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.472 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.3 p -127.02 142.9 51.43 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.515 -179.644 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.404 ' OD1' ' HB3' ' A' ' 13' ' ' ASN . 1.3 m-20 -104.46 150.04 24.91 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.808 179.439 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.488 HG22 ' O ' ' A' ' 26' ' ' PRO . 9.4 m -101.68 5.92 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 O-C-N 123.397 0.436 . . . . 0.0 111.947 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.6 tt0 -100.04 -48.0 4.8 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.522 -179.105 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 36.7 p90 -151.11 1.54 0.41 Allowed 'General case' 0 N--CA 1.477 0.918 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -178.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.404 ' HB3' ' OD1' ' A' ' 9' ' ' ASP . 2.4 t30 -131.55 64.3 72.54 Favored Pre-proline 0 CA--C 1.55 0.972 0 N-CA-C 111.854 0.316 . . . . 0.0 111.854 -179.281 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -73.54 177.79 7.53 Favored 'Trans proline' 0 C--N 1.37 1.658 0 C-N-CA 122.525 2.15 . . . . 0.0 112.429 179.047 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 47.3 m -79.53 138.7 37.59 Favored 'General case' 0 N--CA 1.467 0.385 0 O-C-N 123.188 0.305 . . . . 0.0 110.807 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.01 -52.64 1.01 Allowed Pre-proline 0 N--CA 1.474 0.727 0 CA-C-O 119.025 -0.512 . . . . 0.0 111.983 -179.22 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.41 ' HG2' HD12 ' A' ' 19' ' ' LEU . 64.4 Cg_endo -72.73 175.88 9.66 Favored 'Trans proline' 0 C--N 1.375 1.951 0 C-N-CA 122.166 1.91 . . . . 0.0 112.051 179.372 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.3 Cg_exo -69.6 65.01 1.71 Allowed 'Trans proline' 0 C--N 1.378 2.126 0 C-N-CA 122.375 2.05 . . . . 0.0 112.642 179.458 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.41 HD12 ' HG2' ' A' ' 17' ' ' PRO . 32.6 mt -129.2 159.96 34.42 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.687 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.432 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -111.33 152.71 26.95 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.107 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.7 t -96.39 106.72 19.0 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.232 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.445 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.4 mt -125.99 131.63 24.05 Favored Pre-proline 0 CA--C 1.542 0.67 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.391 -179.482 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -71.1 -39.43 1.42 Allowed 'Cis proline' 0 C--N 1.375 1.944 0 C-N-CA 124.717 -0.951 . . . . 0.0 113.446 -0.289 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.51 31.39 45.86 Favored Glycine 0 C--N 1.344 0.997 0 CA-C-N 116.136 -0.484 . . . . 0.0 113.321 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -136.9 85.45 23.29 Favored Pre-proline 0 CA--C 1.545 0.762 0 C-N-CA 122.234 0.214 . . . . 0.0 111.04 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.488 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.2 Cg_endo -83.22 -34.42 2.41 Favored 'Cis proline' 0 C--N 1.373 1.827 0 C-N-CA 125.237 -0.734 . . . . 0.0 112.978 -0.257 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -98.57 154.15 18.13 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.061 -179.257 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.43 -171.56 18.83 Favored Glycine 0 C--N 1.338 0.681 0 CA-C-N 116.11 -0.495 . . . . 0.0 113.01 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.481 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 41.8 mm -122.3 146.05 28.08 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.494 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.4 m -81.49 107.94 14.68 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.582 179.463 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.481 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.8 m-85 -108.48 158.82 17.2 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.554 -179.389 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tp -91.68 122.84 43.49 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.668 179.622 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.455 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.247 0.93 0 CA-C-O 118.44 -0.79 . . . . 0.0 111.405 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 31.7 p . . . . . 0 N--CA 1.488 1.474 0 CA-C-O 119.486 -0.292 . . . . 0.0 110.892 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -84.73 -177.32 2.82 Favored 'Trans proline' 0 C--N 1.37 1.687 0 C-N-CA 122.079 1.853 . . . . 0.0 113.092 179.406 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . 0.578 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -147.27 -158.6 7.92 Favored Glycine 0 C--N 1.337 0.589 0 CA-C-N 115.723 -0.671 . . . . 0.0 111.947 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -64.79 110.0 2.25 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-O 120.979 0.419 . . . . 0.0 111.713 -179.218 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.29 31.97 10.1 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-N 115.331 -0.849 . . . . 0.0 112.713 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.451 ' HB2' ' H ' ' A' ' 3' ' ' GLY . 36.9 mt-10 -126.65 160.48 30.6 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 120.548 0.213 . . . . 0.0 111.238 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.517 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.5 tt0 -79.98 122.01 26.2 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.585 179.682 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 8.5 p -125.49 149.75 48.0 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.637 -179.062 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -109.69 155.53 21.4 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 115.507 -0.769 . . . . 0.0 109.844 179.104 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.4 m -104.14 4.2 10.54 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.222 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -99.24 -48.67 4.74 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 116.637 -0.256 . . . . 0.0 111.654 -179.056 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 37.9 p90 -148.85 0.97 0.56 Allowed 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -179.056 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -130.87 63.56 70.59 Favored Pre-proline 0 CA--C 1.551 0.99 0 N-CA-C 111.816 0.302 . . . . 0.0 111.816 -179.32 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -76.27 173.5 14.38 Favored 'Trans proline' 0 C--N 1.369 1.638 0 C-N-CA 122.53 2.153 . . . . 0.0 112.594 179.203 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 8' ' ' CYS . 23.6 m -79.75 133.5 36.33 Favored 'General case' 0 N--CA 1.466 0.352 0 O-C-N 123.373 0.421 . . . . 0.0 110.252 179.556 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.55 ' SG ' ' HD3' ' A' ' 17' ' ' PRO . 0.8 OUTLIER -79.59 -45.4 1.59 Allowed Pre-proline 0 N--CA 1.476 0.836 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -179.271 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.55 ' HD3' ' SG ' ' A' ' 16' ' ' CYS . 56.9 Cg_endo -70.6 174.42 10.26 Favored 'Trans proline' 0 C--N 1.374 1.913 0 C-N-CA 121.928 1.752 . . . . 0.0 111.922 178.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_exo -70.04 65.66 1.96 Allowed 'Trans proline' 0 C--N 1.376 2.015 0 C-N-CA 122.266 1.977 . . . . 0.0 112.354 179.341 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.526 HD12 ' HG2' ' A' ' 17' ' ' PRO . 26.5 mt -133.5 162.43 31.91 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.84 -179.52 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.507 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.6 t -112.01 155.69 23.37 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.16 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 t -98.83 108.53 21.24 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.314 179.59 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.43 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -128.09 130.87 23.56 Favored Pre-proline 0 CA--C 1.542 0.637 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.323 -179.805 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -73.17 -39.06 1.54 Allowed 'Cis proline' 0 C--N 1.373 1.859 0 C-N-CA 124.62 -0.992 . . . . 0.0 113.523 -0.265 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.14 39.48 15.99 Favored Glycine 0 C--N 1.344 1.018 0 O-C-N 123.459 0.475 . . . . 0.0 113.138 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.55 83.56 13.13 Favored Pre-proline 0 CA--C 1.547 0.855 0 C-N-CA 122.132 0.173 . . . . 0.0 111.253 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -83.51 -33.43 2.75 Favored 'Cis proline' 0 C--N 1.372 1.794 0 CA-C-N 119.056 0.698 . . . . 0.0 112.812 -0.312 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -107.27 155.75 19.61 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.95 -179.404 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.517 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.59 -154.1 6.55 Favored Glycine 0 C--N 1.338 0.672 0 CA-C-N 115.876 -0.602 . . . . 0.0 112.574 179.767 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.481 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 22.6 mm -128.37 148.22 32.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.578 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 77.9 m -84.68 110.22 18.6 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.239 179.286 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.481 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.6 m-85 -107.73 160.54 15.64 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.876 -178.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 tp -92.39 122.87 44.23 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.638 179.621 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.463 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.378 -0.82 . . . . 0.0 111.465 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 32.1 p . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 119.412 -0.328 . . . . 0.0 110.945 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -84.75 -177.55 2.91 Favored 'Trans proline' 0 C--N 1.369 1.612 0 C-N-CA 122.014 1.809 . . . . 0.0 113.202 179.582 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . 0.584 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -146.92 -161.51 9.39 Favored Glycine 0 C--N 1.338 0.683 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.882 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -62.01 111.13 1.8 Allowed 'General case' 0 N--CA 1.474 0.765 0 CA-C-O 121.069 0.462 . . . . 0.0 111.938 -179.209 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.32 31.66 13.52 Favored Glycine 0 C--N 1.341 0.817 0 CA-C-N 115.242 -0.89 . . . . 0.0 112.718 -179.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.508 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 36.2 mt-10 -125.46 161.48 27.02 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-O 120.551 0.215 . . . . 0.0 111.328 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.493 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.7 tt0 -79.91 120.93 24.8 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.521 179.726 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.9 p -125.16 150.03 47.32 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.627 -179.062 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.461 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 7.9 t70 -110.59 154.67 23.44 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.804 179.257 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.1 m -104.06 3.93 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 CA-C-N 116.125 -0.488 . . . . 0.0 112.178 -179.589 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.461 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.3 mt-10 -98.39 -47.93 5.23 Favored 'General case' 0 C--O 1.234 0.24 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -179.163 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -150.07 0.39 0.46 Allowed 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 113.449 0.907 . . . . 0.0 113.449 -179.025 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -131.01 63.81 71.68 Favored Pre-proline 0 CA--C 1.549 0.928 0 N-CA-C 111.874 0.324 . . . . 0.0 111.874 -179.299 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -76.27 174.49 12.74 Favored 'Trans proline' 0 C--N 1.369 1.646 0 C-N-CA 122.513 2.142 . . . . 0.0 112.618 179.299 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 31.0 m -79.62 133.12 36.4 Favored 'General case' 0 N--CA 1.468 0.438 0 C-N-CA 122.574 0.35 . . . . 0.0 110.303 179.587 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.548 ' SG ' ' HD3' ' A' ' 17' ' ' PRO . 0.9 OUTLIER -79.66 -45.45 1.57 Allowed Pre-proline 0 N--CA 1.477 0.877 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -179.242 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.548 ' HD3' ' SG ' ' A' ' 16' ' ' CYS . 56.0 Cg_endo -69.98 174.81 9.15 Favored 'Trans proline' 0 C--N 1.373 1.856 0 C-N-CA 121.886 1.724 . . . . 0.0 111.956 179.054 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_exo -69.59 65.22 1.7 Allowed 'Trans proline' 0 C--N 1.378 2.127 0 C-N-CA 122.292 1.995 . . . . 0.0 112.534 179.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.52 HD12 ' HG2' ' A' ' 17' ' ' PRO . 15.6 mt -136.12 162.04 34.04 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.673 -179.671 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.579 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 14.7 t -111.31 163.02 14.4 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.078 179.543 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.8 t -102.62 110.74 22.78 Favored 'General case' 0 C--O 1.239 0.538 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.294 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 4.8 mt -127.78 131.09 23.63 Favored Pre-proline 0 CA--C 1.542 0.669 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.339 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -74.55 -37.85 2.05 Favored 'Cis proline' 0 C--N 1.374 1.877 0 C-N-CA 124.461 -1.058 . . . . 0.0 113.242 -0.25 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.83 39.51 11.79 Favored Glycine 0 C--N 1.345 1.046 0 O-C-N 123.508 0.505 . . . . 0.0 113.076 -179.716 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -140.71 82.17 16.01 Favored Pre-proline 0 CA--C 1.55 0.978 0 C-N-CA 122.105 0.162 . . . . 0.0 110.911 -179.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -84.86 -33.7 2.35 Favored 'Cis proline' 0 C--N 1.371 1.761 0 CA-C-N 119.096 0.713 . . . . 0.0 112.972 -0.415 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -105.69 156.67 18.06 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.934 -179.256 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.31 -155.27 7.08 Favored Glycine 0 C--N 1.338 0.682 0 CA-C-N 115.868 -0.606 . . . . 0.0 112.553 179.75 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.508 ' HA ' ' O ' ' A' ' 6' ' ' GLU . 19.4 mm -128.57 149.24 33.18 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.584 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 63.6 m -84.42 110.67 18.81 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.274 179.196 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.41 ' O ' ' HB3' ' A' ' 19' ' ' LEU . 85.3 m-85 -106.24 160.95 14.96 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.128 -0.487 . . . . 0.0 112.056 -178.816 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.1 tp -90.1 126.52 42.95 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.611 179.569 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 38.2 mm . . . . . 0 C--O 1.25 1.124 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.088 -179.606 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.487 1.404 0 CA-C-O 119.528 -0.272 . . . . 0.0 111.164 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -83.78 -178.85 3.78 Favored 'Trans proline' 0 C--N 1.372 1.806 0 C-N-CA 122.47 2.113 . . . . 0.0 113.949 -179.099 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.511 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.27 -152.32 6.45 Favored Glycine 0 C--N 1.342 0.913 0 CA-C-N 115.613 -0.722 . . . . 0.0 112.04 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -73.25 113.76 10.67 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.916 0.389 . . . . 0.0 111.621 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.32 32.47 10.44 Favored Glycine 0 C--N 1.341 0.816 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.795 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.55 162.26 26.86 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-O 120.663 0.268 . . . . 0.0 111.251 -179.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.502 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.8 tt0 -80.09 127.0 31.79 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.816 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.47 150.55 50.76 Favored 'General case' 0 C--O 1.233 0.237 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.664 -179.252 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.451 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.17 154.62 23.08 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.597 -0.729 . . . . 0.0 109.785 179.008 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.7 m -102.93 4.23 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 116.123 -0.49 . . . . 0.0 112.14 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.451 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.0 mt-10 -100.27 -48.57 4.55 Favored 'General case' 0 C--O 1.235 0.329 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.113 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.4 p90 -148.45 2.0 0.62 Allowed 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 113.293 0.849 . . . . 0.0 113.293 -178.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.08 63.46 70.34 Favored Pre-proline 0 CA--C 1.548 0.903 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -74.46 175.59 10.82 Favored 'Trans proline' 0 C--N 1.369 1.649 0 C-N-CA 122.493 2.128 . . . . 0.0 112.594 179.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.7 m -79.69 140.87 36.87 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.503 179.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -80.0 -52.58 1.02 Allowed Pre-proline 0 CA--C 1.543 0.702 0 CA-C-O 118.996 -0.526 . . . . 0.0 112.006 -179.326 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.429 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.6 Cg_endo -73.79 175.98 10.04 Favored 'Trans proline' 0 C--N 1.375 1.928 0 C-N-CA 122.143 1.895 . . . . 0.0 111.963 179.258 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.38 64.78 1.58 Allowed 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 122.387 2.058 . . . . 0.0 112.731 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.429 HD12 ' HG2' ' A' ' 17' ' ' PRO . 39.7 mt -127.46 161.32 29.0 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.748 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.0 t -112.4 149.57 32.33 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.015 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.2 t -93.91 108.61 20.39 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.59 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.426 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -127.91 130.78 23.59 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.301 -179.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -73.36 -38.99 1.56 Allowed 'Cis proline' 0 C--N 1.372 1.802 0 C-N-CA 124.671 -0.97 . . . . 0.0 113.464 -0.232 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.65 39.69 13.86 Favored Glycine 0 C--N 1.344 0.999 0 O-C-N 123.453 0.471 . . . . 0.0 113.047 -179.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -141.19 83.34 13.82 Favored Pre-proline 0 CA--C 1.546 0.791 0 C-N-CA 122.182 0.193 . . . . 0.0 111.315 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.56 -33.5 2.71 Favored 'Cis proline' 0 C--N 1.372 1.779 0 CA-C-N 119.061 0.7 . . . . 0.0 112.826 -0.369 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -106.69 156.32 18.75 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.932 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.502 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.78 -154.2 6.61 Favored Glycine 0 C--N 1.338 0.642 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.526 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.511 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.9 mm -127.62 147.17 32.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.511 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.1 m -84.38 107.93 16.92 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.13 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.511 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.4 m-85 -106.09 158.99 16.41 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.824 -179.073 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -93.29 122.99 45.23 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.6 179.664 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.3 pt . . . . . 0 C--O 1.251 1.141 0 CA-C-O 118.472 -0.775 . . . . 0.0 111.349 179.94 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.37 0 CA-C-O 119.533 -0.27 . . . . 0.0 111.133 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -83.89 -178.83 3.73 Favored 'Trans proline' 0 C--N 1.373 1.816 0 C-N-CA 122.458 2.105 . . . . 0.0 114.008 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.513 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.4 -152.35 6.44 Favored Glycine 0 C--N 1.343 0.922 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.961 179.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -73.08 113.89 10.63 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-O 120.789 0.328 . . . . 0.0 111.641 -179.49 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.06 32.63 10.46 Favored Glycine 0 C--N 1.34 0.757 0 CA-C-N 115.448 -0.796 . . . . 0.0 112.781 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.3 mt-10 -127.6 162.39 26.61 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.647 0.26 . . . . 0.0 111.282 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.514 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.6 tt0 -80.05 127.1 31.89 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.793 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.84 150.7 51.02 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.681 -179.262 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.447 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.54 154.71 23.32 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.775 179.024 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.9 m -102.85 4.07 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-N 116.18 -0.464 . . . . 0.0 112.156 -179.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.447 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.4 mt-10 -100.01 -48.65 4.58 Favored 'General case' 0 C--O 1.235 0.312 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.002 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -148.54 2.13 0.62 Allowed 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 113.407 0.891 . . . . 0.0 113.407 -178.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -131.17 63.68 70.95 Favored Pre-proline 0 CA--C 1.55 0.962 0 N-CA-C 111.678 0.251 . . . . 0.0 111.678 -179.432 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.65 175.71 10.75 Favored 'Trans proline' 0 C--N 1.369 1.641 0 C-N-CA 122.493 2.129 . . . . 0.0 112.663 179.235 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.5 m -79.66 140.87 36.91 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 123.288 0.368 . . . . 0.0 110.618 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.94 -52.58 1.03 Allowed Pre-proline 0 CA--C 1.543 0.705 0 CA-C-O 119.131 -0.462 . . . . 0.0 111.925 -179.212 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.426 ' HG2' HD12 ' A' ' 19' ' ' LEU . 66.4 Cg_endo -73.78 175.87 10.17 Favored 'Trans proline' 0 C--N 1.376 1.986 0 C-N-CA 122.105 1.87 . . . . 0.0 112.01 179.227 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -69.37 64.89 1.57 Allowed 'Trans proline' 0 C--N 1.377 2.068 0 C-N-CA 122.373 2.049 . . . . 0.0 112.721 179.478 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.426 HD12 ' HG2' ' A' ' 17' ' ' PRO . 41.1 mt -127.55 161.45 28.76 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.746 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.7 t -112.34 149.58 32.24 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.084 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -94.02 108.93 20.71 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.496 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mt -128.14 130.68 23.57 Favored Pre-proline 0 CA--C 1.541 0.612 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.314 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -73.55 -38.95 1.58 Allowed 'Cis proline' 0 C--N 1.374 1.872 0 C-N-CA 124.581 -1.008 . . . . 0.0 113.456 -0.181 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.85 39.84 12.98 Favored Glycine 0 C--N 1.345 1.08 0 O-C-N 123.483 0.489 . . . . 0.0 113.111 -179.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -140.98 82.88 14.56 Favored Pre-proline 0 CA--C 1.546 0.818 0 C-N-CA 122.205 0.202 . . . . 0.0 111.26 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -83.76 -33.54 2.65 Favored 'Cis proline' 0 C--N 1.372 1.766 0 CA-C-N 119.066 0.702 . . . . 0.0 112.857 -0.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -106.97 156.32 18.85 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.01 -179.324 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.514 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.76 -152.13 5.89 Favored Glycine 0 C--N 1.337 0.635 0 CA-C-N 115.869 -0.605 . . . . 0.0 112.554 179.815 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.501 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.2 mm -129.11 147.13 33.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.513 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.2 m -84.4 108.13 17.05 Favored 'General case' 0 C--O 1.238 0.48 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.174 179.198 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.501 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.0 m-85 -106.2 159.23 16.25 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.79 -179.056 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.91 123.25 44.94 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.641 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.465 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.173 -0.918 . . . . 0.0 111.495 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.37 0 CA-C-O 119.499 -0.286 . . . . 0.0 111.115 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -83.89 -178.81 3.73 Favored 'Trans proline' 0 C--N 1.372 1.767 0 C-N-CA 122.424 2.083 . . . . 0.0 113.995 -179.161 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.513 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.31 -152.41 6.47 Favored Glycine 0 C--N 1.343 0.965 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.993 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -73.03 113.84 10.52 Favored 'General case' 0 N--CA 1.471 0.594 0 CA-C-O 120.961 0.41 . . . . 0.0 111.669 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.09 32.48 10.62 Favored Glycine 0 C--N 1.342 0.886 0 CA-C-N 115.415 -0.812 . . . . 0.0 112.78 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.54 162.34 26.66 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.63 0.252 . . . . 0.0 111.302 -179.731 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.502 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.15 127.31 32.18 Favored 'General case' 0 C--N 1.346 0.428 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.794 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.4 p -129.7 150.49 50.99 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 115.815 -0.629 . . . . 0.0 111.605 -179.234 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.452 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.1 t70 -110.2 154.58 23.17 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.831 178.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.5 m -102.88 3.94 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 CA-C-N 116.165 -0.47 . . . . 0.0 112.225 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.452 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -99.71 -48.76 4.6 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 111.981 0.363 . . . . 0.0 111.981 -179.046 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -148.64 2.18 0.61 Allowed 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 113.204 0.816 . . . . 0.0 113.204 -178.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.28 63.67 70.74 Favored Pre-proline 0 CA--C 1.548 0.903 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -74.55 176.11 10.17 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 122.434 2.089 . . . . 0.0 112.66 179.209 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 36.2 m -79.81 140.9 36.68 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.557 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.96 -52.64 1.02 Allowed Pre-proline 0 CA--C 1.544 0.75 0 CA-C-O 119.068 -0.491 . . . . 0.0 111.926 -179.197 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.43 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.6 Cg_endo -73.76 175.96 10.04 Favored 'Trans proline' 0 C--N 1.376 1.99 0 C-N-CA 122.114 1.876 . . . . 0.0 112.039 179.26 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.36 64.89 1.57 Allowed 'Trans proline' 0 C--N 1.377 2.069 0 C-N-CA 122.327 2.018 . . . . 0.0 112.747 179.479 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.43 HD12 ' HG2' ' A' ' 17' ' ' PRO . 40.6 mt -127.6 161.42 28.88 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.736 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.9 t -112.34 149.57 32.25 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 115.888 -0.597 . . . . 0.0 111.068 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.2 t -94.06 108.76 20.56 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.551 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.1 mt -127.99 130.75 23.58 Favored Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.337 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.38 -39.02 1.55 Allowed 'Cis proline' 0 C--N 1.374 1.87 0 C-N-CA 124.583 -1.007 . . . . 0.0 113.444 -0.22 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.91 39.68 13.02 Favored Glycine 0 C--N 1.345 1.06 0 O-C-N 123.423 0.452 . . . . 0.0 113.069 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.23 83.39 13.73 Favored Pre-proline 0 CA--C 1.547 0.841 0 C-N-CA 122.116 0.166 . . . . 0.0 111.217 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.65 -33.41 2.73 Favored 'Cis proline' 0 C--N 1.372 1.772 0 C-N-CA 125.335 -0.694 . . . . 0.0 112.841 -0.364 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -106.79 156.2 18.92 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.018 -179.378 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.502 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.53 -153.88 6.46 Favored Glycine 0 C--N 1.338 0.639 0 CA-C-N 115.866 -0.606 . . . . 0.0 112.508 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.507 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.4 mm -127.85 147.11 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.513 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.6 m -84.3 107.9 16.85 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.142 179.26 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.507 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -106.03 159.25 16.2 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.785 -179.094 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -93.06 123.15 45.05 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.622 179.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.466 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.295 -0.86 . . . . 0.0 111.519 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.37 0 CA-C-O 119.576 -0.25 . . . . 0.0 111.05 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -83.75 -178.86 3.8 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.53 2.153 . . . . 0.0 114.019 -179.129 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.513 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.04 -152.29 6.48 Favored Glycine 0 C--N 1.342 0.888 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.996 179.659 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -73.52 113.98 11.23 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-O 120.986 0.422 . . . . 0.0 111.561 -179.54 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.13 32.57 10.48 Favored Glycine 0 C--N 1.341 0.818 0 CA-C-N 115.418 -0.81 . . . . 0.0 112.8 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.44 162.3 26.68 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-O 120.476 0.179 . . . . 0.0 111.345 -179.645 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.511 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.07 127.27 32.1 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.795 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.78 150.38 51.11 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.631 -179.248 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.448 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.42 154.89 22.95 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.821 178.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.7 m -102.93 4.21 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 CA-C-N 116.174 -0.466 . . . . 0.0 112.137 -179.507 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.448 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.3 mt-10 -100.32 -48.57 4.54 Favored 'General case' 0 C--O 1.235 0.307 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -179.123 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.6 p90 -148.28 2.0 0.64 Allowed 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 113.279 0.844 . . . . 0.0 113.279 -178.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.12 63.58 70.7 Favored Pre-proline 0 CA--C 1.548 0.903 0 N-CA-C 111.73 0.27 . . . . 0.0 111.73 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.59 175.36 11.19 Favored 'Trans proline' 0 C--N 1.371 1.712 0 C-N-CA 122.461 2.107 . . . . 0.0 112.61 179.208 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.8 m -79.58 140.69 37.08 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.537 179.664 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.98 -52.57 1.03 Allowed Pre-proline 0 N--CA 1.473 0.687 0 CA-C-O 118.98 -0.533 . . . . 0.0 111.983 -179.367 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.426 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.1 Cg_endo -73.88 175.93 10.14 Favored 'Trans proline' 0 C--N 1.375 1.951 0 C-N-CA 122.135 1.89 . . . . 0.0 111.984 179.287 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.43 64.91 1.61 Allowed 'Trans proline' 0 C--N 1.378 2.102 0 C-N-CA 122.277 1.985 . . . . 0.0 112.769 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.426 HD12 ' HG2' ' A' ' 17' ' ' PRO . 40.7 mt -127.35 161.6 28.26 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.782 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.7 t -112.65 149.38 32.93 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.009 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -93.88 108.81 20.56 Favored 'General case' 0 C--O 1.238 0.49 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.544 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mt -127.99 130.8 23.58 Favored Pre-proline 0 CA--C 1.542 0.665 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.247 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -73.47 -38.82 1.64 Allowed 'Cis proline' 0 C--N 1.374 1.872 0 C-N-CA 124.553 -1.019 . . . . 0.0 113.475 -0.296 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.95 39.66 12.96 Favored Glycine 0 C--N 1.345 1.042 0 O-C-N 123.38 0.425 . . . . 0.0 113.089 -179.743 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -141.24 83.16 13.92 Favored Pre-proline 0 CA--C 1.547 0.827 0 C-N-CA 122.161 0.185 . . . . 0.0 111.265 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -83.84 -33.52 2.64 Favored 'Cis proline' 0 C--N 1.373 1.823 0 CA-C-N 119.052 0.697 . . . . 0.0 112.829 -0.282 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.1 m-85 -106.96 156.42 18.74 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.928 -179.354 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.82 -152.47 5.99 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 115.85 -0.614 . . . . 0.0 112.603 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.505 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.5 mm -129.02 147.04 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 O-C-N 123.8 0.353 . . . . 0.0 110.08 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.513 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 76.6 m -84.18 107.79 16.7 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.262 179.2 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.505 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.1 m-85 -105.91 159.13 16.27 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.835 -179.044 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.9 123.25 44.92 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.627 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.466 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.32 -0.848 . . . . 0.0 111.398 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.371 0 CA-C-O 119.586 -0.245 . . . . 0.0 111.171 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -83.8 -178.82 3.76 Favored 'Trans proline' 0 C--N 1.372 1.805 0 C-N-CA 122.445 2.097 . . . . 0.0 114.031 -179.137 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.51 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.87 -152.18 6.49 Favored Glycine 0 C--N 1.343 0.942 0 CA-C-N 115.539 -0.755 . . . . 0.0 112.002 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.46 114.24 11.46 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-O 120.891 0.377 . . . . 0.0 111.6 -179.569 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.69 32.6 11.08 Favored Glycine 0 C--N 1.34 0.801 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.838 -179.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.403 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 33.5 mt-10 -127.4 162.65 25.83 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 120.625 0.25 . . . . 0.0 111.255 -179.576 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.528 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.07 127.25 32.08 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.805 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.8 p -130.32 150.47 51.54 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.631 -179.372 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.499 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.4 t70 -110.65 154.93 23.12 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.876 178.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.543 HG23 ' OE2' ' A' ' 11' ' ' GLU . 9.6 m -102.9 3.31 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-N 116.172 -0.467 . . . . 0.0 112.152 -179.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.543 ' OE2' HG23 ' A' ' 10' ' ' VAL . 4.9 mp0 -97.85 -49.02 4.96 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.443 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 42.1 p90 -149.26 2.52 0.56 Allowed 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 113.375 0.88 . . . . 0.0 113.375 -178.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -130.69 63.67 70.71 Favored Pre-proline 0 CA--C 1.548 0.887 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -74.66 175.99 10.37 Favored 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 122.507 2.138 . . . . 0.0 112.604 179.3 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 34.8 m -79.7 140.92 36.83 Favored 'General case' 0 CA--C 1.534 0.352 0 O-C-N 123.271 0.357 . . . . 0.0 110.603 179.648 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.89 -52.76 1.03 Allowed Pre-proline 0 CA--C 1.545 0.752 0 CA-C-O 119.039 -0.505 . . . . 0.0 111.939 -179.283 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.426 ' HG2' HD12 ' A' ' 19' ' ' LEU . 63.1 Cg_endo -73.53 175.72 10.28 Favored 'Trans proline' 0 C--N 1.374 1.893 0 C-N-CA 122.097 1.865 . . . . 0.0 112.006 179.251 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.35 64.94 1.56 Allowed 'Trans proline' 0 C--N 1.377 2.064 0 C-N-CA 122.347 2.031 . . . . 0.0 112.792 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.426 HD12 ' HG2' ' A' ' 17' ' ' PRO . 38.5 mt -127.6 161.84 27.89 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.741 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.2 t -112.57 149.74 32.31 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.076 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.4 t -94.14 109.05 20.86 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.555 179.595 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.6 mt -128.02 130.99 23.56 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.251 -179.766 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -73.44 -38.82 1.64 Allowed 'Cis proline' 0 C--N 1.374 1.878 0 C-N-CA 124.686 -0.964 . . . . 0.0 113.56 -0.301 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.37 42.05 10.88 Favored Glycine 0 C--N 1.344 1.009 0 O-C-N 123.379 0.424 . . . . 0.0 113.035 -179.584 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.07 80.68 16.75 Favored Pre-proline 0 CA--C 1.547 0.841 0 C-N-CA 122.194 0.198 . . . . 0.0 111.352 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -84.81 -32.77 2.73 Favored 'Cis proline' 0 C--N 1.372 1.804 0 C-N-CA 125.365 -0.681 . . . . 0.0 112.889 -0.359 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 83.2 m-85 -105.86 156.49 18.29 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.107 -179.173 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.528 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -154.31 -150.95 5.64 Favored Glycine 0 C--N 1.338 0.672 0 CA-C-N 115.883 -0.599 . . . . 0.0 112.452 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.485 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.8 mm -129.25 146.99 33.39 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.51 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.1 m -84.64 108.62 17.47 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.204 179.237 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.485 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.7 m-85 -106.1 158.83 16.53 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.874 -179.002 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tp -93.63 123.89 45.89 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.517 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.623 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.3 pt . . . . . 0 C--O 1.248 0.984 0 CA-C-O 118.115 -0.945 . . . . 0.0 111.279 179.987 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.348 0 CA-C-O 119.554 -0.26 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -83.71 -178.88 3.82 Favored 'Trans proline' 0 C--N 1.372 1.814 0 C-N-CA 122.496 2.131 . . . . 0.0 114.038 -179.088 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.511 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.04 -152.28 6.48 Favored Glycine 0 C--N 1.341 0.86 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.031 179.608 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.1 tt0 -73.45 113.75 10.9 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 120.932 0.396 . . . . 0.0 111.715 -179.66 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.45 32.62 10.14 Favored Glycine 0 C--N 1.34 0.8 0 CA-C-N 115.46 -0.791 . . . . 0.0 112.846 -179.792 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.66 162.07 27.4 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-O 120.58 0.228 . . . . 0.0 111.314 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.508 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.8 tt0 -79.96 127.13 31.9 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.804 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.71 150.67 50.92 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.619 -179.282 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.449 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.1 t70 -110.36 154.9 22.88 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.811 178.834 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.5 m -102.79 4.27 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-N 116.186 -0.461 . . . . 0.0 112.132 -179.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.449 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -100.93 -48.51 4.42 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 112.084 0.401 . . . . 0.0 112.084 -179.052 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 39.9 p90 -147.78 1.8 0.69 Allowed 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 113.42 0.896 . . . . 0.0 113.42 -178.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.05 63.29 69.82 Favored Pre-proline 0 CA--C 1.55 0.97 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 -179.344 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.48 175.06 11.55 Favored 'Trans proline' 0 C--N 1.371 1.759 0 C-N-CA 122.381 2.054 . . . . 0.0 112.617 179.281 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.4 m -79.68 140.81 36.9 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.484 179.733 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.98 -52.56 1.03 Allowed Pre-proline 0 CA--C 1.543 0.7 0 CA-C-O 119.087 -0.483 . . . . 0.0 111.993 -179.368 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.43 ' HG2' HD12 ' A' ' 19' ' ' LEU . 66.6 Cg_endo -73.85 175.94 10.11 Favored 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 122.071 1.848 . . . . 0.0 112.045 179.165 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -69.34 64.83 1.55 Allowed 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 122.384 2.056 . . . . 0.0 112.759 179.547 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.43 HD12 ' HG2' ' A' ' 17' ' ' PRO . 41.8 mt -127.28 161.59 28.23 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.818 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.9 t -112.81 149.26 33.3 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.995 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.2 t -93.78 108.76 20.48 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.551 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.424 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.4 mt -127.95 130.93 23.57 Favored Pre-proline 0 CA--C 1.541 0.626 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.226 -179.748 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -73.34 -39.02 1.56 Allowed 'Cis proline' 0 C--N 1.374 1.91 0 C-N-CA 124.705 -0.956 . . . . 0.0 113.468 -0.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.64 39.64 13.99 Favored Glycine 0 C--N 1.344 0.981 0 O-C-N 123.455 0.472 . . . . 0.0 113.075 -179.682 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -140.89 82.99 14.64 Favored Pre-proline 0 CA--C 1.549 0.925 0 C-N-CA 122.188 0.195 . . . . 0.0 110.956 -179.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -83.92 -33.75 2.53 Favored 'Cis proline' 0 C--N 1.372 1.777 0 CA-C-N 119.101 0.715 . . . . 0.0 112.877 -0.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.7 m-85 -106.6 156.25 18.79 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.025 -179.408 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.508 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.85 -152.74 6.08 Favored Glycine 0 C--N 1.338 0.67 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.538 179.741 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.515 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.2 mm -128.69 147.0 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -179.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.511 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 78.8 m -84.06 107.97 16.72 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.183 179.175 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.515 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.4 m-85 -106.17 159.3 16.19 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.805 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -93.02 122.81 44.81 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.681 179.552 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.466 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.363 -0.827 . . . . 0.0 111.449 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.361 0 CA-C-O 119.522 -0.275 . . . . 0.0 111.098 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -83.7 -178.86 3.82 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.47 2.114 . . . . 0.0 113.967 -179.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.512 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.98 -152.23 6.48 Favored Glycine 0 C--N 1.343 0.945 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.031 179.53 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -73.53 113.84 11.09 Favored 'General case' 0 N--CA 1.471 0.591 0 CA-C-O 120.833 0.349 . . . . 0.0 111.581 -179.504 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.33 32.69 10.15 Favored Glycine 0 C--N 1.339 0.747 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.793 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.62 162.22 27.0 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 120.564 0.221 . . . . 0.0 111.275 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.513 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -79.93 127.26 32.05 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.828 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.6 p -129.92 150.65 51.11 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.592 -179.278 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.445 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.64 154.71 23.42 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.773 178.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.8 m -102.65 4.18 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-N 116.146 -0.479 . . . . 0.0 112.139 -179.56 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.445 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.6 mm-40 -100.48 -48.62 4.49 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -179.088 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.4 p90 -148.02 1.89 0.67 Allowed 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 113.379 0.881 . . . . 0.0 113.379 -178.854 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.09 63.39 70.08 Favored Pre-proline 0 CA--C 1.551 0.993 0 N-CA-C 111.723 0.268 . . . . 0.0 111.723 -179.236 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.51 175.2 11.37 Favored 'Trans proline' 0 C--N 1.37 1.683 0 C-N-CA 122.391 2.061 . . . . 0.0 112.644 179.287 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.5 m -79.75 140.74 36.82 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.559 179.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.89 -52.59 1.04 Allowed Pre-proline 0 N--CA 1.474 0.768 0 CA-C-O 119.057 -0.497 . . . . 0.0 111.975 -179.296 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.426 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.1 Cg_endo -73.89 175.94 10.13 Favored 'Trans proline' 0 C--N 1.376 1.995 0 C-N-CA 122.148 1.899 . . . . 0.0 111.941 179.342 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.3 64.91 1.53 Allowed 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 122.322 2.014 . . . . 0.0 112.732 179.501 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.426 HD12 ' HG2' ' A' ' 17' ' ' PRO . 40.3 mt -127.43 161.58 28.36 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.744 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.9 t -112.73 149.41 32.98 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.026 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -93.9 108.85 20.6 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.539 179.568 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.401 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -127.99 130.81 23.58 Favored Pre-proline 0 CA--C 1.541 0.626 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.264 -179.749 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -73.29 -39.02 1.56 Allowed 'Cis proline' 0 C--N 1.374 1.92 0 C-N-CA 124.692 -0.962 . . . . 0.0 113.439 -0.306 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.86 39.83 12.98 Favored Glycine 0 C--N 1.343 0.971 0 O-C-N 123.43 0.456 . . . . 0.0 113.073 -179.68 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.32 83.09 13.86 Favored Pre-proline 0 CA--C 1.547 0.861 0 C-N-CA 122.222 0.209 . . . . 0.0 111.299 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.91 -33.45 2.65 Favored 'Cis proline' 0 C--N 1.372 1.807 0 C-N-CA 125.345 -0.689 . . . . 0.0 112.755 -0.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.1 m-85 -106.89 156.51 18.62 Favored 'General case' 0 N--CA 1.465 0.313 0 O-C-N 123.593 0.558 . . . . 0.0 111.035 -179.424 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.513 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.05 -152.27 5.95 Favored Glycine 0 C--N 1.339 0.697 0 CA-C-N 115.866 -0.606 . . . . 0.0 112.603 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.512 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.3 mm -129.06 147.15 33.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.512 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 77.8 m -84.36 107.78 16.83 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.108 179.264 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.512 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -105.98 159.24 16.2 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.782 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.92 122.91 44.79 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.669 179.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.467 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 1.014 0 CA-C-O 118.3 -0.857 . . . . 0.0 111.351 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.485 1.319 0 CA-C-O 119.579 -0.248 . . . . 0.0 111.081 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -83.87 -178.91 3.78 Favored 'Trans proline' 0 C--N 1.371 1.747 0 C-N-CA 122.536 2.157 . . . . 0.0 113.941 -179.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.512 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.37 -152.36 6.45 Favored Glycine 0 C--N 1.341 0.857 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.077 179.601 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -73.17 113.85 10.69 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-O 121.015 0.435 . . . . 0.0 111.629 -179.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.22 32.46 10.54 Favored Glycine 0 C--N 1.342 0.913 0 CA-C-N 115.345 -0.843 . . . . 0.0 112.778 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -127.52 162.28 26.79 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-O 120.508 0.194 . . . . 0.0 111.327 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.51 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -80.1 127.28 32.13 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.864 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.76 150.69 50.96 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.631 -179.193 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.447 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.2 t70 -110.5 154.69 23.31 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.775 178.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.6 m -102.98 3.95 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.191 -179.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.447 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.6 mm-40 -99.61 -48.79 4.62 Favored 'General case' 0 C--O 1.234 0.288 0 N-CA-C 111.936 0.346 . . . . 0.0 111.936 -179.053 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.1 p90 -148.63 1.97 0.61 Allowed 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -178.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -131.12 63.83 71.56 Favored Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 111.748 0.277 . . . . 0.0 111.748 -179.37 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -74.66 175.93 10.44 Favored 'Trans proline' 0 C--N 1.37 1.705 0 C-N-CA 122.459 2.106 . . . . 0.0 112.574 179.283 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.8 m -79.62 140.92 36.96 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 123.257 0.348 . . . . 0.0 110.62 179.626 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.96 -52.57 1.03 Allowed Pre-proline 0 CA--C 1.544 0.731 0 CA-C-O 119.01 -0.519 . . . . 0.0 111.954 -179.286 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.426 ' HG2' HD12 ' A' ' 19' ' ' LEU . 66.2 Cg_endo -73.94 175.97 10.1 Favored 'Trans proline' 0 C--N 1.375 1.955 0 C-N-CA 122.132 1.888 . . . . 0.0 112.002 179.27 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.35 64.92 1.56 Allowed 'Trans proline' 0 C--N 1.379 2.16 0 C-N-CA 122.402 2.068 . . . . 0.0 112.71 179.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.426 HD12 ' HG2' ' A' ' 17' ' ' PRO . 40.5 mt -127.63 161.3 29.17 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.799 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.8 t -112.36 149.59 32.25 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.06 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -93.93 108.89 20.64 Favored 'General case' 0 C--O 1.237 0.446 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.512 179.622 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.401 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -128.11 130.8 23.56 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.252 -179.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -73.45 -38.91 1.6 Allowed 'Cis proline' 0 C--N 1.374 1.9 0 C-N-CA 124.562 -1.016 . . . . 0.0 113.507 -0.288 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.93 39.84 12.72 Favored Glycine 0 C--N 1.344 1.009 0 O-C-N 123.437 0.46 . . . . 0.0 113.032 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -141.17 83.12 14.05 Favored Pre-proline 0 CA--C 1.547 0.84 0 CA-C-N 116.646 0.223 . . . . 0.0 111.271 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -83.77 -33.49 2.67 Favored 'Cis proline' 0 C--N 1.371 1.761 0 CA-C-N 119.062 0.701 . . . . 0.0 112.792 -0.272 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 75.8 m-85 -106.82 156.51 18.59 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.069 -179.412 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.51 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.85 -152.82 6.1 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.529 179.775 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.509 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 28.2 mm -128.56 147.18 33.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 -179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.512 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.9 m -84.35 107.98 16.93 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.179 179.229 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.509 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -106.26 159.15 16.33 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.767 -179.031 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.76 122.81 44.55 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.523 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.622 179.65 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.467 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.248 1.017 0 CA-C-O 118.442 -0.789 . . . . 0.0 111.405 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.486 1.361 0 CA-C-O 119.546 -0.264 . . . . 0.0 111.106 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_endo -83.77 -178.93 3.82 Favored 'Trans proline' 0 C--N 1.372 1.764 0 C-N-CA 122.502 2.134 . . . . 0.0 114.091 -179.197 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.512 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.73 -152.34 6.55 Favored Glycine 0 C--N 1.342 0.872 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.989 179.505 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.79 114.0 11.57 Favored 'General case' 0 N--CA 1.471 0.614 0 CA-C-O 120.924 0.392 . . . . 0.0 111.572 -179.43 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.72 32.21 10.39 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-N 115.456 -0.793 . . . . 0.0 112.759 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -127.61 162.26 26.92 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.705 0.288 . . . . 0.0 111.319 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.504 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.7 tt0 -79.94 127.11 31.87 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.798 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 p -129.62 150.51 50.92 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.684 -179.34 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.451 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.0 t70 -110.21 154.65 23.08 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.847 178.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 12.6 m -102.7 4.1 10.63 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.203 -179.544 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.451 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -100.37 -48.51 4.55 Favored 'General case' 0 C--O 1.235 0.336 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.079 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.3 p90 -148.22 1.83 0.64 Allowed 'General case' 0 N--CA 1.476 0.862 0 N-CA-C 113.23 0.826 . . . . 0.0 113.23 -178.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -131.07 63.55 70.69 Favored Pre-proline 0 CA--C 1.549 0.928 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 -179.317 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -74.6 175.44 11.08 Favored 'Trans proline' 0 C--N 1.37 1.662 0 C-N-CA 122.434 2.089 . . . . 0.0 112.626 179.244 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 35.6 m -79.74 140.76 36.83 Favored 'General case' 0 CA--C 1.534 0.363 0 O-C-N 123.255 0.347 . . . . 0.0 110.541 179.69 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.91 -52.67 1.03 Allowed Pre-proline 0 CA--C 1.544 0.721 0 CA-C-O 119.017 -0.516 . . . . 0.0 112.007 -179.291 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.428 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.9 Cg_endo -73.78 175.93 10.1 Favored 'Trans proline' 0 C--N 1.374 1.893 0 C-N-CA 122.118 1.879 . . . . 0.0 112.013 179.212 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -69.39 64.95 1.58 Allowed 'Trans proline' 0 C--N 1.379 2.132 0 C-N-CA 122.347 2.031 . . . . 0.0 112.678 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.428 HD12 ' HG2' ' A' ' 17' ' ' PRO . 39.9 mt -127.49 161.39 28.87 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.751 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 5.8 t -112.51 149.42 32.68 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.89 -0.596 . . . . 0.0 111.081 179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -93.88 108.79 20.54 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.515 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.409 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.2 mt -128.03 130.84 23.57 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.279 -179.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.31 -39.02 1.55 Allowed 'Cis proline' 0 C--N 1.374 1.89 0 C-N-CA 124.651 -0.979 . . . . 0.0 113.427 -0.284 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.75 39.63 13.65 Favored Glycine 0 C--N 1.344 0.98 0 O-C-N 123.469 0.48 . . . . 0.0 113.15 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -141.26 83.26 13.8 Favored Pre-proline 0 CA--C 1.546 0.799 0 C-N-CA 122.169 0.187 . . . . 0.0 111.302 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -83.68 -33.54 2.67 Favored 'Cis proline' 0 C--N 1.373 1.859 0 CA-C-N 119.05 0.697 . . . . 0.0 112.801 -0.271 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -106.71 156.24 18.84 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.018 -179.429 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.504 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.63 -153.35 6.27 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 115.868 -0.606 . . . . 0.0 112.597 179.715 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.51 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.5 mm -128.38 147.08 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.512 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.6 m -84.33 107.88 16.86 Favored 'General case' 0 C--O 1.238 0.48 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.221 179.157 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.51 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 98.2 m-85 -106.02 159.08 16.33 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.767 -178.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -92.91 122.99 44.84 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.662 179.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.465 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.132 -0.937 . . . . 0.0 111.41 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.7 p . . . . . 0 N--CA 1.487 1.417 0 CA-C-O 119.66 -0.21 . . . . 0.0 111.102 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.453 ' HD2' ' O ' ' A' ' 14' ' ' PRO . 91.9 Cg_endo -79.27 -178.87 4.93 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 122.586 2.191 . . . . 0.0 113.785 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -139.77 -144.69 4.57 Favored Glycine 0 C--N 1.339 0.713 0 CA-C-N 115.369 -0.832 . . . . 0.0 111.871 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -84.37 109.88 18.18 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 120.904 0.383 . . . . 0.0 110.81 179.478 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.15 36.88 6.46 Favored Glycine 0 C--N 1.34 0.76 0 CA-C-N 115.465 -0.789 . . . . 0.0 112.733 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.451 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 42.5 mt-10 -133.25 167.13 20.93 Favored 'General case' 0 N--CA 1.467 0.396 0 O-C-N 123.622 0.248 . . . . 0.0 110.909 -179.728 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.532 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.3 tt0 -80.32 124.54 28.94 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.637 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 20.6 p -127.64 143.57 51.15 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.494 -179.267 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.407 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 10.2 t70 -113.8 156.67 23.45 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.696 -0.683 . . . . 0.0 109.919 179.126 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 16.0 m -103.74 7.84 9.78 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 CA-C-N 116.02 -0.536 . . . . 0.0 112.078 -179.563 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.407 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.4 mt-10 -110.16 -49.34 3.08 Favored 'General case' 0 CA--C 1.533 0.298 0 N-CA-C 112.308 0.485 . . . . 0.0 112.308 -178.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.468 ' HZ ' ' HH ' ' A' ' 27' ' ' TYR . 37.3 p90 -141.2 4.16 1.81 Allowed 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 113.236 0.828 . . . . 0.0 113.236 -178.737 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -132.29 65.73 75.62 Favored Pre-proline 0 CA--C 1.546 0.795 0 CA-C-O 120.525 0.203 . . . . 0.0 111.126 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.453 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 50.4 Cg_endo -73.85 161.98 40.34 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.451 2.1 . . . . 0.0 112.81 179.509 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 91.1 m -79.88 140.85 36.59 Favored 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.548 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -83.81 -52.4 0.58 Allowed Pre-proline 0 CA--C 1.544 0.742 0 CA-C-O 118.906 -0.569 . . . . 0.0 112.265 -179.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.471 ' HG2' HD12 ' A' ' 19' ' ' LEU . 72.5 Cg_endo -75.55 172.89 15.45 Favored 'Trans proline' 0 C--N 1.375 1.953 0 C-N-CA 122.15 1.9 . . . . 0.0 112.48 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_exo -71.51 66.05 2.93 Favored 'Trans proline' 0 C--N 1.377 2.051 0 C-N-CA 122.409 2.072 . . . . 0.0 112.464 179.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.471 HD12 ' HG2' ' A' ' 17' ' ' PRO . 58.5 mt -125.43 166.7 16.12 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.818 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.596 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 9.8 t -115.05 143.96 44.37 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.102 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 6.1 t -92.27 109.3 20.68 Favored 'General case' 0 C--O 1.237 0.429 0 O-C-N 123.479 0.487 . . . . 0.0 110.725 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 6.8 mt -126.37 130.9 23.8 Favored Pre-proline 0 CA--C 1.542 0.637 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.991 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -74.18 -37.58 2.16 Favored 'Cis proline' 0 C--N 1.374 1.874 0 C-N-CA 124.565 -1.014 . . . . 0.0 113.567 -0.143 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.8 36.31 19.52 Favored Glycine 0 C--N 1.345 1.043 0 O-C-N 123.343 0.402 . . . . 0.0 113.029 -179.634 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -143.8 82.5 11.15 Favored Pre-proline 0 CA--C 1.55 0.945 0 CA-C-N 116.666 0.233 . . . . 0.0 111.089 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -85.99 -35.52 1.46 Allowed 'Cis proline' 0 C--N 1.373 1.843 0 CA-C-N 119.171 0.74 . . . . 0.0 112.834 -0.421 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.468 ' HH ' ' HZ ' ' A' ' 12' ' ' PHE . 64.5 m-85 -109.85 158.81 17.79 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.991 -179.184 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.532 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -162.49 -152.68 6.85 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-N 115.886 -0.597 . . . . 0.0 112.356 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.451 ' HA ' ' O ' ' A' ' 6' ' ' GLU . 16.0 mm -126.71 144.78 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 179.711 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.596 ' HA ' ' O ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -91.44 117.82 30.02 Favored 'General case' 0 C--O 1.235 0.337 0 O-C-N 123.505 0.503 . . . . 0.0 111.13 -179.977 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -109.04 167.35 10.16 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.731 -178.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.6 tp -95.04 123.62 47.23 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.553 179.526 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.478 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.4 pp . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.371 -0.823 . . . . 0.0 111.319 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.487 1.382 0 CA-C-O 119.658 -0.211 . . . . 0.0 111.098 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -83.37 -179.11 4.07 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.481 2.121 . . . . 0.0 114.087 -179.137 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.495 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.98 -152.47 6.54 Favored Glycine 0 C--N 1.341 0.843 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.771 179.48 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.5 tt0 -73.34 111.85 8.85 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-O 120.83 0.348 . . . . 0.0 111.415 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.79 30.94 10.63 Favored Glycine 0 C--N 1.341 0.817 0 CA-C-N 115.485 -0.779 . . . . 0.0 112.715 -179.728 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.3 mt-10 -126.86 163.76 22.9 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-O 120.599 0.238 . . . . 0.0 111.21 -179.704 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.2 tt0 -79.97 128.67 33.75 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.067 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.474 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.4 p -127.11 142.61 51.47 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.627 -179.557 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -104.42 150.12 24.82 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.707 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.489 HG22 ' O ' ' A' ' 26' ' ' PRO . 9.0 m -101.61 5.38 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.904 -179.885 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -99.2 -47.52 5.17 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.929 -179.204 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -151.76 1.41 0.36 Allowed 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -178.855 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -131.65 64.44 72.9 Favored Pre-proline 0 CA--C 1.549 0.919 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -179.267 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -73.5 178.25 6.93 Favored 'Trans proline' 0 C--N 1.37 1.7 0 C-N-CA 122.538 2.159 . . . . 0.0 112.473 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.0 m -79.51 138.68 37.61 Favored 'General case' 0 N--CA 1.467 0.413 0 O-C-N 123.216 0.322 . . . . 0.0 110.706 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.02 -52.57 1.02 Allowed Pre-proline 0 CA--C 1.544 0.748 0 CA-C-O 118.983 -0.532 . . . . 0.0 112.089 -179.388 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.413 ' HG2' HD12 ' A' ' 19' ' ' LEU . 64.3 Cg_endo -72.76 175.9 9.66 Favored 'Trans proline' 0 C--N 1.375 1.944 0 C-N-CA 122.163 1.908 . . . . 0.0 112.06 179.347 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -69.55 64.87 1.68 Allowed 'Trans proline' 0 C--N 1.378 2.124 0 C-N-CA 122.373 2.049 . . . . 0.0 112.747 179.399 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.413 HD12 ' HG2' ' A' ' 17' ' ' PRO . 32.9 mt -129.09 159.92 34.45 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.721 179.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.431 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -111.09 152.76 26.57 Favored 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.192 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.7 t -96.39 106.47 18.71 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.256 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.443 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.3 mt -125.89 131.51 24.02 Favored Pre-proline 0 CA--C 1.542 0.67 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.478 -179.532 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -71.26 -39.34 1.45 Allowed 'Cis proline' 0 C--N 1.375 1.952 0 C-N-CA 124.649 -0.98 . . . . 0.0 113.389 -0.117 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.59 31.15 46.3 Favored Glycine 0 C--N 1.343 0.947 0 O-C-N 123.408 0.442 . . . . 0.0 113.266 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -136.97 85.64 22.45 Favored Pre-proline 0 CA--C 1.545 0.781 0 C-N-CA 122.198 0.199 . . . . 0.0 111.096 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.489 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.2 Cg_endo -83.13 -34.5 2.4 Favored 'Cis proline' 0 C--N 1.372 1.811 0 C-N-CA 125.246 -0.731 . . . . 0.0 112.94 -0.217 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.3 m-85 -98.66 153.94 18.33 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.02 -179.218 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.14 -171.5 18.58 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 116.072 -0.513 . . . . 0.0 113.06 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.479 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 42.5 mm -122.42 146.0 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.495 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.3 m -81.57 107.79 14.62 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.543 179.492 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.479 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.6 m-85 -108.29 158.6 17.33 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.612 -179.389 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 tp -92.1 123.32 44.17 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.662 179.618 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.453 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.124 -0.941 . . . . 0.0 111.402 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 119.546 -0.264 . . . . 0.0 111.116 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -83.55 -179.04 3.96 Favored 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.479 2.12 . . . . 0.0 114.029 -179.143 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.528 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.68 -152.91 6.52 Favored Glycine 0 C--N 1.342 0.902 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.96 179.623 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -72.18 113.13 8.88 Favored 'General case' 0 N--CA 1.472 0.663 0 CA-C-O 120.941 0.4 . . . . 0.0 111.539 -179.44 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.7 33.32 10.15 Favored Glycine 0 C--N 1.342 0.873 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.761 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.441 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 8.6 mm-40 -127.65 163.55 23.99 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 120.607 0.241 . . . . 0.0 111.266 -179.595 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.535 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 11.6 tt0 -80.15 127.93 32.91 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.837 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.412 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 8.6 p -130.86 148.77 52.67 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.75 -179.319 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.44 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.2 t70 -110.83 155.59 22.35 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.816 178.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.0 m -103.23 3.6 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 112.244 0.461 . . . . 0.0 112.244 -179.49 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.44 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.2 mt-10 -98.89 -48.79 4.78 Favored 'General case' 0 C--O 1.235 0.339 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -179.027 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -148.76 1.99 0.59 Allowed 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -178.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -131.02 63.7 71.26 Favored Pre-proline 0 CA--C 1.55 0.95 0 N-CA-C 111.757 0.28 . . . . 0.0 111.757 -179.371 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -74.81 175.66 10.88 Favored 'Trans proline' 0 C--N 1.37 1.708 0 C-N-CA 122.467 2.111 . . . . 0.0 112.571 179.133 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 38.4 m -79.74 140.1 37.07 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 116.55 -0.295 . . . . 0.0 110.561 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.98 -52.51 1.03 Allowed Pre-proline 0 CA--C 1.544 0.734 0 CA-C-O 119.082 -0.485 . . . . 0.0 112.037 -179.258 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.428 ' HG2' HD12 ' A' ' 19' ' ' LEU . 64.6 Cg_endo -73.52 175.5 10.57 Favored 'Trans proline' 0 C--N 1.376 2.004 0 C-N-CA 122.087 1.858 . . . . 0.0 112.115 179.248 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.1 Cg_exo -69.47 64.93 1.64 Allowed 'Trans proline' 0 C--N 1.377 2.072 0 C-N-CA 122.386 2.057 . . . . 0.0 112.707 179.465 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.428 HD12 ' HG2' ' A' ' 17' ' ' PRO . 36.7 mt -127.83 161.95 27.81 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.761 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.0 t -111.71 150.39 30.27 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.213 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 4.0 t -95.26 108.6 20.76 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.553 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.4 mt -127.66 130.99 23.6 Favored Pre-proline 0 CA--C 1.541 0.616 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.195 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.599 ' HB2' ' OD2' ' A' ' 25' ' ' ASP . 55.6 Cg_endo -72.48 -39.44 1.44 Allowed 'Cis proline' 0 C--N 1.373 1.854 0 C-N-CA 124.668 -0.972 . . . . 0.0 113.476 -0.272 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.56 38.82 11.55 Favored Glycine 0 C--N 1.344 0.998 0 O-C-N 123.483 0.49 . . . . 0.0 113.386 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.599 ' OD2' ' HB2' ' A' ' 23' ' ' PRO . 2.0 p30 -144.9 85.02 8.51 Favored Pre-proline 0 CA--C 1.55 0.952 0 CA-C-N 116.66 0.23 . . . . 0.0 111.473 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -83.88 -33.65 2.58 Favored 'Cis proline' 0 C--N 1.372 1.789 0 CA-C-N 118.985 0.673 . . . . 0.0 112.896 -0.466 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -109.69 156.72 19.9 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.977 -179.314 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.535 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.84 -151.17 5.67 Favored Glycine 0 C--N 1.338 0.661 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.507 179.78 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.487 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 27.7 mm -129.26 147.22 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.528 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 79.1 m -84.35 107.24 16.52 Favored 'General case' 0 CA--C 1.537 0.443 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.286 179.25 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.487 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.7 m-85 -105.14 157.84 16.99 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.544 -179.375 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 tt -94.23 124.42 46.7 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.704 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.459 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.247 0.95 0 CA-C-O 118.357 -0.83 . . . . 0.0 111.408 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.373 0 CA-C-O 119.67 -0.205 . . . . 0.0 111.09 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_endo -83.28 -179.13 4.11 Favored 'Trans proline' 0 C--N 1.373 1.822 0 C-N-CA 122.589 2.193 . . . . 0.0 114.054 -179.057 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.495 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -135.0 -152.26 6.48 Favored Glycine 0 C--N 1.342 0.886 0 CA-C-N 115.41 -0.814 . . . . 0.0 111.777 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.5 tt0 -73.49 111.7 8.87 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 120.835 0.35 . . . . 0.0 111.452 -179.656 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.91 31.07 10.3 Favored Glycine 0 C--N 1.341 0.816 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.651 -179.752 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.1 mt-10 -126.94 163.85 22.75 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-O 120.534 0.207 . . . . 0.0 111.261 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -79.95 128.63 33.7 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.04 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.474 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.5 p -127.13 142.29 51.55 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.59 -179.549 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -104.29 150.03 24.81 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 115.388 -0.824 . . . . 0.0 109.737 179.407 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.491 HG22 ' O ' ' A' ' 26' ' ' PRO . 9.6 m -101.46 5.25 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.906 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -99.02 -47.45 5.23 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.928 -179.202 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -151.86 1.37 0.36 Allowed 'General case' 0 N--CA 1.478 0.947 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 -178.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -131.55 64.31 72.57 Favored Pre-proline 0 CA--C 1.548 0.89 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.273 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.46 178.24 6.93 Favored 'Trans proline' 0 C--N 1.371 1.731 0 C-N-CA 122.544 2.163 . . . . 0.0 112.484 179.034 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 49.3 m -79.49 138.75 37.66 Favored 'General case' 0 N--CA 1.467 0.42 0 O-C-N 123.224 0.328 . . . . 0.0 110.765 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.22 -52.58 0.98 Allowed Pre-proline 0 CA--C 1.544 0.736 0 CA-C-O 119.018 -0.515 . . . . 0.0 112.057 -179.301 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.409 ' HG2' HD12 ' A' ' 19' ' ' LEU . 64.5 Cg_endo -72.7 175.88 9.64 Favored 'Trans proline' 0 C--N 1.375 1.972 0 C-N-CA 122.16 1.906 . . . . 0.0 112.06 179.297 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.59 65.0 1.7 Allowed 'Trans proline' 0 C--N 1.378 2.093 0 C-N-CA 122.381 2.054 . . . . 0.0 112.591 179.475 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.409 HD12 ' HG2' ' A' ' 17' ' ' PRO . 33.2 mt -129.28 159.96 34.49 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.579 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.432 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -110.98 152.68 26.53 Favored 'General case' 0 CA--C 1.536 0.408 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.101 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.8 t -96.33 106.43 18.65 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.366 179.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.444 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.5 mt -125.81 131.56 24.04 Favored Pre-proline 0 CA--C 1.543 0.684 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.396 -179.458 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -71.08 -39.45 1.42 Allowed 'Cis proline' 0 C--N 1.375 1.923 0 C-N-CA 124.683 -0.965 . . . . 0.0 113.402 -0.225 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.65 30.69 47.66 Favored Glycine 0 C--N 1.345 1.043 0 O-C-N 123.463 0.477 . . . . 0.0 113.391 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -136.79 85.8 23.14 Favored Pre-proline 0 CA--C 1.546 0.82 0 C-N-CA 122.259 0.224 . . . . 0.0 111.049 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.491 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.2 Cg_endo -83.07 -34.58 2.37 Favored 'Cis proline' 0 C--N 1.371 1.756 0 C-N-CA 125.273 -0.719 . . . . 0.0 112.95 -0.269 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 -98.64 153.9 18.34 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.044 -179.246 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.2 -171.8 18.9 Favored Glycine 0 C--N 1.339 0.729 0 O-C-N 123.542 0.526 . . . . 0.0 113.079 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.48 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 42.4 mm -122.17 145.91 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.495 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 75.5 m -81.44 107.73 14.45 Favored 'General case' 0 CA--C 1.537 0.469 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.517 179.494 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.48 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.6 m-85 -108.21 158.65 17.26 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.356 -0.383 . . . . 0.0 111.652 -179.447 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 tp -92.29 123.56 44.45 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.558 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.547 179.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.45 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 0.983 0 CA-C-O 118.278 -0.868 . . . . 0.0 111.384 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.488 1.446 0 CA-C-O 119.624 -0.227 . . . . 0.0 111.156 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.439 ' HG2' ' SG ' ' A' ' 30' ' ' CYS . 87.3 Cg_endo -81.94 -179.65 4.94 Favored 'Trans proline' 0 C--N 1.372 1.782 0 C-N-CA 122.652 2.235 . . . . 0.0 113.997 -179.067 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.495 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.27 -151.37 6.39 Favored Glycine 0 C--N 1.34 0.769 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.699 179.429 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.3 tt0 -75.6 110.33 9.91 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-O 120.931 0.396 . . . . 0.0 111.288 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.38 29.82 10.7 Favored Glycine 0 C--N 1.341 0.833 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.524 -179.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -124.25 167.97 13.58 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-O 120.561 0.219 . . . . 0.0 111.133 -179.67 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 -79.9 137.39 36.89 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.072 -179.674 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -126.74 157.04 40.16 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.492 -0.777 . . . . 0.0 111.274 -179.283 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -131.18 140.04 49.84 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.289 179.076 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.521 HG22 ' O ' ' A' ' 26' ' ' PRO . 11.7 m -95.76 7.37 7.18 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 O-C-N 123.202 0.314 . . . . 0.0 111.757 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -99.73 -46.6 5.36 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.772 -179.274 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.0 p90 -154.58 1.17 0.2 Allowed 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 -178.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -132.72 65.61 74.74 Favored Pre-proline 0 CA--C 1.547 0.844 0 CA-C-N 117.931 0.332 . . . . 0.0 111.884 -179.237 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.407 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 55.3 Cg_endo -74.14 177.57 8.06 Favored 'Trans proline' 0 C--N 1.369 1.628 0 C-N-CA 122.574 2.182 . . . . 0.0 112.252 178.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 56.9 m -79.35 139.64 37.71 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 116.705 -0.225 . . . . 0.0 110.898 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.35 -53.7 0.56 Allowed Pre-proline 0 CA--C 1.545 0.75 0 CA-C-O 119.014 -0.517 . . . . 0.0 112.342 -179.073 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.43 ' HG2' HD12 ' A' ' 19' ' ' LEU . 60.0 Cg_endo -71.66 175.32 9.72 Favored 'Trans proline' 0 C--N 1.375 1.971 0 C-N-CA 122.09 1.86 . . . . 0.0 112.265 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_exo -69.6 65.06 1.71 Allowed 'Trans proline' 0 C--N 1.377 2.057 0 C-N-CA 122.369 2.046 . . . . 0.0 112.615 179.456 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.43 HD12 ' HG2' ' A' ' 17' ' ' PRO . 47.4 mt -126.65 161.13 28.8 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.722 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.0 t -109.58 151.51 26.72 Favored 'General case' 0 CA--C 1.534 0.36 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.227 -179.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 5.7 t -96.39 107.56 19.96 Favored 'General case' 0 C--O 1.238 0.47 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.398 179.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.438 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 3.8 mt -126.75 129.5 24.04 Favored Pre-proline 0 CA--C 1.541 0.615 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.761 -179.729 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -71.48 -39.14 1.5 Allowed 'Cis proline' 0 C--N 1.374 1.881 0 C-N-CA 124.591 -1.004 . . . . 0.0 113.305 -0.577 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.01 29.76 40.64 Favored Glycine 0 C--N 1.344 0.995 0 CA-C-N 116.158 -0.473 . . . . 0.0 113.429 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -144.13 89.55 7.06 Favored Pre-proline 0 CA--C 1.546 0.811 0 CA-C-N 116.702 0.251 . . . . 0.0 111.219 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.521 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.5 Cg_endo -83.77 -35.58 1.87 Allowed 'Cis proline' 0 C--N 1.371 1.738 0 CA-C-N 119.198 0.749 . . . . 0.0 112.846 -0.291 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 44.0 m-85 -103.01 156.95 17.32 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.717 -179.331 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -156.43 -164.98 14.0 Favored Glycine 0 C--N 1.339 0.743 0 C-N-CA 120.956 -0.64 . . . . 0.0 113.216 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.461 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 43.4 mm -127.24 147.53 32.09 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.495 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 72.3 m -82.89 109.41 16.99 Favored 'General case' 0 CA--C 1.537 0.478 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.401 179.282 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.461 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.4 m-85 -109.03 158.42 17.75 Favored 'General case' 0 N--CA 1.467 0.391 0 N-CA-C 112.038 0.384 . . . . 0.0 112.038 -179.024 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.1 tp -93.46 124.6 45.95 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.616 179.675 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.453 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.6 pp . . . . . 0 C--O 1.25 1.128 0 CA-C-O 118.185 -0.912 . . . . 0.0 111.44 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.486 1.374 0 CA-C-O 119.649 -0.215 . . . . 0.0 111.104 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -83.48 -179.07 4.0 Favored 'Trans proline' 0 C--N 1.372 1.781 0 C-N-CA 122.467 2.111 . . . . 0.0 114.123 -179.157 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.493 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.82 -152.77 6.64 Favored Glycine 0 C--N 1.341 0.849 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.809 179.433 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.46 111.91 9.04 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-O 120.896 0.379 . . . . 0.0 111.469 -179.753 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.27 30.74 10.46 Favored Glycine 0 C--N 1.341 0.832 0 CA-C-N 115.418 -0.81 . . . . 0.0 112.593 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.5 mt-10 -127.01 163.69 23.16 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-O 120.608 0.242 . . . . 0.0 111.194 -179.693 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -79.96 128.56 33.62 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.969 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.47 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.3 p -127.05 143.18 51.35 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.555 -179.6 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -104.56 150.28 24.77 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.345 -0.843 . . . . 0.0 109.74 179.469 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.485 HG22 ' O ' ' A' ' 26' ' ' PRO . 9.1 m -101.82 5.12 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.844 -179.854 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -99.17 -47.41 5.21 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.904 -179.126 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -151.84 1.53 0.36 Allowed 'General case' 0 N--CA 1.477 0.886 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -178.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -131.7 64.46 72.89 Favored Pre-proline 0 CA--C 1.549 0.927 0 N-CA-C 111.803 0.298 . . . . 0.0 111.803 -179.262 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.63 178.36 6.84 Favored 'Trans proline' 0 C--N 1.369 1.612 0 C-N-CA 122.56 2.173 . . . . 0.0 112.456 179.066 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 48.3 m -79.55 138.91 37.64 Favored 'General case' 0 C--N 1.344 0.367 0 O-C-N 123.163 0.29 . . . . 0.0 110.792 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.03 -52.66 1.01 Allowed Pre-proline 0 CA--C 1.543 0.697 0 CA-C-O 118.999 -0.525 . . . . 0.0 112.103 -179.319 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.416 ' HG2' HD12 ' A' ' 19' ' ' LEU . 63.9 Cg_endo -72.78 175.88 9.7 Favored 'Trans proline' 0 C--N 1.375 1.964 0 C-N-CA 122.126 1.884 . . . . 0.0 112.036 179.337 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_exo -69.44 64.82 1.62 Allowed 'Trans proline' 0 C--N 1.379 2.149 0 C-N-CA 122.38 2.053 . . . . 0.0 112.693 179.47 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.416 HD12 ' HG2' ' A' ' 17' ' ' PRO . 33.0 mt -129.11 159.96 34.34 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.698 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.435 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -111.22 152.88 26.6 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.149 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 t -96.37 106.75 19.03 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.298 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.447 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.5 mt -126.15 131.66 24.04 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.418 -179.538 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -71.12 -39.53 1.4 Allowed 'Cis proline' 0 C--N 1.374 1.895 0 C-N-CA 124.676 -0.969 . . . . 0.0 113.391 -0.326 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.67 31.54 44.52 Favored Glycine 0 C--N 1.342 0.9 0 O-C-N 123.49 0.494 . . . . 0.0 113.393 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -136.82 85.38 23.88 Favored Pre-proline 0 CA--C 1.545 0.783 0 C-N-CA 122.168 0.187 . . . . 0.0 111.072 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.485 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.1 Cg_endo -83.3 -34.37 2.41 Favored 'Cis proline' 0 C--N 1.372 1.767 0 C-N-CA 125.17 -0.763 . . . . 0.0 112.993 -0.217 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 -98.56 153.9 18.31 Favored 'General case' 0 N--CA 1.466 0.369 0 O-C-N 123.586 0.554 . . . . 0.0 110.996 -179.238 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.15 -171.33 18.41 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 116.035 -0.529 . . . . 0.0 113.004 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.483 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 41.8 mm -122.38 146.16 28.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.493 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.5 m -81.7 107.92 14.83 Favored 'General case' 0 CA--C 1.537 0.477 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.509 179.562 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.483 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.6 m-85 -108.5 158.94 17.09 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.53 -179.45 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tp -91.57 122.75 43.29 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.61 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.457 ' OXT' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.116 -0.945 . . . . 0.0 111.326 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.5 p . . . . . 0 N--CA 1.486 1.359 0 CA-C-O 119.628 -0.225 . . . . 0.0 111.149 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.532 ' HD3' ' ND2' ' A' ' 13' ' ' ASN . 86.9 Cg_endo -78.26 -172.57 1.54 Allowed 'Trans proline' 0 C--N 1.37 1.7 0 C-N-CA 122.673 2.248 . . . . 0.0 113.83 -179.346 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -143.2 -144.21 4.24 Favored Glycine 0 C--N 1.339 0.698 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.588 179.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 13.3 tt0 -86.47 109.62 19.2 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-O 120.881 0.372 . . . . 0.0 110.705 179.476 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.53 35.88 6.74 Favored Glycine 0 C--N 1.34 0.774 0 CA-C-N 115.571 -0.74 . . . . 0.0 112.749 -179.664 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -131.85 167.68 19.16 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 122.335 0.254 . . . . 0.0 110.831 -179.709 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -79.9 120.56 24.28 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.715 179.746 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 11.8 p -120.17 135.6 54.91 Favored 'General case' 0 C--O 1.236 0.378 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.288 -179.343 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -104.02 156.15 18.09 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 115.483 -0.78 . . . . 0.0 109.691 179.649 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.428 HG22 ' O ' ' A' ' 26' ' ' PRO . 8.0 m -107.82 14.29 8.14 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.905 -179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -120.54 -45.11 2.43 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.112 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 38.1 p90 -141.28 2.34 1.67 Allowed 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -178.753 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.532 ' ND2' ' HD3' ' A' ' 2' ' ' PRO . 2.0 t30 -135.97 68.21 63.85 Favored Pre-proline 0 CA--C 1.543 0.71 0 CA-C-O 120.524 0.202 . . . . 0.0 111.377 -179.644 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.492 ' O ' ' HD2' ' A' ' 2' ' ' PRO . 50.5 Cg_endo -74.46 164.36 34.13 Favored 'Trans proline' 0 C--N 1.368 1.602 0 C-N-CA 122.614 2.209 . . . . 0.0 112.581 179.009 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 94.1 m -79.6 140.42 37.14 Favored 'General case' 0 N--CA 1.47 0.538 0 O-C-N 123.441 0.463 . . . . 0.0 111.681 -179.455 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 m -84.9 -52.54 0.5 Allowed Pre-proline 0 CA--C 1.545 0.751 0 O-C-N 123.63 0.581 . . . . 0.0 112.168 -179.634 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.482 ' HG2' HD12 ' A' ' 19' ' ' LEU . 65.3 Cg_endo -75.02 172.8 15.66 Favored 'Trans proline' 0 C--N 1.376 2.014 0 C-N-CA 122.066 1.844 . . . . 0.0 112.408 179.741 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo -71.31 66.16 2.76 Favored 'Trans proline' 0 C--N 1.379 2.149 0 C-N-CA 122.357 2.038 . . . . 0.0 112.511 179.613 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.482 HD12 ' HG2' ' A' ' 17' ' ' PRO . 55.5 mt -124.52 168.1 13.55 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.817 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.579 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 8.5 t -118.73 140.99 49.04 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.337 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 6.3 t -90.99 104.25 16.86 Favored 'General case' 0 CA--C 1.536 0.442 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.541 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mt -120.84 131.58 24.43 Favored Pre-proline 0 CA--C 1.543 0.692 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.325 -179.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -72.52 -36.9 2.4 Favored 'Cis proline' 0 C--N 1.374 1.888 0 C-N-CA 124.542 -1.024 . . . . 0.0 113.257 -0.264 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.47 30.57 48.88 Favored Glycine 0 C--N 1.343 0.925 0 CA-C-N 116.171 -0.468 . . . . 0.0 113.297 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -142.24 86.33 10.2 Favored Pre-proline 0 CA--C 1.545 0.783 0 C-N-CA 122.287 0.235 . . . . 0.0 111.161 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.428 ' O ' HG22 ' A' ' 10' ' ' VAL . 1.7 Cg_endo -85.24 -35.59 1.59 Allowed 'Cis proline' 0 C--N 1.373 1.826 0 CA-C-N 119.055 0.698 . . . . 0.0 112.987 -0.377 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 23.6 m-85 -104.45 154.52 19.77 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.906 -179.056 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -161.76 -172.83 29.66 Favored Glycine 0 C--N 1.34 0.761 0 CA-C-N 116.015 -0.538 . . . . 0.0 113.139 179.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 27.2 mm -116.87 145.2 22.94 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 179.747 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.579 ' HA ' ' O ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -89.4 119.56 29.97 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.484 -179.864 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -111.87 167.01 10.7 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.487 -179.111 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 tp -95.42 122.93 47.33 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.464 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.554 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.475 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.5 pp . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.418 -0.801 . . . . 0.0 111.352 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 31.6 p . . . . . 0 N--CA 1.486 1.35 0 CA-C-O 119.48 -0.295 . . . . 0.0 111.027 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -84.61 -177.33 2.85 Favored 'Trans proline' 0 C--N 1.37 1.661 0 C-N-CA 122.161 1.908 . . . . 0.0 113.088 179.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.576 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -146.93 -157.89 7.57 Favored Glycine 0 C--N 1.337 0.613 0 CA-C-N 115.74 -0.663 . . . . 0.0 112.027 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -65.66 110.3 2.72 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 121.042 0.448 . . . . 0.0 111.737 -179.251 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.33 31.57 10.48 Favored Glycine 0 C--N 1.339 0.745 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.723 -179.865 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.447 ' HB2' ' H ' ' A' ' 3' ' ' GLY . 36.7 mt-10 -126.3 159.98 31.64 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 120.606 0.241 . . . . 0.0 111.275 -179.686 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.507 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.7 tt0 -80.04 121.92 26.12 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.566 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.409 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 7.9 p -124.83 149.29 47.61 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 115.795 -0.638 . . . . 0.0 111.673 -179.169 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.441 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 6.1 t70 -109.11 155.35 21.09 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.898 179.14 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.3 m -103.0 3.42 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 -179.543 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.441 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 9.9 mm-40 -98.6 -48.6 4.92 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 111.939 0.348 . . . . 0.0 111.939 -179.037 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -149.15 1.56 0.55 Allowed 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 113.325 0.861 . . . . 0.0 113.325 -178.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -130.73 63.73 70.97 Favored Pre-proline 0 CA--C 1.55 0.965 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 -179.333 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -76.61 172.7 15.75 Favored 'Trans proline' 0 C--N 1.369 1.656 0 C-N-CA 122.438 2.092 . . . . 0.0 112.618 179.115 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.409 ' SG ' ' SG ' ' A' ' 8' ' ' CYS . 21.9 m -79.56 133.33 36.45 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.3 179.623 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.545 ' SG ' ' HD3' ' A' ' 17' ' ' PRO . 0.8 OUTLIER -79.55 -45.46 1.6 Allowed Pre-proline 0 N--CA 1.475 0.782 0 N-CA-C 112.859 0.689 . . . . 0.0 112.859 -179.279 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.545 ' HD3' ' SG ' ' A' ' 16' ' ' CYS . 56.7 Cg_endo -70.69 174.37 10.43 Favored 'Trans proline' 0 C--N 1.374 1.876 0 C-N-CA 121.863 1.709 . . . . 0.0 111.879 178.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 14.2 Cg_exo -70.0 65.71 1.93 Allowed 'Trans proline' 0 C--N 1.377 2.046 0 C-N-CA 122.274 1.983 . . . . 0.0 112.366 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.527 HD12 ' HG2' ' A' ' 17' ' ' PRO . 25.8 mt -133.43 162.38 32.01 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.27 -0.877 . . . . 0.0 110.901 -179.56 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.507 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.6 t -112.28 155.32 24.26 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.244 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.3 t -98.37 108.41 21.1 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.307 179.618 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.422 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.1 mt -128.15 130.86 23.55 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.376 -179.831 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.86 -39.3 1.48 Allowed 'Cis proline' 0 C--N 1.373 1.849 0 C-N-CA 124.624 -0.99 . . . . 0.0 113.533 -0.342 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.29 38.37 18.39 Favored Glycine 0 C--N 1.345 1.049 0 CA-C-N 116.216 -0.447 . . . . 0.0 113.079 -179.725 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -141.23 84.13 13.06 Favored Pre-proline 0 CA--C 1.547 0.847 0 C-N-CA 122.225 0.21 . . . . 0.0 111.338 -179.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -83.16 -34.14 2.54 Favored 'Cis proline' 0 C--N 1.373 1.828 0 CA-C-N 119.047 0.695 . . . . 0.0 112.763 -0.189 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -106.14 156.41 18.46 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.892 -179.35 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.507 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.1 -156.24 7.49 Favored Glycine 0 C--N 1.337 0.622 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.622 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.479 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 23.3 mm -127.4 147.88 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 N-CA-C 110.051 -0.351 . . . . 0.0 110.051 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.576 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 76.7 m -84.74 110.13 18.56 Favored 'General case' 0 CA--C 1.537 0.455 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.114 179.228 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.479 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.4 m-85 -107.38 159.77 16.14 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.899 -178.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.0 tp -93.57 124.1 45.9 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.536 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.6 179.551 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.4 pt . . . . . 0 C--O 1.25 1.119 0 CA-C-O 118.489 -0.767 . . . . 0.0 111.328 179.988 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.487 1.375 0 CA-C-O 119.616 -0.23 . . . . 0.0 111.179 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -83.44 -179.15 4.07 Favored 'Trans proline' 0 C--N 1.371 1.733 0 C-N-CA 122.497 2.131 . . . . 0.0 114.082 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.494 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -134.84 -152.53 6.58 Favored Glycine 0 C--N 1.341 0.843 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.81 179.41 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -73.65 111.83 9.16 Favored 'General case' 0 N--CA 1.472 0.63 0 CA-C-O 120.878 0.371 . . . . 0.0 111.385 -179.661 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.21 30.93 10.22 Favored Glycine 0 C--N 1.341 0.828 0 CA-C-N 115.502 -0.772 . . . . 0.0 112.638 -179.715 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 34.3 mt-10 -127.14 163.75 23.12 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-O 120.559 0.219 . . . . 0.0 111.212 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -79.95 128.48 33.52 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.971 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.472 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 6.3 p -127.02 142.9 51.43 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.515 -179.644 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.404 ' OD1' ' HB3' ' A' ' 13' ' ' ASN . 1.3 m-20 -104.46 150.04 24.91 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.808 179.439 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.488 HG22 ' O ' ' A' ' 26' ' ' PRO . 9.4 m -101.68 5.92 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 O-C-N 123.397 0.436 . . . . 0.0 111.947 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.6 tt0 -100.04 -48.0 4.8 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.522 -179.105 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 36.7 p90 -151.11 1.54 0.41 Allowed 'General case' 0 N--CA 1.477 0.918 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -178.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.404 ' HB3' ' OD1' ' A' ' 9' ' ' ASP . 2.4 t30 -131.55 64.3 72.54 Favored Pre-proline 0 CA--C 1.55 0.972 0 N-CA-C 111.854 0.316 . . . . 0.0 111.854 -179.281 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -73.54 177.79 7.53 Favored 'Trans proline' 0 C--N 1.37 1.658 0 C-N-CA 122.525 2.15 . . . . 0.0 112.429 179.047 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 47.3 m -79.53 138.7 37.59 Favored 'General case' 0 N--CA 1.467 0.385 0 O-C-N 123.188 0.305 . . . . 0.0 110.807 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -80.01 -52.64 1.01 Allowed Pre-proline 0 N--CA 1.474 0.727 0 CA-C-O 119.025 -0.512 . . . . 0.0 111.983 -179.22 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.41 ' HG2' HD12 ' A' ' 19' ' ' LEU . 64.4 Cg_endo -72.73 175.88 9.66 Favored 'Trans proline' 0 C--N 1.375 1.951 0 C-N-CA 122.166 1.91 . . . . 0.0 112.051 179.372 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 15.3 Cg_exo -69.6 65.01 1.71 Allowed 'Trans proline' 0 C--N 1.378 2.126 0 C-N-CA 122.375 2.05 . . . . 0.0 112.642 179.458 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.41 HD12 ' HG2' ' A' ' 17' ' ' PRO . 32.6 mt -129.2 159.96 34.42 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.687 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.432 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.1 t -111.33 152.71 26.95 Favored 'General case' 0 CA--C 1.534 0.353 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.107 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.7 t -96.39 106.72 19.0 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.232 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.445 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 4.4 mt -125.99 131.63 24.05 Favored Pre-proline 0 CA--C 1.542 0.67 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.391 -179.482 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -71.1 -39.43 1.42 Allowed 'Cis proline' 0 C--N 1.375 1.944 0 C-N-CA 124.717 -0.951 . . . . 0.0 113.446 -0.289 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 78.51 31.39 45.86 Favored Glycine 0 C--N 1.344 0.997 0 CA-C-N 116.136 -0.484 . . . . 0.0 113.321 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -136.9 85.45 23.29 Favored Pre-proline 0 CA--C 1.545 0.762 0 C-N-CA 122.234 0.214 . . . . 0.0 111.04 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.488 ' O ' HG22 ' A' ' 10' ' ' VAL . 2.2 Cg_endo -83.22 -34.42 2.41 Favored 'Cis proline' 0 C--N 1.373 1.827 0 C-N-CA 125.237 -0.734 . . . . 0.0 112.978 -0.257 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -98.57 154.15 18.13 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.061 -179.257 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -150.43 -171.56 18.83 Favored Glycine 0 C--N 1.338 0.681 0 CA-C-N 116.11 -0.495 . . . . 0.0 113.01 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.481 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 41.8 mm -122.3 146.05 28.08 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.494 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 74.4 m -81.49 107.94 14.68 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.582 179.463 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.481 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 94.8 m-85 -108.48 158.82 17.2 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.554 -179.389 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tp -91.68 122.84 43.49 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.567 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.668 179.622 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.455 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.247 0.93 0 CA-C-O 118.44 -0.79 . . . . 0.0 111.405 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 31.7 p . . . . . 0 N--CA 1.488 1.474 0 CA-C-O 119.486 -0.292 . . . . 0.0 110.892 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -84.73 -177.32 2.82 Favored 'Trans proline' 0 C--N 1.37 1.687 0 C-N-CA 122.079 1.853 . . . . 0.0 113.092 179.406 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.578 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -147.27 -158.6 7.92 Favored Glycine 0 C--N 1.337 0.589 0 CA-C-N 115.723 -0.671 . . . . 0.0 111.947 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -64.79 110.0 2.25 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-O 120.979 0.419 . . . . 0.0 111.713 -179.218 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.29 31.97 10.1 Favored Glycine 0 C--N 1.34 0.778 0 CA-C-N 115.331 -0.849 . . . . 0.0 112.713 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.451 ' HB2' ' H ' ' A' ' 3' ' ' GLY . 36.9 mt-10 -126.65 160.48 30.6 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 120.548 0.213 . . . . 0.0 111.238 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.517 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.5 tt0 -79.98 122.01 26.2 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.585 179.682 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 15' ' ' CYS . 8.5 p -125.49 149.75 48.0 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.637 -179.062 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -109.69 155.53 21.4 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 115.507 -0.769 . . . . 0.0 109.844 179.104 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 13.4 m -104.14 4.2 10.54 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.222 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -99.24 -48.67 4.74 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 116.637 -0.256 . . . . 0.0 111.654 -179.056 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 37.9 p90 -148.85 0.97 0.56 Allowed 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 113.392 0.886 . . . . 0.0 113.392 -179.056 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -130.87 63.56 70.59 Favored Pre-proline 0 CA--C 1.551 0.99 0 N-CA-C 111.816 0.302 . . . . 0.0 111.816 -179.32 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -76.27 173.5 14.38 Favored 'Trans proline' 0 C--N 1.369 1.638 0 C-N-CA 122.53 2.153 . . . . 0.0 112.594 179.203 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 8' ' ' CYS . 23.6 m -79.75 133.5 36.33 Favored 'General case' 0 N--CA 1.466 0.352 0 O-C-N 123.373 0.421 . . . . 0.0 110.252 179.556 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.55 ' SG ' ' HD3' ' A' ' 17' ' ' PRO . 0.8 OUTLIER -79.59 -45.4 1.59 Allowed Pre-proline 0 N--CA 1.476 0.836 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -179.271 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.55 ' HD3' ' SG ' ' A' ' 16' ' ' CYS . 56.9 Cg_endo -70.6 174.42 10.26 Favored 'Trans proline' 0 C--N 1.374 1.913 0 C-N-CA 121.928 1.752 . . . . 0.0 111.922 178.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_exo -70.04 65.66 1.96 Allowed 'Trans proline' 0 C--N 1.376 2.015 0 C-N-CA 122.266 1.977 . . . . 0.0 112.354 179.341 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.526 HD12 ' HG2' ' A' ' 17' ' ' PRO . 26.5 mt -133.5 162.43 31.91 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.84 -179.52 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.507 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 5.6 t -112.01 155.69 23.37 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.16 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.5 t -98.83 108.53 21.24 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.314 179.59 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.43 ' O ' ' HE2' ' A' ' 31' ' ' TYR . 5.3 mt -128.09 130.87 23.56 Favored Pre-proline 0 CA--C 1.542 0.637 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.323 -179.805 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -73.17 -39.06 1.54 Allowed 'Cis proline' 0 C--N 1.373 1.859 0 C-N-CA 124.62 -0.992 . . . . 0.0 113.523 -0.265 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 80.14 39.48 15.99 Favored Glycine 0 C--N 1.344 1.018 0 O-C-N 123.459 0.475 . . . . 0.0 113.138 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -141.55 83.56 13.13 Favored Pre-proline 0 CA--C 1.547 0.855 0 C-N-CA 122.132 0.173 . . . . 0.0 111.253 -179.728 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -83.51 -33.43 2.75 Favored 'Cis proline' 0 C--N 1.372 1.794 0 CA-C-N 119.056 0.698 . . . . 0.0 112.812 -0.312 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -107.27 155.75 19.61 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.95 -179.404 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.517 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -152.59 -154.1 6.55 Favored Glycine 0 C--N 1.338 0.672 0 CA-C-N 115.876 -0.602 . . . . 0.0 112.574 179.767 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.481 ' HB ' ' CE2' ' A' ' 31' ' ' TYR . 22.6 mm -128.37 148.22 32.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.578 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 77.9 m -84.68 110.22 18.6 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.239 179.286 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.481 ' CE2' ' HB ' ' A' ' 29' ' ' ILE . 97.6 m-85 -107.73 160.54 15.64 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.876 -178.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 tp -92.39 122.87 44.23 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.638 179.621 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.463 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.7 pp . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.378 -0.82 . . . . 0.0 111.465 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 32.1 p . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 119.412 -0.328 . . . . 0.0 110.945 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -84.75 -177.55 2.91 Favored 'Trans proline' 0 C--N 1.369 1.612 0 C-N-CA 122.014 1.809 . . . . 0.0 113.202 179.582 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.584 ' O ' ' HB2' ' A' ' 30' ' ' CYS . . . -146.92 -161.51 9.39 Favored Glycine 0 C--N 1.338 0.683 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.882 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -62.01 111.13 1.8 Allowed 'General case' 0 N--CA 1.474 0.765 0 CA-C-O 121.069 0.462 . . . . 0.0 111.938 -179.209 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.32 31.66 13.52 Favored Glycine 0 C--N 1.341 0.817 0 CA-C-N 115.242 -0.89 . . . . 0.0 112.718 -179.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.508 ' O ' ' HA ' ' A' ' 29' ' ' ILE . 36.2 mt-10 -125.46 161.48 27.02 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-O 120.551 0.215 . . . . 0.0 111.328 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.493 ' HA ' ' O ' ' A' ' 28' ' ' GLY . 12.7 tt0 -79.91 120.93 24.8 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.521 179.726 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.9 p -125.16 150.03 47.32 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-N 115.659 -0.7 . . . . 0.0 111.627 -179.062 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.461 ' OD2' ' HB2' ' A' ' 11' ' ' GLU . 7.9 t70 -110.59 154.67 23.44 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.804 179.257 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.1 m -104.06 3.93 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 CA-C-N 116.125 -0.488 . . . . 0.0 112.178 -179.589 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.461 ' HB2' ' OD2' ' A' ' 9' ' ' ASP . 43.3 mt-10 -98.39 -47.93 5.23 Favored 'General case' 0 C--O 1.234 0.24 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -179.163 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -150.07 0.39 0.46 Allowed 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 113.449 0.907 . . . . 0.0 113.449 -179.025 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -131.01 63.81 71.68 Favored Pre-proline 0 CA--C 1.549 0.928 0 N-CA-C 111.874 0.324 . . . . 0.0 111.874 -179.299 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -76.27 174.49 12.74 Favored 'Trans proline' 0 C--N 1.369 1.646 0 C-N-CA 122.513 2.142 . . . . 0.0 112.618 179.299 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 31.0 m -79.62 133.12 36.4 Favored 'General case' 0 N--CA 1.468 0.438 0 C-N-CA 122.574 0.35 . . . . 0.0 110.303 179.587 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.548 ' SG ' ' HD3' ' A' ' 17' ' ' PRO . 0.9 OUTLIER -79.66 -45.45 1.57 Allowed Pre-proline 0 N--CA 1.477 0.877 0 N-CA-C 112.992 0.738 . . . . 0.0 112.992 -179.242 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.548 ' HD3' ' SG ' ' A' ' 16' ' ' CYS . 56.0 Cg_endo -69.98 174.81 9.15 Favored 'Trans proline' 0 C--N 1.373 1.856 0 C-N-CA 121.886 1.724 . . . . 0.0 111.956 179.054 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_exo -69.59 65.22 1.7 Allowed 'Trans proline' 0 C--N 1.378 2.127 0 C-N-CA 122.292 1.995 . . . . 0.0 112.534 179.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.52 HD12 ' HG2' ' A' ' 17' ' ' PRO . 15.6 mt -136.12 162.04 34.04 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.673 -179.671 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.579 ' O ' ' HA ' ' A' ' 30' ' ' CYS . 14.7 t -111.31 163.02 14.4 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.078 179.543 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.8 t -102.62 110.74 22.78 Favored 'General case' 0 C--O 1.239 0.538 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.294 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 4.8 mt -127.78 131.09 23.63 Favored Pre-proline 0 CA--C 1.542 0.669 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.339 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -74.55 -37.85 2.05 Favored 'Cis proline' 0 C--N 1.374 1.877 0 C-N-CA 124.461 -1.058 . . . . 0.0 113.242 -0.25 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.83 39.51 11.79 Favored Glycine 0 C--N 1.345 1.046 0 O-C-N 123.508 0.505 . . . . 0.0 113.076 -179.716 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -140.71 82.17 16.01 Favored Pre-proline 0 CA--C 1.55 0.978 0 C-N-CA 122.105 0.162 . . . . 0.0 110.911 -179.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -84.86 -33.7 2.35 Favored 'Cis proline' 0 C--N 1.371 1.761 0 CA-C-N 119.096 0.713 . . . . 0.0 112.972 -0.415 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -105.69 156.67 18.06 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.934 -179.256 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' A' ' 7' ' ' GLU . . . -153.31 -155.27 7.08 Favored Glycine 0 C--N 1.338 0.682 0 CA-C-N 115.868 -0.606 . . . . 0.0 112.553 179.75 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.508 ' HA ' ' O ' ' A' ' 6' ' ' GLU . 19.4 mm -128.57 149.24 33.18 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.584 ' HB2' ' O ' ' A' ' 3' ' ' GLY . 63.6 m -84.42 110.67 18.81 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.274 179.196 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.41 ' O ' ' HB3' ' A' ' 19' ' ' LEU . 85.3 m-85 -106.24 160.95 14.96 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.128 -0.487 . . . . 0.0 112.056 -178.816 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 3.1 tp -90.1 126.52 42.95 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.611 179.569 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 38.2 mm . . . . . 0 C--O 1.25 1.124 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.088 -179.606 . . . . . . . . 0 0 . 1 stop_ save_